7352670
D009599_D006973 NONE <e1>nitroprusside</e1> <e2>hypertensive</e2>
D009599_D006973 NONE <e1>snp</e1> infusion demonstrated increase <e2>pressure</e2>
D012504_D006973 NONE <e1>saralasin</e1> prevented nitroprusside <e2>hypertensive</e2>
D012504_D006973 NONE <e1>saralasin-treated</e1> animals showed demonstrated increase <e2>pressure</e2>
D000809_D007022 NONE <e1>angiotensin</e1> system role evaluated <e2>hypotension</e2>
D000809_D007022 NONE <e1>angiotensin</e1> system participation demonstrates antagonizing effects <e2>hypotensive</e2>
D006221_D007022 CID <e1>halothane</e1> anesthesia role evaluated <e2>hypotension</e2>
D006221_D007022 CID <e1>halothane</e1> effects <e2>hypotensive</e2>
D009599_D007022 CID <e1>nitroprusside</e1> anesthesia role evaluated <e2>hypotension</e2>
D009599_D007022 CID <e1>(snp)-induced</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> halothane effects <e2>hypotensive</e2>
15145918
D004967_D007022 NONE <e1>estrogen</e1> <e2>hypotension</e2>
D004967_D007022 NONE <e1>estrogen</e1> modulates effect <e2>hypotensive</e2>
D004967_D007022 NONE <e1>estrogen</e1> downregulates i1-receptor-mediated <e2>hypotension</e2>
D004967_D007022 NONE <e1>alpha-methyldopa-estrogen</e1> interaction role highlight downregulates i1-receptor-mediated <e2>hypotension</e2>
D048288_D007022 NONE <e1>i1-imidazoline</e1> alpha2-adrenergic <e2>hypotension</e2>
D003000_D007022 NONE <e1>clonidine</e1> effect <e2>hypotensive</e2>
C032302_D007022 CID <e1>rilmenidine</e1> rats <e2>hypotension</e2>
C032302_D007022 CID <e1>rilmenidine</e1> hypotension effect enhanced response <e2>hypotensive</e2>
C032302_D007022 CID <e1>rilmenidine</e1> <e2>hypotension</e2>
D008750_D007022 CID <e1>alpha-methyldopa</e1> rilmenidine rats <e2>hypotension</e2>
D008750_D007022 CID <e1>alpha-methyldopa</e1> response <e2>hypotensive</e2>
D008750_D007022 CID <e1>alpha-methyldopa</e1> response enhanced effect <e2>hypotension</e2>
D008750_D007022 CID <e1>alpha-methyldopa</e1> <e2>hypotension</e2>
D008750_D007022 CID <e1>alpha-methyldopa-estrogen</e1> interaction role highlight downregulates i1-receptor-mediated <e2>hypotension</e2>
D008750_D001523 NONE <e1>alpha-methyldopa</e1> hypotension paralleled reduction <e2>activity</e2>
11672959
D012460_D003872 CID <e1>sulphasalazine</e1> course day beginning developed constellation <e2>dermatitis</e2>
D012460_D005334 CID <e1>sulphasalazine</e1> course day beginning developed lymphadenopathy <e2>fever</e2>
D012460_D008206 CID <e1>sulphasalazine</e1> course day beginning developed <e2>lymphadenopathy</e2>
D012460_D056486 CID <e1>sulphasalazine</e1> course day beginning developed lymphadenopathy <e2>hepatitis</e2>
D012460_D001172 NONE <e1>sulphasalazine</e1> <e2>arthritis</e2>
1664218
D000677_D002289 NONE <e1>amsacrine</e1> ci-921 study <e2>cancer</e2>
C042315_D002289 NONE <e1>ci-921</e1> study <e2>cancer</e2>
C042315_D002289 NONE <e1>343499</e1> nsc study <e2>cancer</e2>
6103707
D005445_D010146 CID <e1>flunitrazepam</e1> injection was <e2>pain</e2>
16787750
D014635_D001927 CID <e1>acid</e1> induced cases <e2>encephalopathy--19</e2>
D014635_D001927 CID <e1>vpa-therapy</e1> associated effect induced cases <e2>encephalopathy--19</e2>
D014635_D001927 CID <e1>vpa-induced</e1> hepatotoxicity pancreatitis <e2>encephalopathy</e2>
D014635_D001927 CID <e1>vpa-induced</e1> pancreatitis <e2>encephalopathy</e2>
D014635_D001927 CID <e1>vpa-induced</e1> <e2>encephalopathy</e2>
D014635_D001927 CID <e1>vpa</e1> effect patients <e2>encephalopathy</e2>
D014635_D001927 CID <e1>vpa-associated</e1> <e2>encephalopathy</e2>
D014635_D010195 CID <e1>vpa-induced</e1> hepatotoxicity <e2>pancreatitis</e2>
D014635_D010195 CID <e1>vpa-induced</e1> <e2>pancreatitis</e2>
D014635_D001855 CID <e1>vpa-induced</e1> hepatotoxicity pancreatitis <e2>suppression</e2>
D014635_D001855 CID <e1>vpa-induced</e1> pancreatitis <e2>suppression</e2>
D014635_D056486 CID <e1>vpa-induced</e1> <e2>hepatotoxicity</e2>
D014635_D056486 CID <e1>vpa-induced</e1> pancreatitis <e2>hepatotoxicity</e2>
D014635_D003244 CID <e1>vpa-induced</e1> encephalopathy signs <e2>consciousness</e2>
D014635_D012640 NONE <e1>vpa-induced</e1> encephalopathy signs consciousness increased frequency <e2>seizure</e2>
D014635_D022124 NONE <e1>vpa-induced</e1> encephalopathy signs consciousness <e2>hyperammonemia</e2>
9931093
D016559_D006973 CID <e1>506-induced</e1> <e2>hypertension</e2>
D016559_D006973 CID <e1>506</e1> fk utility complicated <e2>hypertension</e2>
D016559_D006973 CID <e1>506-induced</e1> <e2>hypertension</e2>
D016559_D006973 CID <e1>506</e1> fk effects studied clarify mechanisms <e2>hypertension</e2>
D016559_D006973 CID <e1>506-induced</e1> <e2>hypertension</e2>
D016559_D006973 CID <e1>506-induced</e1> <e2>hypertension</e2>
D016559_D007674 NONE <e1>506</e1> fk utility complicated hypertension <e2>nephrotoxicity</e2>
D009569_D006973 NONE <e1>oxide</e1> synthase activity expression studied clarify mechanisms <e2>hypertension</e2>
C079574_D006973 NONE <e1>139317</e1> fr effect <e2>hypertension</e2>
230316
D006912_D020258 NONE <e1>hydroxyquinolines</e1> <e2>neurotoxicity</e2>
D006912_D020258 NONE <e1>hydroxyquinolines</e1> reactions <e2>neurotoxic</e2>
D007464_D009422 NONE <e1>clioquinol</e1> dose ingestion related encephalopathy consisted <e2>disturbance</e2>
D007464_D001927 CID <e1>clioquinol</e1> dose ingestion related <e2>encephalopathy</e2>
D007464_C538178 NONE <e1>clioquinol</e1> received treatment <e2>enteropathica</e2>
9727773
D001067_D006976 CID <e1>suppressants</e1> associated <e2>hypertension</e2>
D001067_D006976 CID <e1>suppressant</e1> drugs intake associated disease <e2>hypertension</e2>
D001067_D006976 CID <e1>suppressants</e1> taken uncertain diagnosis <e2>hypertension</e2>
D001067_D006976 CID <e1>suppressants</e1> prescription policy lead incidence <e2>hypertension</e2>
8302922
D000527_D007022 CID <e1>e1</e1> flow induced <e2>hypotension</e2>
D000527_D007022 CID <e1>e1</e1> effect evaluate induced <e2>hypotension</e2>
D000527_D007022 CID <e1>pge1</e1> e1 effect evaluate induced <e2>hypotension</e2>
D000527_D007022 CID <e1>pge1</e1> starting decreased remained degree <e2>hypotension</e2>
D000527_D007022 CID <e1>pge1</e1> degree <e2>hypotension</e2>
D000527_D007022 CID <e1>pge1</e1> preferable anaesthesia <e2>hypotensive</e2>
D014294_D007022 CID <e1>trimethaphan</e1> flow induced <e2>hypotension</e2>
D014294_D007022 CID <e1>trimethaphan</e1> e1 effect evaluate induced <e2>hypotension</e2>
D014294_D007022 CID <e1>tmp</e1> trimethaphan e1 effect evaluate induced <e2>hypotension</e2>
D014294_D007022 CID <e1>tmp</e1> pge1 starting decreased remained degree <e2>hypotension</e2>
D014294_D007022 CID <e1>tmp</e1> preferable anaesthesia <e2>hypotensive</e2>
D014294_D007022 CID <e1>tmp</e1> decreased preferable anaesthesia <e2>hypotensive</e2>
D007530_D007022 NONE <e1>isoflurane</e1> anaesthesia underwent patients method using measured induced <e2>hypotension</e2>
3437726
D013034_D064420 NONE <e1>sparteine/debrisoquine</e1> polymorphism phenotype belonging patients experience <e2>reactions</e2>
D003647_D064420 NONE <e1>sparteine/debrisoquine</e1> polymorphism phenotype belonging patients experience <e2>reactions</e2>
12789195
D008914_D004194 NONE <e1>minoxidil</e1> use induced <e2>pseudoacromegaly</e2>
D008914_D004194 NONE <e1>minoxidil</e1> use resulted patient <e2>pseudoacromegaly</e2>
D008914_D004194 NONE <e1>minoxidil</e1> use effect report <e2>pseudoacromegaly</e2>
12198388
D000109_D012640 NONE <e1>acetylcholine</e1> release <e2>seizure-prone</e2>
D000109_D012640 NONE <e1>acetylcholine</e1> release seizure-prone <e2>seizure-resistant</e2>
D000109_D012640 NONE <e1>ach</e1> measured testing <e2>convulsions</e2>
D000109_D012640 NONE <e1>ach</e1> measured testing <e2>convulsions</e2>
D000109_D012640 NONE <e1>ach</e1> elevated measured testing <e2>convulsions</e2>
D000431_D012640 NONE <e1>alcohol-na</e1> <e2>seizure-prone</e2>
D000431_D012640 NONE <e1>ethanol</e1> withdrawal severity associated differences activity sensitivity <e2>convulsants</e2>
D000431_D012640 NONE <e1>alcohol</e1> withdrawal mechanisms implicate associated differences activity sensitivity <e2>convulsants</e2>
D009538_D014202 NONE <e1>nicotine</e1> administered recorded latencies onset <e2>tremor</e2>
D002217_D014202 NONE <e1>carbachol</e1> nicotine administered recorded latencies onset <e2>tremor</e2>
D009388_D014202 NONE <e1>neostigmine</e1> nicotine administered recorded latencies onset <e2>tremor</e2>
D009538_D012640 CID <e1>nicotine</e1> induced endpoints <e2>convulsion</e2>
D002217_D012640 CID <e1>carbachol</e1> nicotine induced endpoints <e2>convulsion</e2>
D009388_D012640 CID <e1>neostigmine</e1> nicotine induced endpoints <e2>convulsion</e2>
6518066
D008094_D004437 CID <e1>lithium</e1> <e2>anomaly</e2>
D008094_D006331 NONE <e1>lithium</e1> exposed newborns screening provide assessment presence <e2>malformations</e2>
D008094_D006331 NONE <e1>lithium-induced</e1> <e2>malformations</e2>
10520387
D004809_D007022 NONE <e1>ephedrine</e1> doses adding order obtund response <e2>hypotensive</e2>
D004809_D007022 NONE <e1>ephedrine</e1> addition appears method obtunding response <e2>hypotensive</e2>
D015742_D007022 CID <e1>propofol</e1> adding order obtund response <e2>hypotensive</e2>
D015742_D007022 CID <e1>propofol</e1> addition appears method obtunding response <e2>hypotensive</e2>
D015742_D007022 CID <e1>propofol</e1> response <e2>hypotensive</e2>
D004809_D013610 CID <e1>ephedrine</e1> use associated <e2>tachycardia</e2>
D004809_D013610 CID <e1>ephedrine/propofol/mixtures</e1> any patients use recommend risk <e2>tachycardia</e2>
D015742_D013610 CID <e1>propofol</e1> combination use associated <e2>tachycardia</e2>
D015742_D013610 CID <e1>ephedrine/propofol/mixtures</e1> any patients use recommend risk <e2>tachycardia</e2>
D004809_D017202 NONE <e1>ephedrine/propofol/mixtures</e1> any patients use recommend risk tachycardia inducing <e2>ischemia</e2>
D015742_D017202 NONE <e1>ephedrine/propofol/mixtures</e1> any patients use recommend risk tachycardia inducing <e2>ischemia</e2>
6888657
D004967_D010911 NONE <e1>estrogen-induced</e1> <e2>tumors</e2>
D004054_D010911 CID <e1>diethylstilbestrol</e1> treatment induced <e2>tumors</e2>
D004054_D010911 CID <e1>des</e1> diethylstilbestrol treatment induced <e2>tumors</e2>
D004054_D009369 NONE <e1>des-induced</e1> <e2>tumor</e2>
15036754
D010755_D012640 NONE <e1>organophosphate-induced</e1> <e2>convulsions</e2>
D010755_D004194 NONE <e1>organophosphate-induced</e1> convulsions <e2>damages</e2>
D010755_D064420 NONE <e1>ops</e1> <e2>toxicity</e2>
D010755_D064420 NONE <e1>op-induced</e1> signs <e2>toxicity</e2>
D000109_D064420 NONE <e1>acetylcholine</e1> levels elevates system binding result <e2>toxicity</e2>
D000109_D064420 NONE <e1>ach</e1> acetylcholine levels elevates system binding result <e2>toxicity</e2>
D007531_D064420 NONE <e1>dfp-atropine</e1> treated rats showed signs <e2>toxicity</e2>
D007531_D064420 NONE <e1>dfp</e1> <e2>toxicity</e2>
D007531_D064420 NONE <e1>dfp</e1> <e2>toxicity</e2>
D001285_D064420 NONE <e1>dfp-atropine</e1> treated rats showed signs <e2>toxicity</e2>
D001285_D064420 NONE <e1>atropine-mk801</e1> offer protection <e2>toxicity</e2>
D001285_D064420 NONE <e1>atropine</e1> combination diazepam cpa prevented reduced <e2>toxicity</e2>
C048599_D011041 NONE <e1>cpa</e1> given prevented delayed shortened occurrence signs <e2>poisoning</e2>
C048599_D011041 NONE <e1>cpa</e1> prevented occurrence signs <e2>poisoning</e2>
D003975_D011041 NONE <e1>diazepam</e1> cpa given prevented delayed shortened occurrence signs <e2>poisoning</e2>
D003975_D011041 NONE <e1>diazepam</e1> cpa prevented occurrence signs <e2>poisoning</e2>
D011220_D011041 NONE <e1>2pam</e1> diazepam cpa given prevented delayed shortened occurrence signs <e2>poisoning</e2>
D011220_D011041 NONE <e1>2pam</e1> diazepam cpa prevented occurrence signs <e2>poisoning</e2>
D007531_D011041 NONE <e1>dfp-atropine</e1> given prevented delayed shortened occurrence signs <e2>poisoning</e2>
D007531_D011041 NONE <e1>dfp</e1> toxicity reduced prevented occurrence signs <e2>poisoning</e2>
D001285_D011041 NONE <e1>dfp-atropine</e1> given prevented delayed shortened occurrence signs <e2>poisoning</e2>
D001285_D011041 NONE <e1>atropine</e1> combination diazepam cpa prevented occurrence signs <e2>poisoning</e2>
D016291_D064420 NONE <e1>atropine-mk801</e1> offer protection <e2>toxicity</e2>
C048599_D064420 NONE <e1>cpa</e1> prevented reduced <e2>toxicity</e2>
D003975_D064420 NONE <e1>diazepam</e1> cpa prevented reduced <e2>toxicity</e2>
D011220_D064420 NONE <e1>2pam</e1> diazepam cpa prevented reduced <e2>toxicity</e2>
2887062
D004967_D015175 CID <e1>estrogen-induced</e1> <e2>prolactinomas</e2>
D004967_D015175 CID <e1>estrogen-induced</e1> cells applied clarify effects bromocriptine cells <e2>prolactinoma</e2>
D004967_D015175 CID <e1>estrogen-induced</e1> cells <e2>prolactinoma</e2>
D001971_D015175 NONE <e1>bromocriptine</e1> treatment immunohistochemical microscopic studies <e2>prolactinomas</e2>
D001971_D015175 NONE <e1>bromocriptine</e1> cells <e2>prolactinoma</e2>
D001971_D015175 NONE <e1>bromocriptine</e1> effects clarify applied cells <e2>prolactinoma</e2>
D001971_D015175 NONE <e1>bromocriptine</e1> injection h cells applied clarify effects bromocriptine cells <e2>prolactinoma</e2>
D001971_D015175 NONE <e1>bromocriptine</e1> injection h cells <e2>prolactinoma</e2>
D001971_D000236 NONE <e1>bromocriptine</e1> treatment cells <e2>adenoma</e2>
10669626
D014859_D061205 CID <e1>warfarin-induced</e1> <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin</e1> doses extent <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin-treated</e1> rats <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin</e1> weeks treatment caused calcification media <e2>artery</e2>
D014859_D061205 CID <e1>warfarin</e1> treatment weeks detected <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin-induced</e1> <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin</e1> groups treatment produced calcification media <e2>artery</e2>
D014859_D061205 CID <e1>warfarin</e1> groups treatment produced <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin-induced</e1> calcification resistant groups either was determined explanation association <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin-induced</e1> calcification resistant groups either was relationship phosphate susceptibility <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin-induced</e1> <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin-induced</e1> <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin</e1> d <e2>calcification</e2>
D014859_D061205 CID <e1>warfarin</e1> doses known cause calcification media <e2>artery</e2>
D014859_D061205 CID <e1>warfarin</e1> d treated rats <e2>calcification</e2>
D014807_D061205 NONE <e1>d.</e1> growth accelerated <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> growth enhance extent <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> doses known cause calcification media <e2>artery</e2>
D014807_D061205 NONE <e1>d</e1> dose effect <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> dose effect parallel suggests induce <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> dose effect effect <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> dose effect effect parallel suggests induce <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> induce suggests parallel effect <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> induce <e2>calcification</e2>
D014807_D061205 NONE <e1>d</e1> treated rats <e2>calcification</e2>
D014807_D002114 NONE <e1>d</e1> growth enhance extent inhibit gamma-carboxylation protein inhibitor <e2>calcification</e2>
D014807_D002114 NONE <e1>d-treated</e1> rats media extent <e2>calcification</e2>
D014807_D002114 NONE <e1>d</e1> produced calcium elevation had explained hypothesis inhibits inhibitor <e2>calcification</e2>
D014807_D002114 NONE <e1>d</e1> warfarin synergy best explained hypothesis inhibits inhibitor <e2>calcification</e2>
D014859_D002114 NONE <e1>warfarin</e1> doses extent inhibit gamma-carboxylation protein inhibitor <e2>calcification</e2>
D014859_D002114 NONE <e1>warfarin</e1> weeks treatment caused calcification rats <e2>calcification</e2>
D014859_D002114 NONE <e1>warfarin</e1> administration increased extent <e2>calcification</e2>
D014859_D002114 NONE <e1>warfarin</e1> treatment had explained hypothesis inhibits inhibitor <e2>calcification</e2>
D014859_D002114 NONE <e1>warfarin</e1> synergy best explained hypothesis inhibits inhibitor <e2>calcification</e2>
D014859_D002114 NONE <e1>warfarin</e1> inhibits inhibitor <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> relationship was determined explanation association <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> susceptibility <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> relationship was either groups resistant <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> levels relationship was determined explanation association <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> levels relationship phosphate susceptibility <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> levels relationship was either groups resistant <e2>calcification</e2>
D010710_D061205 NONE <e1>phosphate</e1> levels related susceptibility <e2>calcification</e2>
D014812_D061205 NONE <e1>k</e1> warfarin doses known cause calcification media <e2>artery</e2>
D002118_D061205 NONE <e1>calcium</e1> elevation effect effect <e2>calcification</e2>
D002118_D061205 NONE <e1>calcium</e1> elevation effect effect parallel suggests induce <e2>calcification</e2>
D002118_D061205 NONE <e1>calcium</e1> effect induce suggests parallel effect <e2>calcification</e2>
D002118_D061205 NONE <e1>calcium</e1> effect induce <e2>calcification</e2>
D002118_D002114 NONE <e1>calcium</e1> elevation had explained hypothesis inhibits inhibitor <e2>calcification</e2>
D015055_D061205 NONE <e1>gamma-carboxylated</e1> showed found sites <e2>calcification</e2>
D015055_D002114 NONE <e1>gamma-carboxyglutamate</e1> residues required function inhibitor <e2>calcification</e2>
D015055_D002114 NONE <e1>gamma-carboxyglutamate</e1> residues required required accumulation sites <e2>calcification</e2>
18004067
D000431_D017114 NONE <e1>alcohol</e1> consumption patients <e2>failure</e2>
D000082_D017114 NONE <e1>paracetamol</e1> ingesting patients <e2>failure</e2>
D000431_D056486 NONE <e1>alcohol</e1> role development <e2>hepatotoxicity</e2>
D000082_D056486 CID <e1>paracetamol</e1> doses associated <e2>hepatotoxicity</e2>
D000082_D056486 CID <e1>acetaminophen</e1> role development <e2>hepatotoxicity</e2>
D000082_D056486 CID <e1>paracetamol</e1> doses treated patients <e2>hepatotoxicity</e2>
D000431_D017093 NONE <e1>alcohol</e1> consumers developed <e2>failure</e2>
D000431_D017093 NONE <e1>alcohol</e1> consumption stopping developed <e2>failure</e2>
D000431_D017093 NONE <e1>alcohol</e1> consumption patients possible <e2>failure</e2>
D000082_D017093 CID <e1>paracetamol/day</e1> g treated stopping developed <e2>failure</e2>
17439425
D019820_D006973 NONE <e1>xanthine</e1> oxidase <e2>hypertension</e2>
D019820_D006973 NONE <e1>xanthine</e1> oxidase role <e2>hypertension</e2>
D019820_D006973 NONE <e1>xanthine</e1> oxidase role hypertension <e2>dex-ht</e2>
D003907_D006973 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone-induced</e1> hypertension <e2>dex-ht</e2>
D003907_D006973 CID <e1>dex-ht</e1> <e2>hypertension</e2>
D003907_D006973 CID <e2><e1>dex-ht</e1></e2>
D003907_D006973 CID <e1>dex</e1> increased <e2>sbp</e2>
D003907_D006973 CID <e2><e1>dex-ht</e1></e2>
D009569_D006973 NONE <e1>oxide-redox</e1> imbalance associated <e2>hypertension</e2>
D009569_D006973 NONE <e1>oxide-redox</e1> imbalance associated hypertension <e2>gc-ht</e2>
D003907_D015431 CID <e1>dex</e1> increased thymus <e2>bodyweights</e2>
D000493_D006973 NONE <e1>allopurinol</e1> prevent <e2>dex-ht</e2>
D000493_D006973 NONE <e1>allopurinol</e1> failed prevent <e2>hypertension</e2>
D000493_D006973 NONE <e1>allopurinol</e1> failed findings suggests determinant <e2>gc-ht</e2>
18996674
D004837_D011317 NONE <e1>epinephrine</e1> treatment <e2>priapism</e2>
D003042_D011317 CID <e1>cocaine</e1> user man presented occasions history <e2>priapism</e2>
D003042_D011317 CID <e1>cocaine</e1> use presented occasions history <e2>priapism</e2>
9653867
D013974_D013971 CID <e1>thyroxine</e1> abuse case <e2>thyrotoxicosis</e2>
D013974_D013971 CID <e1>thyroxine</e1> abuse considered remains cause <e2>thyrotoxicosis</e2>
D013974_D001068 NONE <e1>thyroxine</e1> abuse considered reminds illustrates derangements function seen eating <e2>disorders</e2>
2348231
D010431_D006940 NONE <e1>pentoxifylline</e1> inhibit <e2>hyperemia</e2>
D010431_D006940 NONE <e1>trental</e1> pentoxifylline inhibit <e2>hyperemia</e2>
D010431_D006940 NONE <e1>pentoxifylline</e1> inhibits <e2>hyperemia</e2>
D010431_D006940 NONE <e1>pentoxifylline</e1> dose decreased <e2>hyperemia</e2>
D010431_D006940 NONE <e1>pentoxyifylline</e1> inhibit <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-thallium-201</e1> imaging implications inhibit <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-thallium-201</e1> imaging stopped inhibits <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D004176_D006940 CID <e1>dipyridamole-induced</e1> <e2>hyperemia</e2>
D013793_D006940 NONE <e1>dipyridamole-thallium-201</e1> imaging implications inhibit <e2>hyperemia</e2>
D013793_D006940 NONE <e1>dipyridamole-thallium-201</e1> imaging stopped inhibits <e2>hyperemia</e2>
D004176_D016491 NONE <e1>dipyridamole-thallium-201</e1> imaging performed <e2>disease</e2>
D013793_D016491 NONE <e1>dipyridamole-thallium-201</e1> imaging performed <e2>disease</e2>
D010431_D007383 CID <e1>pentoxifylline</e1> derivative improve <e2>claudication</e2>
D010431_D007383 CID <e1>trental</e1> pentoxifylline derivative improve <e2>claudication</e2>
C008514_D007383 NONE <e1>methylxanthine</e1> derivative improve <e2>claudication</e2>
C008514_D006940 NONE <e1>methylxanthines</e1> <e2>hyperemia</e2>
D013806_D006940 NONE <e1>theophylline</e1> methylxanthines <e2>hyperemia</e2>
D013806_D006940 NONE <e1>theophylline</e1> lower decreased <e2>hyperemia</e2>
10807237
D003042_D000783 NONE <e1>cocaine-related</e1> <e2>aneurysms</e2>
D003042_D000783 NONE <e1>cocaine-related</e1> <e2>aneurysms</e2>
D003042_D000783 NONE <e1>cocaine</e1> use age <e2>aneurysms</e2>
D003042_D017542 CID <e1>cocaine</e1> use <e2>rupture</e2>
3865016
D005047_D054218 NONE <e1>etoposide</e1> effect observed patient <e2>leukemia</e2>
D016572_D054218 NONE <e1>a</e1> etoposide effect observed patient <e2>leukemia</e2>
D005047_D017254 NONE <e1>etoposide</e1> administration resulted eradication <e2>infiltration</e2>
D016572_D017254 NONE <e1>a</e1> etoposide administration resulted eradication <e2>infiltration</e2>
3192036
10791295
D001058_D010554 CID <e1>apomorphine-induced</e1> <e2>behavior</e2>
D001058_D010554 CID <e1>apomorphine-induced</e1> development <e2>behavior</e2>
D001058_D010554 CID <e1>apomorphine</e1> treatment induced development <e2>behavior</e2>
D001058_D010554 CID <e1>apomorphine</e1> treatment induced evidenced intensity <e2>aggressiveness</e2>
D001058_D010554 CID <e1>apomorphine-induced</e1> <e2>behavior</e2>
1992636
D009853_D000743 CID <e1>omeprazole</e1> use associated <e2>anemia</e2>
D009853_D000743 CID <e1>omeprazole</e1> use reaction case <e2>anemia</e2>
D009853_D000743 CID <e1>omeprazole</e1> mechanism caused uncertain <e2>anemia</e2>
D009853_D053609 CID <e1>omeprazole</e1> therapy starting developed weakness <e2>lethargy</e2>
D009853_D004417 CID <e1>omeprazole</e1> therapy starting developed weakness shortness <e2>breath</e2>
9660111
D014299_D007035 NONE <e1>tri</e1> experiment antagonize <e2>hypothermia</e2>
D012110_D007035 CID <e1>reserpine</e1> <e2>hypothermia</e2>
D006916_D007035 NONE <e1>5-hydroxytryptophan</e1> head twitches potentiate antagonize <e2>hypothermia</e2>
D014299_D006948 CID <e1>tri</e1> increases <e2>hyperactivity</e2>
D003913_D006948 CID <e1>d-amphetamine</e1> induced <e2>hyperactivity</e2>
D019257_D006948 CID <e1>quinpirole</e1> d-amphetamine induced <e2>hyperactivity</e2>
D004298_D006948 NONE <e1>dopamine</e1> d2 d-amphetamine induced <e2>hyperactivity</e2>
D010656_D010554 NONE <e1>phenylephrine</e1> evoked stimulation increases <e2>aggressiveness</e2>
D003000_D010554 NONE <e1>clonidine</e1> evoked <e2>aggressiveness</e2>
19211690
D013739_D006973 NONE <e1>testosterone-dependent</e1> <e2>hypertension</e2>
D013739_D006973 NONE <e1>testosterone</e1> contributes development <e2>hypertension</e2>
D017673_D006973 NONE <e1>salt-sensitive</e1> rats <e2>hypertension</e2>
D013739_D007674 NONE <e1>testosterone</e1> mediated angiotensinogen upregulation dimorphism causes increases bp <e2>injury</e2>
D013739_D007674 NONE <e1>testosterone</e1> replacement increased bp <e2>injury</e2>
D013739_D007674 NONE <e1>testosterone</e1> contributes development hypertension <e2>injury</e2>
D000809_D006973 NONE <e1>renin-angiotensin</e1> system upregulation contributes development <e2>hypertension</e2>
D000809_D007674 NONE <e1>renin-angiotensin</e1> system upregulation contributes development hypertension <e2>injury</e2>
18410508
D008694_D020258 NONE <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>meth</e1> caused damage selective system models <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>meth</e1> caused damage selective hypothesized plays <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>meth-induced</e1> neurotoxicity plays hypothesized selective system models <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>meth-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>meth</e1> treated examined <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>meth</e1> <e2>neurotoxicity</e2>
D015632_D009422 CID <e1>mptp-induced</e1> <e2>neurodegeneration</e2>
D015632_D009422 CID <e1>mptp</e1> meth caused <e2>damage</e2>
D004298_D009422 NONE <e1>da</e1> neurons <e2>neurodegeneration</e2>
D004298_D009422 NONE <e1>da</e1> system selective <e2>damage</e2>
D008694_D009422 CID <e1>meth</e1> caused <e2>damage</e2>
D008694_D009422 CID <e1>meth-induced</e1> neurotoxicity plays hypothesized selective <e2>damage</e2>
D015632_D020258 NONE <e1>mptp</e1> meth caused damage selective system models <e2>neurotoxicity</e2>
D015632_D020258 NONE <e1>mptp</e1> meth caused damage selective hypothesized plays <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>da</e1> system models <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>da</e1> system selective hypothesized plays <e2>neurotoxicity</e2>
10743446
D007649_D006930 NONE <e1>ketamine</e1> effects dynamic <e2>hyperalgesia</e2>
D007649_D006930 NONE <e1>ketamine</e1> administration effect pain <e2>hyperalgesia</e2>
D007649_D006930 NONE <e1>ketamine</e1> reduced area <e2>hyperalgesia</e2>
D007649_D006930 NONE <e1>ketamine</e1> effects static <e2>hyperalgesia</e2>
D007649_D006930 NONE <e1>ketamine</e1> effects suggest mediated types <e2>hyperalgesia</e2>
D008012_D006930 NONE <e1>lidocaine</e1> ketamine effects dynamic <e2>hyperalgesia</e2>
D008012_D006930 NONE <e1>lidocaine</e1> ketamine administration effect pain <e2>hyperalgesia</e2>
D008012_D006930 NONE <e1>lidocaine</e1> reduced area <e2>hyperalgesia</e2>
D008012_D006930 NONE <e1>lidocaine</e1> ketamine effects static <e2>hyperalgesia</e2>
D008012_D006930 NONE <e1>lidocaine</e1> ketamine effects suggest mediated types <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> induced effects dynamic <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> induced pain <e2>hyperalgesia</e2>
D007649_D010146 NONE <e1>ketamine</e1> administration effect <e2>pain</e2>
D007649_D010146 NONE <e1>ketamine</e1> reduced tended reduce <e2>pain</e2>
D008012_D010146 NONE <e1>lidocaine</e1> ketamine administration effect <e2>pain</e2>
D002211_D010146 CID <e1>capsaicin</e1> induced <e2>pain</e2>
18442015
D014700_D006471 NONE <e1>verapamil</e1> effect ulcers <e2>hemorrhagic</e2>
D014700_D006471 NONE <e1>verapamil</e1> ameliorated ulcer <e2>hemorrhagic</e2>
D014700_D006471 NONE <e1>verapamil</e1> ameliorated permeability aggravation produce ulcer <e2>hemorrhagic</e2>
D014700_D014456 NONE <e1>verapamil</e1> effect <e2>ulcers</e2>
D014700_D014456 NONE <e1>verapamil</e1> effect model <e2>ulcer</e2>
D014700_D014456 NONE <e1>verapamil</e1> ameliorated <e2>ulcer</e2>
D014700_D014456 NONE <e1>verapamil</e1> ameliorated permeability aggravation produce <e2>ulcer</e2>
D014700_D050197 NONE <e1>verapamil</e1> effect ulcers rats <e2>atherosclerotic</e2>
D014700_D050197 NONE <e1>verapamil</e1> ameliorated permeability aggravation produce <e2>atherosclerosis</e2>
D006632_D006471 NONE <e1>histamine</e1> release role examine modulating <e2>hemorrhage</e2>
D006632_D006471 NONE <e1>histamine</e1> correlation <e2>hemorrhage</e2>
D006632_D006471 NONE <e1>histamine</e1> release aggravation produce ulcer <e2>hemorrhagic</e2>
D006632_D014456 NONE <e1>histamine</e1> release role examine modulating hemorrhage <e2>ulcer</e2>
D006632_D014456 NONE <e1>histamine</e1> concentration back-diffusion permeability areas <e2>ulcer</e2>
D006632_D014456 NONE <e1>histamine</e1> release back-diffusion factors accompanied <e2>ulcers</e2>
D006632_D014456 NONE <e1>histamine</e1> correlation <e2>ulcer</e2>
D006632_D014456 NONE <e1>histamine</e1> release aggravation produce <e2>ulcer</e2>
D006632_D050197 NONE <e1>histamine</e1> release role examine modulating hemorrhage ulcer rats <e2>atherosclerosis</e2>
D006632_D050197 NONE <e1>histamine</e1> correlation found rats <e2>atherosclerotic</e2>
D006632_D050197 NONE <e1>histamine</e1> release aggravation produce <e2>atherosclerosis</e2>
D004872_D006471 CID <e1>d2</e1> coadministration induced atherosclerosis rats ulcer <e2>hemorrhage</e2>
D004872_D014456 CID <e1>d2</e1> coadministration induced atherosclerosis rats <e2>ulcer</e2>
D004872_D050197 CID <e1>d2</e1> coadministration induced <e2>atherosclerosis</e2>
D004872_D050197 CID <e1>d2</e1> containing oil ml/kg days challenged induce <e2>atherosclerosis</e2>
D002784_D006471 CID <e1>cholesterol</e1> d2 coadministration induced atherosclerosis rats ulcer <e2>hemorrhage</e2>
D002784_D014456 CID <e1>cholesterol</e1> d2 coadministration induced atherosclerosis rats <e2>ulcer</e2>
D002784_D050197 CID <e1>cholesterol</e1> d2 coadministration induced <e2>atherosclerosis</e2>
D002784_D050197 CID <e1>cholesterol</e1> d2 containing oil ml/kg days challenged induce <e2>atherosclerosis</e2>
D002784_D050197 CID <e1>cholesterol</e1> calcium parameters <e2>atherosclerotic</e2>
D002784_D050197 CID <e1>cholesterol</e1> calcium parameters obtained rats <e2>atherosclerotic</e2>
D010634_D014456 NONE <e1>luminal</e1> content permeability areas <e2>ulcer</e2>
D010634_D014456 NONE <e1>luminal</e1> content back-diffusion factors accompanied <e2>ulcers</e2>
D002118_D050197 NONE <e1>calcium</e1> parameters <e2>atherosclerotic</e2>
D002118_D050197 NONE <e1>calcium</e1> parameters obtained rats <e2>atherosclerotic</e2>
6286738
D002762_D064420 NONE <e1>d3</e1> <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> toxicity signs observed developed signs <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> toxicity signs developed observed signs <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> doses margin cows <e2>toxicity</e2>
D002762_D064420 NONE <e1>d3</e1> used concluded <e2>toxicity</e2>
D002762_D006934 CID <e1>d3</e1> doses associated <e2>hypercalcemia</e2>
D002762_D006934 CID <e1>d3</e1> doses associated <e2>hypercalcemia</e2>
D002762_D006934 CID <e1>d3</e1> increases <e2>hypercalcemia</e2>
D002762_D054559 CID <e1>d3</e1> doses associated hypercalcemia <e2>hyperphosphatemia</e2>
D002762_D054559 CID <e1>d3</e1> doses associated hypercalcemia <e2>hyperphosphatemia</e2>
D002762_D054559 CID <e1>d3</e1> increases hypercalcemia <e2>hyperphosphatemia</e2>
D002762_D010319 NONE <e1>d3</e1> treated cows none showed signs <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> treated cows none showed cows developed signs <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> toxicity cows margin doses prevent <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> toxicity cows margin doses prevent doses induce <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> toxicity concluded used prevent <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> doses prevent <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> doses prevent doses induce <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> doses margin cows toxicity concluded used prevent <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> used concluded toxicity cows margin doses prevent <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> used concluded toxicity cows margin doses prevent doses induce <e2>fever</e2>
D002762_D010319 NONE <e1>d3</e1> used prevent <e2>fever</e2>
603022
D005702_D062787 NONE <e1>hydrobromide</e1> used patient demonstrating effects <e2>overdosage</e2>
D012601_D062787 CID <e1>scopolamine</e1> <e2>overdosage</e2>
D012601_D062787 CID <e1>hyoscine</e1> <e2>overdosage</e2>
1601297
D003042_D009202 NONE <e1>cocaine</e1> abusers <e2>injury</e2>
D003042_D009202 NONE <e1>cocaine</e1> abusers eleven had evidence <e2>injury</e2>
D003042_D012559 NONE <e1>cocaine-abusing</e1> patients electrocardiograms compared ecgs controls <e2>schizophrenic</e2>
D003042_D009203 CID <e1>cocaine</e1> abusers eleven had evidence injury defined <e2>infarction</e2>
D003042_D007511 NONE <e1>cocaine</e1> abusers eleven had evidence injury defined infarction <e2>ischemia</e2>
D003042_D002037 CID <e1>cocaine</e1> abusers eleven had bundle <e2>block</e2>
8643971
D017239_D006258 NONE <e1>paclitaxel</e1> study therapy head <e2>cancers</e2>
D017239_D006258 NONE <e1>paclitaxel</e1> study results reported rate patients head <e2>cancer</e2>
D017239_D006258 NONE <e1>taxol</e1> company study results reported rate patients head <e2>cancer</e2>
D017239_D006258 NONE <e1>paclitaxel/cisplatin</e1> combination used reported rate patients head <e2>cancer</e2>
D017239_D006258 NONE <e1>paclitaxel</e1> doses escalating response combined support patients head <e2>carcinoma</e2>
D017239_D006258 NONE <e1>paclitaxel/cisplatin</e1> regimen head <e2>cancer</e2>
D002945_D006258 NONE <e1>cisplatin</e1> paclitaxel study therapy head <e2>cancers</e2>
D002945_D006258 NONE <e1>paclitaxel/cisplatin</e1> combination used reported rate patients head <e2>cancer</e2>
D002945_D006258 NONE <e1>cisplatin</e1> combined support patients head <e2>carcinoma</e2>
D002945_D006258 NONE <e1>paclitaxel/cisplatin</e1> regimen head <e2>cancer</e2>
D017239_D010051 NONE <e1>paclitaxel</e1> study results reported used improved duration patients <e2>cancer</e2>
D017239_D010051 NONE <e1>taxol</e1> company study results reported used improved duration patients <e2>cancer</e2>
D017239_D010051 NONE <e1>paclitaxel/cisplatin</e1> combination used improved duration patients <e2>cancer</e2>
D002945_D010051 NONE <e1>paclitaxel/cisplatin</e1> combination used improved duration patients <e2>cancer</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> doses escalating response <e2>toxicity</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> doses escalating incorporate permitted permits <e2>toxicity</e2>
D002945_D064420 NONE <e1>cisplatin</e1> combined response <e2>toxicity</e2>
9523805
D011318_D009422 CID <e1>prilocaine</e1> incidence <e2>symptoms</e2>
D011318_D009422 CID <e1>prilocaine</e1> compares bupivacaine respect duration action <e2>tnss</e2>
D011318_D009422 CID <e1>prilocaine</e1> receiving patients nine patients receiving <e2>tnss</e2>
D011318_D009422 CID <e1>prilocaine</e1> receiving patients nine had had <e2>tnss</e2>
D011318_D009422 CID <e1>prilocaine</e1> preferable has duration incidence <e2>tnss</e2>
D002045_D009422 NONE <e1>bupivacaine</e1> prilocaine incidence <e2>symptoms</e2>
D002045_D009422 NONE <e1>bupivacaine</e1> infrequent follow <e2>symptoms</e2>
D002045_D009422 NONE <e1>bupivacaine</e1> infrequent follow symptoms <e2>tnss</e2>
D002045_D009422 NONE <e1>bupivacaine</e1> respect duration action <e2>tnss</e2>
D002045_D009422 NONE <e1>bupivacaine</e1> receiving patients none had had nine patients receiving <e2>tnss</e2>
D002045_D009422 NONE <e1>bupivacaine</e1> receiving patients none had <e2>tnss</e2>
D008012_D009422 CID <e1>lidocaine</e1> than incidence <e2>symptoms</e2>
D008012_D009422 CID <e1>lidocaine</e1> anesthesia follow <e2>symptoms</e2>
D008012_D009422 CID <e1>lidocaine</e1> anesthesia follow symptoms <e2>tnss</e2>
D008012_D009422 CID <e1>lidocaine</e1> compares bupivacaine respect duration action <e2>tnss</e2>
D008012_D009422 CID <e1>lidocaine</e1> <e2>tnss</e2>
D008012_D009422 CID <e1>lidocaine</e1> tnss receiving patients nine had had <e2>tnss</e2>
D008012_D009422 CID <e1>lidocaine</e1> preferable has duration incidence <e2>tnss</e2>
16167916
D020849_D054556 CID <e1>raloxifene</e1> treatment risk <e2>thromboembolism</e2>
8092427
D000658_D004342 CID <e1>amoxicillin</e1> <e2>reactions</e2>
D000658_D004342 CID <e1>amoxicillin</e1> responses had patients <e2>allergic</e2>
D000658_D004342 CID <e1>amoxicillin</e1> responses <e2>allergic</e2>
D000658_D004342 CID <e1>ax</e1> amoxicillin responses had patients <e2>allergic</e2>
D000658_D004342 CID <e1>ax</e1> amoxicillin responses <e2>allergic</e2>
D000658_D004342 CID <e1>ax</e1> <e2>allergy</e2>
D000658_D004342 CID <e1>ax</e1> tests performed establish diagnosis <e2>reaction</e2>
D000658_D004342 CID <e1>ax</e1> <e2>reaction</e2>
D000658_D004342 CID <e1>ax</e1> test performed establish diagnosis <e2>reaction</e2>
D000658_D004342 CID <e2><e1>ax-allergic</e1></e2>
D047090_D004342 NONE <e1>beta-lactam</e1> antibiotics <e2>reactions</e2>
D047090_D004342 NONE <e1>beta-lactam</e1> antibiotics <e2>allergic</e2>
D047090_D004342 NONE <e1>beta-lactam</e1> antibiotics allergic patients had responses <e2>allergic</e2>
D047090_D004342 NONE <e1>beta-lactam</e1> antibiotics <e2>allergic</e2>
D010406_D004342 NONE <e1>penicillin</e1> derivatives cross-reacting had patients <e2>allergic</e2>
D010406_D004342 NONE <e1>penicillin</e1> derivatives cross-reacting had responses <e2>allergic</e2>
D010400_D004342 NONE <e1>pg</e1> tolerance cases <e2>allergy</e2>
D010400_D004342 NONE <e1>pg</e1> tolerated patients <e2>ax-allergic</e2>
-1_D007645 NONE <e1>bpo</e1> negative test negative <e2>mdm</e2>
D010400_D007645 NONE <e1>pg</e1> negative <e2>mdm</e2>
11807648
D014148_D004827 NONE <e1>acid</e1> containing sealants application <e2>seizures</e2>
D014148_D004827 NONE <e1>tamca</e1> shown cause <e2>seizures</e2>
D014148_D012640 CID <e1>tamca</e1> retains action <e2>convulsive</e2>
D014148_D012640 CID <e1>tamca</e1> containing fs caused activity associated behaviours <e2>convulsive</e2>
D014148_D012640 CID <e1>tamca</e1> concentration increased degree <e2>seizures</e2>
D014148_D012640 CID <e1>tamca</e1> containing fs evoked <e2>seizures</e2>
D014148_D012640 CID <e1>tamca</e1> containing fs evoked evoked episodes potentials <e2>convulsive</e2>
D014148_D012640 CID <e1>tamca</e1> concentration evoked evoked <e2>seizures</e2>
D014148_D012640 CID <e1>tamca</e1> concentration evoked episodes potentials <e2>convulsive</e2>
D014148_D012640 CID <e1>acid</e1> retains action <e2>convulsive</e2>
3101906
D007654_D003643 NONE <e1>ketoconazole</e1> treatment associated <e2>deaths</e2>
D007654_D007565 CID <e1>ketoconazole</e1> treatment associated deaths two continued onset <e2>jaundice</e2>
D007654_D056486 CID <e1>ketoconazole</e1> treatment associated deaths two continued onset jaundice symptoms <e2>hepatitis</e2>
D007654_D056486 CID <e1>ketoconazole</e1> treatment advised monitoring evidence <e2>hepatitis</e2>
D007654_D056486 CID <e1>ketoconazole</e1> treatment advised prevent <e2>injury</e2>
17244258
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
26094
D008750_D003866 CID <e1>dopa</e1> treated patients occurring <e2>depressions</e2>
D008750_D001523 NONE <e1>dopa</e1> treated patients histories <e2>psychiatric</e2>
1428568
D013999_D005901 NONE <e1>timolol</e1> 0.5%/12h treated patients <e2>glaucomatous</e2>
D013999_D003866 CID <e1>timolol</e1> 0.5%/12h treated patients suffering <e2>depression</e2>
D013999_D003866 CID <e1>timolol</e1> treatment patients presented values <e2>depression</e2>
D013999_D003866 CID <e1>timolol</e1> less <e2>depression-inducer</e2>
D015784_D003866 NONE <e1>betaxolol</e1> less <e2>depression-inducer</e2>
20722491
-1_D009369 NONE <e1>fluoropyrimidines</e1> importance mainstay treatment <e2>tumors</e2>
-1_D015179 NONE <e1>fluoropyrimidines</e1> importance mainstay treatment tumors colorectal <e2>cancers</e2>
-1_D001943 NONE <e1>fluoropyrimidines</e1> importance mainstay treatment tumors colorectal <e2>cancers</e2>
-1_D006258 NONE <e1>fluoropyrimidines</e1> importance mainstay treatment tumors colorectal <e2>cancers</e2>
D005472_D009369 NONE <e1>5-fluorouracil</e1> fluoropyrimidines importance mainstay treatment <e2>tumors</e2>
D005472_D009369 NONE <e1>5-fu</e1> 5-fluorouracil fluoropyrimidines importance mainstay treatment <e2>tumors</e2>
D005472_D015179 NONE <e1>5-fluorouracil</e1> fluoropyrimidines importance mainstay treatment tumors colorectal <e2>cancers</e2>
D005472_D015179 NONE <e1>5-fu</e1> 5-fluorouracil fluoropyrimidines importance mainstay treatment tumors colorectal <e2>cancers</e2>
D005472_D001943 NONE <e1>5-fluorouracil</e1> fluoropyrimidines importance mainstay treatment tumors colorectal <e2>cancers</e2>
D005472_D001943 NONE <e1>5-fu</e1> 5-fluorouracil fluoropyrimidines importance mainstay treatment tumors colorectal <e2>cancers</e2>
D005472_D006258 NONE <e1>5-fluorouracil</e1> fluoropyrimidines importance mainstay treatment tumors colorectal <e2>cancers</e2>
D005472_D006258 NONE <e1>5-fu</e1> 5-fluorouracil fluoropyrimidines importance mainstay treatment tumors colorectal <e2>cancers</e2>
C110904_D007674 NONE <e1>capecitabine</e1> safety populations patients <e2>disease</e2>
C110904_D007674 NONE <e1>capecitabine</e1> has given patients <e2>dysfunctions</e2>
C110904_D003967 CID <e1>capecitabine</e1> effects reported <e2>diarrhea</e2>
C110904_D009325 CID <e1>capecitabine</e1> effects reported diarrhea <e2>nausea</e2>
C110904_D014839 CID <e1>capecitabine</e1> effects reported diarrhea nausea <e2>vomiting</e2>
C110904_D013280 CID <e1>capecitabine</e1> effects reported diarrhea nausea vomiting <e2>stomatitis</e2>
C110904_D060831 CID <e1>capecitabine</e1> effects reported diarrhea <e2>syndrome</e2>
C110904_D008107 NONE <e1>capecitabine</e1> has given patients <e2>dysfunctions</e2>
9855119
D016559_D005922 NONE <e1>fk506</e1> nephropathy rejection <e2>nephropathy</e2>
D016559_D005922 NONE <e1>fk506</e1> nephropathy rejection <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> nephropathy rejection <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> nephropathy rejection <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> group <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> group patients levels higher those group <e2>fk506-nephropathy</e2>
D016559_D007674 NONE <e1>fk506-nephropathy</e1> group those higher levels patients group <e2>nephropathy</e2>
D016559_D007674 NONE <e2><e1>fk506-nephropathy</e1></e2>
D016559_D007674 NONE <e1>fk506</e1> <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> nephropathy consists demonstrates suggests condition <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> nephropathy condition suggests demonstrates consists <e2>nephropathy</e2>
D016559_D007674 NONE <e1>fk506</e1> <e2>nephropathy</e2>
D016559_D005923 CID <e1>fk506</e1> nephropathy consisted vacuolization <e2>glomerulosclerosis</e2>
D016559_D005355 NONE <e1>fk506</e1> nephropathy consisted vacuolization form <e2>fibrosis</e2>
D003404_D007674 NONE <e1>creatinine</e1> levels patients group <e2>nephropathy</e2>
D003404_D007674 NONE <e1>creatinine</e1> levels higher those group <e2>fk506-nephropathy</e2>
16755009
D003975_D000647 CID <e1>diazepam-</e1> <e2>amnesia</e2>
D003975_D000647 CID <e1>diazepam</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-</e1> diazepam- <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> induced <e2>amnesia</e2>
D010936_D000647 NONE <e1>dce</e1> reversed <e2>amnesia</e2>
D010936_D003072 NONE <e1>dce</e1> prove remedy management <e2>dysfunctions</e2>
D002784_D003072 NONE <e1>cholesterol</e1> activity remedy management <e2>dysfunctions</e2>
19843802
D004837_D006973 CID <e1>epinephrine</e1> bolus provoked crisis <e2>hypertensive</e2>
6534871
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
7449470
D004317_D066126 NONE <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>adriamycin</e1> use limits complication <e2>toxicity</e2>
11419773
D002110_D001145 NONE <e1>caffeine-induced</e1> <e2>arrhythmia</e2>
D002110_D008945 NONE <e1>caffeine</e1> concentration containing drink describe woman <e2>prolapse</e2>
D002110_D014693 CID <e1>caffeine</e1> concentration containing drink describe woman prolapse developed <e2>fibrillation</e2>
6287825
D013831_D010523 CID <e1>thiamine</e1> deficiency <e2>neuropathy</e2>
D013831_D010523 CID <e1>thiamine</e1> deficiency neuropathy common presented sensory <e2>neuropathy</e2>
D013831_D044342 NONE <e1>thiamine</e1> <e2>deficiency</e2>
D012256_D010523 CID <e1>riboflavin</e1> thiamine deficiency <e2>neuropathy</e2>
D012256_D010523 CID <e1>riboflavin</e1> thiamine deficiency neuropathy common presented sensory <e2>neuropathy</e2>
D012256_D044342 NONE <e1>riboflavin</e1> thiamine <e2>deficiency</e2>
D007538_D009422 NONE <e1>isoniazid</e1> agent <e2>neuropathy</e2>
19820426
C558899_D066126 NONE <e1>lopinavir/ritonavir</e1> therapy related <e2>toxicity</e2>
C558899_D006327 CID <e1>lopinavir/ritonavir</e1> therapy related dilated developed <e2>block</e2>
C558899_D002311 CID <e1>lopinavir/ritonavir</e1> therapy related <e2>cardiomyopathy</e2>
C558899_D001919 CID <e1>lopinavir/ritonavir</e1> therapy related dilated developed developed <e2>bradycardia</e2>
9766615
D003024_D001480 NONE <e1>clozapine</e1> threshold lowered have risk <e2>eps</e2>
D003024_D001480 NONE <e1>clozapine</e1> lowered have risk <e2>eps</e2>
D003024_D015430 NONE <e1>clozapine</e1> threshold lowered have effects effects <e2>gain</e2>
D003024_D015430 NONE <e1>clozapine</e1> lowered have effects effects <e2>gain</e2>
D003024_D012735 NONE <e1>clozapine</e1> threshold lowered have effects <e2>dysfunction</e2>
D003024_D012735 NONE <e1>clozapine</e1> lowered have effects <e2>dysfunction</e2>
D003024_D012640 NONE <e1>clozapine</e1> threshold <e2>seizure</e2>
D003024_D012640 NONE <e1>clozapine</e1> lowered threshold <e2>seizure</e2>
D003024_D000380 CID <e1>clozapine</e1> threshold <e2>agranulocytosis</e2>
D003024_D000380 CID <e1>clozapine</e1> lowered threshold <e2>agranulocytosis</e2>
16330766
C040029_D009437 NONE <e1>gabapentin</e1> drug effective patients <e2>pain</e2>
C040029_D006930 NONE <e1>gabapentin-induced</e1> modulation response stimulation skin <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin-induced</e1> <e2>hyperalgesia</e2>
6640832
D004317_D001749 NONE <e1>adriamycin</e1> <e2>carcinoma</e2>
D004317_D001749 NONE <e1>adriamycin</e1> administered resection <e2>tumors</e2>
D004317_D002277 NONE <e1>adriamycin</e1> <e2>carcinoma</e2>
8421099
D015282_D042882 CID <e1>octreotide</e1> analog effects function formation <e2>gallstone</e2>
D015282_D042882 CID <e1>octreotide</e1> withdrawal patients <e2>gallstones</e2>
D015282_D042882 CID <e1>octreotide</e1> therapy cholecystitis sludge <e2>gallstones</e2>
D015282_D000172 NONE <e1>octreotide</e1> analog effects function patients <e2>acromegalic</e2>
D015282_D000172 NONE <e1>octreotide</e1> injection treated <e2>acromegaly</e2>
D015282_D000172 NONE <e1>octreotide</e1> therapy patients <e2>acromegalic</e2>
D015282_D000172 NONE <e1>octreotide</e1> therapy patients <e2>acromegalic</e2>
D015282_D002764 NONE <e1>octreotide</e1> therapy <e2>cholecystitis</e2>
7453952
D008094_D003919 CID <e1>lithium-induced</e1> <e2>syndrome</e2>
D008094_D003919 CID <e1>lithium-induced</e1> <e2>syndrome</e2>
D008094_D003919 CID <e1>lithium</e1> concentration ratio reduction accompanied attenuation <e2>syndrome</e2>
D000584_D003919 NONE <e1>amiloride</e1> attenuation <e2>syndrome</e2>
D000584_D003919 NONE <e1>amiloride</e1> attenuation <e2>syndrome</e2>
D000584_D059606 NONE <e1>amiloride</e1> effect <e2>polydipsia</e2>
D000584_D059606 NONE <e1>amiloride</e1> administration patients suffering <e2>polydipsia</e2>
D000584_D059606 NONE <e1>amiloride</e1> supplementation patients relieve administration patients suffering <e2>polydipsia</e2>
D000584_D011141 NONE <e1>amiloride</e1> effect polydipsia <e2>polyuria</e2>
D000584_D011141 NONE <e1>amiloride</e1> administration patients suffering <e2>polyuria</e2>
D000584_D011141 NONE <e1>amiloride</e1> supplementation patients relieve administration patients suffering <e2>polyuria</e2>
D008094_D059606 NONE <e1>lithium-induced</e1> <e2>polydipsia</e2>
D008094_D059606 NONE <e1>lithium</e1> concentration effect <e2>polydipsia</e2>
D008094_D059606 NONE <e1>lithium-treated</e1> patients suffering <e2>polydipsia</e2>
D008094_D059606 NONE <e1>lithium</e1> levels result concluded relieve administration patients suffering <e2>polydipsia</e2>
D008094_D011141 NONE <e1>lithium-induced</e1> polydipsia <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium</e1> concentration effect polydipsia <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium-treated</e1> patients suffering <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium</e1> levels result concluded relieve administration patients suffering <e2>polyuria</e2>
D018021_D059606 NONE <e1>licl</e1> treated investigated effect <e2>polydipsia</e2>
D018021_D011141 NONE <e1>licl</e1> treated investigated effect polydipsia <e2>polyuria</e2>
D011188_D003919 NONE <e1>potassium</e1> level elevation levels reduction accompanied attenuation <e2>syndrome</e2>
3564823
D008012_D013035 NONE <e1>lidocaine</e1> relieved <e2>spasm</e2>
D013874_D002545 NONE <e1>pentothal</e1> infused minimize <e2>ischaemia</e2>
D008012_D020301 NONE <e1>lidocaine</e1> given counteract <e2>vasospasm</e2>
2304736
D011224_D014550 CID <e1>prazosin-induced</e1> <e2>incontinence</e2>
D011224_D014550 CID <e1>prazosin</e1> case <e2>incontinence</e2>
D011224_D014550 CID <e1>prazosin</e1> taking present <e2>incontinence</e2>
D011224_D014549 NONE <e1>prazosin</e1> taking present patients change resolve <e2>incontinence</e2>
4071154
D007213_D051437 NONE <e1>indomethacin-induced</e1> <e2>insufficiency</e2>
D007213_D051437 NONE <e1>indomethacin</e1> therapy pulmonale cirrhosis patient <e2>failure</e2>
D007213_D006947 CID <e1>indomethacin</e1> therapy pulmonale cirrhosis patient failure <e2>hyperkalemia</e2>
D007213_D005355 CID <e1>indomethacin</e1> therapy pulmonale <e2>cirrhosis</e2>
D007213_D001201 CID <e1>indomethacin</e1> therapy pulmonale cirrhosis <e2>ascites</e2>
D007213_D011660 CID <e1>indomethacin</e1> therapy <e2>pulmonale</e2>
D007213_D009846 CID <e1>indomethacin</e1> dose re-exposure followed caused recurrence <e2>oliguria</e2>
3800626
D010423_D009408 CID <e1>pentazocine-induced</e1> myopathy neuropathy <e2>nerve</e2>
D010423_D009408 CID <e1>pentazocine-induced</e1> myopathy affected <e2>neuropathy</e2>
D010423_D020425 CID <e1>pentazocine-induced</e1> myopathy neuropathy <e2>nerve</e2>
D010423_D005355 CID <e1>pentazocine-induced</e1> <e2>myopathy</e2>
D010423_D005355 CID <e1>pentazocine</e1> injection effect <e2>myopathy</e2>
D010423_D005355 CID <e1>pentazocine-induced</e1> <e2>myopathy</e2>
D010423_D005355 CID <e1>pentazocine-induced</e1> myopathy woman showed addition <e2>myopathy</e2>
D010423_D009135 CID <e1>pentazocine-induced</e1> <e2>myopathy</e2>
D010423_D009135 CID <e1>pentazocine</e1> injection effect <e2>myopathy</e2>
D010423_D009135 CID <e1>pentazocine-induced</e1> <e2>myopathy</e2>
D010423_D009135 CID <e1>pentazocine-induced</e1> <e2>myopathy</e2>
D010423_D009135 CID <e1>pentazocine-induced</e1> myopathy woman showed addition <e2>myopathy</e2>
15804801
D017239_D003323 CID <e1>paclitaxel-eluting</e1> stent implantation <e2>aneurysm</e2>
D017239_D003323 CID <e1>paclitaxel-eluting</e1> stent receiving developed <e2>aneurysm</e2>
11773892
D016572_D007674 CID <e1>cyclosporine</e1> inhibitors known <e2>nephrotoxic</e2>
D016559_D007674 CID <e1>tacrolimus</e1> cyclosporine inhibitors known <e2>nephrotoxic</e2>
D003404_D007676 NONE <e1>creatinine</e1> crf divided groups controls <e2>crf</e2>
D003404_D007676 NONE <e1>creatinine</e1> crf divided groups controls crf <e2>esrd</e2>
D003404_D007676 NONE <e1>creatinine</e1> <e2>crf</e2>
D003404_D007676 NONE <e1>creatinine</e1> crf <e2>esrd</e2>
D003404_D007676 NONE <e1>creatinine</e1> levels had patients <e2>crf</e2>
D003404_D007676 NONE <e1>creatinine</e1> levels had patients <e2>esrd</e2>
D003404_D007676 NONE <e1>creatinine</e1> had patients <e2>crf</e2>
D003404_D007676 NONE <e1>creatinine</e1> had patients <e2>esrd</e2>
D003404_D007676 NONE <e1>creatinine</e1> increase factors development <e2>crf</e2>
D003404_D007676 NONE <e1>creatinine</e1> increase factors development crf <e2>esrd</e2>
D003404_D007676 NONE <e1>creatinine</e1> have patients develop <e2>esrd</e2>
D003404_D007676 NONE <e1>creatinine</e1> increase predictive development <e2>crf</e2>
D003404_D007676 NONE <e1>creatinine</e1> increase predictive development crf <e2>esrd</e2>
D003404_D006530 NONE <e1>creatinine</e1> levels percentage patients <e2>syndrome</e2>
D003404_D006530 NONE <e1>creatinine</e1> had levels percentage patients <e2>syndrome</e2>
D003404_D006530 NONE <e1>creatinine</e1> have likely have <e2>syndrome</e2>
17466854
D008775_D002386 NONE <e1>methylprednisolone</e1> administration end surgery <e2>cataract</e2>
D005839_D002386 NONE <e1>gentamicin</e1> methylprednisolone administration end surgery <e2>cataract</e2>
D008775_D020250 CID <e1>methylprednisolone</e1> administration related incidence effects nausea <e2>vomiting</e2>
D008775_D006261 CID <e1>methylprednisolone</e1> administration related incidence effects nausea <e2>headache</e2>
D005839_D020250 CID <e1>gentamicin</e1> methylprednisolone administration related incidence effects nausea <e2>vomiting</e2>
D005839_D006261 CID <e1>gentamicin</e1> methylprednisolone administration related incidence effects nausea <e2>headache</e2>
8590259
C016986_D015814 CID <e1>apraclonidine-treated</e1> eyes significant effects <e2>hypotensive</e2>
C016986_D015814 CID <e1>apraclonidine</e1> administration significant significant effects <e2>hypotensive</e2>
14568327
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias <e2>lids</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy duration rate degree evaluated involved development <e2>lids</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy initiation monkeys developed <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> administration days <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy initiation monkeys resistant developing <e2>lids</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy initiation monkeys resistant developed <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> administration days developed resistant developing <e2>lids</e2>
D007980_D004409 CID <e1>levodopa</e1> administration days developed <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> prior develop <e2>lids</e2>
D007980_D004409 CID <e1>levodopa</e1> prior develop demonstrate studying pathophysiology <e2>lids</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias development monkeys <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias present problem management patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias present problem management patients disease <e2>pd</e2>
D015632_D010302 CID <e1>mptp-induced</e1> <e2>parkinsonism</e2>
D015632_D004409 NONE <e1>mptp-induced</e1> parkinsonism types using evaluated involved development <e2>lids</e2>
D015632_D004409 NONE <e1>mptp</e1> exposure monkeys developed <e2>dyskinesia</e2>
D015632_D004409 NONE <e1>mptp</e1> exposure monkeys resistant developing <e2>lids</e2>
D015632_D004409 NONE <e1>mptp</e1> exposure monkeys resistant developed <e2>dyskinesia</e2>
D007980_D010302 NONE <e1>levodopa</e1> therapy duration rate degree evaluated using types <e2>parkinsonism</e2>
9522143
D011318_D034381 CID <e1>prilocaine</e1> patients likely develop <e2>loss</e2>
D011318_D034381 CID <e1>prilocaine</e1> db <e2>loss</e2>
D002045_D034381 CID <e1>bupivacaine</e1> likely develop <e2>loss</e2>
D002045_D034381 CID <e1>bupivacaine</e1> db db <e2>loss</e2>
15233872
C007145_D009203 NONE <e1>crataegus</e1> tincture effect <e2>infarction</e2>
C007145_D009203 NONE <e1>tcr</e1> effect <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
1378968
D008094_D007676 CID <e1>lithium-induced</e1> <e2>failure</e2>
D008094_D007674 NONE <e1>lithium-induced</e1> <e2>nephropathy</e2>
D008094_D007674 NONE <e1>li-induced</e1> <e2>nephropathy</e2>
D008094_D051437 NONE <e1>lithium-induced</e1> nephropathy rats subjected attempt induce hyperfiltration <e2>failure</e2>
D008094_D051437 NONE <e1>lithium</e1> rats decrease increase tended failed accentuante progression <e2>failure</e2>
D008094_D011507 CID <e1>lithium</e1> caused <e2>proteinuria</e2>
D008094_D011507 CID <e1>li-induced</e1> nephropathy associated <e2>proteinuria</e2>
D008094_D006973 CID <e1>lithium</e1> caused proteinuria <e2>hypertension</e2>
D008094_D006973 CID <e1>li-induced</e1> nephropathy associated proteinuria <e2>hypertension</e2>
D008094_D005921 NONE <e1>lithium</e1> caused absence <e2>glomerulosclerosis</e2>
D003404_D051437 NONE <e1>creatinine</e1> levels decrease increase tended failed accentuante progression <e2>failure</e2>
3503576
D003676_D006311 NONE <e1>deferoxamine</e1> therapy receiving patients <e2>neurotoxicity</e2>
D003676_D006311 NONE <e1>deferoxamine</e1> therapy receiving patients documented <e2>neurotoxicity</e2>
D003676_D006311 NONE <e1>deferoxamine</e1> doses receiving restarted degree <e2>abnormality</e2>
D003676_D006311 NONE <e1>deferoxamine</e1> receiving patients demonstrated evidence relation administration <e2>ototoxicity</e2>
D003676_D006311 NONE <e1>deferoxamine</e1> administration <e2>ototoxicity</e2>
D007501_D014786 NONE <e1>iron</e1> therapy receiving patients documented <e2>neurotoxicity</e2>
D007501_D006311 NONE <e1>iron</e1> therapy receiving patients documented <e2>neurotoxicity</e2>
D007501_D000740 NONE <e1>iron</e1> therapy receiving patients <e2>anemia</e2>
D003676_D014786 NONE <e1>deferoxamine</e1> therapy receiving patients documented <e2>neurotoxicity</e2>
D003676_D000740 NONE <e1>deferoxamine</e1> therapy receiving patients <e2>anemia</e2>
D003676_D064420 NONE <e1>deferoxamine</e1> doses receiving restarted exception cases demonstrated <e2>toxicity</e2>
7628595
D014805_D064420 NONE <e1>b12</e1> role study supplementation preventing <e2>toxicity</e2>
D002955_D064420 NONE <e1>acid</e1> supplementation preventing <e2>toxicity</e2>
D015215_D064420 NONE <e1>zidovudine</e1> <e2>toxicity</e2>
D014805_D001855 NONE <e1>b12</e1> role supplementation preventing <e2>suppression</e2>
D014805_D001855 NONE <e1>b12</e1> correlation was folate levels development <e2>myelosuppression</e2>
D014805_D001855 NONE <e1>b12</e1> seem preventing reducing <e2>myelotoxicity</e2>
D002955_D001855 NONE <e1>acid</e1> supplementation preventing <e2>suppression</e2>
D002955_D001855 NONE <e1>acid</e1> supplementation b12 seem preventing reducing <e2>myelotoxicity</e2>
D015215_D001855 CID <e1>zidovudine</e1> <e2>suppression</e2>
D015215_D001855 CID <e1>(zdv)-induced</e1> <e2>suppression</e2>
D015215_D001855 CID <e1>zdv</e1> therapy supplementation b12 seem preventing reducing <e2>myelotoxicity</e2>
D015215_D001855 CID <e1>zdv-induced</e1> <e2>myelotoxicity</e2>
D015215_D015658 NONE <e1>zdv</e1> receive randomized patients <e2>(hiv)-infected</e2>
D002955_D015658 NONE <e1>acid</e1> combination receive randomized patients <e2>(hiv)-infected</e2>
D014805_D015658 NONE <e1>b12</e1> combination receive randomized patients <e2>(hiv)-infected</e2>
D005492_D001855 NONE <e1>folate</e1> levels development <e2>myelosuppression</e2>
16298782
D019331_D006311 NONE <e1>ester</e1> protector <e2>ototoxicity</e2>
D005839_D006311 NONE <e1>gentamicin</e1> <e2>ototoxicity</e2>
D009569_D006316 NONE <e1>oxide</e1> ester act otoprotectant <e2>loss</e2>
D009569_D006316 NONE <e1>no</e1> ester act otoprotectant <e2>loss</e2>
D019331_D006316 NONE <e1>ester</e1> act otoprotectant <e2>loss</e2>
D019331_D006316 NONE <e1>l-name</e1> ester act otoprotectant <e2>loss</e2>
D005839_D006316 NONE <e1>gentamicin</e1> caused <e2>loss</e2>
D009569_D006311 NONE <e1>no</e1> production involves problem <e2>ototoxicity</e2>
D009569_D006311 NONE <e1>no</e1> production involves mechanism <e2>ototoxic</e2>
D009569_D006311 NONE <e1>no</e1> inhibitors use assess need problem <e2>ototoxicity</e2>
D009569_D006311 NONE <e1>no</e1> inhibitors use assess need problem involves mechanism <e2>ototoxic</e2>
D009569_D006319 NONE <e1>no</e1> production involves problem need assess use prevention <e2>loss</e2>
D009569_D006319 NONE <e1>no</e1> inhibitors use prevention <e2>loss</e2>
D000617_D006311 NONE <e1>aminoglycoside-induced</e1> loss prevention use assess need problem <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-induced</e1> loss prevention use assess need problem involves mechanism <e2>ototoxic</e2>
D000617_D006319 NONE <e1>aminoglycoside-induced</e1> <e2>loss</e2>
D019331_D034381 NONE <e1>l-name</e1> reduced <e2>loss</e2>
D005839_D034381 CID <e1>gentamicin-induced</e1> <e2>loss</e2>
6538499
D011092_D064420 NONE <e1>400</e1> glycol effect <e2>toxicity</e2>
D004317_D064420 NONE <e1>adriamycin</e1> <e2>toxicity</e2>
D004317_D009202 CID <e1>adr-induced</e1> <e2>alterations</e2>
D004317_D007939 NONE <e1>adr</e1> antitumor activity <e2>leukemia</e2>
D004317_D002286 NONE <e1>adr</e1> antitumor activity leukemia <e2>tumor</e2>
12653683
D012964_D009404 NONE <e1>sodium</e1> channel expression rats <e2>syndrome</e2>
D012964_D009404 NONE <e1>sodium</e1> excretion decreased <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside-induced</e1> <e2>syndrome</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> <e2>syndrome</e2>
D011692_D009404 CID <e1>(pan)-induced</e1> <e2>syndrome</e2>
D011692_D009404 CID <e1>pan-induced</e1> <e2>syndrome</e2>
D012964_D011507 NONE <e1>sodium</e1> excretion courses concentration <e2>proteinuria</e2>
D012964_D011507 NONE <e1>sodium</e1> excretion kinetics appearance <e2>proteinuria</e2>
D000450_D011507 NONE <e1>aldosterone</e1> concentration <e2>proteinuria</e2>
D011692_D011507 CID <e1>pan</e1> dose treated rats studied courses concentration <e2>proteinuria</e2>
D000450_D009404 NONE <e1>aldosterone</e1> regulation escape appears increased phase model <e2>syndrome</e2>
3615541
D000661_D006948 CID <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D002116_D006948 NONE <e1>calcitonin</e1> injections localization antagonism <e2>hyperactivity</e2>
20084309
D008874_D020521 NONE <e1>mz</e1> dose duration variables age <e2>stroke</e2>
D008874_D009202 NONE <e1>mz</e1> dose duration variables age stroke <e2>myocardiopathy</e2>
D008874_D009202 NONE <e1>mz</e1> dose duration variables age stroke myocardiopathy <e2>mp</e2>
D008874_D009202 NONE <e1>mz</e1> doses mr <e2>mp</e2>
D008874_D008944 NONE <e1>mz</e1> dose duration <e2>regurgitation</e2>
D008874_D008944 NONE <e1>mz</e1> dose duration regurgitation <e2>mr</e2>
D008874_D008944 NONE <e1>mz</e1> doses <e2>mr</e2>
D008874_D000860 CID <e1>mz</e1> use caused hypoxia event <e2>hypoxia</e2>
D008874_D000860 CID <e1>mz</e1> use caused hypoxia event presented <e2>hypoxia</e2>
D008874_D000860 CID <e1>mz</e1> use caused <e2>hypoxia</e2>
D008874_D000402 NONE <e1>mz</e1> use caused hypoxia event presented <e2>obstruction</e2>
1786266
D000928_D001480 NONE <e1>antidepressant</e1> use <e2>syndrome</e2>
15325671
D003520_D066126 NONE <e1>cyclophosphamide-based</e1> high-dose chemotherapy association observed <e2>toxicity</e2>
D003520_D066126 NONE <e1>cyclophosphamide-related</e1> <e2>toxicity</e2>
D003520_D001943 NONE <e1>cyclophosphamide-based</e1> high-dose chemotherapy <e2>cancer</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> melphalan paclitaxel combined regimen patients <e2>cancer</e2>
D003520_D001943 NONE <e1>cyclophosphamide</e1> receiving <e2>cancer</e2>
D017239_D001943 NONE <e1>paclitaxel</e1> combined regimen patients <e2>cancer</e2>
D008558_D001943 NONE <e1>melphalan</e1> paclitaxel combined regimen patients <e2>cancer</e2>
D013852_D001943 NONE <e1>thiotepa</e1> cyclophosphamide melphalan paclitaxel combined regimen patients <e2>cancer</e2>
D016190_D001943 NONE <e1>carboplatin</e1> cyclophosphamide melphalan paclitaxel combined regimen patients <e2>cancer</e2>
D003520_D006333 CID <e1>cyclophosphamide</e1> receiving cancer women performed part assess association presence <e2>failure</e2>
D003520_D006333 CID <e1>cyclophosphamide</e1> receiving cancer women performed part assess association presence failure <e2>chf</e2>
D003520_D006333 CID <e1>cyclophosphamide</e1> developed <e2>chf</e2>
D003520_D006333 CID <e1>cyclophosphamide</e1> monitoring predict development <e2>chf</e2>
D003520_D006973 NONE <e1>cyclophosphamide</e1> receiving cancer women performed presence <e2>hypertension</e2>
D003520_D003920 NONE <e1>cyclophosphamide</e1> receiving cancer women performed presence history smoking <e2>mellitus</e2>
D018943_D001943 NONE <e1>anthracyclines</e1> use presence performed women <e2>cancer</e2>
D018943_D006333 NONE <e1>anthracyclines</e1> use presence performed part assess association presence <e2>failure</e2>
D018943_D006333 NONE <e1>anthracyclines</e1> use presence performed part assess association presence failure <e2>chf</e2>
D018943_D006973 NONE <e1>anthracyclines</e1> use presence <e2>hypertension</e2>
D018943_D003920 NONE <e1>anthracyclines</e1> use presence history smoking <e2>mellitus</e2>
2802551
D012964_D007674 NONE <e1>sodium</e1> status influences <e2>nephrotoxicity</e2>
D000666_D007674 CID <e1>b</e1> <e2>nephrotoxicity</e2>
D000666_D007674 CID <e1>b</e1> potential <e2>nephrotoxic</e2>
2505783
C004656_D006470 CID <e1>chloroacetaldehyde</e1> metabolite indicating data carried order elucidate role development <e2>cystitis</e2>
C004656_D006470 CID <e1>caa</e1> chloroacetaldehyde metabolite indicating data carried order elucidate role development <e2>cystitis</e2>
C004656_D006470 CID <e1>caa</e1> role development <e2>cystitis</e2>
C004656_D003556 CID <e1>chloroacetaldehyde</e1> metabolite indicating data carried order elucidate role development <e2>cystitis</e2>
C004656_D003556 CID <e1>caa</e1> chloroacetaldehyde metabolite indicating data carried order elucidate role development <e2>cystitis</e2>
C004656_D003556 CID <e1>caa</e1> role development <e2>cystitis</e2>
C004656_D001745 NONE <e1>caa</e1> contribute <e2>damage</e2>
11532387
D018967_D013375 CID <e1>risperidone</e1> reduction <e2>syndrome</e2>
D018967_D013375 CID <e1>risperidone</e1> profile related mechanism <e2>rs</e2>
D018967_D001480 CID <e1>risperidone</e1> reduction <e2>syndrome</e2>
D018967_D001480 CID <e1>risperidone</e1> reduction developed <e2>rs</e2>
D018967_D001480 CID <e1>risperidone</e1> profile related mechanism <e2>rs</e2>
D018967_D001480 CID <e1>risperidone</e1> profile related suggesting influence development <e2>rs</e2>
D012701_D013375 NONE <e1>serotonin-dopamine</e1> antagonist risperidone profile related mechanism <e2>rs</e2>
D012701_D013375 NONE <e1>serotonin</e1> system influence suggesting related mechanism <e2>rs</e2>
D012701_D001480 NONE <e1>serotonin-dopamine</e1> antagonist risperidone profile related mechanism <e2>rs</e2>
D012701_D001480 NONE <e1>serotonin-dopamine</e1> antagonist risperidone profile related suggesting influence development <e2>rs</e2>
D012701_D001480 NONE <e1>serotonin</e1> system influence suggesting related mechanism <e2>rs</e2>
D012701_D001480 NONE <e1>serotonin</e1> system influence development <e2>rs</e2>
D004298_D013375 NONE <e1>serotonin-dopamine</e1> antagonist risperidone profile related mechanism <e2>rs</e2>
D004298_D001480 NONE <e1>serotonin-dopamine</e1> antagonist risperidone profile related mechanism <e2>rs</e2>
D004298_D001480 NONE <e1>serotonin-dopamine</e1> antagonist risperidone profile related suggesting influence development <e2>rs</e2>
7420681
D014031_D007674 NONE <e1>tobramycin</e1> <e2>nephrotoxicity</e2>
D014031_D007674 NONE <e1>sulfate</e1> continue demonstrate ototoxicity <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gentamicin</e1> tobramycin <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>sulfate</e1> sulfate continue demonstrate ototoxicity <e2>nephrotoxicity</e2>
D005839_D006311 NONE <e1>sulfate</e1> sulfate continue demonstrate <e2>ototoxicity</e2>
D014031_D006311 NONE <e1>sulfate</e1> continue demonstrate <e2>ototoxicity</e2>
D005839_D051437 CID <e1>sulfate</e1> mg/kg/day treated patients followed development <e2>failure</e2>
D005839_D051437 CID <e1>gentamicin-treated</e1> patients patients five had <e2>failure</e2>
D005839_D051437 CID <e1>gentamicin</e1> associated <e2>failure</e2>
D014031_D051437 CID <e1>sulfate</e1> patients followed development <e2>failure</e2>
D014031_D051437 CID <e1>tobramycin-treated</e1> patients five had <e2>failure</e2>
D014031_D051437 CID <e1>tobramycin</e1> often associated <e2>failure</e2>
D000617_D051437 NONE <e1>aminoglycoside-related</e1> <e2>failure</e2>
12905102
D003024_D003693 CID <e1>clozapine</e1> treatment <e2>delirium</e2>
D003024_D003693 CID <e1>clozapine</e1> treatment factors <e2>delirium</e2>
D003024_D003693 CID <e1>clozapine</e1> treated inpatients identify used reviewed score incidence severity <e2>delirium</e2>
D003024_D003693 CID <e1>clozapine-treated</e1> inpatients % found <e2>delirium</e2>
D003024_D001523 NONE <e1>clozapine</e1> treated inpatients <e2>psychiatric</e2>
8864707
D010672_D004827 NONE <e1>phenytoin</e1> overdosages volumetry patients <e2>epileptic</e2>
D010672_D062787 CID <e1>phenytoin</e1> <e2>overdosages</e2>
D010672_D062787 CID <e1>phenytoin</e1> <e2>overdosage</e2>
D010672_D062787 CID <e1>phenytoin</e1> medication cause is conclude result <e2>overdosage</e2>
D010672_D002526 NONE <e1>phenytoin</e1> medication <e2>atrophy</e2>
D010672_D002526 NONE <e1>phenytoin</e1> overdosage result <e2>atrophy</e2>
D010672_D002526 NONE <e1>phenytoin</e1> overdosage result conclude is cause <e2>atrophy</e2>
D010672_D002526 NONE <e1>phenytoin</e1> medication cause is conclude result <e2>atrophy</e2>
D010672_D002526 NONE <e1>phenytoin</e1> medication cause <e2>atrophy</e2>
D010672_D012640 NONE <e1>phenytoin</e1> levels elevation duration <e2>seizure</e2>
8372922
20003049
C031942_D013921 NONE <e1>argatroban</e1> elevation patient history <e2>thrombocytopenia</e2>
C031942_D013921 NONE <e1>argatroban</e1> administered patient history <e2>hitt</e2>
C031942_D013927 NONE <e1>argatroban</e1> elevation patient history <e2>thrombosis</e2>
C031942_D013927 NONE <e1>argatroban</e1> administered patient history <e2>hitt</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> thrombocytopenia <e2>hit</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> thrombocytopenia <e2>hit</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> thrombocytopenia hit thrombosis <e2>hitt</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia history <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia hit <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia hit thrombosis <e2>hitt</e2>
C031942_D016638 NONE <e1>argatroban</e1> administered patient <e2>ill</e2>
C031942_D008107 NONE <e1>argatroban</e1> concentrations measured results minutes minutes <e2>impairment</e2>
C031942_D008107 NONE <e1>argatroban</e1> life observed measured results minutes minutes <e2>impairment</e2>
C031942_D001778 NONE <e1>argatroban</e1> concentration correlation suggest contributed <e2>coagulopathy</e2>
C031942_D001778 NONE <e1>argatroban</e1> levels contributed <e2>coagulopathy</e2>
C031942_D001778 NONE <e1>argatroban</e1> concentration measure extended <e2>coagulopathy</e2>
17111419
C102006_D064420 NONE <e1>citrate</e1> <e2>toxicity</e2>
C102006_D064420 NONE <e1>citrate</e1> <e2>toxicity</e2>
C102006_D064420 NONE <e1>citrate</e1> <e2>toxicity</e2>
D002125_C536214 NONE <e1>gluconate</e1> treatment initiated subsided <e2>contractions</e2>
D002118_D006996 NONE <e1>calcium</e1> chelation reaction resulting <e2>hypocalcemia</e2>
C102006_D006996 CID <e1>citrate</e1> anticoagulant reaction resulting <e2>hypocalcemia</e2>
C102006_D006996 CID <e1>citrate</e1> toxicity prevent help recommended screening medications underlying conditions predisposing <e2>hypocalcemia</e2>
D002034_D006996 NONE <e1>bumetanide</e1> diuretic cause <e2>hypocalcemia</e2>
D049994_D006996 NONE <e1>diuretic</e1> cause <e2>hypocalcemia</e2>
2070391
D008012_D010146 CID <e1>lidocaine</e1> using reduction <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> injection associated <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> ph adjust addition reduce <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> receiving quantify severity <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> buffered quantify severity <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> score <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> score lower score <e2>pain</e2>
D008012_D010146 CID <e1>lidocaine</e1> adjustment accomplished results reduction <e2>pain</e2>
2611118
D004008_D006521 NONE <e1>sodium</e1> therapy associated <e2>hepatitis</e2>
D004008_D006521 NONE <e1>sodium</e1> therapy developed <e2>hepatitis</e2>
D004008_D056486 CID <e1>diclofenac</e1> induced hepatitis recorded abnormalities <e2>function</e2>
D004008_D056486 CID <e1>diclofenac</e1> induced <e2>hepatitis</e2>
2484011
D000547_D003866 NONE <e1>amantadine</e1> activity <e2>depressed</e2>
D000547_D011596 CID <e1>amantadine</e1> readministration motility strains exception mice occurred suppression <e2>motility</e2>
D000547_D011596 CID <e1>amantadine</e1> caused <e2>depression</e2>
D000588_D011596 NONE <e1>amines</e1> results suggest decrease increase o-methylation account <e2>depression</e2>
D002395_D011596 NONE <e1>catecholamine</e1> rate decrease increase o-methylation account <e2>depression</e2>
D009638_D011596 NONE <e1>norepinephrine</e1> o-methylation account <e2>depression</e2>
9754849
D008691_D002819 CID <e1>methadone</e1> adjustment associated <e2>movements</e2>
D008691_D002819 CID <e1>methadone</e1> adjustment induced <e2>movements</e2>
D003042_D002819 CID <e1>cocaine</e1> intoxications abnormalities known <e2>hyperkinesias</e2>
D003042_D002819 CID <e1>cocaine</e1> heroine abusing inpatient induced <e2>movements</e2>
D003042_D006948 CID <e1>cocaine</e1> intoxications abnormalities known <e2>hyperkinesias</e2>
D003042_D020820 NONE <e1>cocaine</e1> intoxications <e2>abnormalities</e2>
D003932_D002819 NONE <e1>heroine</e1> abusing inpatient induced <e2>movements</e2>
354896
D008012_D006323 CID <e1>lidocaine-induced</e1> <e2>asystole</e2>
D008012_D003866 NONE <e1>lidocaine</e1> bolus administration resulted <e2>depression</e2>
D008012_D001919 NONE <e1>lidocaine</e1> idiosyncrasy represented had conditions predisposed development <e2>bradyarrhythmias</e2>
20619828
D002997_D001008 CID <e1>clomipramine</e1> exposure produced changes include <e2>anxiety</e2>
D002997_-1 NONE <e1>clomipramine</e1> exposure produced results <e2>inflexibility</e2>
D002997_-1 NONE <e1>clomipramine</e1> exposure produced results impairment <e2>dysfunction</e2>
D002997_D008569 CID <e1>clomipramine</e1> exposure produced results <e2>impairment</e2>
D002997_D060845 CID <e1>clomipramine</e1> exposure produced results impairment <e2>hoarding</e2>
18329269
D006220_D002375 CID <e1>haloperidol-induced</e1> model <e2>catalepsy</e2>
D006220_D010300 NONE <e1>haloperidol-induced</e1> model <e2>disease</e2>
18752389
C492458_D017093 NONE <e1>simvastatin-ezetimibe-induced</e1> transplantation <e2>failure</e2>
C492458_D017093 NONE <e1>simvastatin-ezetimibe-induced</e1> <e2>failure</e2>
C108606_D056486 NONE <e1>ezetimibe</e1> published events <e2>hepatotoxic</e2>
C108606_D056486 NONE <e1>ezetimibe</e1> undergoes resulting exposure <e2>hepatotoxicity</e2>
C108606_D056486 NONE <e1>ezetimibe</e1> inhibition exposure mechanism <e2>hepatotoxicity</e2>
C492458_D056486 CID <e1>simvastatin-ezetimibe</e1> ezetimibe published events <e2>hepatotoxic</e2>
C492458_D056486 CID <e1>simvastatinezetimibe</e1> discontinued excluded causes <e2>hepatotoxicity</e2>
C492458_D056486 CID <e1>simvastatinezetimibe-induced</e1> <e2>hepatotoxicity</e2>
C492458_D056486 CID <e1>simvastatin-ezetimibe</e1> <e2>hepatotoxicity</e2>
D019821_D017114 NONE <e1>simvastatin</e1> conversion developed transplantation <e2>failure</e2>
C492458_D017114 CID <e1>mg/day</e1> developed transplantation <e2>failure</e2>
D019821_D056486 NONE <e1>simvastatin</e1> maintained conversion evidence <e2>hepatotoxicity</e2>
D019821_D056486 NONE <e1>simvastatin</e1> exposure <e2>hepatotoxicity</e2>
D019821_D056486 NONE <e1>simvastatin</e1> exposure mechanism <e2>hepatotoxicity</e2>
C492458_D003866 NONE <e1>simvastatinezetimibe</e1> taking <e2>depression</e2>
D015283_D003866 NONE <e1>escitalopram</e1> simvastatinezetimibe taking <e2>depression</e2>
D015283_D056486 NONE <e1>escitalopram</e1> simvastatinezetimibe discontinued excluded causes <e2>hepatotoxicity</e2>
D014530_D056486 NONE <e1>diphosphate</e1> glucoronosyltransferases undergoes resulting exposure <e2>hepatotoxicity</e2>
C532833_D056486 NONE <e1>acid</e1> glucuronidation inhibited undergoes resulting exposure <e2>hepatotoxicity</e2>
8996652
D000617_D006311 NONE <e1>aminoglycosides</e1> appeared <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycosides</e1> appeared related administration dose drugs <e2>ototoxic</e2>
D005665_D006311 NONE <e1>furosemide</e1> aminoglycosides appeared <e2>ototoxicity</e2>
D005665_D006311 NONE <e1>furosemide</e1> aminoglycosides appeared related administration dose drugs <e2>ototoxic</e2>
19759529
D004298_D012559 NONE <e1>dopamine</e1> neurotransmission dysfunction associated <e2>schizophrenia</e2>
D018698_D012559 NONE <e1>glutamate</e1> receptor antagonists produce symptoms <e2>schizophrenic-like</e2>
D016202_D012559 NONE <e1>n-methyl-d-aspartate</e1> receptor antagonists produce symptoms <e2>schizophrenic-like</e2>
D016202_D012559 NONE <e1>nmda</e1> receptor antagonists produce symptoms <e2>schizophrenic-like</e2>
D016202_D012559 NONE <e1>nmda</e1> receptor dysfunctioning idea led observation produce symptoms <e2>schizophrenic-like</e2>
-1_D006948 NONE <e1>ssr103800</e1> properties investigating aimed focus models <e2>hyperactivity</e2>
-1_D006948 NONE <e1>ssr103800</e1> blocked <e2>hyperactivity</e2>
-1_D006948 NONE <e1>ssr103800</e1> blocked <e2>hyperactivity</e2>
-1_D006948 NONE <e1>ssr103800</e1> failed affect <e2>hyperactivity</e2>
D000661_D006948 CID <e1>amphetamine</e1> challenge study aimed focus models <e2>hyperactivity</e2>
D000661_D006948 CID <e1>amphetamine</e1> induced <e2>hyperactivity</e2>
D016291_D006948 CID <e1>mk-801</e1> amphetamine challenge study aimed focus models <e2>hyperactivity</e2>
D016291_D006948 CID <e1>mk-801</e1> antagonist induced <e2>hyperactivity</e2>
D016291_D006948 CID <e1>mk-801</e1> antagonist induced hyperactivity blocked <e2>hyperactivity</e2>
D016202_D006948 NONE <e1>nmda</e1> nr1(neo-/- mice challenge study aimed focus models <e2>hyperactivity</e2>
D016202_D006948 NONE <e1>nmda</e1> antagonist induced <e2>hyperactivity</e2>
D016202_D006948 NONE <e1>nmda</e1> antagonist induced hyperactivity blocked <e2>hyperactivity</e2>
D016202_D006948 NONE <e1>nmda</e1> nr1(neo-/- hyperactivity blocked <e2>hyperactivity</e2>
D016202_D006948 NONE <e1>nmda</e1> nr1(neo-/- <e2>hyperactivity</e2>
D004298_D006948 NONE <e1>dopamine</e1> transporter observed affect <e2>hyperactivity</e2>
D006220_D006948 NONE <e1>haloperidol</e1> classical antipsychotics effective models <e2>hyperactivity</e2>
C076029_D006948 NONE <e1>olanzapine</e1> classical antipsychotics effective models <e2>hyperactivity</e2>
D003024_D006948 NONE <e1>clozapine</e1> olanzapine classical antipsychotics effective models <e2>hyperactivity</e2>
C094645_D006948 NONE <e1>aripiprazole</e1> olanzapine classical antipsychotics effective models <e2>hyperactivity</e2>
-1_D002375 NONE <e1>ssr103800</e1> produce <e2>catalepsy</e2>
-1_D002375 NONE <e1>ssr103800</e1> inhibitor produces show produce <e2>catalepsy</e2>
8170551
D000086_D053040 NONE <e1>acetazolamide-induced</e1> <e2>nephrolithiasis</e2>
D000086_D053040 NONE <e1>acetazolamide</e1> complication <e2>nephrolithiasis</e2>
D000086_D009468 NONE <e1>acetazolamide-induced</e1> nephrolithiasis implications treatment <e2>disorders</e2>
D000086_D007669 CID <e1>acetazolamide</e1> patients developed <e2>calculi</e2>
10342929
D000806_D000799 CID <e1>inhibitors</e1> <e2>angioedema</e2>
D000806_D000799 CID <e1>inhibitor</e1> treatment incidence <e2>angioedema</e2>
15275829
D000109_D012640 NONE <e1>acetylcholine</e1> subunits necessary <e2>seizures</e2>
D000109_D012640 NONE <e1>acetylcholine</e1> receptors binding elicits series behaviors go <e2>seizures</e2>
D000109_D006948 NONE <e1>acetylcholine</e1> subunits necessary seizures <e2>hypolocomotion</e2>
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine</e1> binding elicits series behaviors go <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine</e1> effects sensitive doses measured sensitivity <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D006948 NONE <e1>nicotine-induced</e1> seizures <e2>hypolocomotion</e2>
D009538_D006948 NONE <e1>nicotine-induced</e1> seizures <e2>hypolocomotion</e2>
D009538_D006948 NONE <e1>nicotine-induced</e1> seizures <e2>hypolocomotion</e2>
D009538_D014202 NONE <e1>nicotine</e1> binding elicits series behaviors go exploration sedation <e2>tremors</e2>
D009538_D003643 NONE <e1>nicotine</e1> binding elicits series behaviors go seizures <e2>death</e2>
D000109_D014202 NONE <e1>acetylcholine</e1> receptors binding elicits series behaviors go exploration sedation <e2>tremors</e2>
D000109_D003643 NONE <e1>acetylcholine</e1> receptors binding elicits series behaviors go seizures <e2>death</e2>
9812111
D006220_D011618 NONE <e1>haloperidol</e1> trial <e2>psychosis</e2>
D006220_D011618 NONE <e1>haloperidol</e1> doses efficacy treatment <e2>psychosis</e2>
D006220_D011618 NONE <e1>haloperidol</e1> efficacious superior haloperidol placebo scores factor <e2>psychosis</e2>
D006220_D011618 NONE <e1>haloperidol</e1> placebo scores factor <e2>psychosis</e2>
D006220_D011618 NONE <e1>haloperidol</e1> observed window apply neuroleptics used patients <e2>psychosis</e2>
D006220_D019958 NONE <e1>haloperidol</e1> trial psychosis <e2>behaviors</e2>
D006220_D019958 NONE <e1>haloperidol</e1> doses efficacy treatment psychosis <e2>behaviors</e2>
D006220_D019958 NONE <e1>haloperidol</e1> observed window apply neuroleptics used patients psychosis <e2>behaviors</e2>
D006220_D000544 NONE <e1>haloperidol</e1> trial psychosis <e2>disease</e2>
D006220_D000544 NONE <e1>haloperidol</e1> doses efficacy treatment patients <e2>disease</e2>
D006220_D000544 NONE <e1>haloperidol</e1> random-assignment method compared outpatients <e2>disease</e2>
D006220_D000544 NONE <e1>haloperidol</e1> random-assignment method compared outpatients <e2>disease</e2>
D006220_D000544 NONE <e1>haloperidol</e1> observed window apply neuroleptics used patients <e2>disease</e2>
D006220_D011595 NONE <e1>haloperidol</e1> efficacious superior haloperidol placebo scores factor <e2>agitation</e2>
D006220_D011595 NONE <e1>haloperidol</e1> placebo scores factor <e2>agitation</e2>
D006220_D001480 CID <e1>haloperidol</e1> profile indicated developed moderate <e2>signs</e2>
9351491
D018967_D011618 NONE <e1>risperidone</e1> profile produce efficacy <e2>symptoms</e2>
D018967_D010302 CID <e1>risperidone</e1> treated subjects observed <e2>parkinsonism</e2>
D006220_D010302 CID <e1>haloperidol</e1> risperidone treated subjects observed <e2>parkinsonism</e2>
8829025
D016559_D006973 CID <e1>tacrolimus</e1> receiving patients groups compared group comprising patients <e2>hypertensive</e2>
D016559_D006973 CID <e1>tacrolimus</e1> associated nephrotoxicity reducing impact factor selecting agent treat <e2>hypertension</e2>
D009543_D006973 NONE <e1>nifedipine</e1> receiving patients <e2>hypertensive</e2>
D009543_D006973 NONE <e1>nifedipine</e1> receiving patients other group comprising patients <e2>hypertensive</e2>
D009543_D006973 NONE <e1>nifedipine</e1> impact factor selecting agent treat <e2>hypertension</e2>
D009543_D007674 NONE <e1>nifedipine</e1> impact reducing <e2>nephrotoxicity</e2>
D016559_D007674 NONE <e1>tacrolimus</e1> associated <e2>nephrotoxicity</e2>
2670794
D000809_D011665 NONE <e1>angiotensin</e1> enzyme inhibitor effects <e2>insufficiency</e2>
D000809_D011665 NONE <e1>angiotensin</e1> enzyme inhibitor injection reduced <e2>insufficiency</e2>
D000809_D051437 NONE <e1>angiotensin</e1> enzyme inhibitor effects <e2>insufficiency</e2>
D000809_D051437 NONE <e1>angiotensin</e1> enzyme inhibitor injection reduced <e2>insufficiency</e2>
D000809_D004211 NONE <e1>angiotensin</e1> enzyme inhibitor effects <e2>coagulation</e2>
D002216_D011665 NONE <e1>captopril</e1> inhibitor effects <e2>insufficiency</e2>
D002216_D011665 NONE <e1>captopril</e1> injection reduced <e2>insufficiency</e2>
D002216_D051437 NONE <e1>captopril</e1> inhibitor effects <e2>insufficiency</e2>
D002216_D051437 NONE <e1>captopril</e1> injection reduced <e2>insufficiency</e2>
D002216_D004211 NONE <e1>captopril</e1> inhibitor effects <e2>coagulation</e2>
D014148_D004211 CID <e1>acid</e1> injection inhibition induction <e2>coagulation</e2>
D014148_D004211 CID <e1>amca</e1> acid injection inhibition induction <e2>coagulation</e2>
D014148_D011665 NONE <e1>acid</e1> injection inhibition induction gives pulmonary <e2>insufficiency</e2>
D014148_D011665 NONE <e1>amca</e1> acid injection inhibition induction gives pulmonary <e2>insufficiency</e2>
D014148_D051437 NONE <e1>acid</e1> injection inhibition induction gives pulmonary <e2>insufficiency</e2>
D014148_D051437 NONE <e1>amca</e1> acid injection inhibition induction gives pulmonary <e2>insufficiency</e2>
D014148_D014947 NONE <e1>acid</e1> injection inhibition induction gives pulmonary occurring <e2>trauma</e2>
D014148_D014947 NONE <e1>amca</e1> acid injection inhibition induction gives pulmonary occurring <e2>trauma</e2>
D014148_D018805 NONE <e1>acid</e1> injection inhibition induction gives pulmonary occurring trauma <e2>sepsis</e2>
D014148_D018805 NONE <e1>amca</e1> acid injection inhibition induction gives pulmonary occurring trauma <e2>sepsis</e2>
D014508_D007674 NONE <e1>urea</e1> increase reflected <e2>damage</e2>
D002216_D007674 NONE <e1>captopril</e1> prevented <e2>damage</e2>
D002216_D007674 NONE <e1>captopril</e1> reduce diminishing result deposited produced <e2>damage</e2>
1728522
D019980_D006099 CID <e1>acid</e1> combination <e2>hepatitis</e2>
D019980_D006099 CID <e1>acid-induced</e1> hepatitis patient <e2>granulomas</e2>
D019980_D056486 CID <e1>acid</e1> combination <e2>hepatitis</e2>
D019980_D056486 CID <e1>acid-induced</e1> <e2>hepatitis</e2>
7890216
D015282_D042882 CID <e1>octreotide</e1> associated <e2>stones</e2>
D015282_D042882 CID <e1>octreotide</e1> induces <e2>stones</e2>
D015282_D042882 CID <e1>octreotide</e1> treated patients <e2>stones</e2>
D015282_D042882 CID <e1>octreotide</e1> <e2>stones</e2>
D015282_D042882 CID <e1>octreotide</e1> stones small rich although common <e2>disease</e2>
D015282_D042882 CID <e1>octreotide</e1> stones small have duct <e2>stones</e2>
D014580_D042882 NONE <e1>acid</e1> response composition <e2>stones</e2>
D015282_D000172 NONE <e1>octreotide</e1> treatment <e2>acromegaly</e2>
D015282_D000172 NONE <e1>octreotide</e1> treated patients <e2>acromegalic</e2>
D002784_D042882 NONE <e1>cholesterol</e1> contained showed retrieved analysis <e2>stones</e2>
D002784_D042882 NONE <e1>cholesterol</e1> rich suggesting showed gall dissolution <e2>stone</e2>
D002784_D042882 NONE <e1>cholesterol</e1> multiple small <e2>stones</e2>
D002784_D042882 NONE <e1>cholesterol</e1> multiple small rich although common <e2>disease</e2>
D002784_D042882 NONE <e1>cholesterol</e1> multiple small have duct <e2>stones</e2>
D002118_D042882 NONE <e1>calcium</e1> containing stones duct have small <e2>stones</e2>
D002118_D042882 NONE <e1>calcium</e1> containing stones duct have small rich although common <e2>disease</e2>
D002118_D042882 NONE <e1>calcium</e1> containing <e2>stones</e2>
9390208
D008942_D001943 NONE <e1>mitoxantrone</e1> treatment <e2>cancer</e2>
D008942_D001943 NONE <e1>mitoxantrone</e1> treated patients <e2>cancer</e2>
D008942_D064420 NONE <e1>mitoxantrone</e1> treatment benefit <e2>toxicity</e2>
D005472_D001943 NONE <e1>5-fu</e1> infusion treatment <e2>cancer</e2>
D005472_D001943 NONE <e1>5-fu</e1> infusion day treated patients <e2>cancer</e2>
D005472_D064420 NONE <e1>5-fu</e1> infusion treatment benefit <e2>toxicity</e2>
D002955_D001943 NONE <e1>leucovorin</e1> 5-fu infusion treatment <e2>cancer</e2>
D002955_D001943 NONE <e1>leucovorin</e1> treated patients <e2>cancer</e2>
D002955_D064420 NONE <e1>leucovorin</e1> 5-fu infusion treatment benefit <e2>toxicity</e2>
C085788_D001943 NONE <e1>mfl</e1> benefit treatment <e2>cancer</e2>
C085788_D064420 NONE <e1>mfl</e1> benefit <e2>toxicity</e2>
C085788_D064420 NONE <e1>regimen</e1> achieves induces <e2>toxicity</e2>
7088431
D004054_D018262 CID <e1>des-exposed</e1> offspring development <e2>adenocarcinoma</e2>
D004054_D018262 CID <e1>diethylstilbestrol</e1> exposed women follow-up detected <e2>vagina</e2>
D004054_D014625 CID <e1>diethylstilbestrol</e1> exposed women follow-up detected <e2>vagina</e2>
18417364
D009538_D009759 CID <e1>nicotine-induced</e1> <e2>nystagmus</e2>
D009538_D009759 CID <e1>nicotine-induced</e1> <e2>nystagmus</e2>
D009538_D009759 CID <e1>nicotine-induced</e1> nystagmus <e2>nin</e2>
D010100_D009759 NONE <e1>oxygen</e1> level-dependent levels correlated <e2>nin</e2>
9869257
C087567_D000647 NONE <e1>pg-9</e1> mg/kg test administered prevented <e2>amnesia</e2>
C087567_D000647 NONE <e1>pg-9</e1> microg able prevent <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> induced <e2>amnesia</e2>
C098725_D000647 CID <e1>s-(-)-et-126</e1> scopolamine induced <e2>amnesia</e2>
3015567
D009599_D007022 CID <e1>nitroprusside-induced</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside-induced</e1> <e2>hypotension</e2>
D003345_D007022 NONE <e1>corticosterone</e1> level occurs observed suppression response <e2>hypotension</e2>
8739323
D008466_D007674 NONE <e1>nitrogranulogen</e1> drugs action <e2>nephrotoxic</e2>
D008466_D007674 NONE <e1>ng</e1> nitrogranulogen drugs action <e2>nephrotoxic</e2>
D008727_D007674 NONE <e1>methotrexate</e1> action <e2>nephrotoxic</e2>
D008727_D007674 NONE <e1>mtx</e1> methotrexate action <e2>nephrotoxic</e2>
D008727_D007674 NONE <e1>mtx</e1> 5-fluorouracil methotrexate action <e2>nephrotoxic</e2>
D008727_D007674 NONE <e1>mtx</e1> <e2>nephrotoxicity</e2>
D005472_D007674 NONE <e1>5-fluorouracil</e1> methotrexate action <e2>nephrotoxic</e2>
D005472_D007674 NONE <e1>5-fu</e1> 5-fluorouracil methotrexate action <e2>nephrotoxic</e2>
D005472_D007674 NONE <e1>5-fu</e1> mtx 5-fluorouracil methotrexate action <e2>nephrotoxic</e2>
D005472_D007674 NONE <e1>5-fu</e1> mtx <e2>nephrotoxicity</e2>
D003520_D007674 NONE <e1>cyclophosphamide</e1> 5-fluorouracil methotrexate action <e2>nephrotoxic</e2>
D003520_D007674 NONE <e1>cy</e1> cyclophosphamide 5-fluorouracil methotrexate action <e2>nephrotoxic</e2>
D003520_D007674 NONE <e1>cy</e1> mtx 5-fluorouracil methotrexate action <e2>nephrotoxic</e2>
D003520_D007674 NONE <e1>cy</e1> mtx <e2>nephrotoxicity</e2>
D003520_D006470 CID <e1>cy</e1> caused <e2>cystitis</e2>
D003520_D003556 CID <e1>cy</e1> caused <e2>cystitis</e2>
D005472_D006470 NONE <e1>5-fu</e1> combined cause caused <e2>cystitis</e2>
D005472_D003556 NONE <e1>5-fu</e1> combined cause caused <e2>cystitis</e2>
D008727_D006470 NONE <e1>mtx</e1> 5-fu combined cause caused <e2>cystitis</e2>
D008727_D003556 NONE <e1>mtx</e1> 5-fu combined cause caused <e2>cystitis</e2>
20880751
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> drug treatment <e2>disease</e2>
D004298_D004409 NONE <e1>dopamine</e1> precursor use complicated fluctuations <e2>dyskinesias</e2>
D004298_D004409 NONE <e1>dopamine</e1> receptor subtypes mechanisms role focus lines data pathophysiology <e2>dyskinesias</e2>
D018698_D004409 NONE <e1>glutamate</e1> receptors data pathophysiology <e2>dyskinesias</e2>
20098969
D008694_D001145 NONE <e1>methamphetamine</e1> addictive stimulant increases produce effects <e2>dysrhythmias</e2>
D008694_D006973 NONE <e1>methamphetamine</e1> addictive stimulant increases produce effects dysrhythmias <e2>hypertension</e2>
D008694_D006212 NONE <e1>methamphetamine</e1> addictive stimulant increases produce effects dysrhythmias hypertension <e2>hallucinations</e2>
D008694_D001523 NONE <e1>methamphetamine</e1> addictive stimulant increases produce effects dysrhythmias <e2>behavior</e2>
D008694_D014987 NONE <e1>methamphetamine</e1> abusing patients present hygiene <e2>xerostomia</e2>
D008694_D003731 CID <e1>methamphetamine</e1> abusing patients present hygiene <e2>caries</e2>
D008694_D003731 CID <e1>methamphetamine</e1> use reported experienced <e2>episodes</e2>
D008694_-1 NONE <e1>methamphetamine</e1> abusing patients present hygiene caries <e2>mouth</e2>
D008694_-1 NONE <e1>methamphetamines</e1> abusing patients manage recognize help presented case showing manifestations <e2>mouth</e2>
D008694_D057085 NONE <e1>methamphetamine</e1> abusing patients present hygiene <e2>wear</e2>
16428221
D008774_D020293 CID <e1>methylphenidate</e1> intake <e2>vasculitis</e2>
D008774_D020293 CID <e1>methylphenidate</e1> intake reported documented <e2>vasculitis</e2>
D008774_D019969 NONE <e1>methylphenidate</e1> intake reported documented vasculitis associated <e2>abuse</e2>
D008774_D002544 NONE <e1>methylphenidate</e1> intake reported <e2>stroke</e2>
D008774_D002544 NONE <e1>methylphenidate</e1> treated suffered <e2>strokes</e2>
D008774_D006948 NONE <e1>methylphenidate</e1> treated <e2>hyperactivity</e2>
D008774_D014657 NONE <e1>methylphenidate</e1> <e2>vasculitis</e2>
D008774_D014657 NONE <e1>methylphenidate</e1> therapy history patients considered <e2>vasculitis</e2>
220563
C023470_D010523 CID <e1>maleate</e1> <e2>neuropathy</e2>
C023470_D010523 CID <e1>maleate</e1> complication noted <e2>neuropathy</e2>
C023470_D000787 NONE <e1>maleate</e1> complication noted treatment <e2>pectoris</e2>
9721172
D007052_D001649 NONE <e1>ibuprofen</e1> use associated described child developed <e2>syndrome</e2>
D007052_D013262 CID <e1>ibuprofen</e1> use associated described <e2>syndrome</e2>
D014580_D002779 NONE <e1>acid</e1> therapy unrelenting <e2>disease</e2>
D014580_D005355 NONE <e1>acid</e1> therapy unrelenting <e2>cirrhosis</e2>
D011241_D002779 NONE <e1>prednisone</e1> acid therapy unrelenting <e2>disease</e2>
D011241_D005355 NONE <e1>prednisone</e1> acid therapy unrelenting <e2>cirrhosis</e2>
D016559_D002779 NONE <e1>tacrolimus</e1> acid therapy unrelenting <e2>disease</e2>
D016559_D005355 NONE <e1>tacrolimus</e1> acid therapy unrelenting <e2>cirrhosis</e2>
7919560
D000667_D004892 CID <e1>ampicillin</e1> caused myocarditis <e2>multiforme</e2>
D000667_D004892 CID <e1>ampicillin</e1> caused myocarditis case erythema <e2>multiforme</e2>
D000667_D009205 CID <e1>ampicillin</e1> caused <e2>myocarditis</e2>
D000667_D009205 CID <e1>ampicillin</e1> caused <e2>myocarditis</e2>
D000667_D018805 NONE <e1>ampicillin</e1> treated <e2>septicemia</e2>
D005839_D018805 NONE <e1>gentamicin</e1> ampicillin treated <e2>septicemia</e2>
D010406_D009205 NONE <e1>penicillins</e1> allergy manifestation <e2>myocarditis</e2>
D010406_D004342 NONE <e1>penicillins</e1> <e2>allergy</e2>
2425813
D011239_D006529 CID <e1>prednisolone</e1> administration occurred <e2>enlargement</e2>
D011239_D009133 CID <e1>prednisolone</e1> administration occurred enlargement <e2>wastage</e2>
12695819
D016559_D020258 NONE <e1>tacrolimus-induced</e1> <e2>neurotoxicity</e2>
D016559_D020258 NONE <e1>tacrolimus-induced</e1> <e2>neurotoxicity</e2>
D016559_D009422 NONE <e1>tacrolimus</e1> developed <e2>complications</e2>
6133211
D012460_D015212 NONE <e1>sulphasalazine</e1> treatment received mothers <e2>disease</e2>
D012460_D000013 NONE <e1>sulphasalazine</e1> treatment received mothers born infants found have <e2>anomalies</e2>
2355241
D007980_D002543 NONE <e1>levodopa</e1> effect reflect incidence <e2>haemorrhage</e2>
D007980_D003643 NONE <e1>levodopa</e1> effect reflect incidence cause <e2>death</e2>
D007980_D010300 NONE <e1>levodopa</e1> effect reflect incidence cause patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> effect mechanism levels brain <e2>parkinsonian</e2>
D007980_D007022 CID <e1>levodopa</e1> effect <e2>hypotensive</e2>
D007980_D007022 CID <e1>levodopa</e1> effect mechanism <e2>hypotensive</e2>
D009638_D002543 NONE <e1>noradrenaline</e1> levels mechanism effect reflect incidence <e2>haemorrhage</e2>
D009638_D003643 NONE <e1>noradrenaline</e1> levels mechanism effect reflect incidence cause <e2>death</e2>
D009638_D010300 NONE <e1>noradrenaline</e1> levels mechanism effect reflect incidence cause patients <e2>disease</e2>
D009638_D010300 NONE <e1>noradrenaline</e1> levels brain <e2>parkinsonian</e2>
D009638_D007022 NONE <e1>noradrenaline</e1> levels mechanism effect <e2>hypotensive</e2>
D009638_D007022 NONE <e1>noradrenaline</e1> levels mechanism <e2>hypotensive</e2>
17608141
D008694_D020258 NONE <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008694_D020258 NONE <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008070_D020258 NONE <e1>lipopolysaccharide</e1> pretreatment attenuation <e2>neurotoxicity</e2>
D008070_D020258 NONE <e1>lipopolysaccharide</e1> roles examined modulating <e2>neurotoxicity</e2>
D008070_D020258 NONE <e1>lipopolysaccharide</e1> pretreatment window concluded exerting protection <e2>neurotoxicity</e2>
D008694_D009422 NONE <e1>methamphetamine-induced</e1> <e2>damage</e2>
D004298_D020258 NONE <e1>dopamine</e1> <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>dopamine</e1> <e2>neurotoxicity</e2>
D008070_D005334 NONE <e1>lipopolysaccharide</e1> pretreatment affect temperature <e2>hyperthermia</e2>
D008694_D005334 CID <e1>methamphetamine-elicited</e1> <e2>hyperthermia</e2>
1130930
D002512_D007674 NONE <e1>cephalothin-gentamicin</e1> regimen <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>cephalothin-gentamicin</e1> regimen <e2>nephrotoxicity</e2>
D002512_D007683 CID <e1>sodium</e1> combination receiving developed <e2>necrosis</e2>
D002512_D009846 NONE <e1>sodium</e1> combination receiving developed necrosis characterized <e2>failure</e2>
D002512_D051437 NONE <e1>sodium</e1> combination receiving developed necrosis characterized <e2>failure</e2>
D005839_D007683 CID <e1>sulfate</e1> therapy sodium combination receiving developed <e2>necrosis</e2>
D005839_D009846 NONE <e1>sulfate</e1> therapy sodium combination receiving developed necrosis characterized <e2>failure</e2>
D005839_D051437 NONE <e1>sulfate</e1> therapy sodium combination receiving developed necrosis characterized <e2>failure</e2>
8649546
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesia improvement propranolol <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesia <e2>pd</e2>
D011433_D004409 NONE <e1>propranolol</e1> improvement <e2>dyskinesia</e2>
D011433_D004409 NONE <e1>propranolol</e1> received patients suffering <e2>dyskinesia</e2>
D011433_D010300 NONE <e1>propranolol</e1> <e2>disease</e2>
D011433_D010300 NONE <e1>propranolol</e1> received patients suffering <e2>disease</e2>
D011433_D010300 NONE <e1>propranolol</e1> received patients suffering disease <e2>pd</e2>
9406968
D014667_D003919 NONE <e1>vasopressin</e1> gene expression upregulation paraventricular rat <e2>insipidus</e2>
D008094_D003919 NONE <e1>lithium-induced</e1> rat <e2>insipidus</e2>
D008094_D003919 NONE <e1>li-induced</e1> rat <e2>insipidus</e2>
D001127_D011141 NONE <e1>vasopressin</e1> gene expression investigated rats <e2>polyuria</e2>
D001127_D011141 NONE <e1>avp</e1> gene expression investigated rats <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium</e1> <e2>polyuria</e2>
D008094_D011141 NONE <e1>(li)-induced</e1> <e2>polyuria</e2>
D018021_D011141 CID <e1>licl</e1> contained diet consuming developed <e2>polyuria</e2>
D001127_D003681 NONE <e1>avp</e1> elevation contribute <e2>dehydration</e2>
D001127_D003681 NONE <e1>avp</e1> expression upregulation elevation contribute <e2>dehydration</e2>
D001127_D003919 NONE <e1>avp</e1> elevation upregulation pvn rat <e2>insipidus</e2>
D001127_D003919 NONE <e1>avp</e1> expression upregulation pvn rat <e2>insipidus</e2>
D008094_D003681 NONE <e1>li-induced</e1> rat pvn upregulation elevation contribute <e2>dehydration</e2>
3187073
D005472_D002637 CID <e1>5-fu</e1> treatment patients supervision discontinued observed <e2>pain</e2>
D005472_D013610 NONE <e1>5-fu</e1> treatment patients supervision discontinued observed pain <e2>tachyarrhythmia</e2>
17400887
D013726_D020078 NONE <e1>terbutaline</e1> treatment abnormalities <e2>neuroinflammation</e2>
D013726_D001523 NONE <e1>terbutaline</e1> treatment <e2>abnormalities</e2>
D013726_D001321 CID <e1>terbutaline</e1> treatment abnormalities implications <e2>autism</e2>
D013726_D001321 CID <e1>terbutaline</e1> associated concordance <e2>autism</e2>
D013726_D007752 NONE <e1>terbutaline</e1> agonist used arrest <e2>labor</e2>
9522152
D002045_D009461 NONE <e1>bupivacaine</e1> injection <e2>deficit</e2>
D002045_D009461 NONE <e1>bupivacaine</e1> mg occurred <e2>deficit</e2>
17562951
D007479_D051436 NONE <e1>iopamidol</e1> comparison patients <e2>disease</e2>
C044834_D051436 NONE <e1>iodixanol</e1> iopamidol comparison patients <e2>disease</e2>
D000111_D003920 NONE <e1>n-acetylcysteine</e1> use patients presence <e2>mellitus</e2>
D007479_D003920 NONE <e1>iopamidol</e1> increases patients <e2>diabetes</e2>
D007479_D003920 NONE <e1>iopamidol</e1> less patients <e2>diabetes</e2>
D007479_D003920 NONE <e1>iopamidol</e1> administration different <e2>mellitus</e2>
C044834_D003920 NONE <e1>iodixanol</e1> iopamidol increases patients <e2>diabetes</e2>
C044834_D003920 NONE <e1>iodixanol</e1> iopamidol administration different <e2>mellitus</e2>
D007479_D007674 CID <e1>iopamidol</e1> administration different rate <e2>nephropathy</e2>
C044834_D007674 CID <e1>iodixanol</e1> iopamidol administration different rate <e2>nephropathy</e2>
12574103
D003907_D006973 CID <e1>dexamethasone</e1> programs <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone</e1> programmed increase <e2>pressure</e2>
D003907_D006973 CID <e1>dexamethasone</e1> received rats had <e2>pressures</e2>
D003907_D006973 CID <e1>dexamethasone</e1> results reduction number <e2>hypertension</e2>
D003907_D007674 CID <e1>dexamethasone</e1> programs hypertension <e2>injury</e2>
D003907_D007674 CID <e1>dexamethasone</e1> programmed increase pressure <e2>injury</e2>
D003907_D007674 CID <e1>dexamethasone</e1> administered had reduction <e2>number</e2>
D003907_D007674 CID <e1>dexamethasone</e1> received rats had have reduction <e2>number</e2>
D003907_D007674 CID <e1>dexamethasone</e1> results reduction <e2>number</e2>
D003907_D005921 NONE <e1>dexamethasone</e1> given had <e2>glomerulosclerosis</e2>
D003907_D005921 NONE <e1>dexamethasone</e1> results reduction number <e2>glomerulosclerosis</e2>
18023325
D004221_D014826 CID <e1>disulfiram</e1> intoxication <e2>palsy</e2>
D004221_D014826 CID <e1>disulfiram</e1> overdose caused neuropathy rare is report leading <e2>palsy</e2>
D004221_D010523 CID <e1>disulfiram</e1> overdose caused <e2>neuropathy</e2>
D004221_D062787 NONE <e1>disulfiram</e1> <e2>overdose</e2>
D004221_D010243 NONE <e1>disulfiram</e1> intoxication caused polyneuropathy superimposed case <e2>palsy</e2>
D004221_D011115 NONE <e1>disulfiram</e1> intoxication caused <e2>polyneuropathy</e2>
12369736
D003042_D009069 CID <e1>cocaine-induced</e1> <e2>hyperactivity</e2>
D003042_D009069 CID <e1>cocaine</e1> induced <e2>hyperactivity</e2>
D003042_D009069 CID <e1>cocaine</e1> prior gr attenuated <e2>hyperactivity</e2>
D003042_D009069 CID <e1>cocaine</e1> induced modified <e2>hyperlocomotion</e2>
C103477_D009069 NONE <e1>55562</e1> gr attenuated <e2>hyperactivity</e2>
C103477_D009069 NONE <e1>55562</e1> gr antagonist effects inhibitory consisting modification indicate modified <e2>hyperlocomotion</e2>
C065046_D009069 CID <e1>93129</e1> cp agonist antagonist effects inhibitory consisting modification indicate modified <e2>hyperlocomotion</e2>
8953972
D004837_D013345 CID <e1>epinephrine</e1> use associated <e2>bleeding</e2>
D004837_D012128 NONE <e1>epinephrine</e1> administer led onset <e2>distress</e2>
D004837_D005076 NONE <e1>epinephrine</e1> administer led onset distress <e2>rash</e2>
D004837_D006323 CID <e1>epinephrine</e1> has role <e2>arrest</e2>
D004837_D004342 NONE <e1>epinephrine</e1> has viewed use paramedics patients <e2>reaction</e2>
D004837_D006973 NONE <e1>epinephrine</e1> has viewed <e2>hypertension</e2>
20588063
D011692_D009401 CID <e1>aminonucleoside</e1> <e2>nephrosis</e2>
D011692_D009401 CID <e1>aminonucleoside</e1> <e2>nephrosis</e2>
9293063
D003613_D001650 CID <e1>danazol</e1> treatment association occurring <e2>hamartoma</e2>
D003613_D001650 CID <e1>danazol</e1> treatment patient developed case <e2>hamartoma</e2>
D003613_D006222 CID <e1>danazol</e1> treatment association occurring <e2>hamartoma</e2>
D003613_D006222 CID <e1>danazol</e1> treatment patient developed case <e2>hamartoma</e2>
6634932
C002616_D017180 NONE <e1>um-272</e1> administered dogs <e2>tachycardias</e2>
C002616_D017180 NONE <e1>n-dimethylpropranolol</e1> n um-272 administered dogs <e2>tachycardias</e2>
C002616_D017180 NONE <e1>um-272</e1> converted <e2>tachycardia</e2>
D010042_D017180 CID <e1>ouabain-induced</e1> <e2>tachycardias</e2>
15602202
D017963_D009395 CID <e1>azithromycin</e1> induced <e2>nephritis</e2>
D017963_D009395 CID <e1>azithromycin-induced</e1> recurrent <e2>nephritis</e2>
8638206
D001279_D010243 CID <e1>atracurium</e1> use <e2>paralysis</e2>
D001279_D010243 CID <e1>besylate</e1> associated <e2>paralysis</e2>
D001279_D010243 CID <e1>atracurium-related</e1> <e2>paralysis</e2>
D014673_D010243 CID <e1>bromide</e1> nmbas involved have reports <e2>paralysis</e2>
-1_D010243 NONE <e1>benzylisoquinolinium</e1> nmba besylate associated <e2>paralysis</e2>
15632880
D013148_D051437 CID <e1>spironolactone-induced</e1> <e2>insufficiency</e2>
D013148_D051437 CID <e1>spironolactone</e1> use evaluating trial reported risk hyperkalemia <e2>insufficiency</e2>
D013148_D051437 CID <e1>spironolactone</e1> treated patients prevalence associations hyperkalemia <e2>insufficiency</e2>
D013148_D051437 CID <e1>spironolactone</e1> discontinuation hyperkalemia <e2>failure</e2>
D013148_D051437 CID <e1>spironolactone-induced</e1> hyperkalemia <e2>insufficiency</e2>
D013148_D006947 CID <e1>spironolactone-induced</e1> insufficiency <e2>hyperkalemia</e2>
D013148_D006947 CID <e1>spironolactone</e1> use evaluating trial reported risk <e2>hyperkalemia</e2>
D013148_D006947 CID <e1>spironolactone</e1> treated patients prevalence associations <e2>hyperkalemia</e2>
D013148_D006947 CID <e1>spironolactone</e1> discontinuation <e2>hyperkalemia</e2>
D013148_D006947 CID <e1>spironolactone-induced</e1> <e2>hyperkalemia</e2>
D013148_D006333 NONE <e1>spironolactone-induced</e1> insufficiency patients <e2>failure</e2>
D013148_D006333 NONE <e1>spironolactone</e1> use patients <e2>failure</e2>
D013148_D006333 NONE <e1>spironolactone</e1> benefits reported changed treatments <e2>failure</e2>
D013148_D006333 NONE <e1>spironolactone</e1> treated patients <e2>failure</e2>
D013148_D006333 NONE <e1>spironolactone</e1> treated patients <e2>failure</e2>
D011188_D006947 NONE <e1>k(+</e1> <e2>hyperkalemia</e2>
D011188_D006947 NONE <e1>potassium</e1> levels had older patients developed <e2>hyperkalemia</e2>
D011188_D006947 NONE <e1>potassium</e1> doses levels had older patients developed <e2>hyperkalemia</e2>
D011188_D051437 NONE <e1>k(+</e1> hyperkalemia developed patients <e2>insufficiency</e2>
D002857_D006947 NONE <e1>cr</e1> or=2.5 patients developed <e2>hyperkalemia</e2>
D002857_D051437 NONE <e1>cr</e1> or=2.5 patients <e2>insufficiency</e2>
D011188_D003920 NONE <e1>potassium</e1> levels had older likely have <e2>diabetes</e2>
D011188_D003920 NONE <e1>potassium</e1> doses levels had older likely have <e2>diabetes</e2>
D003404_D051437 NONE <e1>creatinine</e1> weight had patients developed <e2>insufficiency</e2>
D049971_D051437 NONE <e1>thiazide</e1> diuretics treated likely had patients developed <e2>insufficiency</e2>
6386793
D004308_D003866 NONE <e1>hydrochloride</e1> efficacy study treatment <e2>disorder</e2>
D004308_D003866 NONE <e1>dothiepin</e1> study compared placebo treatment outpatients <e2>depressed</e2>
D004308_D003866 NONE <e1>dothiepin</e1> effective alleviating symptoms <e2>illness</e2>
D004308_D003866 NONE <e1>dothiepin</e1> found drug associated effects amitriptyline treatment outpatients <e2>depressed</e2>
D000639_D003866 NONE <e1>amitriptyline</e1> dothiepin study compared placebo treatment outpatients <e2>depressed</e2>
D000639_D003866 NONE <e1>amitriptyline</e1> dothiepin effective alleviating symptoms <e2>illness</e2>
D000639_D003866 NONE <e1>amitriptyline</e1> treatment outpatients <e2>depressed</e2>
D004308_D014786 NONE <e1>dothiepin</e1> less incidence frequency <e2>vision</e2>
D004308_D014987 NONE <e1>dothiepin</e1> less incidence frequency vision <e2>mouth</e2>
D000639_D014786 CID <e1>amitriptyline</e1> less incidence frequency <e2>vision</e2>
D000639_D014987 CID <e1>amitriptyline</e1> less incidence frequency vision <e2>mouth</e2>
D000928_D003866 NONE <e1>antidepressant</e1> drug associated effects amitriptyline treatment outpatients <e2>depressed</e2>
2673163
D003042_D020521 NONE <e1>cocaine</e1> use associated <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use related <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use followed <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use related <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use related stroke incidence increasing occurs <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use related stroke incidence increasing follow <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use related stroke incidence increasing <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use related stroke incidence increasing 5 <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke occurs increasing incidence <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke occurs increasing follow <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke occurs increasing <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke occurs increasing 5 <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> administration route follow increasing incidence <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> administration route follow increasing occurs <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> administration route follow <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> administration route follow increasing <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> administration route follow increasing 5 <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use stroke increasing incidence <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use stroke increasing occurs <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use stroke increasing follow <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> use stroke increasing 5 <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke 5 increasing incidence <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke 5 increasing occurs <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke 5 increasing follow <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> stroke 5 increasing <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine-associated</e1> <e2>stroke</e2>
D003042_D002532 NONE <e1>cocaine</e1> use related stroke incidence increasing associated <e2>aneurysms</e2>
D003042_D002532 NONE <e1>cocaine-associated</e1> stroke occurs increasing associated <e2>aneurysms</e2>
D003042_D002532 NONE <e1>cocaine</e1> administration route follow increasing associated <e2>aneurysms</e2>
D003042_D002532 NONE <e1>cocaine</e1> use stroke increasing associated <e2>aneurysms</e2>
D003042_D002532 NONE <e1>cocaine-associated</e1> stroke 5 increasing associated <e2>aneurysms</e2>
D003042_D001165 NONE <e1>cocaine</e1> use related stroke incidence increasing associated aneurysms <e2>malformations</e2>
D003042_D001165 NONE <e1>cocaine-associated</e1> stroke occurs increasing associated aneurysms <e2>malformations</e2>
D003042_D001165 NONE <e1>cocaine</e1> administration route follow increasing associated aneurysms <e2>malformations</e2>
D003042_D001165 NONE <e1>cocaine</e1> use stroke increasing associated aneurysms <e2>malformations</e2>
D003042_D001165 NONE <e1>cocaine-associated</e1> stroke 5 increasing associated aneurysms <e2>malformations</e2>
D003042_D020300 NONE <e1>cocaine</e1> use related stroke incidence increasing 5 frequency exceeds <e2>hemorrhage</e2>
D003042_D020300 NONE <e1>cocaine-associated</e1> stroke occurs increasing 5 frequency exceeds <e2>hemorrhage</e2>
D003042_D020300 NONE <e1>cocaine</e1> administration route follow increasing 5 frequency exceeds <e2>hemorrhage</e2>
D003042_D020300 NONE <e1>cocaine</e1> use stroke increasing 5 frequency exceeds <e2>hemorrhage</e2>
D003042_D020300 NONE <e1>cocaine-associated</e1> stroke 5 frequency exceeds <e2>hemorrhage</e2>
D003042_D002544 CID <e1>cocaine</e1> use related stroke incidence increasing 5 that <e2>infarction</e2>
D003042_D002544 CID <e1>cocaine-associated</e1> stroke occurs increasing 5 that <e2>infarction</e2>
D003042_D002544 CID <e1>cocaine</e1> administration route follow increasing 5 that <e2>infarction</e2>
D003042_D002544 CID <e1>cocaine</e1> use stroke increasing 5 that <e2>infarction</e2>
D003042_D002544 CID <e1>cocaine-associated</e1> stroke 5 that <e2>infarction</e2>
19803309
D013390_D009224 NONE <e1>suxamethonium</e1> dose developed primigravida case <e2>congenita</e2>
D013390_D014313 CID <e1>suxamethonium</e1> dose developed life threatening <e2>spasm</e2>
234669
D000628_D014693 CID <e1>aminophylline</e1> effects initiating <e2>fibrillation</e2>
D000628_D014693 CID <e1>aminophylline</e1> effects threshold <e2>fibrillation</e2>
D000628_D014693 CID <e1>aminophylline</e1> infusion reduced threshold <e2>fibrillation</e2>
D000628_D014693 CID <e1>aminophylline</e1> infusion resulted decrease threshold <e2>fibrillation</e2>
D000628_D012131 NONE <e1>aminophylline</e1> effects initiating <e2>failure</e2>
D000628_D012131 NONE <e1>aminophylline</e1> effects conditions <e2>failure</e2>
D000628_D012131 NONE <e1>aminophylline</e1> infusion resulted produced <e2>failure</e2>
D000628_D012131 NONE <e1>aminophylline</e1> agents <e2>failure</e2>
D010100_D014693 NONE <e1>oxygen</e1> pressures ph kept reduced threshold <e2>fibrillation</e2>
C093415_D014693 NONE <e1>po2</e1> oxygen pressures ph kept reduced threshold <e2>fibrillation</e2>
D002245_D014693 NONE <e1>dioxide</e1> oxygen pressures ph kept reduced threshold <e2>fibrillation</e2>
D002245_D014693 NONE <e1>co2</e1> dioxide oxygen pressures ph kept reduced threshold <e2>fibrillation</e2>
D000628_D007040 NONE <e1>aminophylline</e1> infusion resulted produced <e2>hypoventilation</e2>
D000628_D001145 NONE <e1>aminophylline</e1> agents failure <e2>arrhythmias</e2>
3985451
D014859_D006470 NONE <e1>warfarin-induced</e1> <e2>hemorrhage</e2>
D014859_D020428 CID <e1>warfarin-induced</e1> hemorrhage <e2>palsy</e2>
D014859_D020428 CID <e1>warfarin-induced</e1> neuropathy form represents <e2>palsy</e2>
D014859_D009135 CID <e1>warfarin</e1> therapy man sustained <e2>tear</e2>
D014859_D010146 NONE <e1>warfarin</e1> therapy man sustained developed <e2>pain</e2>
D014859_D010146 NONE <e1>warfarin-induced</e1> neuropathy form represents characterized <e2>pain</e2>
D014859_D003286 NONE <e1>warfarin</e1> therapy man sustained developed pain <e2>contracture</e2>
D014859_D003286 NONE <e1>warfarin-induced</e1> neuropathy form represents characterized degrees <e2>contracture</e2>
D014859_D010523 NONE <e1>warfarin-induced</e1> <e2>neuropathy</e2>
D014859_D015417 NONE <e1>warfarin-induced</e1> neuropathy form represents characterized degrees <e2>impairment</e2>
19356053
D020123_D011507 CID <e1>sirolimus</e1> administration <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> use linked <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> use associated <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> therapy <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> therapy commencement association implicated etiology <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> implicated association commencement therapy <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> implicated etiology <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> initiation development <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> therapy correlated <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> discontinuation resulted decrease <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> induces aggravates <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> withdrawn improve <e2>proteinuria</e2>
D020123_D007674 NONE <e1>sirolimus</e1> agent have <e2>nephrotoxicity</e2>
D003404_D011507 NONE <e1>creatinine</e1> ratios samples assessed magnitude <e2>proteinuria</e2>
D003404_D011507 NONE <e1>creatinine</e1> ratios estimate grams <e2>proteinuria/day</e2>
D020123_D009404 NONE <e1>sirolimus</e1> initiation development proteinuria <e2>nephrotic-range</e2>
7802851
D000525_D016584 NONE <e1>alprazolam</e1> placebo <e2>disorder</e2>
D000525_D016584 NONE <e1>alprazolam</e1> randomised london patients met criteria <e2>disorder</e2>
D000525_D000379 NONE <e1>alprazolam</e1> placebo <e2>agoraphobia</e2>
D000525_D000379 NONE <e1>alprazolam</e1> randomised london patients met <e2>agoraphobia</e2>
D000525_D003866 CID <e1>alprazolam</e1> patients developed reactions <e2>depression</e2>
D000525_D004775 CID <e1>alprazolam</e1> patients developed reactions depression <e2>enuresis</e2>
D000525_D001523 NONE <e1>alprazolam</e1> patients developed reactions depression disinhibition <e2>aggression</e2>
D000525_D001523 NONE <e1>alprazolam</e1> patients developed side-effects sedation <e2>irritability</e2>
D000525_D008569 CID <e1>alprazolam</e1> patients developed side-effects <e2>memory</e2>
D000525_D015431 CID <e1>alprazolam</e1> patients developed side-effects <e2>loss</e2>
D000525_D001259 CID <e1>alprazolam</e1> patients developed side-effects loss <e2>ataxia</e2>
6503301
D003606_D006504 CID <e1>dacarbazine</e1> therapy <e2>disease</e2>
D003606_D006504 CID <e1>dtic</e1> therapy <e2>disease</e2>
D003606_D006504 CID <e1>dacarbazine</e1> therapy outcome case disease <e2>liver</e2>
D003606_D006504 CID <e1>dtic</e1> therapy outcome case disease <e2>liver</e2>
D003606_D008545 NONE <e1>dacarbazine</e1> therapy <e2>melanoma</e2>
D003606_D008545 NONE <e1>dtic</e1> therapy <e2>melanoma</e2>
D003606_D008545 NONE <e1>dacarbazine</e1> therapy <e2>melanoma</e2>
D003606_D008545 NONE <e1>dtic</e1> therapy <e2>melanoma</e2>
3714122
C005238_D020258 NONE <e1>mipafox-induced</e1> damage inhibition <e2>neurotoxic</e2>
C005238_D020258 NONE <e1>mipafox</e1> exposed rats examined correlation damage esterase <e2>neurotoxic</e2>
C005238_D020258 NONE <e1>mipafox</e1> organophosphate <e2>neurotoxic</e2>
C005238_D020258 NONE <e1>n'-diisopropylphosphorodiamidofluoridate</e1> mipafox exposed rats examined correlation damage esterase <e2>neurotoxic</e2>
C005238_D020258 NONE <e1>n'-diisopropylphosphorodiamidofluoridate</e1> mipafox organophosphate <e2>neurotoxic</e2>
C005238_D009422 NONE <e1>mipafox-induced</e1> <e2>damage</e2>
C005238_D009422 NONE <e1>mipafox</e1> exposed rats examined correlation <e2>damage</e2>
C005238_D009422 NONE <e1>mipafox</e1> exposed rats examined correlation damage esterase enzyme <e2>neuropathy</e2>
C005238_D009422 NONE <e1>n'-diisopropylphosphorodiamidofluoridate</e1> mipafox exposed rats examined correlation <e2>damage</e2>
C005238_D009422 NONE <e1>n'-diisopropylphosphorodiamidofluoridate</e1> mipafox exposed rats examined correlation damage esterase enzyme <e2>neuropathy</e2>
C005238_D009422 NONE <e1>mipafox</e1> exposure predict <e2>damage</e2>
D010755_D009422 NONE <e1>organophosphate</e1> mipafox exposed rats examined correlation <e2>damage</e2>
D010755_D009422 NONE <e1>organophosphate</e1> mipafox exposed rats examined correlation damage esterase enzyme <e2>neuropathy</e2>
D010755_D020258 NONE <e1>organophosphate</e1> mipafox exposed rats examined correlation damage esterase <e2>neurotoxic</e2>
D010755_D020258 NONE <e1>organophosphate</e1> <e2>neurotoxic</e2>
C005238_D013118 CID <e1>mipafox</e1> dosages produced degree <e2>damage</e2>
2559236
D004317_D007674 NONE <e1>adriamycin-induced</e1> <e2>nephropathy</e2>
D004317_D007674 NONE <e1>adriamycin</e1> nephrosis assess effect enalapril progression <e2>injury</e2>
D004656_D009401 NONE <e1>enalapril</e1> effect assessed rats <e2>nephrosis</e2>
D004656_D009401 NONE <e1>enalapril</e1> effect assess <e2>nephrosis</e2>
D004317_D009401 CID <e1>adriamycin</e1> <e2>nephrosis</e2>
D004317_D009401 CID <e1>adriamycin</e1> <e2>nephrosis</e2>
D004317_D000419 CID <e1>adriamycin</e1> dose given divided groups matched <e2>albuminuria</e2>
D004656_D000419 NONE <e1>enalapril</e1> reduced reducing <e2>albuminuria</e2>
D004656_D000419 NONE <e1>enalapril</e1> treatment reduced reducing <e2>albuminuria</e2>
D004656_D007674 NONE <e1>enalapril</e1> progression <e2>injury</e2>
10739826
D003276_D054556 CID <e1>contraceptives</e1> risk <e2>thromboembolism</e2>
D003276_D054556 CID <e1>contraceptives</e1> associated <e2>thromboembolism</e2>
D003276_D054556 CID <e1>contraceptives</e1> associated thromboembolism <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> contraceptives associated <e2>thromboembolism</e2>
D003276_D054556 CID <e1>oc</e1> contraceptives associated thromboembolism <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> use patterns distinguish studies assessed risk <e2>thromboembolism</e2>
D003276_D054556 CID <e1>oc</e1> use patterns distinguish studies assessed risk thromboembolism <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> users ratio <e2>vte</e2>
12627929
C067311_D054556 CID <e1>docetaxel</e1> combination <e2>thromboembolism</e2>
C067311_D054556 CID <e1>docetaxel</e1> treated patients <e2>thromboembolism</e2>
C067311_D054556 CID <e1>docetaxel</e1> treated patients thromboembolism <e2>vte</e2>
C067311_D054556 CID <e1>docetaxel</e1> received patients none developed <e2>vte</e2>
C067311_D054556 CID <e1>docetaxel</e1> received patients none developed developed <e2>vte</e2>
C067311_D054556 CID <e1>docetaxel</e1> received 9 developed developed <e2>vte</e2>
C067311_D054556 CID <e1>docetaxel</e1> received 9 developed <e2>vte</e2>
C067311_D054556 CID <e1>docetaxel</e1> addition increases frequency <e2>vte</e2>
C067311_D011471 NONE <e1>docetaxel</e1> combination thromboembolism thalidomide patients <e2>cancer</e2>
C067311_D011471 NONE <e1>docetaxel</e1> treated patients <e2>cancer</e2>
C067311_D011471 NONE <e1>docetaxel</e1> treatment <e2>cancer</e2>
D013792_D054556 CID <e1>thalidomide</e1> <e2>thromboembolism</e2>
D013792_D054556 CID <e1>thalidomide</e1> combination <e2>thromboembolism</e2>
D013792_D054556 CID <e1>thalidomide</e1> combination thromboembolism <e2>vte</e2>
D013792_D054556 CID <e1>thalidomide</e1> docetaxel received 9 developed developed <e2>vte</e2>
D013792_D054556 CID <e1>thalidomide</e1> docetaxel received 9 developed <e2>vte</e2>
D013792_D054556 CID <e1>thalidomide</e1> addition increases frequency <e2>vte</e2>
D013792_D011471 NONE <e1>thalidomide</e1> patients <e2>cancer</e2>
D013792_D011471 NONE <e1>thalidomide</e1> combination thromboembolism patients <e2>cancer</e2>
D013792_D011471 NONE <e1>thalidomide</e1> addition docetaxel treatment <e2>cancer</e2>
8919272
D014635_D001927 CID <e1>valproate</e1> features <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate</e1> application revealed valproate <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate</e1> <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate</e1> <e2>encephalopathy</e2>
D014635_D009422 NONE <e1>valproate</e1> application revealed <e2>disorders</e2>
D014635_D009422 NONE <e1>valproate</e1> revealed <e2>disorders</e2>
D014635_D002526 NONE <e1>valproate</e1> application revealed disorders indicating <e2>damage</e2>
D014635_D002526 NONE <e1>valproate</e1> revealed disorders indicating <e2>damage</e2>
D014635_D056486 NONE <e1>valproate</e1> encephalopathy development influence <e2>damage</e2>
D014635_D022124 NONE <e1>valproate</e1> encephalopathy development influence damage <e2>hyperammonemia</e2>
18439803
C108761_D012640 NONE <e1>n-(2-propylpentanoyl)urea</e1> effects <e2>seizure</e2>
C108761_D012640 NONE <e1>vpu</e1> potent <e2>seizure</e2>
C108761_D012640 NONE <e1>vpu</e1> protect <e2>seizure</e2>
C108761_D012640 NONE <e1>vpu</e1> reduce finding account activity observed <e2>seizure</e2>
D000596_D012640 NONE <e1>acid</e1> neurotransmitters effects <e2>seizure</e2>
D000596_D012640 NONE <e1>acid</e1> neurotransmitters reduction minor suggested based finding protect <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> rats protecting exhibiting potent <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> increases reduce finding account activity observed <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizure</e2>
D014635_D012640 NONE <e1>vpa</e1> potent <e2>seizure</e2>
D014635_D012640 NONE <e1>vpa</e1> value mg/kg <e2>seizure</e2>
D014635_D012640 NONE <e1>vpa</e1> vpu protect <e2>seizure</e2>
D014635_D012640 NONE <e1>vpa</e1> account activity observed <e2>seizure</e2>
D018698_D012640 NONE <e1>glutamate</e1> reduction offset minor suggested based finding protect <e2>seizure</e2>
D018698_D012640 NONE <e1>glutamate</e1> increases reduce finding account activity observed <e2>seizure</e2>
D001224_D012640 NONE <e1>aspartate</e1> glutamate reduction offset minor suggested based finding protect <e2>seizure</e2>
D001224_D012640 NONE <e1>aspartate</e1> glutamate increases reduce finding account activity observed <e2>seizure</e2>
1720453
D007069_D007674 CID <e1>ifosfamide</e1> <e2>toxicity</e2>
D007069_C535700 NONE <e1>ifosfamide</e1> toxicity children treated <e2>tumors</e2>
D007069_C535700 NONE <e1>ifosfamide</e1> protocol received function children <e2>tumors</e2>
D007069_C535700 NONE <e1>ifosfamide</e1> protocol society study <e2>tumor</e2>
D007069_C535700 NONE <e1>ifosfamide</e1> efficacy respect treatment <e2>tumors</e2>
D003404_D006030 NONE <e1>creatinine</e1> clearance plasma <e2>glucosuria</e2>
D003404_D011507 NONE <e1>creatinine</e1> clearance plasma glucosuria <e2>proteinuria</e2>
D003404_D000608 NONE <e1>creatinine</e1> clearance plasma glucosuria proteinuria <e2>aminoaciduria</e2>
D010710_D006030 NONE <e1>phosphate</e1> reabsorption measuring plasma <e2>glucosuria</e2>
D010710_D011507 NONE <e1>phosphate</e1> reabsorption measuring plasma glucosuria <e2>proteinuria</e2>
D010710_D000608 NONE <e1>phosphate</e1> reabsorption measuring plasma glucosuria proteinuria <e2>aminoaciduria</e2>
D010710_D064420 NONE <e1>phosphate</e1> reabsorption patients included identified patients developed <e2>toxicity</e2>
D010710_D005198 NONE <e1>phosphate</e1> reabsorption patients included identified patients developed toxicity resulting <e2>syndrome</e2>
D010710_D005198 NONE <e1>phosphate</e1> reabsorption patients included identified patients developed toxicity resulting syndrome <e2>tdfs</e2>
D007069_D064420 NONE <e1>ifosfamide</e1> g/m2 dose correlated <e2>toxicity</e2>
D007069_D009369 NONE <e1>ifosfamide</e1> g/m2 dose predominance involvement <e2>tumor</e2>
9245658
D009538_D002318 CID <e1>nicotine</e1> role <e2>disease</e2>
D009538_D002318 CID <e1>nicotine</e1> activates contribute <e2>disease</e2>
D009538_D050197 CID <e1>nicotine</e1> play accelerating <e2>atherosclerosis</e2>
D009538_D013927 NONE <e1>nicotine</e1> appear enhance <e2>thrombosis</e2>
9746003
D002220_D004832 CID <e1>carbamazepine</e1> use <e2>seizures</e2>
D002220_D004832 CID <e1>carbamazepine</e1> contraindicated <e2>seizures</e2>
D020888_D004832 CID <e1>vigabatrin</e1> carbamazepine use <e2>seizures</e2>
D020888_D004832 CID <e1>vigabatrin</e1> carbamazepine contraindicated <e2>seizures</e2>
D002220_D009207 CID <e1>carbamazepine</e1> treated children two <e2>jerks</e2>
D002220_D009207 CID <e1>carbamazepine</e1> withdrawal resolved children two <e2>jerks</e2>
18081909
C026098_D001927 CID <e1>levetiracetam</e1> induced <e2>encephalopathy</e2>
C026098_D001927 CID <e1>levetiracetam</e1> (lev)-induced <e2>encephalopathy</e2>
C026098_D001927 CID <e1>(lev)-induced</e1> <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate</e1> added <e2>encephalopathy</e2>
C026098_C562694 NONE <e1>lev</e1> treated man suffering <e2>epilepsy</e2>
C026098_D012640 NONE <e1>lev</e1> treated man suffering <e2>seizures</e2>
C026098_D012640 NONE <e1>lev</e1> discontinuation improved <e2>seizure</e2>
D014635_C562694 NONE <e1>valproate</e1> added lev treated man suffering <e2>epilepsy</e2>
D014635_C562694 NONE <e1>vpa</e1> valproate added lev treated man suffering <e2>epilepsy</e2>
D014635_D012640 NONE <e1>valproate</e1> added lev treated man suffering <e2>seizures</e2>
D014635_D012640 NONE <e1>vpa</e1> valproate added lev treated man suffering <e2>seizures</e2>
20520283
C522667_D012559 NONE <e1>asenapine</e1> efficacy trial patients exacerbation <e2>schizophrenia</e2>
C522667_D012559 NONE <e1>asenapine</e1> approved administration adults treatment <e2>schizophrenia</e2>
C522667_D012559 NONE <e1>asenapine</e1> treatment assigned patients <e2>schizophrenia</e2>
C522667_D012559 NONE <e1>asenapine</e1> assigned patients <e2>schizophrenia</e2>
D006220_D012559 NONE <e1>haloperidol-controlled</e1> placebo- trial patients exacerbation <e2>schizophrenia</e2>
D006220_D012559 NONE <e1>haloperidol</e1> asenapine assigned patients <e2>schizophrenia</e2>
C522667_D001714 NONE <e1>asenapine</e1> approved administration adults treatment schizophrenia episodes <e2>manic</e2>
C522667_D001714 NONE <e1>asenapine</e1> approved administration adults treatment schizophrenia episodes associated <e2>disorder</e2>
C522667_D011618 NONE <e1>asenapine</e1> approved administration adults treatment schizophrenia episodes associated features <e2>psychotic</e2>
C522667_D001480 CID <e1>asenapine</e1> % reported <e2>symptoms</e2>
C522667_D001480 CID <e1>asenapine</e1> similar indicated seen aes <e2>symptoms</e2>
D006220_D001480 CID <e1>haloperidol</e1> bid % reported <e2>symptoms</e2>
D006220_D001480 CID <e1>haloperidol</e1> asenapine similar indicated seen aes <e2>symptoms</e2>
7504976
D002231_D056486 CID <e1>carbimazole</e1> cross-reactivity one cases <e2>hepatitis</e2>
D002231_D056486 CID <e1>carbimazole</e1> induced <e2>hepatitis</e2>
D002231_D056486 CID <e1>omercazole</e1> carbimazole induced <e2>hepatitis</e2>
D002231_D056486 CID <e1>carbimazole</e1> had <e2>hepatitis</e2>
D002231_D056486 CID <e1>carbimazole</e1> replaced experienced <e2>hepatitis</e2>
C019269_D056486 NONE <e1>benzylthiouracil</e1> carbimazole cross-reactivity one cases <e2>hepatitis</e2>
C019269_D056486 NONE <e1>benzylthiouracil</e1> appeared <e2>hepatitis</e2>
C019269_D056486 NONE <e1>ne</e1> benzylthiouracil appeared <e2>hepatitis</e2>
D002231_D002779 CID <e1>carbimazole</e1> induced <e2>hepatitis</e2>
D002231_D002779 CID <e1>omercazole</e1> carbimazole induced <e2>hepatitis</e2>
D002231_D002779 CID <e1>carbimazole</e1> had hepatitis mixed <e2>cholestatic</e2>
11007689
D016572_D057049 CID <e1>cyclosporine</e1> <e2>microangiopathy</e2>
D016572_D057049 CID <e1>cyclosporine</e1> use associated <e2>microangiopathy</e2>
D016572_D057049 CID <e1>cyclosporine</e1> use associated microangiopathy <e2>tma</e2>
D016572_D057049 CID <e1>cyclosporine-induced</e1> <e2>tma</e2>
D016572_D057049 CID <e1>cyclosporine</e1> exposed patients recurrence <e2>tma</e2>
D016572_D057049 CID <e1>cyclosporine-induced</e1> <e2>tma</e2>
D016572_D057049 CID <e1>cyclosporine</e1> withdrawal responded <e2>tma</e2>
D016572_D057049 CID <e1>cyclosporine</e1> switched patients monitored signs <e2>tma</e2>
D016559_D057049 CID <e1>tacrolimus-associated</e1> cyclosporine <e2>microangiopathy</e2>
D016559_D057049 CID <e1>tacrolimus</e1> switching reported option setting <e2>tma</e2>
D016559_D057049 CID <e1>tacrolimus</e1> application recognized <e2>tma</e2>
D016559_D057049 CID <e1>tacrolimus-associated</e1> <e2>tma</e2>
D016559_D057049 CID <e1>tacrolimus</e1> cyclosporine exposed patients recurrence <e2>tma</e2>
D016559_D057049 CID <e1>tacrolimus</e1> introduction resulted recurrence <e2>tma</e2>
D016559_D057049 CID <e1>tacrolimus</e1> switched patients monitored signs <e2>tma</e2>
8682684
D000082_D007022 CID <e1>acetaminophen-induced</e1> <e2>hypotension</e2>
D000082_D007022 CID <e1>acetaminophen</e1> demonstrated produce symptoms <e2>hypotension</e2>
D000082_D007022 CID <e1>acetaminophen</e1> administration developed episodes <e2>hypotension</e2>
D000082_D007022 CID <e1>acetaminophen</e1> consider patients <e2>hypotension</e2>
D000082_D002318 NONE <e1>acetaminophen</e1> produce <e2>toxicities</e2>
D000082_D000707 NONE <e1>acetaminophen</e1> demonstrated produce symptoms <e2>anaphylaxis</e2>
D000082_D016638 NONE <e1>acetaminophen</e1> administration developed patients <e2>ill</e2>
15737522
D002443_D001660 CID <e1>ceftriaxone-associated</e1> <e2>pseudolithiasis</e2>
D002443_D001660 CID <e1>ceftriaxone</e1> leads <e2>pseudolithiasis</e2>
D002443_D001660 CID <e1>ceftriaxone</e1> treatment receiving patients incidence <e2>pseudolithiasis</e2>
19767176
C020972_D013226 NONE <e1>dithiocarbamate</e1> protects model <e2>epilepticus</e2>
C020972_D013226 NONE <e1>pdtc</e1> effect loss <e2>epilepticus-associated</e2>
C020972_D013226 NONE <e1>pdtc</e1> treatment <e2>epilepticus</e2>
C020972_D013226 NONE <e1>pdtc</e1> administration exert effects development <e2>epilepticus</e2>
C020972_D013226 NONE <e1>pdtc-treated</e1> vehicle- identified <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> model <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> model fractionated evaluated effect loss <e2>epilepticus-associated</e2>
D010100_D009410 NONE <e1>oxygen</e1> species production implicated <e2>damage</e2>
D010100_D009410 NONE <e1>oxygen</e1> species generation plays <e2>damage</e2>
C020972_D009410 NONE <e1>pdtc</e1> inhibitor protected affect <e2>loss</e2>
D010100_D012640 NONE <e1>oxygen</e1> species generation plays damage <e2>seizure-associated</e2>
10193204
C009438_D013927 NONE <e1>tetrandrine</e1> effects <e2>thrombosis</e2>
C009438_D013927 NONE <e1>tet</e1> effects <e2>thrombosis</e2>
C009438_D013927 NONE <e1>tet</e1> administration showed inhibition <e2>thrombosis</e2>
C009438_D001791 NONE <e1>tetrandrine</e1> effects thrombosis mice <e2>aggregation</e2>
C009438_D001791 NONE <e1>tet</e1> effects investigate undertaken <e2>aggregation</e2>
C009438_D001791 NONE <e1>tet</e1> tests used agonists induced <e2>aggregations</e2>
C060802_D013927 NONE <e1>fangchinoline</e1> tetrandrine effects <e2>thrombosis</e2>
C060802_D013927 NONE <e1>fan</e1> tet effects <e2>thrombosis</e2>
C060802_D013927 NONE <e1>fan</e1> tet administration showed inhibition <e2>thrombosis</e2>
C060802_D001791 NONE <e1>fangchinoline</e1> tetrandrine effects thrombosis mice <e2>aggregation</e2>
C060802_D001791 NONE <e1>fan</e1> tet effects investigate undertaken <e2>aggregation</e2>
C060802_D001791 NONE <e1>fan</e1> tet tests used agonists induced <e2>aggregations</e2>
C009438_D001778 NONE <e1>tet</e1> effects investigate undertaken aggregation <e2>coagulation</e2>
C060802_D001778 NONE <e1>fan</e1> tet effects investigate undertaken aggregation <e2>coagulation</e2>
D004837_D013927 CID <e1>epinephrine</e1> collagen induced <e2>thrombosis</e2>
D004837_D013927 CID <e1>ep</e1> epinephrine collagen induced <e2>thrombosis</e2>
D004837_D001791 NONE <e1>epinephrine</e1> collagen induced thrombosis effects investigate undertaken <e2>aggregation</e2>
D004837_D001791 NONE <e1>ep</e1> epinephrine collagen induced thrombosis effects investigate undertaken <e2>aggregation</e2>
D004837_D001778 NONE <e1>epinephrine</e1> collagen induced thrombosis effects investigate undertaken aggregation <e2>coagulation</e2>
D004837_D001778 NONE <e1>ep</e1> epinephrine collagen induced thrombosis effects investigate undertaken aggregation <e2>coagulation</e2>
D001241_D013927 NONE <e1>acid</e1> showed showed inhibition <e2>thrombosis</e2>
D001241_D013927 NONE <e1>asa</e1> acid showed showed inhibition <e2>thrombosis</e2>
7083920
D000638_D006327 CID <e1>amiodarone</e1> treatment occurring <e2>block</e2>
D000638_D013617 NONE <e1>amiodarone</e1> treatment <e2>tachycardia</e2>
D000638_D006345 NONE <e1>amiodarone</e1> treatment tachycardia patient <e2>abnormalities</e2>
D000638_D001282 NONE <e1>amiodarone</e1> discontinuation days showed <e2>flutter</e2>
8558192
C030852_C562729 NONE <e1>vinorelbine</e1> trial <e2>carcinoma</e2>
C030852_C562729 NONE <e1>vinorelbine</e1> effects rate administered agent <e2>carcinoma</e2>
C030852_C562729 NONE <e1>vnb</e1> vinorelbine effects rate administered agent <e2>carcinoma</e2>
C030852_C562729 NONE <e1>vnb</e1> agent <e2>carcinoma</e2>
D002945_D064420 NONE <e1>cisplatin-based</e1> chemotherapy pretreated assessable <e2>toxicity</e2>
C030852_D064420 NONE <e1>vnb</e1> tolerated occurred instances <e2>toxicity</e2>
C030852_D064420 NONE <e1>vnb</e1> evaluation warranted profile <e2>toxicity</e2>
19299179
D015662_D002779 NONE <e1>co-trimoxazole</e1> treatment <e2>cholestasis</e2>
D015662_D011020 NONE <e1>co-trimoxazole</e1> treatment <e2>pneumonia</e2>
D015662_D011020 NONE <e1>co-trimoxazole</e1> doses treated <e2>pneumonia</e2>
D015662_D011020 NONE <e1>co-trimoxazole</e1> doses treated pneumonia <e2>pcp</e2>
D015662_D011020 NONE <e1>co-trimoxazole</e1> treatment <e2>pcp</e2>
D015662_D015658 NONE <e1>co-trimoxazole</e1> treatment pneumonia patients <e2>hiv-infected</e2>
D015662_D015658 NONE <e1>co-trimoxazole</e1> doses treated pneumonia infection individuals <e2>hiv-infected</e2>
D015662_D015658 NONE <e1>co-trimoxazole</e1> treatment lesions report cases patients <e2>hiv-infected</e2>
D015662_D009894 NONE <e1>co-trimoxazole</e1> doses treated pneumonia <e2>infection</e2>
D015662_D002780 CID <e1>co-trimoxazole</e1> treatment lesions report cases patients developed <e2>cholestasis</e2>
D015662_D008100 NONE <e1>co-trimoxazole</e1> treatment lesions mimicking formation <e2>abscess</e2>
19889778
12639165
D013988_D002779 CID <e1>ticlopidine-induced</e1> <e2>hepatitis</e2>
D013988_D002779 CID <e1>ticlopidine-induced</e1> <e2>hepatitis</e2>
D013988_D002779 CID <e1>ticlopidine</e1> receiving developed <e2>hepatitis</e2>
D013988_D002779 CID <e1>ticlopidine</e1> complication <e2>hepatitis</e2>
D013988_D002779 CID <e1>ticlopidine</e1> treatment developed showed characteristics <e2>hepatitis</e2>
D013988_D002779 CID <e1>ticlopidine-induced</e1> <e2>cholestasis</e2>
D013988_D002779 CID <e1>ticlopidine</e1> effect <e2>hepatitis</e2>
D013988_D056486 CID <e1>ticlopidine-induced</e1> <e2>hepatitis</e2>
D013988_D056486 CID <e1>ticlopidine-induced</e1> <e2>hepatitis</e2>
D013988_D056486 CID <e1>ticlopidine</e1> receiving developed <e2>hepatitis</e2>
D013988_D056486 CID <e1>ticlopidine</e1> complication <e2>hepatitis</e2>
D013988_D056486 CID <e1>ticlopidine</e1> treatment developed showed characteristics <e2>hepatitis</e2>
D013988_D056486 CID <e1>ticlopidine</e1> effect <e2>hepatitis</e2>
D013988_D007565 CID <e1>ticlopidine</e1> treatment developed <e2>jaundice</e2>
12063090
D004177_D003248 NONE <e1>metamizol</e1> potentiates antinociception <e2>constipation</e2>
D004177_D003248 NONE <e1>metamizol</e1> evaluates effects antinociceptive <e2>constipating</e2>
D004177_D003248 NONE <e1>metamizol</e1> potentiate <e2>constipation</e2>
D009020_D003248 CID <e1>morphine</e1> antinociception <e2>constipation</e2>
D009020_D003248 CID <e1>morphine</e1> combination effects antinociceptive <e2>constipating</e2>
D009020_D003248 CID <e1>morphine</e1> inhibited suggesting develop effects <e2>constipating</e2>
D009020_D003248 CID <e1>morphine</e1> produced that similar transit inhibited suggesting potentiate <e2>constipation</e2>
D009020_D003248 CID <e1>morphine-induced</e1> <e2>constipation</e2>
D002606_D010146 NONE <e1>charcoal</e1> meal test used assessed using model nociception model <e2>pain-induced</e2>
D009020_D059350 NONE <e1>morphine</e1> interaction show suggesting useful treatment <e2>pain</e2>
D004177_D059350 NONE <e1>metamizol</e1> morphine interaction show suggesting useful treatment <e2>pain</e2>
9672936
D008614_D012640 CID <e1>pethidine-associated</e1> <e2>seizure</e2>
D008614_D012640 CID <e1>pethidine</e1> <e2>seizure</e2>
D008614_D010149 NONE <e1>pethidine-associated</e1> seizure pethidine control <e2>pain</e2>
D008614_D010149 NONE <e1>pethidine</e1> control <e2>pain</e2>
D008614_D010149 NONE <e1>pethidine</e1> doses received pump management control <e2>pain</e2>
1749407
D003042_D009203 CID <e1>cocaine-induced</e1> <e2>infarction</e2>
D003042_D009203 CID <e1>cocaine</e1> result <e2>infarction</e2>
D003042_D009203 CID <e1>cocaine-induced</e1> increase associated demand increase result individuals <e2>infarction</e2>
D010100_D009203 NONE <e1>oxygen</e1> demand increase result individuals <e2>infarction</e2>
D003042_D013035 NONE <e1>cocaine-induced</e1> vasoconstriction locus remains circumstantial regard <e2>spasm</e2>
D003042_D013927 NONE <e1>cocaine</e1> effect primary <e2>thrombotic</e2>
4812392
D001379_D011565 NONE <e1>azathioprine</e1> treatment <e2>psoriasis</e2>
D001379_D011565 NONE <e1>azathioprine</e1> treatment benefited patients suffering <e2>psoriasis</e2>
D001379_D056486 NONE <e1>azathioprine</e1> therapy continued detected <e2>damage</e2>
18343374
D002996_D012170 CID <e1>clomiphene-induced</e1> ovulation associated <e2>occlusion</e2>
D002996_D012170 CID <e1>citrate</e1> associated <e2>occlusion</e2>
D002996_D012170 CID <e1>cc</e1> citrate associated <e2>occlusion</e2>
D002996_D012170 CID <e1>cc</e1> induction <e2>occlusion</e2>
D002996_D012170 CID <e1>cc</e1> courses developed <e2>occlusion</e2>
D002996_D012170 CID <e1>cc</e1> treatment case <e2>occlusion</e2>
D002996_D013923 NONE <e1>cc</e1> complications <e2>thromboembolic</e2>
D002996_D013923 NONE <e1>cc</e1> intake disturbance uncommon include search literature complications <e2>thromboembolic</e2>
D002996_D014786 CID <e1>cc</e1> complications literature search include uncommon <e2>disturbance</e2>
D002996_D014786 CID <e1>cc</e1> intake <e2>disturbance</e2>
D002996_D007247 NONE <e1>cc</e1> patients <e2>infertility</e2>
6203452
D002945_D002277 NONE <e1>cisplatin</e1> treatment developed patients <e2>carcinoma</e2>
D002945_D057049 NONE <e1>cisplatin</e1> treatment developed <e2>microangiopathy</e2>
D002945_D051437 NONE <e1>cisplatin</e1> treatment developed microangiopathy characterized <e2>insufficiency</e2>
D002945_D051437 NONE <e1>cisplatin</e1> nephrotoxicity ascribed <e2>failure</e2>
D002945_D000743 NONE <e1>cisplatin</e1> treatment developed microangiopathy characterized insufficiency <e2>anemia</e2>
D002945_D013921 NONE <e1>cisplatin</e1> treatment developed microangiopathy characterized insufficiency <e2>thrombocytopenia</e2>
D002945_D013921 NONE <e1>cisplatin</e1> nephrotoxicity anemia <e2>thrombocytopenia</e2>
D001761_D002277 NONE <e1>bleomycin</e1> cisplatin treatment developed patients <e2>carcinoma</e2>
D001761_D057049 NONE <e1>bleomycin</e1> cisplatin treatment developed <e2>microangiopathy</e2>
D001761_D051437 NONE <e1>bleomycin</e1> cisplatin treatment developed microangiopathy characterized <e2>insufficiency</e2>
D001761_D000743 NONE <e1>bleomycin</e1> cisplatin treatment developed microangiopathy characterized insufficiency <e2>anemia</e2>
D001761_D013921 NONE <e1>bleomycin</e1> cisplatin treatment developed microangiopathy characterized insufficiency <e2>thrombocytopenia</e2>
D014748_D002277 NONE <e1>alkaloid</e1> cisplatin treatment developed patients <e2>carcinoma</e2>
D014748_D057049 NONE <e1>alkaloid</e1> cisplatin treatment developed <e2>microangiopathy</e2>
D014748_D051437 NONE <e1>alkaloid</e1> cisplatin treatment developed microangiopathy characterized <e2>insufficiency</e2>
D014748_D000743 NONE <e1>alkaloid</e1> cisplatin treatment developed microangiopathy characterized insufficiency <e2>anemia</e2>
D014748_D013921 NONE <e1>alkaloid</e1> cisplatin treatment developed microangiopathy characterized insufficiency <e2>thrombocytopenia</e2>
D002945_D007674 CID <e1>cisplatin</e1> <e2>nephrotoxicity</e2>
D002945_D000740 NONE <e1>cisplatin</e1> nephrotoxicity <e2>anemia</e2>
D002945_D001855 NONE <e1>cisplatin</e1> nephrotoxicity ascribed <e2>suppression</e2>
11279304
D018943_D066126 NONE <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2>
D018943_D066126 NONE <e1>anthracyclines</e1> drugs cause <e2>cardiotoxicity</e2>
D018943_D066126 NONE <e1>anthracycline</e1> therapy <e2>cardiotoxicity</e2>
D018943_D066126 NONE <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2>
D018943_D066126 NONE <e1>anthracycline-induced</e1> <e2>cardiotoxicity</e2>
D018943_D006331 NONE <e1>anthracycline</e1> therapy cardiotoxicity highlights need search methods sensitive capable predicting <e2>dysfunction</e2>
D018943_D015470 NONE <e1>anthracycline-induced</e1> cardiotoxicity patients <e2>leukemia</e2>
D003630_D066126 NONE <e1>daunorubicin</e1> regimen treated leukemia patients <e2>cardiotoxicity</e2>
D003630_D066126 NONE <e1>(dnr)-containing</e1> regimen treated leukemia patients <e2>cardiotoxicity</e2>
D003630_D015470 NONE <e1>daunorubicin</e1> regimen treated <e2>leukemia</e2>
D003630_D015470 NONE <e1>(dnr)-containing</e1> regimen treated <e2>leukemia</e2>
D003630_D015470 NONE <e1>dnr-containing</e1> regimen treated patients <e2>leukemia</e2>
D003630_D006333 CID <e1>dnr</e1> <e2>failure</e2>
20067456
D016642_D012735 NONE <e1>bupropion</e1> <e2>dysfunction</e2>
D016642_D012735 NONE <e1>bupropion</e1> sustained-release safety <e2>dysfunction</e2>
D016642_D012735 NONE <e1>bupropion</e1> sustained-release safety dysfunction <e2>sd</e2>
D016642_D012735 NONE <e1>bupropion</e1> sustained-release safety determine side-effect <e2>sd</e2>
D016642_D012735 NONE <e1>bupropion</e1> treatment <e2>sd</e2>
D017367_D012735 NONE <e1>inhibitor</e1> induced <e2>dysfunction</e2>
D017367_D012735 NONE <e1>inhibitor</e1> induced <e2>dysfunction</e2>
D017367_D012735 NONE <e1>inhibitor</e1> induced dysfunction <e2>sd</e2>
D017367_D012735 NONE <e1>inhibitor</e1> induced dysfunction safety determine side-effect <e2>sd</e2>
D017367_D012735 NONE <e1>ssri</e1> inhibitor induced <e2>dysfunction</e2>
D017367_D012735 NONE <e1>ssri</e1> inhibitor induced dysfunction <e2>sd</e2>
D017367_D012735 NONE <e1>ssri</e1> inhibitor induced dysfunction safety determine side-effect <e2>sd</e2>
D017367_D012735 NONE <e1>ssris</e1> side-effect determine safety <e2>dysfunction</e2>
D017367_D012735 NONE <e1>ssris</e1> side-effect determine safety dysfunction <e2>sd</e2>
D017367_D012735 NONE <e1>ssris</e1> side-effect <e2>sd</e2>
D017367_D012735 NONE <e1>ssri</e1> type <e2>sd</e2>
D017367_D012735 NONE <e1>ssris</e1> induced <e2>sd</e2>
8231633
D002118_D064420 NONE <e1>calcium</e1> channel blockers effects <e2>toxicity</e2>
D002118_D064420 NONE <e1>calcium</e1> channel blockers influence <e2>toxicity</e2>
D002045_D064420 NONE <e1>bupivacaine-induced</e1> <e2>toxicity</e2>
D002045_D064420 NONE <e1>bupivacaine-induced</e1> <e2>toxicity</e2>
D002045_D012640 CID <e1>bupivacaine</e1> activity modified decreased time obtain <e2>convulsions</e2>
D002045_D012640 CID <e1>bupivacaine-induced</e1> <e2>convulsions</e2>
D002118_D012640 NONE <e1>calcium</e1> channel blockers decreased time obtain <e2>convulsions</e2>
D015764_D012640 NONE <e1>bepridil</e1> pronounced modified decreased time obtain <e2>convulsions</e2>
2549018
D005473_D017109 CID <e1>fluoxetine-induced</e1> <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine</e1> receiving patients developed <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> symptoms indistinguishable those <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> akathisia symptoms identical reported patients experienced <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine</e1> effect appeared <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> akathisia caused inhibition identical jitteriness antidepressant-induced pathophysiology <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> akathisia pathophysiology antidepressant-induced jitteriness identical inhibition caused <e2>akathisia</e2>
D005473_D017109 CID <e1>fluoxetine-induced</e1> <e2>akathisia</e2>
D005473_D009771 NONE <e1>fluoxetine</e1> treatment <e2>disorder</e2>
D005473_D003865 NONE <e1>fluoxetine</e1> treatment disorder <e2>depression</e2>
D005473_D001008 NONE <e1>fluoxetine-induced</e1> symptoms <e2>anxiety</e2>
D011433_D017109 NONE <e1>propranolol</e1> treatment responded appeared <e2>akathisia</e2>
D000928_D017109 NONE <e1>antidepressant-induced</e1> jitteriness identical inhibition caused <e2>akathisia</e2>
D000928_D017109 NONE <e1>antidepressant-induced</e1> pathophysiology <e2>akathisia</e2>
3997294
D000638_D010996 CID <e1>amiodarone</e1> therapy neuropathy <e2>effusion</e2>
D000638_D010490 CID <e1>amiodarone</e1> therapy neuropathy <e2>effusion</e2>
D000638_D009422 NONE <e1>amiodarone</e1> therapy <e2>neuropathy</e2>
D000638_D002318 NONE <e1>amiodarone</e1> treated patient <e2>disease</e2>
D000638_D013617 NONE <e1>amiodarone</e1> treated control <e2>tachyarrhythmias</e2>
D000638_D011014 CID <e1>amiodarone</e1> <e2>pneumonitis</e2>
D000638_D011014 CID <e1>amiodarone</e1> withdrawal <e2>pneumonitis</e2>
D013256_D011014 NONE <e1>steroid</e1> therapy prompt indicates need diagnosis <e2>pneumonitis</e2>
2265898
C009265_D004827 CID <e1>levodopa/carbidopa</e1> administration caused <e2>epilepsy</e2>
C009265_D007676 NONE <e1>carbidopa/levodopa</e1> preparation receiving presented had <e2>failure</e2>
C009265_D001523 NONE <e1>carbidopa/levodopa</e1> preparation receiving presented had onset seizures <e2>hallucinosis</e2>
C009265_D012640 NONE <e1>carbidopa/levodopa</e1> preparation receiving presented had onset <e2>seizures</e2>
1147734
D011441_D008107 NONE <e1>propylthiouracil</e1> caused <e2>disease</e2>
D011441_D006521 CID <e1>propylthiouracil</e1> administration caused patient <e2>hepatitis</e2>
14659530
D009569_D008881 NONE <e1>no-induced</e1> attack <e2>migraine</e2>
D015740_D008881 NONE <e1>peptide</e1> increase attack <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> peptide increase attack <e2>migraine</e2>
D015740_D008881 NONE <e1>peptide</e1> concentration changes investigate content attack <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentration changes investigate content attack <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentration increased attack <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentration increased returned cessation <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentrations failed change subjects attack <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentration higher tended lower subjects experienced attack <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentration correlates timing severity headache <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> concentration correlates fact suggests relationship cgrp <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> relationship suggests fact correlates timing severity headache <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> <e2>migraine</e2>
D015740_D008881 NONE <e1>cgrp</e1> release headache counteract provoke <e2>migraine</e2>
D012701_D008881 NONE <e1>serotonin</e1> release correlation increase attack <e2>migraine</e2>
D012701_D008881 NONE <e1>serotonin</e1> concentration changes investigate content attack <e2>migraine</e2>
D012701_D008881 NONE <e1>5-hydroxytriptamine</e1> serotonin concentration changes investigate content attack <e2>migraine</e2>
D012701_D008881 NONE <e1>5-ht</e1> 5-hydroxytriptamine serotonin concentration changes investigate content attack <e2>migraine</e2>
D012701_D008881 NONE <e1>5-ht</e1> content tended lower subjects experienced attack <e2>migraine</e2>
D012701_D008881 NONE <e1>serotonin</e1> content decreased nitroglycerin subjects attack <e2>migraine</e2>
D012701_D008881 NONE <e1>serotonin</e1> content decreased observed patients attack <e2>migraine</e2>
D012701_D008881 NONE <e1>serotonin</e1> release provoke <e2>migraine</e2>
D015740_D006261 NONE <e1>peptide</e1> concentration changes investigate content <e2>headache</e2>
D015740_D006261 NONE <e1>cgrp</e1> concentration changes investigate content <e2>headache</e2>
D015740_D006261 NONE <e1>cgrp</e1> concentrations failed change <e2>headache</e2>
D015740_D006261 NONE <e1>cgrp</e1> concentration correlates timing severity <e2>headache</e2>
D015740_D006261 NONE <e1>cgrp</e1> relationship suggests fact correlates timing severity <e2>headache</e2>
D015740_D006261 NONE <e1>cgrp</e1> release <e2>headache</e2>
D012701_D006261 NONE <e1>serotonin</e1> concentration changes investigate content <e2>headache</e2>
D012701_D006261 NONE <e1>5-hydroxytriptamine</e1> serotonin concentration changes investigate content <e2>headache</e2>
D012701_D006261 NONE <e1>5-ht</e1> 5-hydroxytriptamine serotonin concentration changes investigate content <e2>headache</e2>
D012701_D006261 NONE <e1>serotonin</e1> release provoke counteract <e2>headache</e2>
D005996_D006261 NONE <e1>nitroglycerin</e1> provoked attack content <e2>headache</e2>
D005996_D008881 NONE <e1>nitroglycerin</e1> provoked attack <e2>migraine</e2>
D005996_D008881 NONE <e1>nitroglycerin</e1> application min beginning attack <e2>migraine</e2>
D005996_D008881 NONE <e1>nitroglycerin</e1> subjects attack <e2>migraine</e2>
D005996_D008881 NONE <e1>nitroglycerin</e1> decreased observed patients attack <e2>migraine</e2>
9034419
C047426_D012640 CID <e1>venlafaxine</e1> overdose resulting <e2>seizure</e2>
C047426_D012640 CID <e1>venlafaxine</e1> tablets ingestion experienced <e2>seizure</e2>
C047426_D012640 CID <e1>venlafaxine</e1> overdose case resulted <e2>seizure</e2>
C047426_D012640 CID <e1>venlafaxine</e1> overdose resulted episode <e2>seizure</e2>
C047426_D062787 CID <e1>venlafaxine</e1> <e2>overdose</e2>
C047426_D062787 CID <e1>venlafaxine</e1> <e2>overdose</e2>
C047426_D062787 CID <e1>venlafaxine</e1> <e2>overdose</e2>
C047426_D062787 CID <e1>venlafaxine</e1> <e2>overdose</e2>
C047426_D062787 CID <e1>venlafaxine</e1> <e2>overdose</e2>
C047426_D003865 NONE <e1>venlafaxine</e1> overdose took woman <e2>depression</e2>
18560792
D010479_D006349 NONE <e1>pergolide</e1> treated patients <e2>disease</e2>
D010479_D006349 NONE <e1>pergolide</e1> treated patients reported <e2>abnormalities</e2>
D010479_D006349 NONE <e1>pergolide</e1> role suggestive pattern <e2>regurgitation</e2>
D010479_D006349 NONE <e1>pergolide</e1> discontinued patients <e2>disease</e2>
D010479_D006349 NONE <e1>pergolide</e1> treated patients <e2>regurgitation</e2>
D010479_D010300 NONE <e1>pergolide</e1> treated patients <e2>disease</e2>
D010479_D010300 NONE <e1>pergolide</e1> treated patients <e2>disease</e2>
D010479_D010300 NONE <e1>pergolide</e1> treated patients disease <e2>pd</e2>
D010479_D010300 NONE <e1>pergolide</e1> treated area patients <e2>pd</e2>
D010479_D010300 NONE <e1>pergolide</e1> treated patients <e2>pd</e2>
D010479_D006333 NONE <e1>pergolide</e1> role suggestive pattern observed patients two <e2>failure</e2>
D010479_D006333 NONE <e1>pergolide</e1> discontinued resulting grade patients <e2>failure</e2>
D004298_D006349 NONE <e1>dopamine</e1> agonists converted usual reveals supports frequency <e2>regurgitation</e2>
D004298_D010300 NONE <e1>dopamine</e1> agonists converted usual reveals supports frequency regurgitation patients <e2>pd</e2>
16181582
D014635_D001927 CID <e1>valproate-induced</e1> <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate-induced</e1> <e2>encephalopathy</e2>
D014635_D001927 CID <e1>valproate-induced</e1> <e2>encephalopathy</e2>
D014635_D004827 NONE <e1>valproate-induced</e1> encephalopathy syndrome manifest individuals <e2>epileptic</e2>
869641
D007980_D001919 NONE <e1>l-dopa</e1> mediation <e2>bradycardia</e2>
D007980_D001919 NONE <e1>l-dopa</e1> enhanced <e2>bradycardia</e2>
D007980_D001919 NONE <e1>l-dopa</e1> hypotension <e2>bradycardia</e2>
D007980_D001919 NONE <e1>l-dopa</e1> restored <e2>bradycardia</e2>
D007980_D001919 NONE <e1>l-dopa</e1> enhances <e2>bradycardia</e2>
D004298_D001919 NONE <e1>dopamine</e1> formation mediation <e2>bradycardia</e2>
D004298_D001919 NONE <e1>dopamine-beta-oxidase</e1> inhibitor fla-63 have effect hypotension <e2>bradycardia</e2>
D009638_D001919 CID <e1>norepinephrine</e1> caused <e2>bradycardia</e2>
D009638_D001919 CID <e1>norepinephrine</e1> responses rate had enhanced <e2>bradycardia</e2>
D009638_D001919 CID <e1>norepinephrine</e1> caused <e2>bradycardia</e2>
D009638_D001919 CID <e1>norepinephrine</e1> decreased <e2>bradycardia</e2>
D015103_D001919 NONE <e1>dl-threo-dihydroxyphenylserine</e1> had enhanced <e2>bradycardia</e2>
D005406_D007022 NONE <e1>fla-63</e1> have effect <e2>hypotension</e2>
D005406_D001919 NONE <e1>fla-63</e1> have effect hypotension <e2>bradycardia</e2>
D004298_D007022 NONE <e1>dopamine-beta-oxidase</e1> inhibitor fla-63 have effect <e2>hypotension</e2>
D007980_D007022 NONE <e1>l-dopa</e1> <e2>hypotension</e2>
D006916_D001919 NONE <e1>5-htp</e1> decreased decreased <e2>bradycardia</e2>
7423039
D004317_D066126 CID <e1>adriamycin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>adriamycin</e1> effects <e2>cardiotoxic</e2>
8386779
D017693_D004414 NONE <e1>bicarbonate</e1> alleviates penile <e2>pain</e2>
D017693_D004414 NONE <e1>bicarbonate</e1> addition injections incidence comparing study performed whether acidity <e2>pain</e2>
D017693_D004414 NONE <e1>bicarbonate</e1> addition injections incidence <e2>pain</e2>
D017693_D004414 NONE <e1>bicarbonate</e1> patients complained <e2>pain</e2>
D017693_D004414 NONE <e1>bicarbonate</e1> patients complained complained <e2>pain</e2>
D017693_D004414 NONE <e1>bicarbonate</e1> received 1 complained complained <e2>pain</e2>
D017693_D004414 NONE <e1>bicarbonate</e1> received 1 complained <e2>pain</e2>
D017693_D007172 NONE <e1>bicarbonate</e1> alleviates penile pain induced injections <e2>dysfunction</e2>
D017693_D007172 NONE <e1>bicarbonate</e1> addition total patients presented <e2>impotence</e2>
D010208_D004414 NONE <e1>papaverine</e1> received attempt determine performed whether acidity <e2>pain</e2>
D010208_D004414 NONE <e1>papaverine</e1> received attempt determine performed study comparing incidence <e2>pain</e2>
D010208_D007172 NONE <e1>papaverine</e1> received attempt determine performed study comparing incidence injections addition total patients presented <e2>impotence</e2>
11569530
D016593_D016171 CID <e1>terfenadine</e1> withdrawal led side-effect <e2>tdp</e2>
D016593_D016171 CID <e1>terfenadine</e1> investigated <e2>tdp</e2>
D016593_D016171 CID <e1>terfenadine</e1> clinic shown <e2>tdp</e2>
C010637_D016171 CID <e1>terodiline</e1> terfenadine withdrawal led side-effect <e2>tdp</e2>
C010637_D016171 CID <e1>terodiline</e1> terfenadine investigated <e2>tdp</e2>
C010637_D016171 CID <e1>terodiline</e1> terfenadine clinic shown <e2>tdp</e2>
D020117_D016171 CID <e1>cisapride</e1> terfenadine investigated <e2>tdp</e2>
D020117_D016171 CID <e1>cisapride</e1> terfenadine clinic shown <e2>tdp</e2>
C063968_D016171 NONE <e1>e4031</e1> terfenadine investigated <e2>tdp</e2>
6308277
D002110_D064420 NONE <e1>caffeine</e1> <e2>toxicity</e2>
D002110_D064420 NONE <e1>caffeine</e1> effects augment reported focused possibility reduced <e2>toxicity</e2>
D002110_D064420 NONE <e1>caffeine</e1> <e2>toxicity</e2>
D000082_D064420 NONE <e1>acetaminophen</e1> reduction <e2>toxicity</e2>
D000082_D064420 NONE <e1>acetaminophen</e1> presence reduced <e2>toxicity</e2>
D000082_D012640 NONE <e1>acetaminophen</e1> pretreatment increased interval administration onset <e2>convulsions</e2>
D000082_D012640 NONE <e1>acetaminophen</e1> pretreatment increased reduced incidence <e2>seizures</e2>
D000082_D012640 NONE <e1>acetaminophen</e1> pretreatment reduced increased interval administration onset <e2>convulsions</e2>
D000082_D012640 NONE <e1>acetaminophen</e1> pretreatment reduced incidence <e2>seizures</e2>
D000082_D012640 NONE <e1>acetaminophen</e1> reduced frequency <e2>seizures</e2>
D000082_D012640 NONE <e1>acetaminophen</e1> modify <e2>seizures</e2>
D002110_D012640 CID <e1>caffeine</e1> administration onset <e2>convulsions</e2>
D002110_D012640 CID <e1>caffeine</e1> administration interval increased reduced incidence <e2>seizures</e2>
D002110_D012640 CID <e1>caffeine</e1> presence produced seizures incidence reduced increased interval administration onset <e2>convulsions</e2>
D002110_D012640 CID <e1>caffeine</e1> presence produced <e2>seizures</e2>
D002110_D012640 CID <e1>caffeine</e1> frequency <e2>seizures</e2>
D002110_D012640 CID <e1>caffeine</e1> absence modify <e2>seizures</e2>
D010433_D012640 CID <e1>pentylenetetrezol</e1> dose alter modify <e2>seizures</e2>
16574712
D018817_D003072 CID <e1>mdma</e1> users show impairments coupled <e2>processes</e2>
D018817_D008569 NONE <e1>mdma</e1> users reported years working <e2>deficits</e2>
D018817_D008569 NONE <e1>3,4-methylenedioxymethamphetamine</e1> mdma users reported years working <e2>deficits</e2>
D018817_D008569 NONE <e1>ecstasy</e1> 3,4-methylenedioxymethamphetamine mdma users reported years working <e2>deficits</e2>
6773726
D005996_D007022 CID <e1>nitroglycerin</e1> provocation <e2>hypotension</e2>
D005996_D003929 NONE <e1>nitroglycerin</e1> provocation <e2>neuropathy</e2>
D005996_D003920 NONE <e1>nitroglycerin</e1> effect compared subjects subjects <e2>diabetic</e2>
D005996_D003920 NONE <e1>nitroglycerin</e1> effect compared subjects <e2>diabetic</e2>
D005996_D003920 NONE <e1>nitroglycerin</e1> magnitude similar subjects normal <e2>diabetic</e2>
D005996_D003920 NONE <e1>nitroglycerin</e1> magnitude similar occurred subjects <e2>diabetic</e2>
D005996_D009422 NONE <e1>nitroglycerin</e1> effect compared <e2>neuropathy</e2>
D005996_D009422 NONE <e1>nitroglycerin</e1> effect compared subjects <e2>neuropathy</e2>
D005996_D009422 NONE <e1>nitroglycerin</e1> magnitude similar <e2>neuropathy</e2>
D005996_D009422 NONE <e1>nitroglycerin</e1> magnitude similar occurred <e2>neuropathy</e2>
15130900
D003520_D001749 CID <e1>cyclophosphamide</e1> relation risks <e2>cancer</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> relation assess risk <e2>cancer</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> <e2>cancer</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> increment doubled risk <e2>cancer</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> risk <e2>cancer</e2>
D003520_D014890 NONE <e1>cyclophosphamide</e1> relation risks cancer <e2>granulomatosis</e2>
D003520_D014890 NONE <e1>cyclophosphamide</e1> relation assess patients <e2>granulomatosis</e2>
D003520_D014890 NONE <e1>cyclophosphamide</e1> relationship indicate possibility factors operating <e2>granulomatosis</e2>
150790
D011736_D002653 NONE <e1>pyridoxine-dependent</e1> <e2>disorder</e2>
D007538_D002653 CID <e1>isoniazid</e1> unmasked <e2>disorder</e2>
D007538_D002653 CID <e1>isoniazid</e1> administration sleeping had <e2>deterioration</e2>
D007538_D006948 CID <e1>isoniazid</e1> administration sleeping had deterioration <e2>hyperkinesis</e2>
D007538_D001523 NONE <e1>isoniazid</e1> administration sleeping had deterioration hyperkinesis <e2>irritability</e2>
D007538_D012893 NONE <e1>isoniazid</e1> administration sleeping <e2>difficulties</e2>
D011736_D006948 NONE <e1>pyridoxine</e1> withdrawal associated return <e2>hyperkinesis</e2>
3719553
D005472_D004342 NONE <e1>5-fluorouracil</e1> infusion <e2>reaction</e2>
D005472_D004342 NONE <e1>5-fluorouracil</e1> secondary edema consisting <e2>reaction</e2>
D005472_D000799 CID <e1>5-fluorouracil</e1> secondary <e2>edema</e2>
D005472_D009062 NONE <e1>5-fluorouracil</e1> secondary edema consisting reaction occurred patient carcinoma <e2>cavity</e2>
D005472_D005355 NONE <e1>5-fluorouracil</e1> secondary edema consisting reaction occurred patient carcinoma cavity <e2>cirrhosis</e2>
D005472_D007674 NONE <e1>5-fluorouracil</e1> secondary edema consisting reaction occurred patient carcinoma cavity <e2>function</e2>
D002945_D004342 NONE <e1>cisplatin-induced</e1> function cavity carcinoma patient occurred <e2>reaction</e2>
D002945_D000799 NONE <e1>cisplatin-induced</e1> function cavity carcinoma patient occurred reaction consisting <e2>edema</e2>
D002945_D009062 NONE <e1>cisplatin-induced</e1> function <e2>cavity</e2>
D002945_D005355 NONE <e1>cisplatin-induced</e1> function cavity <e2>cirrhosis</e2>
D002945_D007674 NONE <e1>cisplatin-induced</e1> <e2>function</e2>
D004155_D004342 NONE <e1>diphenhydramine</e1> ineffective preventing recurrence <e2>reaction</e2>
D011241_D004342 NONE <e1>prednisone</e1> diphenhydramine ineffective preventing recurrence <e2>reaction</e2>
12090760
D015215_D000740 CID <e1>azidothymidine-induced</e1> <e2>anemia</e2>
D015215_D000740 CID <e1>azidothymidine</e1> <e2>anemia</e2>
D015215_D000740 CID <e1>(azt)-induced</e1> <e2>anemia</e2>
15120741
D010862_D013226 CID <e1>pilocarpine</e1> injection causes <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> injection causes epilepticus <e2>se</e2>
D010862_D013226 CID <e1>pilocarpine-treated</e1> mice mice cells experience <e2>se</e2>
D010862_D012640 CID <e1>pilocarpine</e1> injection causes epilepticus development <e2>seizures</e2>
D008274_D013226 NONE <e1>mg(2+)-free</e1> medium resulted cells experience <e2>se</e2>
D001640_D013226 NONE <e1>bicuculline</e1> containing medium resulted cells experience <e2>se</e2>
D018698_D013226 NONE <e1>glutamate</e1> antagonists blocked resulted survivors <e2>se</e2>
D018698_D013226 NONE <e1>glutamate</e1> photostimulation resulted responses duration slices survivors <e2>se</e2>
14765563
D011803_D020922 NONE <e1>quinine</e1> available banned use <e2>cramps</e2>
D011803_D002493 NONE <e1>quinine</e1> containing products produce <e2>complications</e2>
D011803_D003221 CID <e1>quinine</e1> containing products produce complications <e2>confusion</e2>
D011803_D012640 CID <e1>quinine</e1> containing products produce complications confusion <e2>seizures</e2>
D011803_D003128 CID <e1>quinine</e1> containing products produce complications confusion <e2>coma</e2>
10835440
D009553_D020521 NONE <e1>nimodipine</e1> effect outcome <e2>stroke</e2>
D009553_D020521 NONE <e1>nimodipine</e1> european trial <e2>stroke</e2>
D009553_D020521 NONE <e1>nimodipine</e1> european trial found correlation reduction outcome <e2>stroke</e2>
D009553_D020521 NONE <e1>nimodipine-induced</e1> reduction correlation found trial <e2>stroke</e2>
D009553_D020521 NONE <e1>nimodipine-induced</e1> reduction outcome <e2>stroke</e2>
D009553_D020521 NONE <e1>nimodipine</e1> administration worsening associated <e2>stroke</e2>
D009553_D007022 CID <e1>nimodipine</e1> european trial found correlation reduction <e2>pressure</e2>
D009553_D007022 CID <e1>nimodipine-induced</e1> reduction <e2>pressure</e2>
D009553_D007022 CID <e1>nimodipine</e1> treatment resulted reduction <e2>bp</e2>
D009553_D002544 NONE <e1>nimodipine</e1> placebo receive allocated patients diagnosis <e2>stroke</e2>
D009553_D002544 NONE <e1>nimodipine</e1> placebo receive allocated patients diagnosis <e2>stroke</e2>
18464113
D019259_D006509 NONE <e1>lamivudine</e1> prevention reactivation <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine</e1> received patients have malignancies <e2>infection</e2>
D019259_D006509 NONE <e1>lamivudine</e1> receive group compared ct prior received patients have malignancies <e2>infection</e2>
D019259_D009369 NONE <e1>lamivudine</e1> patients <e2>cancer</e2>
D019259_D009369 NONE <e1>lamivudine</e1> received patients <e2>cancer</e2>
D019259_D009369 NONE <e1>lamivudine</e1> receive group compared ct prior received patients <e2>cancer</e2>
D019259_D009369 NONE <e1>lamivudine</e1> decreases incidence morbidity patients <e2>cancer</e2>
D006514_D006509 CID <e1>antigen</e1> reactivation <e2>b</e2>
D006514_D006509 CID <e1>hbsag</e1> antigen reactivation <e2>b</e2>
D006514_D009369 NONE <e1>antigen</e1> reactivation prevention lamivudine patients <e2>cancer</e2>
D006514_D009369 NONE <e1>hbsag</e1> antigen reactivation prevention lamivudine patients <e2>cancer</e2>
D019259_D019337 NONE <e1>lamivudine</e1> received patients have <e2>malignancies</e2>
D019259_D019337 NONE <e1>lamivudine</e1> receive group compared ct prior received patients have <e2>malignancies</e2>
D019259_D056486 NONE <e1>lamivudine</e1> group observed <e2>hepatitis</e2>
2924746
D002220_D064420 NONE <e1>carbamazepine</e1> treatment efficacy <e2>toxicity</e2>
D005492_D064420 NONE <e1>folate</e1> concentrations treatment efficacy <e2>toxicity</e2>
D019946_D012640 NONE <e1>glycol</e1> vehicle course found exhibit properties <e2>seizures</e2>
D019946_D015430 NONE <e1>glycol</e1> vehicle course found exhibit inhibited <e2>gain</e2>
D005481_D012640 CID <e1>ether</e1> induced <e2>seizures</e2>
D005481_D012640 CID <e1>ether</e1> induced seizures found measure <e2>seizures</e2>
D005481_D012640 CID <e1>hfde</e1> ether induced <e2>seizures</e2>
D005481_D012640 CID <e1>hfde</e1> ether induced seizures found measure <e2>seizures</e2>
D005481_D012640 CID <e1>hfde-induced</e1> <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> measure found <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> measure <e2>seizures</e2>
D002220_D012640 NONE <e1>cbz</e1> administration protective <e2>seizures</e2>
D002220_D015430 NONE <e1>cbz</e1> administration protective toxic measured <e2>gain</e2>
D005481_D015430 NONE <e1>hfde-induced</e1> seizures protective toxic measured <e2>gain</e2>
2224762
C027260_D009369 NONE <e1>4'-0-tetrahydropyranyladriamycin</e1> bolus study done <e2>tumors</e2>
C027260_D009369 NONE <e1>pirarubicin</e1> bolus study done <e2>tumors</e2>
10721819
D007545_D013610 NONE <e1>isoproterenol</e1> <e2>tachycardia</e2>
D007545_D013610 NONE <e1>isoproterenol</e1> pretreatment reduced mediated <e2>tachycardia</e2>
D007545_D013610 NONE <e1>isoproterenol</e1> pretreatment abolish <e2>tachycardia</e2>
D007545_D013610 NONE <e1>isoproterenol</e1> pretreatment unaffected reversed <e2>tachycardia</e2>
D007545_D013610 NONE <e1>isoproterenol</e1> pretreatment abolished <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine-induced</e1> <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine-induced</e1> <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine-induced</e1> <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine</e1> rats induced hypotension <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine-induced</e1> hypotension unaffected reversed <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine-induced</e1> <e2>tachycardia</e2>
D001971_D013610 CID <e1>bromocriptine</e1> <e2>tachycardia</e2>
D004298_D013610 NONE <e1>dopamine</e1> activation mediated <e2>tachycardia</e2>
D004298_D013610 NONE <e1>dopamine</e1> receptors mask predominate appears <e2>tachycardia</e2>
D007545_D006332 CID <e1>isoproterenol</e1> pretreatment caused <e2>hypertrophy</e2>
D001971_D007022 CID <e1>bromocriptine</e1> rats induced <e2>hypotension</e2>
D001971_D007022 CID <e1>bromocriptine-induced</e1> <e2>hypotension</e2>
D001971_D001919 NONE <e1>bromocriptine-induced</e1> hypotension unaffected reversed <e2>bradycardia</e2>
D001971_D001919 NONE <e1>bromocriptine-induced</e1> tachycardia abolished <e2>bradycardia</e2>
D001971_D001919 NONE <e1>bromocriptine</e1> tachycardia appears predominate mask <e2>bradycardia</e2>
D007545_D007022 NONE <e1>isoproterenol</e1> pretreatment unaffected <e2>hypotension</e2>
D007545_D001919 CID <e1>isoproterenol</e1> pretreatment unaffected reversed <e2>bradycardia</e2>
D007545_D001919 CID <e1>isoproterenol</e1> pretreatment abolished <e2>bradycardia</e2>
D004294_D007022 NONE <e1>domperidone</e1> reduced effect unaffected <e2>hypotension</e2>
D004294_D013610 NONE <e1>domperidone</e1> reduced effect unaffected reversed <e2>tachycardia</e2>
D004294_D001919 CID <e1>domperidone</e1> reduced effect unaffected reversed <e2>bradycardia</e2>
D004298_D001919 NONE <e1>dopamine</e1> receptors mask <e2>bradycardia</e2>
18754075
D004164_D011507 NONE <e1>bisphosphonate</e1> administration <e2>proteinuria</e2>
D004164_D011507 NONE <e1>bisphosphonates</e1> aggravate <e2>proteinuria</e2>
D004164_D058186 NONE <e1>bisphosphonate</e1> administration proteinuria <e2>failure</e2>
D004164_D058186 NONE <e1>bisphosphonate</e1> days decreased increased g <e2>failure</e2>
D004164_D058186 NONE <e1>bisphosphonates</e1> aggravate proteinuria <e2>failure</e2>
D004164_D005923 NONE <e1>bisphosphonate</e1> administration patient <e2>glomerulosclerosis</e2>
D019386_D011507 CID <e1>alendronate</e1> administration <e2>proteinuria</e2>
D019386_D058186 CID <e1>alendronate</e1> administration proteinuria <e2>failure</e2>
D019386_D058186 CID <e1>sodium</e1> bisphosphonate days decreased increased g <e2>failure</e2>
D019386_D005923 NONE <e1>alendronate</e1> administration patient <e2>glomerulosclerosis</e2>
D013256_D009404 NONE <e1>steroid</e1> therapy responding man <e2>syndrome</e2>
D013256_D005923 NONE <e1>steroid</e1> therapy responding man <e2>glomerulosclerosis</e2>
6747681
D002330_D005910 NONE <e1>bcnu</e1> chemotherapy treatment <e2>gliomas</e2>
D002330_D005910 NONE <e1>bcnu</e1> clearance provide advantage administration treatment <e2>gliomas</e2>
D002330_D005910 NONE <e1>1,3-bis-(2-chloroethyl)-1-nitrosourea</e1> bcnu clearance provide advantage administration treatment <e2>gliomas</e2>
D002330_D001254 NONE <e1>bcnu</e1> therapy courses received patients <e2>astrocytomas</e2>
D000431_D014786 NONE <e1>ethanol</e1> diluent concentration decreased frequency <e2>loss</e2>
2522601
D002220_D004342 CID <e1>carbamazepine</e1> <e2>hypersensitivity</e2>
D002220_D004342 CID <e1>carbamazepine</e1> <e2>hypersensitivity</e2>
D002220_D007955 CID <e1>carbamazepine</e1> presenting <e2>reaction</e2>
D002220_D007955 CID <e1>carbamazepine</e1> hypersensitivity presented erythroderma <e2>reaction</e2>
D002220_D004802 NONE <e1>carbamazepine</e1> presenting reaction <e2>eosinophilia</e2>
D002220_D004802 NONE <e1>carbamazepine</e1> hypersensitivity presented erythroderma <e2>eosinophilia</e2>
D002220_D003873 CID <e1>carbamazepine</e1> presenting reaction eosinophilia <e2>erythroderma</e2>
D002220_D003873 CID <e1>carbamazepine</e1> hypersensitivity presented <e2>erythroderma</e2>
D002220_D051437 CID <e1>carbamazepine</e1> presenting reaction eosinophilia <e2>failure</e2>
D002220_D051437 CID <e1>carbamazepine</e1> hypersensitivity presented erythroderma <e2>failure</e2>
D002220_D007010 CID <e1>carbamazepine</e1> hypersensitivity presented erythroderma <e2>hyponatremia</e2>
11426838
-1_D012640 NONE <e1>bd1018</e1> mice pre-treatment attenuated <e2>convulsions</e2>
-1_D012640 NONE <e1>lr132</e1> bd1018 mice pre-treatment attenuated <e2>convulsions</e2>
C093337_D012640 NONE <e1>bd1063</e1> bd1018 mice pre-treatment attenuated <e2>convulsions</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>convulsions</e2>
D003042_D012640 CID <e1>anti-cocaine</e1> effects involved hypothesis validate shown attenuate <e2>convulsive</e2>
D003042_D012640 CID <e1>cocaine</e1> effects <e2>convulsive</e2>
C050232_D064420 NONE <e1>di-o-tolylguanidine</e1> worsened <e2>toxicity</e2>
C050232_D064420 NONE <e1>dtg</e1> di-o-tolylguanidine worsened <e2>toxicity</e2>
-1_D064420 NONE <e1>bd1031</e1> agonist di-o-tolylguanidine worsened <e2>toxicity</e2>
-1_D064420 NONE <e1>3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane</e1> bd1031 agonist di-o-tolylguanidine worsened <e2>toxicity</e2>
D003042_D064420 NONE <e1>cocaine</e1> <e2>toxicity</e2>
D009838_D012640 NONE <e1>oligodeoxynucleotide</e1> receptors antagonism involved hypothesis validate shown attenuate <e2>convulsive</e2>
19957053
D010656_D002534 CID <e1>phenylephrine</e1> reduces <e2>oxygenation</e2>
D010656_D007022 NONE <e1>phenylephrine</e1> reduces <e2>hypotension</e2>
D010656_D007022 NONE <e1>phenylephrine</e1> effect <e2>hypotension</e2>
D010656_D007022 NONE <e1>phenylephrine</e1> utilization correct <e2>hypotension</e2>
D004809_D002534 NONE <e1>ephedrine</e1> phenylephrine reduces <e2>oxygenation</e2>
D004809_D007022 NONE <e1>ephedrine</e1> phenylephrine reduces <e2>hypotension</e2>
D004809_D007022 NONE <e1>ephedrine</e1> phenylephrine effect <e2>hypotension</e2>
D004809_D007022 NONE <e1>ephedrine</e1> maintains has utilization correct <e2>hypotension</e2>
12684739
D020888_D019966 NONE <e1>gvg</e1> effects explored objectives success treating <e2>abuse</e2>
D020888_D005128 CID <e1>gvg</e1> effects explored objectives success treating abuse risk <e2>defects</e2>
D020888_D005128 CID <e1>gvg</e1> effects explored objectives success treating abuse risk defects <e2>vfd</e2>
D003042_D019966 NONE <e1>cocaine-induced</e1> increases effects explored objectives success treating <e2>abuse</e2>
D003042_D005128 NONE <e1>cocaine-induced</e1> increases effects explored objectives success treating abuse risk <e2>defects</e2>
D003042_D005128 NONE <e1>cocaine-induced</e1> increases effects explored objectives success treating abuse risk defects <e2>vfd</e2>
D004298_D019966 NONE <e1>dopamine</e1> increases effects explored objectives success treating <e2>abuse</e2>
D004298_D019966 NONE <e1>da</e1> dopamine increases effects explored objectives success treating <e2>abuse</e2>
D004298_D005128 NONE <e1>dopamine</e1> increases effects explored objectives success treating abuse risk <e2>defects</e2>
D004298_D005128 NONE <e1>dopamine</e1> increases effects explored objectives success treating abuse risk defects <e2>vfd</e2>
D004298_D005128 NONE <e1>da</e1> dopamine increases effects explored objectives success treating abuse risk <e2>defects</e2>
D004298_D005128 NONE <e1>da</e1> dopamine increases effects explored objectives success treating abuse risk defects <e2>vfd</e2>
17919553
C106791_D056486 CID <e1>telithromycin</e1> exposure attack <e2>hepatitis</e2>
C106791_D056486 CID <e1>telithromycin</e1> usage occurred suffered episode <e2>hepatitis</e2>
C106791_D056486 CID <e1>telithromycin</e1> cause <e2>hepatitis</e2>
C106791_D056486 CID <e1>telithromycin</e1> cause suggested <e2>hepatitis</e2>
C106791_D056486 CID <e1>telithromycin</e1> prescribed physician communicated avoided recurrence attack <e2>hepatitis</e2>
C106791_D056486 CID <e1>telithromycin</e1> administration associated <e2>hepatitis</e2>
C106791_D012141 NONE <e1>telithromycin</e1> prescribed treat <e2>infection</e2>
C106791_D064420 NONE <e1>telithromycin</e1> cause score scale probability <e2>reaction</e2>
7248170
D010634_D006529 CID <e1>phenobarbitone-induced</e1> enlargement <e2>liver</e2>
D010634_D006529 CID <e1>phenobarbitone-primed</e1> rat given tetrachloride doses defined increased giving dose peak enlargement <e2>liver</e2>
D010634_D006529 CID <e1>phenobarbitone-induced</e1> enlargement <e2>liver</e2>
D010634_D005355 NONE <e1>phenobarbitone-induced</e1> enlargement relationship <e2>cirrhosis</e2>
D002251_D006529 NONE <e1>tetrachloride-induced</e1> cirrhosis relationship enlargement <e2>liver</e2>
D002251_D006529 NONE <e1>tetrachloride</e1> doses defined increased giving dose peak enlargement <e2>liver</e2>
D002251_D006529 NONE <e1>tetrachloride</e1> dose peak enlargement <e2>liver</e2>
D002251_D005355 NONE <e1>tetrachloride-induced</e1> <e2>cirrhosis</e2>
D002251_D008103 CID <e1>tetrachloride</e1> doses defined yield cirrhosis <e2>liver</e2>
D002251_D008103 CID <e1>tetrachloride</e1> dose giving increased defined yield cirrhosis <e2>liver</e2>
D002251_D001201 NONE <e1>tetrachloride</e1> doses defined <e2>ascites</e2>
D002251_D001201 NONE <e1>tetrachloride</e1> dose giving increased defined <e2>ascites</e2>
D002251_D013163 NONE <e1>tetrachloride</e1> doses defined <e2>splenomegaly</e2>
D002251_D013163 NONE <e1>tetrachloride</e1> dose giving increased defined <e2>splenomegaly</e2>
D002251_D001284 NONE <e1>tetrachloride</e1> doses defined <e2>atrophy</e2>
D002251_D001284 NONE <e1>tetrachloride</e1> dose giving increased defined <e2>atrophy</e2>
D010634_D008103 CID <e1>phenobarbitone-primed</e1> rat given tetrachloride doses defined yield cirrhosis <e2>liver</e2>
D010634_D008103 CID <e1>phenobarbitone-induced</e1> enlargement peak dose giving increased defined yield cirrhosis <e2>liver</e2>
D010634_D001201 NONE <e1>phenobarbitone-primed</e1> rat given tetrachloride doses defined <e2>ascites</e2>
D010634_D001201 NONE <e1>phenobarbitone-induced</e1> enlargement peak dose giving increased defined <e2>ascites</e2>
D010634_D013163 NONE <e1>phenobarbitone-primed</e1> rat given tetrachloride doses defined <e2>splenomegaly</e2>
D010634_D013163 NONE <e1>phenobarbitone-induced</e1> enlargement peak dose giving increased defined <e2>splenomegaly</e2>
D010634_D001284 NONE <e1>phenobarbitone-primed</e1> rat given tetrachloride doses defined <e2>atrophy</e2>
D010634_D001284 NONE <e1>phenobarbitone-induced</e1> enlargement peak dose giving increased defined <e2>atrophy</e2>
17242861
D010862_D012640 NONE <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine-induced</e1> seizures susceptibility qtls reported used localize genes <e2>seizure</e2>
D010862_D012640 NONE <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D004833 CID <e1>pilocarpine-induced</e1> seizures susceptibility qtls model <e2>epilepsy</e2>
15278670
C009250_D012640 NONE <e1>sevoflurane</e1> effects <e2>convulsions</e2>
C009250_D012640 NONE <e1>sevoflurane</e1> influence <e2>convulsions</e2>
C009250_D012640 NONE <e1>sevoflurane</e1> concentration % increasing l(-1 threshold <e2>convulsive</e2>
C009250_D012640 NONE <e1>sevoflurane</e1> threshold <e2>convulsive</e2>
C009250_D012640 NONE <e1>sevoflurane</e1> concentrations administered decreased pressure <e2>convulsions</e2>
C009250_D012640 NONE <e1>sevoflurane</e1> decreased pressure <e2>convulsions</e2>
C009250_D012640 NONE <e1>sevoflurane</e1> reduces effect <e2>convulsive</e2>
D008012_D012640 CID <e1>lidocaine-induced</e1> <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine-induced</e1> <e2>convulsions</e2>
D008012_D012640 CID <e1>lidocaine</e1> infusion l(-1 threshold <e2>convulsive</e2>
D008012_D012640 CID <e1>lidocaine</e1> toxicity effect <e2>convulsive</e2>
D004737_D012640 NONE <e1>enflurane</e1> sevoflurane threshold <e2>convulsive</e2>
D004737_D012640 NONE <e1>enflurane</e1> sevoflurane concentrations administered decreased pressure <e2>convulsions</e2>
D004737_D012640 NONE <e1>enflurane</e1> became marked administered decreased pressure <e2>convulsions</e2>
D001030_D012640 NONE <e1>apamin</e1> had tendency decrease threshold <e2>convulsive</e2>
C009250_D064420 NONE <e1>sevoflurane</e1> reduces effect <e2>toxicity</e2>
C009250_D003866 NONE <e1>sevoflurane</e1> reduces carries <e2>depression</e2>
D008012_D064420 NONE <e1>lidocaine</e1> <e2>toxicity</e2>
D008012_D003866 NONE <e1>lidocaine</e1> toxicity effect reduces carries <e2>depression</e2>
3856631
D008727_D008577 NONE <e1>methotrexate</e1> induction <e2>leukemia</e2>
D008727_D054198 NONE <e1>methotrexate</e1> treated children <e2>leukemia</e2>
D008727_D054198 NONE <e1>methotrexate</e1> concentrations maintain achieve designed regimen methotrexate treated children <e2>leukemia</e2>
D008727_D054198 NONE <e1>methotrexate</e1> treatment induction relapse <e2>leukemia</e2>
D008727_D002493 NONE <e1>methotrexate</e1> treated children developed <e2>disease</e2>
D008727_D002493 NONE <e1>methotrexate</e1> concentrations maintain achieve designed regimen methotrexate treated children developed <e2>disease</e2>
D001663_D064420 NONE <e1>bilirubin</e1> transaminase <e2>toxicities</e2>
D001663_D009503 NONE <e1>bilirubin</e1> transaminase elevations <e2>neutropenia</e2>
D001663_D052016 NONE <e1>bilirubin</e1> transaminase elevations <e2>mucositis</e2>
15957009
C507242_D008569 NONE <e1>ro4368554</e1> restores performance models <e2>deficiency</e2>
C507242_D008569 NONE <e1>ro4368554</e1> <e2>deficits</e2>
C507242_D008569 NONE <e1>ro4368554</e1> improve reversed cholinergic <e2>deficit</e2>
C507242_D008569 NONE <e1>ro4368554</e1> facilitation involved suggesting reversed cholinergic <e2>deficit</e2>
D014236_D008569 NONE <e1>metrifonate</e1> ro4368554 <e2>deficits</e2>
D012601_D008569 CID <e1>scopolamine</e1> induced <e2>deficits</e2>
D014364_D008569 NONE <e1>trp</e1> depletion scopolamine induced <e2>deficits</e2>
D012701_D008569 NONE <e1>5-ht(6</e1> antagonists facilitation involved suggesting reversed cholinergic <e2>deficit</e2>
15188772
D004837_D018487 NONE <e1>epinephrine</e1> overdose left systolic <e2>dysfunction</e2>
D004837_D018487 NONE <e1>epinephrine</e1> mg injected left systolic <e2>dysfunction</e2>
D004837_D062787 NONE <e1>epinephrine</e1> <e2>overdose</e2>
D002395_D009202 NONE <e1>catecholamine-induced</e1> <e2>cardiomyopathy</e2>
D002395_D009202 NONE <e1>catecholamines</e1> excess <e2>cardiomyopathy</e2>
D004837_D017682 CID <e1>epinephrine</e1> mg injected developed <e2>stunning</e2>
D004837_D009202 NONE <e1>epinephrine</e1> mg injected markers <e2>necrosis</e2>
17615423
D019821_D012206 CID <e1>simvastatin</e1> use secondary <e2>rhabdomyolysis</e2>
D019821_D012206 CID <e1>simvastatin</e1> interaction resulting <e2>rhabdomyolysis</e2>
D019821_D012206 CID <e1>simvastatin</e1> metabolism inhibit drugs presence increased risk <e2>rhabdomyolysis</e2>
D019821_D058186 CID <e1>simvastatin</e1> use secondary rhabdomyolysis <e2>failure</e2>
D019821_D058186 CID <e1>simvastatin</e1> interaction resulting rhabdomyolysis <e2>failure</e2>
D000638_D012206 CID <e1>amiodarone</e1> simvastatin use secondary <e2>rhabdomyolysis</e2>
D000638_D012206 CID <e1>amiodarone</e1> simvastatin interaction resulting <e2>rhabdomyolysis</e2>
D000638_D058186 CID <e1>amiodarone</e1> simvastatin use secondary rhabdomyolysis <e2>failure</e2>
D000638_D058186 CID <e1>amiodarone</e1> simvastatin interaction resulting rhabdomyolysis <e2>failure</e2>
C413408_D012206 CID <e1>atazanavir</e1> amiodarone simvastatin use secondary <e2>rhabdomyolysis</e2>
C413408_D012206 CID <e1>atazanavir</e1> simvastatin interaction resulting <e2>rhabdomyolysis</e2>
C413408_D058186 CID <e1>atazanavir</e1> amiodarone simvastatin use secondary rhabdomyolysis <e2>failure</e2>
C413408_D058186 CID <e1>atazanavir</e1> simvastatin interaction resulting rhabdomyolysis <e2>failure</e2>
D019821_D015658 NONE <e1>simvastatin</e1> medications <e2>virus</e2>
D000638_D015658 NONE <e1>amiodarone</e1> simvastatin medications <e2>virus</e2>
12584269
D020123_D007674 CID <e1>srl</e1> seems <e2>nephrotoxic</e2>
D020123_D007674 CID <e1>srl</e1> seems displaying effects <e2>nephrotoxic</e2>
D020123_D007674 CID <e1>srl</e1> combined indications effect <e2>nephrotoxic</e2>
D020123_D007674 CID <e1>srl</e1> csa effect <e2>nephrotoxic</e2>
D020123_D007674 CID <e1>srl</e1> fk506 tolerated demonstrated effect <e2>nephrotoxic</e2>
D016572_D005355 NONE <e1>csa</e1> treated group worst showed analysis grade <e2>fibrosis</e2>
D020123_D005355 NONE <e1>srl</e1> csa treated group worst showed analysis grade <e2>fibrosis</e2>
D020123_D005355 NONE <e1>srl</e1> combination showed degree <e2>fibrosis</e2>
D016559_D005355 NONE <e1>fk506</e1> combination showed degree <e2>fibrosis</e2>
D016572_D007674 CID <e1>csa</e1> effect <e2>nephrotoxic</e2>
D016559_D007674 CID <e1>fk506</e1> tolerated demonstrated effect <e2>nephrotoxic</e2>
14976857
D011405_-1 NONE <e1>propafenone</e1> overdose induced <e2>syndrome</e2>
D011405_D062787 NONE <e1>propafenone</e1> <e2>overdose</e2>
D011405_D062787 NONE <e1>propafenone</e1> <e2>overdose</e2>
D011405_D004437 NONE <e1>propafenone</e1> overdose induced woman <e2>anomaly</e2>
D011405_D054092 NONE <e1>propafenone</e1> overdose precipitated occurred shunt <e2>ovale</e2>
11166519
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> injection induced <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
6209318
D008801_D001145 NONE <e1>mexiletine</e1> report <e2>arrhythmia</e2>
D008801_D009203 NONE <e1>mexiletine</e1> form effects evaluated trial patients <e2>infarction</e2>
D008801_D009203 NONE <e1>mexitil-perlongets</e1> form effects evaluated trial patients <e2>infarction</e2>
D008801_D003643 NONE <e1>mexiletine</e1> group <e2>deaths</e2>
D008801_D014202 CID <e1>mexiletine</e1> group frequent recognized effects <e2>tremor</e2>
D008801_D012817 CID <e1>mexiletine</e1> group frequent recognized effects tremor <e2>problems</e2>
20196116
D000995_D017114 CID <e1>antituberculosis</e1> <e2>failure</e2>
D000995_D017114 CID <e1>antituberculosis</e1> therapy (att)-associated <e2>failure</e2>
D000995_D017114 CID <e1>antituberculosis</e1> therapy (att)-associated failure <e2>att-alf</e2>
D000995_D017114 CID <e1>antituberculosis</e1> therapy (att)-associated <e2>alf</e2>
D001663_D001927 NONE <e1>bilirubin</e1> iii/iv <e2>encephalopathy</e2>
20477932
D003042_D008569 CID <e1>cocaine</e1> causes <e2>impairments</e2>
D003042_D007859 CID <e1>cocaine</e1> causes <e2>impairments</e2>
C052342_D008569 NONE <e1>topiramate</e1> prevention causes <e2>impairments</e2>
C052342_D007859 NONE <e1>topiramate</e1> prevention causes <e2>impairments</e2>
D003042_D064420 NONE <e1>cocaine</e1> <e2>toxicity</e2>
D003042_D064420 NONE <e1>cocaine</e1> brain induced-behaviour status association <e2>toxicity</e2>
D009569_D019970 NONE <e1>oxide</e1> synthase activity activity therapy <e2>addiction</e2>
C052342_D019970 NONE <e1>topiramate</e1> effect activity therapy <e2>addiction</e2>
D003042_D019970 NONE <e1>cocaine</e1> administration model evaluated activity therapy <e2>addiction</e2>
7265370
D014223_D053040 CID <e1>triamterene</e1> <e2>nephrolithiasis</e2>
D014223_D053040 CID <e1>triamterene</e1> <e2>nephrolithiasis</e2>
D014223_D053040 CID <e1>triamterene</e1> <e2>nephrolithiasis</e2>
C020743_D053040 NONE <e1>dyazide</e1> therapy complicating <e2>nephrolithiasis</e2>
C020743_D053040 NONE <e1>hydrochlorothiazide-triamterene</e1> therapy years reported case <e2>nephrolithiasis</e2>
D014223_D006973 NONE <e1>triamterene</e1> nephrolithiasis case reported years therapy <e2>hypertension</e2>
C020743_D006973 NONE <e1>hydrochlorothiazide-triamterene</e1> therapy <e2>hypertension</e2>
424937
D008750_D056486 CID <e1>methyldopa</e1> induced <e2>injury</e2>
D008750_D056486 CID <e1>methyldopa-induced</e1> <e2>hepatitis</e2>
D008750_D056486 CID <e1>methyldopa</e1> dysfunction relationship proved recurrence <e2>hepatitis</e2>
D008750_D008107 NONE <e1>methyldopa</e1> related <e2>disease</e2>
D008750_D008107 NONE <e1>methyldopa</e1> <e2>dysfunction</e2>
D008750_D017093 NONE <e1>methyldopa</e1> taking another presented <e2>failure</e2>
D008750_D017114 NONE <e1>methyldopa-induced</e1> hepatitis episode recommenced developed <e2>hepatitis</e2>
20470218
D008727_D056784 NONE <e1>methotrexate</e1> included syndrome <e2>leukoencephalopathy</e2>
D008727_D020521 NONE <e1>methotrexate</e1> included syndrome <e2>stroke</e2>
D008727_D004833 NONE <e1>methotrexate</e1> included syndrome <e2>epilepsy</e2>
D008727_D064420 NONE <e1>methotrexate</e1> <e2>toxicity</e2>
D008727_D007177 NONE <e1>methotrexate</e1> toxicity syndrome <e2>secretion</e2>
15572383
D004317_D007674 NONE <e1>adriamycin-induced</e1> <e2>damage</e2>
D004317_D007674 NONE <e1>adriamycin</e1> injection induced <e2>damage</e2>
D004317_D007674 NONE <e1>adriamycin</e1> elicited proteinuria <e2>damage</e2>
D004317_D007674 NONE <e1>adriamycin-induced</e1> <e2>damage</e2>
D004317_D011507 CID <e1>adriamycin</e1> induced <e2>proteinuria</e2>
D004317_D011507 CID <e1>adriamycin</e1> elicited <e2>proteinuria</e2>
D004317_D011507 CID <e1>adriamycin</e1> rise <e2>proteinuria</e2>
D004317_D009404 NONE <e1>adriamycin</e1> elicited proteinuria <e2>nephrotic</e2>
D004317_D005923 NONE <e1>adriamycin</e1> elicited proteinuria damage <e2>glomerulosclerosis</e2>
7582165
D000305_D004342 NONE <e1>corticosteroids</e1> <e2>reactions</e2>
D010248_D004342 NONE <e1>paramethasone</e1> different corticosteroids produced reactions <e2>hypersensitivity</e2>
D010248_D004342 NONE <e1>paramethasone</e1> caused <e2>pseudo-allergy</e2>
18208574
D006493_D013927 CID <e1>heparin-induced</e1> thrombocytopenia patients <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin-induced</e1> thrombocytopenia two-step assay <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin</e1> concentration characteristics utilizes objectives correlate inhibition assay <e2>thrombosis</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> thrombocytopenia <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> concentration characteristics utilizes objectives correlate inhibition assay two-step <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> concentration characteristics utilizes objectives correlate inhibition assay two-step thrombocytopenia <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> exposure patients patients decrease count <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> concentration inhibition density patients patients decrease count <e2>thrombocytopenia</e2>
19884587
D013449_D000757 CID <e1>sulfonamides</e1> associated <e2>anencephaly</e2>
D013449_D018636 CID <e1>sulfonamides</e1> associated <e2>syndrome</e2>
D013449_D001017 CID <e1>sulfonamides</e1> associated syndrome coarctation <e2>aorta</e2>
D013449_D002754 CID <e1>sulfonamides</e1> associated syndrome coarctation aorta <e2>atresia</e2>
D013449_D017880 CID <e1>sulfonamides</e1> associated <e2>deficiency</e2>
D013449_D006548 CID <e1>sulfonamides</e1> associated <e2>hernia</e2>
D009582_D000853 CID <e1>nitrofurantoins</e1> associated <e2>anophthalmia</e2>
D009582_D008850 CID <e1>nitrofurantoins</e1> associated anophthalmia <e2>microphthalmos</e2>
D009582_D018636 CID <e1>nitrofurantoins</e1> associated <e2>syndrome</e2>
D009582_D006344 CID <e1>nitrofurantoins</e1> associated syndrome <e2>defects</e2>
D009582_D002971 CID <e1>nitrofurantoins</e1> associated cleft <e2>lip</e2>
D009582_D002972 CID <e1>nitrofurantoins</e1> associated cleft <e2>palate</e2>
D010406_D000014 NONE <e1>penicillins</e1> conclusions associated <e2>defects</e2>
D004917_D000014 NONE <e1>erythromycins</e1> penicillins conclusions associated <e2>defects</e2>
D002511_D000014 NONE <e1>cephalosporins</e1> erythromycins penicillins conclusions associated <e2>defects</e2>
D013449_D000014 CID <e1>sulfonamides</e1> associated <e2>defects</e2>
D009582_D000014 CID <e1>nitrofurantoins</e1> sulfonamides associated <e2>defects</e2>
17343925
D012906_D034381 CID <e1>smoking</e1> influence estimated associated hearing <e2>loss</e2>
D012906_D034381 CID <e1>smoking</e1> associated hearing <e2>loss</e2>
8387218
D016049_D064420 NONE <e1>didanosine</e1> use <e2>toxicity</e2>
D016049_D064420 NONE <e1>ddi</e1> didanosine use <e2>toxicity</e2>
D016049_D015658 NONE <e1>didanosine</e1> use individuals <e2>antibody-positive</e2>
D016049_D015658 NONE <e1>ddi</e1> didanosine use individuals <e2>antibody-positive</e2>
D015215_D064420 NONE <e1>zidovudine</e1> intolerant individuals use <e2>toxicity</e2>
D015215_D064420 NONE <e1>azt</e1> zidovudine intolerant individuals use <e2>toxicity</e2>
D015215_D015658 NONE <e1>zidovudine</e1> intolerant individuals <e2>antibody-positive</e2>
D015215_D015658 NONE <e1>azt</e1> zidovudine intolerant individuals <e2>antibody-positive</e2>
D016049_D018149 CID <e1>didanosine</e1> returned require mild developed <e2>curves</e2>
D016049_D003920 NONE <e1>didanosine</e1> returned require mild developed curves characteristic <e2>diabetes</e2>
1639466
D002118_D009400 NONE <e1>calcium</e1> channel blocker nitrendipine <e2>nephrosclerosis</e2>
D002118_D006978 NONE <e1>calcium</e1> channel blocker nitrendipine nephrosclerosis rats <e2>hypertension</e2>
D002118_D006978 NONE <e1>calcium</e1> channel nitrendipine treatment effect studied clip <e2>hypertension</e2>
D009568_D009400 CID <e1>nitrendipine</e1> <e2>nephrosclerosis</e2>
D009568_D006978 NONE <e1>nitrendipine</e1> nephrosclerosis rats <e2>hypertension</e2>
D009568_D006978 NONE <e1>nitrendipine</e1> treatment effect studied clip <e2>hypertension</e2>
D002118_D000419 NONE <e1>calcium</e1> channel nitrendipine treatment effect enalapril pressure <e2>albuminuria</e2>
D009568_D000419 CID <e1>nitrendipine</e1> treatment effect enalapril pressure <e2>albuminuria</e2>
D009568_D000419 CID <e1>nitrendipine-treated</e1> <e2>albuminuria</e2>
D000809_D000419 NONE <e1>angiotensin</e1> inhibitor nitrendipine treatment effect enalapril pressure <e2>albuminuria</e2>
D000809_D006978 NONE <e1>angiotensin</e1> inhibitor nitrendipine treatment effect studied clip <e2>hypertension</e2>
D004656_D000419 NONE <e1>enalapril</e1> pressure <e2>albuminuria</e2>
D004656_D006978 NONE <e1>enalapril</e1> effect studied clip <e2>hypertension</e2>
D004656_D006973 NONE <e1>enalapril-treated</e1> n controls assigned weeks clipping artery rats <e2>hypertensive</e2>
D004656_D006973 NONE <e1>enalapril-treated</e1> n controls <e2>hypertensive</e2>
D004656_D006973 NONE <e1>enalapril-treated</e1> group lower higher controls <e2>hypertensive</e2>
D009568_D006973 NONE <e1>nitrendipine-treated</e1> n enalapril-treated n controls assigned weeks clipping artery rats <e2>hypertensive</e2>
D009568_D006973 NONE <e1>nitrendipine-treated</e1> n enalapril-treated n controls <e2>hypertensive</e2>
D009568_D006973 NONE <e1>nitrendipine-treated</e1> albuminuria increased hr controls <e2>hypertensive</e2>
D009568_D006973 NONE <e1>nitrendipine-treated</e1> group increased controls <e2>hypertensive</e2>
D009568_D006973 NONE <e1>nitrendipine-treated</e1> group higher controls <e2>hypertensive</e2>
D004656_D005921 NONE <e1>enalapril</e1> treatment change excretion <e2>glomerulosclerosis</e2>
D009568_D005921 NONE <e1>nitrendipine-treated</e1> group increased index <e2>glomerulosclerosis</e2>
16858720
D014859_D002543 CID <e1>warfarin</e1> induced <e2>haemorrhage</e2>
D014859_D002543 CID <e1>warfarin-induced</e1> <e2>haemorrhages</e2>
D014859_D002543 CID <e1>warfarin</e1> interactions evaluate frequency <e2>haemorrhages</e2>
D014859_D002543 CID <e1>warfarin-drug</e1> warfarin interactions evaluate frequency <e2>haemorrhages</e2>
D014859_D002543 CID <e1>warfarin</e1> interactions caused <e2>haemorrhage</e2>
D014859_D002543 CID <e1>warfarin-drug</e1> warfarin interactions caused <e2>haemorrhage</e2>
D014859_D002543 CID <e1>warfarin</e1> treatment related assessed patients <e2>haemorrhage</e2>
D014859_D002543 CID <e1>warfarin-induced</e1> <e2>haemorrhages</e2>
D014859_D002543 CID <e1>warfarin-related</e1> <e2>haemorrhages</e2>
D014859_D002543 CID <e1>warfarin</e1> interact known drugs taken prevented proportion <e2>haemorrhages</e2>
D014859_D006470 NONE <e1>warfarin-drug</e1> interaction contributed <e2>haemorrhage</e2>
D014859_D006470 NONE <e1>warfarin-drug</e1> interaction contributed considered complication <e2>bleeding</e2>
D014859_D006470 NONE <e1>warfarin</e1> patients contributed <e2>haemorrhage</e2>
D014859_D006470 NONE <e1>warfarin</e1> patients contributed considered complication <e2>bleeding</e2>
3173179
D014700_D009203 CID <e1>verapamil</e1> withdrawal cause <e2>infarction</e2>
D014700_D009203 CID <e1>verapamil</e1> withdrawal introduction coincided <e2>infarction</e2>
D014700_D006973 NONE <e1>verapamil</e1> withdrawal cause infarction woman <e2>hypertensive</e2>
D014700_D006973 NONE <e1>verapamil</e1> withdrawal woman <e2>hypertension</e2>
D002216_D009203 NONE <e1>captopril</e1> introduction coincided <e2>infarction</e2>
D002216_D006973 NONE <e1>captopril</e1> introduction withdrawal woman <e2>hypertension</e2>
12202650
D002211_D063806 NONE <e1>capsaicin-induced</e1> <e2>pain</e2>
D002211_D010146 CID <e1>capsaicin</e1> injected induce <e2>pain</e2>
1833784
D004298_D006948 NONE <e1>dopamine</e1> receptors involvement mediating <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine-induced</e1> <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine</e1> caused increase <e2>activity</e2>
D009538_D006948 CID <e1>nicotine-induced</e1> <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine-induced</e1> <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine</e1> injection induces <e2>hyperactivity</e2>
C534628_D006948 NONE <e1>23390</e1> sch blocked <e2>hyperactivity</e2>
D020891_D006948 NONE <e1>raclopride</e1> blocked <e2>hyperactivity</e2>
D005476_D006948 NONE <e1>fluphenazine</e1> raclopride blocked <e2>hyperactivity</e2>
-1_D006948 NONE <e1>phno</e1> pretreatment enhanced <e2>hyperactivity</e2>
D015647_D006948 NONE <e1>38393</e1> skf had enhanced <e2>hyperactivity</e2>
3371379
D014700_D020258 CID <e1>verapamil-induced</e1> <e2>neurotoxicity</e2>
D014700_D020258 CID <e1>verapamil</e1> treatment patients signs <e2>neurotoxicity</e2>
D002220_D020258 CID <e1>carbamazepine</e1> <e2>neurotoxicity</e2>
D002220_D020258 CID <e1>carbamazepine</e1> <e2>neurotoxicity</e2>
D002118_D020258 NONE <e1>calcium</e1> blocker discontinuation showed patients signs <e2>neurotoxicity</e2>
20080419
D010862_D004827 CID <e1>pilocarpine</e1> induced <e2>epilepsy</e2>
10457883
16938416
D013739_D050197 CID <e1>testosterone</e1> associated <e2>atherosclerosis</e2>
D013739_D050197 CID <e1>estrogen-testosterone</e1> therapy <e2>atherosclerosis</e2>
D013739_D050197 CID <e1>testosterone</e1> therapy affect <e2>atherosclerosis</e2>
D004967_D050197 NONE <e1>estrogen-testosterone</e1> therapy <e2>atherosclerosis</e2>
C032109_D050197 NONE <e1>esters</e1> estradiol- therapy <e2>atherosclerosis</e2>
D002784_D003920 NONE <e1>cholesterol</e1> level <e2>diabetes</e2>
D000431_D003920 NONE <e1>alcohol</e1> use pressure remained adjustment <e2>diabetes</e2>
17612891
D003024_D009205 CID <e1>clozapine</e1> associated <e2>myocarditis</e2>
D003024_D009205 CID <e1>clozapine</e1> commencement associated <e2>myocarditis</e2>
D003024_D009205 CID <e1>clozapine</e1> commencement onset <e2>myocarditis</e2>
D003024_D009205 CID <e1>clozapine</e1> use associated complication <e2>myocarditis</e2>
D003024_D012559 NONE <e1>clozapine</e1> commencement onset developed male <e2>schizophrenia</e2>
D003024_D011618 NONE <e1>clozapine</e1> remains standard treatment <e2>psychosis</e2>
12716030
D006493_D002543 NONE <e1>heparin</e1> enhanced using induction <e2>ich</e2>
D006493_D002543 NONE <e1>heparin</e1> enhanced volume 3.4-fold that seen animals <e2>ich</e2>
D006493_D006406 CID <e1>heparin</e1> enhanced volume <e2>hematoma</e2>
D006493_D006470 NONE <e1>heparin</e1> enhanced volume 3.4-fold that seen animals <e2>bleeding</e2>
16274958
D017255_D055154 CID <e1>acitretin</e1> <e2>dysphonia</e2>
D017255_D055154 CID <e1>acitretin</e1> treated report case complaining <e2>dysphonia</e2>
D017255_D055154 CID <e1>acitretin-induced</e1> <e2>dysphonia</e2>
19631624
D018817_D007859 CID <e1>ecstasy</e1> users <e2>deficits</e2>
D018817_D007859 CID <e1>ecstasy</e1> users display learning <e2>memory</e2>
D018817_D008569 CID <e1>ecstasy</e1> users <e2>deficits</e2>
D018817_D008569 CID <e1>ecstasy</e1> users display learning <e2>memory</e2>
D002188_D007859 NONE <e1>cannabis</e1> users hyperactivity deficits learning <e2>memory</e2>
D002188_D008569 NONE <e1>cannabis</e1> users hyperactivity deficits learning <e2>memory</e2>
D002188_D006948 NONE <e1>cannabis</e1> users <e2>hyperactivity</e2>
D018817_D006948 NONE <e1>ecstasy-specific</e1> <e2>hyperactivity</e2>
D018817_D020258 NONE <e1>ecstasy-specific</e1> effects related vulnerability effects <e2>neurotoxic</e2>
D018817_D020258 NONE <e1>ecstasy</e1> effects <e2>neurotoxic</e2>
1732369
D004280_D009369 NONE <e1>dobutamine</e1> echocardiography indicator survivors <e2>cancer</e2>
D004280_D009369 NONE <e1>dobutamine</e1> infusion using differentiate survivors <e2>cancer</e2>
D004317_D009369 NONE <e1>doxorubicin-treated</e1> survivors <e2>cancer</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> damage test develop performed using differentiate survivors <e2>cancer</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> treated <e2>cancer</e2>
D004317_D009202 CID <e1>doxorubicin</e1> agent known cause <e2>cardiomyopathy</e2>
D004317_D006331 NONE <e1>doxorubicin</e1> <e2>damage</e2>
D004317_D006331 NONE <e1>doxorubicin</e1> treated cancer survivors differentiate using performed develop test <e2>damage</e2>
D004280_D006331 NONE <e1>dobutamine</e1> infusion using performed develop test <e2>damage</e2>
3629586
D015790_D006402 NONE <e1>cefonicid</e1> effects model <e2>hematotoxicity</e2>
D015790_D006402 NONE <e1>cefonicid</e1> receiving % occurred compromising <e2>cytopenias</e2>
D015790_D006402 NONE <e1>cefonicid</e1> dogs reproduced <e2>syndrome</e2>
D015790_D006402 NONE <e1>cefonicid</e1> doses administration induce <e2>hematotoxicity</e2>
D015790_D006402 NONE <e1>cefonicid</e1> doses administration induce hematotoxicity similar <e2>dyscrasias</e2>
C021341_D006402 NONE <e1>cefazedone</e1> cefonicid effects model <e2>hematotoxicity</e2>
C021341_D006402 NONE <e1>cefazedone</e1> cefonicid receiving % occurred compromising <e2>cytopenias</e2>
C021341_D006402 NONE <e1>cefazedone)-treated</e1> cefonicid dogs reproduced <e2>syndrome</e2>
C021341_D006402 NONE <e1>cefazedone</e1> cefonicid doses administration induce <e2>hematotoxicity</e2>
C021341_D006402 NONE <e1>cefazedone</e1> cefonicid doses administration induce hematotoxicity similar <e2>dyscrasias</e2>
D002511_D006402 NONE <e1>cephalosporin</e1> <e2>hematotoxicity</e2>
D002511_D006402 NONE <e1>cephalosporin</e1> antibiotics cause variety <e2>disturbances</e2>
D002511_D006402 NONE <e1>cephalosporin</e1> rechallenge reproduced <e2>syndrome</e2>
D002511_D006402 NONE <e1>cephalosporin-induced</e1> dyscrasias similar <e2>hematotoxicity</e2>
D002511_D006402 NONE <e1>cephalosporin-induced</e1> <e2>dyscrasias</e2>
D015790_D064420 NONE <e1>cefonicid</e1> administration caused studies <e2>toxicity</e2>
D015790_D000740 CID <e1>cefonicid</e1> administration caused incidence <e2>anemia</e2>
D015790_D000740 CID <e1>cefonicid</e1> receiving % occurred compromising <e2>anemia</e2>
D015790_D009503 CID <e1>cefonicid</e1> administration caused incidence anemia <e2>neutropenia</e2>
D015790_D013921 CID <e1>cefonicid</e1> administration caused incidence anemia <e2>thrombocytopenia</e2>
C021341_D064420 NONE <e1>cefazedone</e1> cefonicid administration caused studies <e2>toxicity</e2>
C021341_D000740 CID <e1>cefazedone</e1> cefonicid administration caused incidence <e2>anemia</e2>
C021341_D000740 CID <e1>cefazedone</e1> cefonicid receiving % occurred compromising <e2>anemia</e2>
C021341_D009503 CID <e1>cefazedone</e1> cefonicid administration caused incidence anemia <e2>neutropenia</e2>
C021341_D013921 CID <e1>cefazedone</e1> cefonicid administration caused incidence anemia <e2>thrombocytopenia</e2>
14698717
D010672_D011605 NONE <e1>phenytoin</e1> treatment <e2>psychosis</e2>
D010672_D011605 NONE <e1>phenytoin</e1> treatment developed <e2>psychosis</e2>
D010672_D011605 NONE <e1>phenytoin</e1> treatment occur <e2>symptoms</e2>
D010672_D014277 NONE <e1>phenytoin</e1> treatment <e2>neuralgia</e2>
D010672_D004827 NONE <e1>phenytoin</e1> treatment patients <e2>epileptic</e2>
D010672_D012640 NONE <e1>phenytoin</e1> treatment occur symptoms result unrelated <e2>seizures</e2>
17931375
D006493_D003288 CID <e1>heparin</e1> injection duration effect <e2>bruising</e2>
D006493_D003288 CID <e1>heparin</e1> injection administration effect <e2>bruising</e2>
D006493_D003288 CID <e1>heparin</e1> injection prevent <e2>bruising</e2>
D006493_D003288 CID <e1>heparin</e1> injection prevent studied background documented effect occurrence <e2>bruising</e2>
D006493_D003288 CID <e1>heparin</e1> areas <e2>bruising</e2>
D006493_D003288 CID <e1>heparin</e1> administration effect <e2>bruising</e2>
D006493_D010146 CID <e1>heparin</e1> injection duration effect bruising <e2>pain</e2>
D006493_D010146 CID <e1>heparin</e1> injection administration effect bruising <e2>pain</e2>
D006493_D010146 CID <e1>heparin</e1> injection prevent bruising <e2>pain</e2>
D006493_D010146 CID <e1>heparin</e1> injection prevent studied background documented effect occurrence bruising <e2>pain</e2>
D006493_D010146 CID <e1>heparin</e1> administration effect bruising <e2>pain</e2>
2696505
D007741_D007022 CID <e1>labetalol</e1> comparison <e2>hypotension</e2>
D007741_D007022 CID <e1>labetalol-induced</e1> <e2>hypotension</e2>
D007741_D007022 CID <e1>labetalol-induced</e1> hypotension <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> labetalol comparison <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside-induced</e1> hypotension <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside-induced</e1> <e2>hypotension</e2>
D009599_D016534 CID <e1>nitroprusside</e1> discontinuation patients observed associated increase <e2>output</e2>
D009599_D006973 NONE <e1>nitroprusside</e1> discontinuation patients observed <e2>hypertension</e2>
10579464
C121249_D006948 NONE <e1>nra0160</e1> <e2>hyperactivity</e2>
D003024_D006948 NONE <e1>clozapine</e1> nra0160 <e2>hyperactivity</e2>
D008694_D006948 CID <e1>methamphetamine</e1> induced <e2>hyperactivity</e2>
D008694_D006948 CID <e1>map</e1> methamphetamine induced <e2>hyperactivity</e2>
C121249_D002375 CID <e1>nra0160</e1> induced <e2>catalepsy</e2>
D003024_D002375 CID <e1>clozapine</e1> nra0160 induced <e2>catalepsy</e2>
19356307
D012601_D003704 NONE <e1>scopolamine</e1> induced <e2>dementia</e2>
C008281_D003704 NONE <e1>s-limonene</e1> effects <e2>anti-dementia</e2>
C032208_D003704 NONE <e1>alcohol</e1> s-limonene effects <e2>anti-dementia</e2>
D012601_D008569 CID <e1>scopolamine</e1> <e2>impaired</e2>
D012601_D008569 CID <e1>scopolamine</e1> impaired memory improve ability showed relieved deficit <e2>memory</e2>
C032208_D008569 NONE <e1>alcohol</e1> relieved showed ability improve memory <e2>impaired</e2>
C032208_D008569 NONE <e1>alcohol</e1> relieved deficit <e2>memory</e2>
2273650
D012601_D000647 CID <e1>scopolamine</e1> produced <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> reversed <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> reversed failed reverse <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> amnesia reversed failed reverse <e2>amnesia</e2>
D003513_D000647 CID <e1>cycloheximide</e1> scopolamine produced <e2>amnesia</e2>
D003513_D000647 CID <e1>cycloheximide</e1> failed reversed <e2>amnesia</e2>
D003513_D000647 CID <e1>cycloheximide</e1> failed reverse <e2>amnesia</e2>
D003513_D000647 CID <e1>cycloheximide-induced</e1> amnesia reverse failed reversed <e2>amnesia</e2>
D003513_D000647 CID <e1>cycloheximide-induced</e1> <e2>amnesia</e2>
D009020_D000647 NONE <e1>morphine</e1> reversed <e2>amnesia</e2>
D009020_D000647 NONE <e1>morphine</e1> facilitated reversed <e2>amnesia</e2>
D009270_D000647 NONE <e1>naloxone</e1> administered animals retrieval facilitated reversed <e2>amnesia</e2>
18217897
D013792_D008228 NONE <e1>thalidomide</e1> limited activity <e2>lymphomas</e2>
D013792_D009369 NONE <e1>thalidomide</e1> limited trial b. group <e2>cancer</e2>
D013792_D007938 NONE <e1>thalidomide</e1> limited trial b. group cancer <e2>leukemia</e2>
D013792_D009101 NONE <e1>thalidomide</e1> agent activity <e2>myeloma</e2>
D013792_D020522 NONE <e1>thalidomide</e1> agent activity myeloma <e2>lymphoma</e2>
D013792_D008223 NONE <e1>thalidomide</e1> agent activity myeloma <e2>lymphoma</e2>
D013792_D008223 NONE <e1>thalidomide</e1> received patients <e2>lymphomas</e2>
D013792_D008223 NONE <e1>thalidomide</e1> <e2>lymphomas</e2>
C467567_D008223 NONE <e1>lenalidomide</e1> agent reported level contrast demonstrate rate thalidomide <e2>lymphomas</e2>
3070035
D002216_D051437 NONE <e1>captopril-induced</e1> <e2>insufficiency</e2>
D002216_D051437 NONE <e1>captopril-induced</e1> <e2>failure</e2>
D002216_D006978 NONE <e1>captopril-induced</e1> insufficiency reversibility case <e2>hypertension</e2>
D002216_D006973 NONE <e1>captopril</e1> treatment developed case <e2>hypertension</e2>
D002216_D058186 CID <e1>captopril</e1> treatment developed deterioration <e2>function</e2>
1987816
D008094_D011141 CID <e1>lithium-induced</e1> <e2>polyuria</e2>
4008111
D000638_D012848 CID <e1>amiodarone-induced</e1> <e2>block</e2>
D000638_D012848 CID <e1>amiodarone</e1> administration observed <e2>block</e2>
D000638_D012848 CID <e1>amiodarone</e1> dosage reduction resulted disappearance <e2>block</e2>
D000638_D009202 NONE <e1>amiodarone</e1> administration boy <e2>cardiomyopathy</e2>
D000638_D014927 NONE <e1>amiodarone</e1> administration <e2>syndrome</e2>
D000638_D013617 NONE <e1>amiodarone</e1> administration syndrome <e2>tachycardia</e2>
D000638_D012804 NONE <e1>amiodarone</e1> dosage reduction resulted disappearance block persistence <e2>bradycardia</e2>
3425586
D003622_D000743 CID <e1>dapsone-associated</e1> <e2>anemia</e2>
D003622_D000743 CID <e1>dapsone</e1> dose taking developed <e2>anemia</e2>
D003622_D000743 CID <e1>dapsone</e1> cause <e2>anemia</e2>
D003622_D007918 NONE <e1>dapsone</e1> dose taking developed woman trait <e2>leprosy</e2>
D003622_D006461 NONE <e1>dapsone</e1> dose taking associated <e2>hemolysis</e2>
15338796
D000420_D014202 CID <e1>salbutamol</e1> effects <e2>tremor</e2>
D000420_D014202 CID <e1>salbutamol</e1> method effects <e2>tremor</e2>
D000420_D014202 CID <e1>salbutamol</e1> doses administration patients assessed <e2>tremor</e2>
D000420_D014202 CID <e1>salbutamol</e1> increased severity <e2>tremor</e2>
D000420_D008173 NONE <e1>salbutamol</e1> doses administration patients <e2>disease</e2>
3358181
D012312_D014693 CID <e1>ritodrine</e1> therapy section <e2>tachyarrhythmias</e2>
D012312_D007752 NONE <e1>ritodrine</e1> receiving patients <e2>labor</e2>
D012312_D007752 NONE <e1>ritodrine</e1> effects interactions risk patients <e2>labor</e2>
D012312_D002318 NONE <e1>ritodrine</e1> infusion cessation result <e2>complications</e2>
D010656_D007022 NONE <e1>phenylephrine</e1> treat patients <e2>hypotensive</e2>
D010656_D013610 NONE <e1>phenylephrine</e1> treat patients <e2>tachycardia</e2>
19581773
C417083_D009157 CID <e1>interferon</e1> treatment development <e2>myasthenia</e2>
C417083_D009157 CID <e1>alpha-2b</e1> therapy associated <e2>myasthenia</e2>
C417083_D009157 CID <e1>ifn</e1> therapy complications review present reported <e2>myasthenia</e2>
C417083_D019698 NONE <e1>interferon</e1> treatment <e2>c.</e2>
C417083_D019698 NONE <e1>alpha-2b</e1> ribavirin <e2>c</e2>
C417083_D019698 NONE <e1>alpha-2b</e1> ribavirin c <e2>chc</e2>
C417083_D019698 NONE <e1>alpha-2b</e1> therapy <e2>chc</e2>
C417083_D019698 NONE <e1>ifn</e1> therapy complications review present reported myasthenia associated therapy <e2>chc</e2>
D012254_D009157 CID <e1>ribavirin</e1> interferon treatment development <e2>myasthenia</e2>
D012254_D009157 CID <e1>ribavirin</e1> alpha-2b therapy associated <e2>myasthenia</e2>
D012254_D019698 NONE <e1>ribavirin</e1> interferon treatment <e2>c.</e2>
D012254_D019698 NONE <e1>ribavirin</e1> <e2>c</e2>
D012254_D019698 NONE <e1>ribavirin</e1> c <e2>chc</e2>
D012254_D019698 NONE <e1>ribavirin</e1> alpha-2b therapy <e2>chc</e2>
C417083_D004172 NONE <e1>alpha-2b</e1> administration weeks experienced <e2>diplopia</e2>
D012254_D004172 NONE <e1>ribavirin</e1> alpha-2b administration weeks experienced <e2>diplopia</e2>
9088814
D000527_D007022 CID <e1>e1-induced</e1> <e2>hypotension</e2>
D000527_D007022 CID <e1>e1</e1> effects (pge1)-induced <e2>hypotension</e2>
D000527_D007022 CID <e1>(pge1)-induced</e1> <e2>hypotension</e2>
D000527_D007022 CID <e1>pge1</e1> induced <e2>hypotension</e2>
D000527_D007022 CID <e1>pge1-induced</e1> <e2>hypotension</e2>
D000527_D020141 NONE <e1>e1-induced</e1> hypotension <e2>haemodilution</e2>
D000527_D020141 NONE <e1>e1</e1> effects (pge1)-induced hypotension <e2>haemodilution</e2>
D000527_D020141 NONE <e1>(pge1)-induced</e1> hypotension <e2>haemodilution</e2>
D000527_D020141 NONE <e1>pge1-induced</e1> hypotension min <e2>haemodilution</e2>
D003911_D020141 NONE <e1>dextran</e1> solution amount replacing withdrawing produced <e2>haemodilution</e2>
D001663_D007022 NONE <e1>bilirubin</e1> sgot showed decrease start <e2>hypotension</e2>
D000527_D008107 CID <e1>pge1-induced</e1> hypotension min combination cause impairment <e2>function</e2>
18726058
D010208_D020301 NONE <e1>hydrochloride</e1> vasodilator used manage <e2>vasospasm</e2>
D010208_D020301 NONE <e1>papaverine</e1> received <e2>vasospasm</e2>
D010208_D020301 NONE <e1>papaverine</e1> used action manage <e2>vasospasm</e2>
D010208_D020301 NONE <e1>papaverine</e1> treatment <e2>vasospasm</e2>
D010208_D003389 NONE <e1>papaverine</e1> cases described <e2>dysfunction</e2>
D010208_D003389 NONE <e1>papaverine</e1> <e2>deficits</e2>
17639754
D014859_D006470 CID <e1>warfarin</e1> interaction result appear cases complications <e2>bleeding</e2>
D064704_D006470 CID <e1>levofloxacin</e1> warfarin interaction result appear cases complications <e2>bleeding</e2>
19473225
D018698_D010523 NONE <e1>glutamate</e1> supplementation failed protect <e2>neurotoxicity</e2>
D018698_D010523 NONE <e1>glutamate</e1> claimed factor <e2>neuropathy</e2>
D018698_D010523 NONE <e1>glutamine</e1> glutamate claimed factor <e2>neuropathy</e2>
D018698_D010523 NONE <e1>glutamate</e1> supplementation preventing <e2>neuropathy</e2>
D018698_D010523 NONE <e1>glutamate</e1> fails protect <e2>neurotoxicity</e2>
D017239_D010523 CID <e1>paclitaxel</e1> <e2>neurotoxicity</e2>
D017239_D010523 CID <e1>paclitaxel</e1> chemotherapy factor <e2>neuropathy</e2>
D017239_D010523 CID <e1>pac</e1> paclitaxel chemotherapy factor <e2>neuropathy</e2>
D017239_D010523 CID <e1>pac</e1> neurotoxicity ameliorate claimed factor <e2>neuropathy</e2>
D017239_D010523 CID <e1>pac-induced</e1> <e2>neuropathy</e2>
D017239_D010523 CID <e1>pac</e1> <e2>neurotoxicity</e2>
D017239_D020258 NONE <e1>paclitaxel</e1> chemotherapy factor claimed ameliorate <e2>neurotoxicity</e2>
D017239_D020258 NONE <e1>pac</e1> paclitaxel chemotherapy factor claimed ameliorate <e2>neurotoxicity</e2>
D017239_D020258 NONE <e1>pac</e1> <e2>neurotoxicity</e2>
D018698_D020258 NONE <e1>glutamate</e1> claimed ameliorate <e2>neurotoxicity</e2>
D018698_D020258 NONE <e1>glutamine</e1> glutamate claimed ameliorate <e2>neurotoxicity</e2>
D000596_D010523 NONE <e1>acid</e1> glutamine glutamate claimed factor <e2>neuropathy</e2>
D000596_D020258 NONE <e1>acid</e1> glutamine glutamate claimed ameliorate <e2>neurotoxicity</e2>
D017239_D010051 NONE <e1>pac-containing</e1> regimen cycles available patients <e2>cancer</e2>
D018698_D010051 NONE <e1>glutamate</e1> supplemented available patients <e2>cancer</e2>
435349
D013390_D005207 CID <e1>suxamethonium</e1> rate <e2>fasciculations</e2>
D013390_D013746 NONE <e1>sch</e1> mg exceeded discontinued was response stimulation <e2>tetanic</e2>
3827439
D000666_D058186 CID <e1>amphotericin</e1> <e2>failure</e2>
D000666_D058186 CID <e1>b</e1> administration following developed <e2>failure</e2>
D000666_D058186 CID <e1>amphotericin</e1> activate contributing <e2>failure</e2>
D000666_D005355 NONE <e1>b</e1> administration following developed patient <e2>cirrhosis</e2>
D000666_D013174 NONE <e1>b</e1> administration following developed patient cirrhosis <e2>sporotrichosis</e2>
20667451
D003474_D003072 NONE <e1>curcumin</e1> ameliorates <e2>dysfunction</e2>
D003474_D003072 NONE <e1>curcumin</e1> administration effect phenobarbitone- <e2>impairment</e2>
D003474_D003072 NONE <e1>curcumin</e1> administration prevented <e2>impairment</e2>
D003474_D003072 NONE <e1>curcumin</e1> has mitigating deterioration <e2>functions</e2>
D003474_D003072 NONE <e1>curcumin</e1> considered adjuvant therapy preventing <e2>impairment</e2>
D010634_D003072 CID <e1>phenobarbitone</e1> rats <e2>dysfunction</e2>
D010634_D003072 CID <e1>phenobarbitone</e1> drugs known cause <e2>impairment</e2>
D010634_D003072 CID <e1>phenobarbitone-</e1> <e2>impairment</e2>
D010634_D003072 CID <e1>phenobarbitone</e1> administration caused impairment learning <e2>memory</e2>
D010634_D003072 CID <e1>phenobarbitone</e1> treated rats damage deterioration <e2>functions</e2>
D010634_D003072 CID <e1>phenobarbitone</e1> therapy preventing <e2>impairment</e2>
D002220_D003072 CID <e1>carbamazepine</e1> phenobarbitone rats <e2>dysfunction</e2>
D002220_D003072 CID <e1>carbamazepine</e1> phenobarbitone drugs known cause <e2>impairment</e2>
D002220_D003072 CID <e1>carbamazepine-induced</e1> phenobarbitone- <e2>impairment</e2>
D002220_D003072 CID <e1>carbamazepine</e1> phenobarbitone administration caused impairment learning <e2>memory</e2>
D002220_D003072 CID <e1>carbamazepine</e1> phenobarbitone treated rats damage deterioration <e2>functions</e2>
D002220_D003072 CID <e1>carbamazepine</e1> phenobarbitone therapy preventing <e2>impairment</e2>
12907309
C121465_D020258 NONE <e1>mpep</e1> action <e2>neurotoxicity</e2>
C121465_D005334 NONE <e1>mpep</e1> action associated decrease inhibition <e2>hyperthermia</e2>
C121465_D005334 NONE <e1>mpep</e1> rendered neuroprotection associated decrease <e2>hyperthermia</e2>
D008694_D020258 NONE <e1>methamphetamine-induced</e1> <e2>neurotoxicity</e2>
D008694_D005334 CID <e1>methamphetamine-induced</e1> neurotoxicity action associated decrease inhibition <e2>hyperthermia</e2>
D008694_D005334 CID <e1>methamphetamine</e1> <e2>hyperthermia</e2>
D008694_D005334 CID <e1>methamphetamine-induced</e1> efflux reduction associated decrease <e2>hyperthermia</e2>
D004298_D020258 NONE <e1>dopamine</e1> outflow decrease associated action <e2>neurotoxicity</e2>
D004298_D005334 NONE <e1>dopamine</e1> outflow decrease inhibition <e2>hyperthermia</e2>
D004298_D005334 NONE <e1>dopamine</e1> efflux reduction associated decrease <e2>hyperthermia</e2>
C121465_D064420 NONE <e1>mpep</e1> blockade protect <e2>toxicity</e2>
D008694_D064420 NONE <e1>methamphetamine-induced</e1> <e2>toxicity</e2>
11391224
D003042_D006974 NONE <e1>cocaine-related</e1> failure cases <e2>hypertension</e2>
D003042_D057049 NONE <e1>cocaine-related</e1> failure cases hypertension <e2>microangiopathy</e2>
D003042_D008181 NONE <e1>cocaine-related</e1> failure cases hypertension <e2>nephritis</e2>
D003042_D011695 NONE <e1>cocaine-related</e1> failure cases hypertension <e2>nephritis</e2>
D003042_D005921 NONE <e1>cocaine-related</e1> failure cases hypertension <e2>glomerulonephritis</e2>
D003042_D058186 CID <e1>cocaine-related</e1> <e2>failure</e2>
14596845
D000661_D019966 NONE <e1>amphetamine</e1> dose cross-sensitization causes <e2>dependency</e2>
D000661_D006948 CID <e1>amphetamine</e1> dose <e2>cross-sensitization</e2>
D000661_D006948 CID <e1>amphetamine</e1> dose <e2>cross-sensitization</e2>
D000661_D006948 CID <e1>amphetamine</e1> <e2>hyperactive</e2>
D000661_D006948 CID <e1>amphetamine</e1> injection followed groups <e2>hyperactive</e2>
D000661_D006948 CID <e1>amphetamine</e1> injection followed chow groups <e2>hyperactive</e2>
D000661_D006948 CID <e1>amphetamine</e1> chow <e2>hyperactive</e2>
D013395_D006948 CID <e1>sucrose</e1> experienced animals <e2>hyperactive</e2>
D013395_D006948 CID <e1>sucrose</e1> libitum groups <e2>hyperactive</e2>
D013395_D006948 CID <e1>sucrose</e1> chow <e2>hyperactive</e2>
19445921
C066201_D009203 NONE <e1>a</e1> effect <e2>infarction</e2>
C066201_D009203 NONE <e1>a</e1> <e2>infarction</e2>
C066201_D009203 NONE <e1>a</e1> has effect <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D000244_D012131 NONE <e1>adp/o</e1> ratio characterized <e2>dysfunction</e2>
D007545_D012131 NONE <e1>isoproterenol-treated</e1> rats observed <e2>dysfunction</e2>
C066201_D006331 NONE <e1>a</e1> administration attenuated <e2>dysfunction</e2>
C066201_D009202 NONE <e1>a</e1> administration attenuated dysfunction <e2>injury</e2>
C066201_D009202 NONE <e1>a</e1> role <e2>damage</e2>
D007545_D006331 NONE <e1>isoproterenol-induced</e1> <e2>dysfunction</e2>
D007545_D009202 NONE <e1>isoproterenol-induced</e1> dysfunction <e2>injury</e2>
D007545_D009202 NONE <e1>isoproterenol-induced</e1> <e2>damage</e2>
7930386
D002997_D012893 CID <e1>clomipramine-induced</e1> <e2>disturbance</e2>
D002997_D012893 CID <e1>clomipramine</e1> administration induced undertaken examine role <e2>disturbance</e2>
9587734
D013390_D006323 CID <e1>suxamethonium-induced</e1> <e2>arrest</e2>
D013390_D006323 CID <e1>suxamethonium</e1> use result case <e2>arrest</e2>
D013390_D006323 CID <e1>suxamethonium</e1> <e2>arrest</e2>
D013390_D003643 NONE <e1>suxamethonium-induced</e1> arrest <e2>death</e2>
D013390_D003643 NONE <e1>suxamethonium</e1> use result case arrest <e2>death</e2>
D013390_D003643 NONE <e1>suxamethonium</e1> hypersensitivity caused <e2>death</e2>
D013390_D006947 CID <e1>suxamethonium</e1> use result <e2>hyperkalaemia</e2>
D013390_D006947 CID <e1>suxamethonium</e1> administration were signs damage any conditions <e2>hyperkalaemia</e2>
D013390_D001919 CID <e1>suxamethonium</e1> <e2>bradycardia</e2>
D013390_D004342 CID <e1>suxamethonium</e1> <e2>hypersensitivity</e2>
11752354
D003276_D009203 CID <e1>contraceptives</e1> risk <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptives</e1> use risk <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptives</e1> type investigated identified enrolled years had <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptives</e1> type investigated identified enrolled years had infarction women had <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptive</e1> type used women <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptives</e1> used women 3.0 increased risk <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptives</e1> used women increased risk <e2>infarction</e2>
D003276_D009203 CID <e1>contraceptives</e1> used women similar risk <e2>infarction</e2>
D011372_D009203 NONE <e1>progestagen</e1> type investigated identified enrolled years had <e2>infarction</e2>
D011372_D009203 NONE <e1>progestagen</e1> type investigated identified enrolled years had infarction women had <e2>infarction</e2>
D017135_D009203 NONE <e1>desogestrel</e1> third-generation included type investigated identified enrolled years had <e2>infarction</e2>
D017135_D009203 NONE <e1>desogestrel</e1> third-generation included type investigated identified enrolled years had infarction women had <e2>infarction</e2>
C033273_D009203 NONE <e1>gestodene</e1> desogestrel third-generation included type investigated identified enrolled years had <e2>infarction</e2>
C033273_D009203 NONE <e1>gestodene</e1> desogestrel third-generation included type investigated identified enrolled years had infarction women had <e2>infarction</e2>
D016912_D009203 NONE <e1>levonorgestrel</e1> second-generation third-generation included type investigated identified enrolled years had <e2>infarction</e2>
D016912_D009203 NONE <e1>levonorgestrel</e1> second-generation third-generation included type investigated identified enrolled years had infarction women had <e2>infarction</e2>
D004967_D009203 NONE <e1>estrogen</e1> dose type investigated identified enrolled years had <e2>infarction</e2>
D004967_D009203 NONE <e1>estrogen</e1> dose type investigated identified enrolled years had infarction women had <e2>infarction</e2>
7444978
D013307_D020258 NONE <e1>streptomycin</e1> effects <e2>neurotoxic</e2>
D013307_D004409 CID <e1>streptomycin</e1> sensitive indicating occurred occurred <e2>movements</e2>
D013307_D004409 CID <e1>streptomycin</e1> sensitive site responsible <e2>dyskinesias</e2>
D013307_D003638 CID <e1>streptomycin</e1> sensitive indicating occurred occurred movements <e2>deafness</e2>
18544179
D005283_D009325 NONE <e1>fentanyl</e1> reduces <e2>nausea</e2>
D005283_D009325 NONE <e1>fentanyl</e1> omission reduce reduce incidence vomiting moderate <e2>nausea</e2>
D005283_D009325 NONE <e1>fentanyl</e1> discharge reduce incidence vomiting moderate <e2>nausea</e2>
D005283_D009325 NONE <e1>fentanyl-dexamethasone</e1> fentanyl discharge reduce incidence vomiting moderate <e2>nausea</e2>
D005283_D009325 NONE <e1>fentanyl</e1> groups combining revealed reducing nausea vomiting <e2>nausea</e2>
D005283_D009325 NONE <e1>fentanyl</e1> groups combining revealed decreased <e2>nausea</e2>
D005283_D014839 NONE <e1>fentanyl</e1> reduces nausea <e2>vomiting</e2>
D005283_D014839 NONE <e1>fentanyl</e1> omission reduce reduce incidence <e2>vomiting</e2>
D005283_D014839 NONE <e1>fentanyl</e1> discharge reduce incidence <e2>vomiting</e2>
D005283_D014839 NONE <e1>fentanyl-dexamethasone</e1> fentanyl discharge reduce incidence <e2>vomiting</e2>
D005283_D010146 NONE <e1>fentanyl</e1> reduces increasing <e2>pain</e2>
D005283_D010146 NONE <e1>fentanyl</e1> omission unaffected severity <e2>pain</e2>
C009250_D009325 NONE <e1>sevoflurane</e1> reduces <e2>nausea</e2>
C009250_D014839 NONE <e1>sevoflurane</e1> reduces nausea <e2>vomiting</e2>
C009250_D010146 NONE <e1>sevoflurane</e1> reduces increasing <e2>pain</e2>
C009250_D010146 NONE <e1>sevoflurane</e1> anaesthesia h examined incidence nausea <e2>pain</e2>
C009250_D020250 NONE <e1>sevoflurane</e1> induction advantages nausea <e2>vomiting</e2>
C009250_D020250 NONE <e1>sevoflurane</e1> anaesthesia h examined incidence nausea <e2>vomiting</e2>
C009250_D020250 NONE <e1>sevoflurane</e1> supplement appears conclusion nausea <e2>vomiting</e2>
D005283_D020250 CID <e1>fentanyl</e1> omission reduce incidence nausea <e2>vomiting</e2>
D005283_D020250 CID <e1>fentanyl</e1> discharge reduce reduce incidence nausea <e2>vomiting</e2>
D005283_D020250 CID <e1>fentanyl-dexamethasone</e1> fentanyl discharge reduce reduce incidence nausea <e2>vomiting</e2>
D005283_D020250 CID <e1>fentanyl</e1> groups combining revealed reducing nausea <e2>vomiting</e2>
D005283_D020250 CID <e1>fentanyl</e1> nausea <e2>vomiting</e2>
D003907_D020250 NONE <e1>fentanyl-dexamethasone</e1> fentanyl discharge reduce reduce incidence nausea <e2>vomiting</e2>
D003907_D020250 NONE <e1>dexamethasone</e1> had incidence nausea <e2>vomiting</e2>
D003907_D014839 NONE <e1>fentanyl-dexamethasone</e1> fentanyl discharge reduce incidence <e2>vomiting</e2>
D003907_D009325 NONE <e1>fentanyl-dexamethasone</e1> fentanyl discharge reduce incidence vomiting moderate <e2>nausea</e2>
D005283_D012131 CID <e1>fentanyl</e1> reduce had effect <e2>depression</e2>
D005283_D007022 CID <e1>fentanyl</e1> reduce had effect depression <e2>hypotension</e2>
D005283_D001919 CID <e1>fentanyl</e1> reduce had effect depression hypotension <e2>bradycardia</e2>
C009250_D012131 NONE <e1>sevoflurane-sparing</e1> effect <e2>depression</e2>
C009250_D007022 NONE <e1>sevoflurane-sparing</e1> effect depression <e2>hypotension</e2>
C009250_D001919 NONE <e1>sevoflurane-sparing</e1> effect depression hypotension <e2>bradycardia</e2>
D005283_D010149 NONE <e1>fentanyl</e1> nausea vomiting improvement <e2>pain</e2>
C009250_D010149 NONE <e1>sevoflurane</e1> supplement appears conclusion nausea vomiting improvement <e2>pain</e2>
17241784
D019821_D009135 CID <e1>statin</e1> therapy associated mhc-i up-regulation <e2>myopathy</e2>
D019821_D009135 CID <e1>statins</e1> cause <e2>myopathy</e2>
D019821_D009135 CID <e1>statins</e1> induce <e2>myopathy</e2>
D019821_D009135 CID <e1>statins</e1> initiate <e2>myopathy</e2>
D019821_D009135 CID <e1>statins</e1> induction involve uncertain mechanism <e2>myopathy</e2>
D019821_-1 NONE <e1>statins</e1> cause myopathy <e2>hyperckaemia</e2>
19308880
D014635_D003221 CID <e1>acid</e1> reaction <e2>confusion</e2>
D014635_D003221 CID <e1>acid</e1> observed reaction <e2>confusion</e2>
D014635_D003221 CID <e1>acid</e1> reported cases <e2>confusion</e2>
D014635_D003221 CID <e1>acid</e1> reported cases <e2>confusion</e2>
D014635_D003221 CID <e1>acid</e1> exposure occurred <e2>confusion</e2>
D014635_D003221 CID <e1>acid</e1> <e2>confusion</e2>
18182964
D003000_D001289 NONE <e1>clonidine</e1> <e2>disorder</e2>
D003000_D001289 NONE <e1>clonidine</e1> used methylphenidate children <e2>disorder</e2>
D003000_D001289 NONE <e1>clonidine</e1> used methylphenidate children disorder <e2>adhd</e2>
D003000_D001289 NONE <e1>clonidine</e1> assigned children <e2>adhd</e2>
D003000_D001289 NONE <e1>clonidine</e1> clonidine assigned children <e2>adhd</e2>
D003000_D001289 NONE <e1>clonidine</e1> appears tolerated <e2>adhd</e2>
D008774_D001289 NONE <e1>methylphenidate</e1> children <e2>disorder</e2>
D008774_D001289 NONE <e1>methylphenidate</e1> children disorder <e2>adhd</e2>
D008774_D001289 NONE <e1>methylphenidate</e1> clonidine assigned children <e2>adhd</e2>
D008774_D001289 NONE <e1>methylphenidate</e1> clonidine assigned children <e2>adhd</e2>
D008774_D001289 NONE <e1>methylphenidate</e1> used clonidine appears tolerated <e2>adhd</e2>
D003000_D001919 CID <e1>clonidine</e1> treated subjects incidents <e2>bradycardia</e2>
D003000_D001919 CID <e1>clonidine</e1> treated those were incidents <e2>bradycardia</e2>
D003000_D001919 CID <e1>clonidine</e1> monitor <e2>bradycardia</e2>
D003000_D006970 NONE <e1>clonidine</e1> common <e2>drowsiness</e2>
D003000_D006970 NONE <e1>clonidine</e1> monitor advise patients likelihood <e2>drowsiness</e2>
20528871
C104457_D015458 NONE <e1>nelarabine</e1> therapy leukaemia <e2>lymphoma</e2>
C104457_D015458 NONE <e1>nelarabine</e1> d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
C104457_D015458 NONE <e1>arag</e1> nelarabine d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
C104457_D016399 NONE <e1>nelarabine</e1> therapy leukaemia <e2>lymphoma</e2>
C104457_D016399 NONE <e1>nelarabine</e1> d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
C104457_D016399 NONE <e1>arag</e1> nelarabine d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D005047_D015458 NONE <e1>etoposide</e1> nelarabine therapy leukaemia <e2>lymphoma</e2>
D005047_D015458 NONE <e1>etoposide</e1> d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D005047_D015458 NONE <e1>vp</e1> etoposide d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D005047_D016399 NONE <e1>etoposide</e1> nelarabine therapy leukaemia <e2>lymphoma</e2>
D005047_D016399 NONE <e1>etoposide</e1> d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D005047_D016399 NONE <e1>vp</e1> etoposide d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D003520_D015458 NONE <e1>cyclophosphamide</e1> nelarabine therapy leukaemia <e2>lymphoma</e2>
D003520_D015458 NONE <e1>cyclophosphamide</e1> etoposide d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D003520_D015458 NONE <e1>cpm</e1> cyclophosphamide etoposide d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D003520_D016399 NONE <e1>cyclophosphamide</e1> nelarabine therapy leukaemia <e2>lymphoma</e2>
D003520_D016399 NONE <e1>cyclophosphamide</e1> etoposide d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
D003520_D016399 NONE <e1>cpm</e1> cyclophosphamide etoposide d combination used therapy children refractory leukaemia <e2>lymphoma</e2>
C104457_D009422 CID <e1>arag</e1> attributable effects included pain <e2>neuropathy</e2>
C104457_D009422 CID <e1>arag</e1> giving safety supports monitored <e2>toxicity</e2>
C104457_D059352 CID <e1>arag</e1> attributable effects included <e2>pain</e2>
C104457_D006402 CID <e1>arag</e1> combination greater <e2>toxicity</e2>
D005047_D009422 NONE <e1>etoposide</e1> synchrony therapy giving safety supports monitored <e2>toxicity</e2>
D003520_D009422 NONE <e1>cyclophosphamide</e1> etoposide synchrony therapy giving safety supports monitored <e2>toxicity</e2>
10704919
D013629_D006461 CID <e1>tamoxifen</e1> induced erythrocytes <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> induces <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> microm induces variable extension <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> microm induces <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> effect <e2>hemolytic</e2>
D013629_D006461 CID <e1>tam</e1> effect prevented indicating related <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam-induced</e1> hemolysis related indicating prevented effect <e2>hemolytic</e2>
D013629_D006461 CID <e1>tam-induced</e1> <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam-induced</e1> <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> caused <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> caused hemolysis preceded excluding mechanism <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam</e1> incorporation related protection <e2>hemolysis</e2>
D013629_D006461 CID <e1>tam-induced</e1> <e2>hemolysis</e2>
D013629_D001943 NONE <e1>tamoxifen</e1> drug prescribed chemotherapy <e2>cancer</e2>
D013629_D001943 NONE <e1>tam</e1> tamoxifen drug prescribed chemotherapy <e2>cancer</e2>
D013629_D000743 CID <e1>tamoxifen</e1> induces changes shape erythrocytes <e2>anemia</e2>
D013629_D000743 CID <e1>tam</e1> tamoxifen induces changes shape erythrocytes <e2>anemia</e2>
D013629_D000743 CID <e1>tam</e1> effects evaluates attempting identify mechanisms <e2>anemia</e2>
D013629_D000743 CID <e1>tam-induced</e1> <e2>anemia</e2>
D013629_D000743 CID <e1>tam</e1> promoted stability decreased resulting <e2>anemia</e2>
D024502_D006461 NONE <e1>alpha-tocopherol</e1> concentrations prevented effect <e2>hemolytic</e2>
D024502_D006461 NONE <e1>alpha-tocopherol</e1> concentrations prevented indicating related <e2>hemolysis</e2>
D024502_D006461 NONE <e1>alpha-t</e1> alpha-tocopherol concentrations prevented effect <e2>hemolytic</e2>
D024502_D006461 NONE <e1>alpha-t</e1> alpha-tocopherol concentrations prevented indicating related <e2>hemolysis</e2>
D024502_D006461 NONE <e1>acetate</e1> alpha-tocopherol concentrations prevented effect <e2>hemolytic</e2>
D024502_D006461 NONE <e1>acetate</e1> alpha-tocopherol concentrations prevented indicating related <e2>hemolysis</e2>
D024502_D006461 NONE <e1>alpha-tac</e1> acetate alpha-tocopherol concentrations prevented effect <e2>hemolytic</e2>
D024502_D006461 NONE <e1>alpha-tac</e1> acetate alpha-tocopherol concentrations prevented indicating related <e2>hemolysis</e2>
D017665_D006461 NONE <e1>hydroxyl</e1> inactivated alpha-tocopherol concentrations prevented effect <e2>hemolytic</e2>
D017665_D006461 NONE <e1>hydroxyl</e1> inactivated alpha-tocopherol concentrations prevented indicating related <e2>hemolysis</e2>
D010100_D006461 NONE <e1>oxygen</e1> consumption absence evidenced determined parallel <e2>hemolysis</e2>
D011188_D006461 NONE <e1>k(+</e1> leakage preceded <e2>hemolysis</e2>
D011188_D006461 NONE <e1>k(+</e1> leakage preceded excluding mechanism <e2>hemolysis</e2>
D024505_D006461 NONE <e1>tocopherols</e1> protection <e2>hemolysis</e2>
10683478
D001058_D007035 CID <e1>apomorphine</e1> selected ability induce <e2>hypothermia</e2>
D001058_D007035 CID <e1>apomorphine</e1> <e2>hypothermia</e2>
D018491_D007035 NONE <e1>agonist</e1> apomorphine selected ability induce <e2>hypothermia</e2>
D004298_D007035 NONE <e1>dopamine</e1> turnover changes produce selected ability induce <e2>hypothermia</e2>
D001058_D006948 CID <e1>apomorphine-induced</e1> <e2>hyperactivity</e2>
12041669
D000961_D000741 NONE <e1>globulin</e1> treatment <e2>anemia</e2>
D000961_D000741 NONE <e1>globulin</e1> therapy <e2>anemia</e2>
D000961_D000741 NONE <e1>globulin</e1> use treatment <e2>anemia</e2>
D010396_D000741 CID <e1>d-penicillamine-induced</e1> <e2>anemia</e2>
D010396_D000741 CID <e1>d-penicillamine</e1> therapy received therapy <e2>anemia</e2>
D010396_D000741 CID <e1>d-penicillamine-induced</e1> <e2>anemia</e2>
12536034
D002220_D004832 CID <e1>carbamazepine</e1> administration present patients <e2>epilepsy</e2>
D020888_D004832 CID <e1>vigabatrin</e1> carbamazepine administration present patients <e2>epilepsy</e2>
D005680_D004832 NONE <e1>acid-transmitted</e1> gamma-aminobutyric accounts part neurophysiology <e2>epilepsy</e2>
10365197
D003042_D019964 CID <e1>cocaine-induced</e1> <e2>disorder</e2>
D003042_D019964 CID <e1>cocaine-dependent</e1> sample <e2>disorder</e2>
D003042_D019964 CID <e1>cocaine-dependent</e1> outpatients <e2>disorder</e2>
D003042_D019964 CID <e1>cocaine-dependent</e1> outpatients disorder <e2>disorders</e2>
D003042_D019964 CID <e1>cocaine-dependent</e1> outpatients disorder <e2>disorder</e2>
D003042_D019964 CID <e1>cocaine-induced</e1> <e2>disorder</e2>
D003042_D019964 CID <e1>cocaine-induced</e1> disorder <e2>disorders</e2>
D003042_D019964 CID <e1>cocaine-induced</e1> disorder <e2>disorder</e2>
D003042_D001523 NONE <e1>cocaine-induced</e1> disorder rates symptoms <e2>psychiatric</e2>
D003042_D001523 NONE <e1>cocaine-dependent</e1> sample disorder rates symptoms <e2>psychiatric</e2>
D003042_D001523 NONE <e1>cocaine-dependent</e1> outpatients compared measures symptoms <e2>psychiatric</e2>
D003042_D001523 NONE <e1>cocaine-induced</e1> disorder outpatients compared measures symptoms <e2>psychiatric</e2>
D003042_D019970 NONE <e1>cocaine-dependent</e1> outpatients disorder <e2>cimd</e2>
D003042_D019970 NONE <e1>cocaine-induced</e1> disorder <e2>cimd</e2>
16160878
D014579_D006973 NONE <e1>u-ii</e1> injection causes <e2>hypertension</e2>
D014579_D001919 NONE <e1>u-ii</e1> injection causes hypertension <e2>bradycardia</e2>
D014579_D010409 NONE <e1>u-ii</e1> administration had temperature <e2>erection</e2>
D001058_D010409 CID <e1>apomorphine-induced</e1> <e2>erection</e2>
D003345_D010409 NONE <e1>corticosterone</e1> level temperature <e2>erection</e2>
D014579_D001523 NONE <e1>u-ii</e1> involved aspects <e2>disorders</e2>
2385256
D008274_D009157 CID <e1>magnesium</e1> administration presenting <e2>gravis</e2>
D008274_D009157 CID <e1>magnesium</e1> administration paralysis described patients <e2>gravis</e2>
D008274_D009468 NONE <e1>magnesium</e1> administration became history <e2>disease</e2>
D008274_D011782 NONE <e1>magnesium</e1> administration became <e2>quadriplegic</e2>
D008274_D011225 NONE <e1>magnesium</e1> administration <e2>preeclampsia</e2>
D008274_D010243 NONE <e1>magnesium</e1> administration <e2>paralysis</e2>
D008274_D020511 NONE <e1>magnesium</e1> effects sensitive patients suspected having disorder <e2>transmission</e2>
3076126
D008148_D009135 NONE <e1>lovastatin</e1> reported <e2>myopathy</e2>
D008148_D009212 CID <e1>lovastatin</e1> reported myopathy associated <e2>myoglobinuria</e2>
D008148_D051437 CID <e1>lovastatin</e1> reported myopathy associated cases <e2>failure</e2>
D016572_D009135 CID <e1>cyclosporin</e1> treated patients reported <e2>myopathy</e2>
D016572_D009212 NONE <e1>cyclosporin</e1> treated patients reported myopathy associated <e2>myoglobinuria</e2>
D016572_D051437 NONE <e1>cyclosporin</e1> treated patients reported myopathy associated cases <e2>failure</e2>
D015248_D009135 CID <e1>gemfibrozil</e1> patients reported <e2>myopathy</e2>
D015248_D009212 NONE <e1>gemfibrozil</e1> patients reported myopathy associated <e2>myoglobinuria</e2>
D015248_D051437 NONE <e1>gemfibrozil</e1> patients reported myopathy associated cases <e2>failure</e2>
D009525_D009135 CID <e1>niacin</e1> gemfibrozil patients reported <e2>myopathy</e2>
D009525_D009212 NONE <e1>niacin</e1> gemfibrozil patients reported myopathy associated <e2>myoglobinuria</e2>
D009525_D051437 NONE <e1>niacin</e1> gemfibrozil patients reported myopathy associated cases <e2>failure</e2>
1592014
D003042_D012640 CID <e1>cocaine</e1> benzoylecgonine induced <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> half-life short occur some consequences <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> metabolite potential evaluated cause <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> amounts induced those latencies had occurred <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-injected</e1> animals activity had <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-injected</e1> animals <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-</e1> <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-</e1> differ finding suggests mechanism <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> seizures mechanism suggests finding differ cocaine- <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> metabolite importance emphasizes suggests finding differ cocaine- <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> metabolite importance emphasizes suggests mechanism <e2>seizures</e2>
C005618_D012640 CID <e1>benzoylecgonine</e1> induced <e2>seizures</e2>
C005618_D012640 CID <e1>benzoylecgonine</e1> cocaine metabolite potential evaluated cause <e2>seizures</e2>
C005618_D012640 CID <e1>be</e1> benzoylecgonine cocaine metabolite potential evaluated cause <e2>seizures</e2>
C005618_D012640 CID <e1>be-induced</e1> <e2>seizures</e2>
C005618_D012640 CID <e1>be</e1> induced those prolonged characterized <e2>seizures</e2>
C005618_D012640 CID <e1>be-injected</e1> rats had <e2>seizures</e2>
C005618_D012640 CID <e1>be-injected</e1> rats had activity animals <e2>seizures</e2>
C005618_D012640 CID <e1>be-induced</e1> cocaine- <e2>seizures</e2>
C005618_D012640 CID <e1>be-induced</e1> cocaine- differ finding suggests mechanism <e2>seizures</e2>
C005618_D012640 CID <e1>be</e1> metabolite importance emphasizes suggests finding differ cocaine- <e2>seizures</e2>
C005618_D012640 CID <e1>be</e1> metabolite importance emphasizes suggests mechanism <e2>seizures</e2>
D003042_D020521 NONE <e1>cocaine</e1> half-life short occur some consequences seizures <e2>strokes</e2>
D003042_D003643 NONE <e1>cocaine-induced</e1> seizures characterized resulted <e2>death</e2>
D003042_D003643 NONE <e1>cocaine-induced</e1> seizures characterized prolonged resulted <e2>death</e2>
C005618_D003643 NONE <e1>be</e1> induced those prolonged characterized resulted <e2>death</e2>
C005618_D003643 NONE <e1>be</e1> induced those prolonged resulted <e2>death</e2>
1867351
D015767_D008288 NONE <e1>mefloquine</e1> treatment prophylaxis <e2>malaria</e2>
21029050
D013390_D001049 CID <e1>succinylcholine</e1> patients <e2>apnea</e2>
D013390_D001049 CID <e1>succinylcholine</e1> action duration patients eleven had indicating reason period <e2>apnea</e2>
322550
D009599_D007022 CID <e1>nitroprusside-induced</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> infusion cpap produced decrease <e2>pressure</e2>
D009599_D007022 CID <e1>nitroprusside</e1> caused decreases <e2>pressure</e2>
D009599_D007022 NONE <e1>nitroprusside</e1> levels alter decreasing produce decreases pressure <e2>output</e2>
D014867_D007022 NONE <e1>h2o</e1> cpap produced decrease <e2>pressure</e2>
D014867_D007022 NONE <e1>h2o</e1> cm levels alter decreasing produce decreases pressure <e2>output</e2>
D014867_D002303 NONE <e1>h2o</e1> cpap produced increased decreased <e2>output</e2>
D014867_D002303 NONE <e1>h2o</e1> cm levels alter decreasing produce decreases pressure <e2>output</e2>
D009599_D002303 NONE <e1>nitroprusside</e1> infusion cpap produced increased decreased <e2>output</e2>
D009599_D002303 NONE <e1>nitroprusside</e1> levels alter decreasing produce decreases pressure <e2>output</e2>
3031535
D013759_D002375 CID <e1>9-tetrahydrocannabinol</e1> induced <e2>catalepsy</e2>
D013759_D002375 CID <e1>thc</e1> induced <e2>catalepsy</e2>
D013759_D002375 CID <e1>thc</e1> induced catalepsy manifestation role have important <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced catalepsy important have role manifestation <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
9284778
-1_D008107 NONE <e1>hydrochlorofluorocarbons</e1> caused epidemic <e2>disease</e2>
D010126_D008107 NONE <e1>ozone-sparing</e1> substitutes used hydrochlorofluorocarbons caused epidemic <e2>disease</e2>
D017402_D008107 NONE <e1>chlorofluorocarbons</e1> substitutes used hydrochlorofluorocarbons caused epidemic <e2>disease</e2>
C067411_D008107 CID <e1>1,1-dichloro-2,2,2-trifluoroethane</e1> mixture exposure repeated <e2>disease</e2>
C067411_D008107 CID <e1>123</e1> hcfc 1,1-dichloro-2,2,2-trifluoroethane mixture exposure repeated <e2>disease</e2>
C067411_D008107 CID <e1>124</e1> hcfcs result <e2>disease</e2>
C072959_D008107 CID <e1>1-chloro-1,2,2,2-tetrafluoroethane</e1> 1,1-dichloro-2,2,2-trifluoroethane mixture exposure repeated <e2>disease</e2>
C072959_D008107 CID <e1>124</e1> hcfc 1-chloro-1,2,2,2-tetrafluoroethane 1,1-dichloro-2,2,2-trifluoroethane mixture exposure repeated <e2>disease</e2>
C072959_D008107 CID <e1>124</e1> hcfcs result <e2>disease</e2>
D006221_D056486 NONE <e1>1-bromo-1-chloro-2,2,2-trifluoroethane</e1> way metabolised form intermediates implicated <e2>hepatotoxicity</e2>
D006221_D056486 NONE <e1>halothane</e1> 1-bromo-1-chloro-2,2,2-trifluoroethane way metabolised form intermediates implicated <e2>hepatotoxicity</e2>
D006221_D056486 NONE <e1>halothane</e1> <e2>hepatotoxicity</e2>
D014269_D056486 NONE <e1>trifluoroacetyl</e1> halide intermediates implicated <e2>hepatotoxicity</e2>
D014269_D056486 NONE <e1>trifluoroacetyl-altered</e1> proteins involved suggest known mechanism <e2>hepatotoxicity</e2>
C067411_D056486 NONE <e1>124</e1> hcfcs exposure result <e2>injury</e2>
C072959_D056486 NONE <e1>124</e1> hcfcs exposure result <e2>injury</e2>
8752018
D008094_D003072 CID <e1>lithium-associated</e1> cognitive <e2>deficits</e2>
D008094_D003072 CID <e1>lithium</e1> effects management written remain effects <e2>deficits</e2>
D008094_D003072 CID <e1>lithium</e1> effects management written remain effects deficits loss <e2>creativity</e2>
D008094_D003072 CID <e1>lithium</e1> effects management written remain effects deficits <e2>impairments</e2>
D008094_D003072 CID <e1>lithium</e1> effects <e2>deficits</e2>
D008094_D003072 CID <e1>lithium</e1> effects deficits loss <e2>creativity</e2>
D008094_D003072 CID <e1>lithium</e1> effects deficits <e2>impairments</e2>
D008094_D003072 CID <e1>lithium</e1> patients switching summarizes alleviate <e2>impairments</e2>
D008094_D003072 CID <e1>lithium</e1> substitution cases report helpful reducing cognitive <e2>deficits</e2>
D008094_D003072 CID <e1>lithium</e1> attributed <e2>deficits</e2>
D008094_D003072 CID <e1>lithium</e1> alternative patients experiencing <e2>deficits</e2>
D008094_D003072 CID <e1>lithium</e1> alternative patients experiencing deficits loss <e2>creativity</e2>
D008094_D003072 CID <e1>lithium</e1> alternative patients experiencing deficits <e2>impairments</e2>
D014635_D003072 NONE <e1>sodium</e1> switch reduced <e2>deficits</e2>
D014635_D003072 NONE <e1>sodium</e1> divalproex switching summarizes alleviate <e2>impairments</e2>
D014635_D003072 NONE <e1>sodium</e1> helpful reducing cognitive <e2>deficits</e2>
D014635_D003072 NONE <e1>sodium</e1> alternative patients experiencing <e2>deficits</e2>
D014635_D003072 NONE <e1>sodium</e1> alternative patients experiencing deficits loss <e2>creativity</e2>
D014635_D003072 NONE <e1>sodium</e1> alternative patients experiencing deficits <e2>impairments</e2>
D008094_D001714 NONE <e1>lithium</e1> remains treatment treatment <e2>disorder</e2>
D008094_D001714 NONE <e1>lithium</e1> patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium</e1> substitution cases report helpful reducing cognitive deficits attributed patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium</e1> attributed patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium</e1> alternative patients <e2>bipolar</e2>
D008094_D011141 NONE <e1>lithium</e1> effects <e2>polyuria</e2>
D008094_D011141 NONE <e1>lithium</e1> effects remain written management effects <e2>polyuria</e2>
D008094_D014202 NONE <e1>lithium</e1> effects polyuria <e2>tremor</e2>
D008094_D014202 NONE <e1>lithium</e1> effects remain written management effects polyuria <e2>tremor</e2>
D014635_D001714 NONE <e1>sodium</e1> divalproex switching patients <e2>bipolar</e2>
D014635_D001714 NONE <e1>sodium</e1> helpful reducing cognitive deficits attributed patients <e2>bipolar</e2>
D014635_D001714 NONE <e1>sodium</e1> alternative patients <e2>bipolar</e2>
7516729
D014700_D001919 CID <e1>verapamil</e1> induced <e2>bradycardia</e2>
6727060
D008787_D004409 CID <e1>metoclopramide</e1> caused <e2>dyskinesia</e2>
D008787_D004409 CID <e1>metoclopramide</e1> took appeared <e2>movements</e2>
D008787_D004409 CID <e1>metoclopramide</e1> administration discontinued improved <e2>movements</e2>
D008787_D005767 NONE <e1>metoclopramide</e1> took <e2>disorder</e2>
983936
D001241_D009202 NONE <e1>acid</e1> hydrocortisone <e2>injury</e2>
D004176_D009202 NONE <e1>dipyridamole</e1> acid hydrocortisone <e2>injury</e2>
D006854_D009202 NONE <e1>hydrocortisone</e1> <e2>injury</e2>
D004837_D009202 CID <e1>epinephrine-induced</e1> <e2>injury</e2>
D004837_D009202 CID <e1>epinephrine</e1> infusion <e2>injury</e2>
D004837_D009203 NONE <e1>epinephrine</e1> infusion injury producing model developed study effects agents alter evolution <e2>infarction</e2>
11431197
D011899_D009395 CID <e1>ranitidine-induced</e1> <e2>nephritis</e2>
D011899_D009395 CID <e1>ranitidine-induced</e1> <e2>nephritis</e2>
12757899
D004958_D012640 NONE <e1>estradiol</e1> reduces injury <e2>seizure-induced</e2>
D004958_D012640 NONE <e1>estradiol</e1> effects threshold <e2>seizure</e2>
D004958_D001930 NONE <e1>estradiol</e1> reduces <e2>injury</e2>
D007608_D001930 NONE <e1>acid-induced</e1> epilepticus induced <e2>injury</e2>
D007608_D013226 NONE <e1>acid-induced</e1> <e2>epilepticus</e2>
D007608_D013226 NONE <e1>acid-induced</e1> epilepticus <e2>se</e2>
D004958_D013226 NONE <e1>17beta-estradiol</e1> effects rats subjected <e2>se</e2>
D008094_D013226 CID <e1>lithium-pilocarpine-induced</e1> <e2>se</e2>
D010862_D013226 CID <e1>lithium-pilocarpine-induced</e1> <e2>se</e2>
D012834_D013226 NONE <e1>silver-stained</e1> ca3 neurons extent evaluated <e2>se</e2>
8073369
C007112_D001176 CID <e1>coniine</e1> failed produce <e2>arthrogryposis</e2>
C007112_D001176 CID <e1>coniine-induced</e1> <e2>arthrogryposis</e2>
C007112_D009140 NONE <e1>coniine</e1> caused <e2>deformations</e2>
C007112_D009140 NONE <e1>coniine</e1> caused deformations flexion <e2>toes</e2>
D009538_D009140 NONE <e1>nicotine</e1> sulfate coniine caused <e2>deformations</e2>
D009538_D009140 NONE <e1>nicotine</e1> sulfate coniine caused deformations flexion <e2>toes</e2>
D009538_D002543 CID <e1>nicotine</e1> sulfate-treated chicks occurred <e2>hemorrhage</e2>
15863244
C106876_D064420 NONE <e1>dfu</e1> comparison <e2>toxicity</e2>
C106876_D064420 NONE <e1>dfu</e1> phenyl-2(5h)-furanon inhibitors <e2>toxicity</e2>
C106876_D064420 NONE <e1>phenyl-2(5h)-furanon</e1> inhibitors <e2>toxicity</e2>
C106876_D064420 NONE <e1>dfu</e1> <e2>toxicity</e2>
D010894_D064420 NONE <e1>piroxicam</e1> dfu comparison <e2>toxicity</e2>
D010894_D064420 NONE <e1>piroxicam</e1> non-selective inhibitors <e2>toxicity</e2>
D010894_D064420 NONE <e1>piroxicam</e1> dose treated rats found <e2>toxicity</e2>
D010894_D006345 NONE <e1>piroxicam</e1> exposed fetuses performed analysis septal <e2>defects</e2>
D010894_D009436 NONE <e1>piroxicam</e1> exposed fetuses performed analysis septal <e2>defects</e2>
D010894_D005317 CID <e1>piroxicam</e1> dose treated rats found toxicity <e2>retardation</e2>
D010894_D009139 CID <e1>piroxicam</e1> dose treated rats found toxicity increase <e2>variations</e2>
9495837
C087567_D000647 NONE <e1>(+/-)-pg-9</e1> able prevent <e2>amnesia</e2>
C087567_D000647 NONE <e1>(+/-)-pg-9</e1> profiles shown ratio responsible antinociception effect <e2>anti-amnesic</e2>
C087567_D000647 NONE <e1>(+/-)-pg-9</e1> induced antinociception effect <e2>anti-amnesic</e2>
D012601_D000647 CID <e1>scopolamine</e1> induced <e2>amnesia</e2>
D004025_D000647 CID <e1>dicyclomine</e1> kg-1 prevent <e2>amnesia</e2>
D000109_D000647 NONE <e1>acetylcholine</e1> levels increase induced antinociception effect <e2>anti-amnesic</e2>
11875660
D001374_D009436 NONE <e1>5-azacytidine</e1> induced <e2>exencephaly</e2>
17532790
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> dyskinesia <e2>lid</e2>
D007980_D004409 CID <e1>l-dopa</e1> treatment arise complications <e2>dyskinesia</e2>
D007980_D004409 CID <e1>l-dopa</e1> treatment arise complications dyskinesia <e2>lid</e2>
D007980_D004409 CID <e1>l-dopa</e1> treated rats allocated groups based presence <e2>lid</e2>
D007980_D010300 NONE <e1>l-dopa-induced</e1> dyskinesia complications arise patients <e2>disease</e2>
D007980_D010300 NONE <e1>l-dopa-induced</e1> dyskinesia complications arise patients disease <e2>pd</e2>
D007980_D010300 NONE <e1>l-dopa</e1> treatment arise patients <e2>disease</e2>
D007980_D010300 NONE <e1>l-dopa</e1> treatment arise patients disease <e2>pd</e2>
D007980_D010300 NONE <e1>l-dopa</e1> saline treated <e2>pd</e2>
D016627_D010300 NONE <e1>6-hydroxydopamine-lesion</e1> model <e2>pd</e2>
D001971_D010300 NONE <e1>bromocriptine</e1> saline treated <e2>pd</e2>
11198499
C023754_D007022 CID <e1>tizanidine</e1> initiation <e2>hypotension</e2>
C023754_D007022 CID <e1>tizanidine</e1> addition developed <e2>hypotension</e2>
C023754_D006973 NONE <e1>tizanidine</e1> initiation patient treated inhibitor <e2>hypertension</e2>
C023754_D006973 NONE <e1>tizanidine</e1> addition developed <e2>hypertension</e2>
C023754_D006973 NONE <e1>tizanidine</e1> interaction kept therapy treat <e2>hypertension</e2>
D000809_D007022 NONE <e1>angiotensin</e1> inhibitor treated patient initiation <e2>hypotension</e2>
D000809_D007022 NONE <e1>angiotensin</e1> inhibitors treated adults have ability respond <e2>hypotension</e2>
D000809_D007022 NONE <e1>angiotensin</e1> inhibitor boy present hypertension developed <e2>hypotension</e2>
D000809_D006973 NONE <e1>angiotensin</e1> inhibitor <e2>hypertension</e2>
D000809_D006973 NONE <e1>angiotensin</e1> inhibitor boy present <e2>hypertension</e2>
D017706_D006973 NONE <e1>lisinopril</e1> treated boy present <e2>hypertension</e2>
D017706_D007022 CID <e1>lisinopril</e1> treated boy present hypertension developed <e2>hypotension</e2>
D017706_D009128 NONE <e1>lisinopril</e1> treated boy present treatment <e2>spasticity</e2>
D000809_D009128 NONE <e1>angiotensin</e1> inhibitor boy present treatment <e2>spasticity</e2>
C023754_D009128 NONE <e1>tizanidine</e1> addition developed hypertension present treatment <e2>spasticity</e2>
C023754_D009128 NONE <e1>tizanidine</e1> interaction kept therapy treat hypertension <e2>spasticity</e2>
8423889
D005473_D009069 CID <e1>fluoxetine</e1> medication increase <e2>disability</e2>
D005473_D009069 CID <e1>fluoxetine</e1> exposure amount <e2>disability</e2>
D000928_D009069 NONE <e1>antidepressant</e1> fluoxetine exposure amount <e2>disability</e2>
D000928_D010300 NONE <e1>antidepressant</e1> fluoxetine exposure amount disability patients <e2>disease</e2>
D005473_D010300 NONE <e1>fluoxetine</e1> exposure amount disability patients <e2>disease</e2>
D005473_D010300 NONE <e1>fluoxetine</e1> capacity patients <e2>disease</e2>
D004298_D010300 NONE <e1>dopamine-antagonistic</e1> capacity patients <e2>disease</e2>
1420741
D005672_D003424 NONE <e1>acid</e1> treatment <e2>disease</e2>
D005672_D003424 NONE <e1>acid</e1> treatment pharmacodynamics estimate undertaken need development treatments <e2>disease</e2>
D005672_D003424 NONE <e1>acid</e1> benefit patients <e2>disease</e2>
D016572_D003424 NONE <e1>cyclosporin</e1> similar properties antibiotic acid treatment <e2>disease</e2>
D005672_D015212 NONE <e1>acid</e1> use level <e2>disease</e2>
18703024
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D016291_D002375 NONE <e1>mk-801-induced</e1> locomotion <e2>catalepsy</e2>
11679859
D011346_D017109 CID <e1>prochlorperazine</e1> administration affect incidence <e2>akathisia</e2>
D011346_D017109 CID <e1>prochlorperazine</e1> administration rate <e2>akathisia</e2>
D011346_D017109 CID <e1>prochlorperazine</e1> administered conclusion reduction incidence <e2>akathisia</e2>
D011346_D006261 NONE <e1>prochlorperazine</e1> treated <e2>headache</e2>
D011346_D006261 NONE <e1>prochlorperazine</e1> efficacy treatment <e2>headache</e2>
D011346_D009325 NONE <e1>prochlorperazine</e1> treated headache <e2>nausea</e2>
D011346_D009325 NONE <e1>prochlorperazine</e1> efficacy treatment headache <e2>nausea</e2>
D011346_D014839 NONE <e1>prochlorperazine</e1> treated headache <e2>vomiting</e2>
3828020
D010665_D002544 CID <e1>phenylpropanolamine</e1> dose <e2>infarction</e2>
D010665_D002544 CID <e1>ppa</e1> dose taking suffered <e2>infarction</e2>
2396046
D002794_D006528 CID <e1>choline-supplemented</e1> diet fed developed nodules <e2>carcinomas</e2>
D002794_D006528 CID <e1>choline-supplemented</e1> diet fed developed developed nodule <e2>carcinoma</e2>
D002794_D006528 CID <e1>choline-devoid</e1> diet fed % incidence nodules <e2>carcinomas</e2>
D002794_D006528 CID <e1>choline-devoid</e1> diet fed % incidence nodules <e2>carcinomas</e2>
D010634_D006528 NONE <e1>phenobarbital</e1> containing diet fed developed developed nodules <e2>carcinomas</e2>
D010634_D006528 NONE <e1>phenobarbital</e1> containing diet fed developed nodule <e2>carcinoma</e2>
D010634_D006528 NONE <e1>phenobarbital-containing</e1> diet fed % incidence nodules <e2>carcinomas</e2>
9698967
D008619_D006973 CID <e1>mepivacaine</e1> block performance min observed increase <e2>pressure</e2>
D008619_D001281 CID <e1>mepivacaine</e1> block performance min observed increase accompanied <e2>fibrillation</e2>
D008619_D011595 NONE <e1>mepivacaine</e1> block performance min observed increase accompanied fibrillation <e2>agitation</e2>
D008619_D019954 NONE <e1>mepivacaine</e1> block performance min observed increase accompanied fibrillation agitation <e2>shouts</e2>
D008619_D014474 NONE <e1>mepivacaine</e1> block performance min observed increase accompanied fibrillation agitation shouts loss <e2>consciousness</e2>
D008619_D004387 NONE <e1>mepivacaine</e1> block performance min observed correction <e2>contracture</e2>
D004837_D006973 CID <e1>adrenaline</e1> mg containing mg mepivacaine block performance min observed increase <e2>pressure</e2>
D004837_D001281 CID <e1>adrenaline</e1> mg containing mg mepivacaine block performance min observed increase accompanied <e2>fibrillation</e2>
D004837_D011595 NONE <e1>adrenaline</e1> mg containing mg mepivacaine block performance min observed increase accompanied fibrillation <e2>agitation</e2>
D004837_D019954 NONE <e1>adrenaline</e1> mg containing mg mepivacaine block performance min observed increase accompanied fibrillation agitation <e2>shouts</e2>
D004837_D014474 NONE <e1>adrenaline</e1> mg containing mg mepivacaine block performance min observed increase accompanied fibrillation agitation shouts loss <e2>consciousness</e2>
D004837_D004387 NONE <e1>adrenaline</e1> mg containing mg mepivacaine block performance min observed correction <e2>contracture</e2>
1616457
D010424_D000647 CID <e1>pentobarbital</e1> caused learning rats <e2>amnesia</e2>
D010424_D000647 CID <e1>pentobarbital</e1> produced state <e2>amnesia</e2>
12589964
D004317_D009202 CID <e1>doxorubicin-induced</e1> rats <e2>damage</e2>
D004317_D009202 CID <e1>doxorubicin-induced</e1> rats <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> model diagnosis <e2>damage</e2>
D004317_D009202 CID <e1>doxorubicin</e1> model <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>(dox)-induced</e1> doxorubicin model diagnosis <e2>damage</e2>
D004317_D009202 CID <e1>(dox)-induced</e1> doxorubicin model <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>dox</e1> injury markers showed ability detect <e2>damage</e2>
D004317_D006331 NONE <e1>doxorubicin</e1> model diagnosis value investigated examined relationship ctni development <e2>disorders</e2>
D004317_D006331 NONE <e1>(dox)-induced</e1> doxorubicin model diagnosis value investigated examined relationship ctni development <e2>disorders</e2>
D004317_D064420 NONE <e1>dox</e1> rats eighteen died <e2>toxicity</e2>
D004317_D005355 NONE <e1>dox</e1> rats evaluation revealed degrees <e2>fibrosis</e2>
D004317_D017202 NONE <e1>dox</e1> <e2>injury</e2>
D004317_D066126 NONE <e1>dox</e1> amount discrepancy was is likely indicates damage determined magnitude injury induced marker prediction <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox</e1> rats ctnt indicates damage determined magnitude injury induced marker prediction <e2>cardiotoxicity</e2>
11379838
D000928_D001714 CID <e1>antidepressant-induced</e1> <e2>mania</e2>
D000928_D001714 CID <e1>antidepressant-induced</e1> mania patients <e2>bipolar</e2>
D000928_D001714 CID <e1>antidepressants</e1> associated <e2>mania</e2>
D000928_D001714 CID <e1>antidepressants</e1> associated mania switching risks concerns continue interfere establishment paradigm <e2>depression</e2>
D000928_D001714 CID <e1>antidepressant</e1> therapy type age variables did those compared patients experienced switch <e2>manic</e2>
D000928_D001714 CID <e1>antidepressant</e1> therapy type age variables did those compared patients experienced switch manic <e2>hypomanic</e2>
D000928_D001714 CID <e1>antidepressant</e1> therapy type age diagnosis bipolar <e2>i</e2>
D000928_D001714 CID <e1>antidepressant</e1> therapy type age diagnosis bipolar bipolar <e2>ii</e2>
D000928_D001714 CID <e1>antidepressant</e1> therapy type age number episodes <e2>manic</e2>
D000928_D001714 CID <e1>antidepressant</e1> drugs therapy those compared patients experienced switch <e2>manic</e2>
D000928_D001714 CID <e1>antidepressant</e1> drugs therapy those compared patients experienced switch manic <e2>hypomanic</e2>
D000928_D001714 CID <e1>antidepressant</e1> drugs therapy those did variables age diagnosis bipolar <e2>i</e2>
D000928_D001714 CID <e1>antidepressant</e1> drugs therapy those did variables age diagnosis bipolar bipolar <e2>ii</e2>
D000928_D001714 CID <e1>antidepressant</e1> drugs therapy those did variables age number episodes <e2>manic</e2>
D017367_D001714 CID <e1>inhibitors</e1> therapy those compared patients experienced switch <e2>manic</e2>
D017367_D001714 CID <e1>inhibitors</e1> therapy those compared patients experienced switch manic <e2>hypomanic</e2>
D017367_D001714 CID <e1>inhibitors</e1> therapy those did variables age diagnosis bipolar <e2>i</e2>
D017367_D001714 CID <e1>inhibitors</e1> therapy those did variables age diagnosis bipolar bipolar <e2>ii</e2>
D017367_D001714 CID <e1>inhibitors</e1> therapy those did variables age number episodes <e2>manic</e2>
D017367_D001714 CID <e1>ssris</e1> therapy those compared patients experienced switch <e2>manic</e2>
D017367_D001714 CID <e1>ssris</e1> therapy those compared patients experienced switch manic <e2>hypomanic</e2>
D017367_D001714 CID <e1>ssris</e1> therapy those did variables age diagnosis bipolar <e2>i</e2>
D017367_D001714 CID <e1>ssris</e1> therapy those did variables age diagnosis bipolar bipolar <e2>ii</e2>
D017367_D001714 CID <e1>ssris</e1> therapy those did variables age number episodes <e2>manic</e2>
D017367_D001714 CID <e1>ssris</e1> treated patients subgroup % results occurred switches <e2>hypomania</e2>
D017367_D001714 CID <e1>ssris</e1> treated patients subgroup % results occurred switches hypomania <e2>mania</e2>
D017367_D001714 CID <e1>ssris</e1> treated patients subgroup % results experienced episodes <e2>manic</e2>
D017367_D001714 CID <e1>ssris</e1> treated patients subgroup % results experienced experienced episodes <e2>hypomanic</e2>
D008094_D001714 NONE <e1>lithium</e1> anticonvulsants use those compared patients experienced switch <e2>manic</e2>
D008094_D001714 NONE <e1>lithium</e1> anticonvulsants use those compared patients experienced switch manic <e2>hypomanic</e2>
D008094_D001714 NONE <e1>lithium</e1> anticonvulsants use those did variables age diagnosis bipolar <e2>i</e2>
D008094_D001714 NONE <e1>lithium</e1> anticonvulsants use those did variables age diagnosis bipolar bipolar <e2>ii</e2>
D008094_D001714 NONE <e1>lithium</e1> anticonvulsants use those did variables age number episodes <e2>manic</e2>
7977601
11206082
C036150_D012640 CID <e1>beta-carboline-induced</e1> <e2>seizures</e2>
C036150_D012640 CID <e1>beta-carboline-3-carboxylate</e1> injection sensitivity <e2>seizures</e2>
C036150_D012640 CID <e1>beta-ccm</e1> beta-carboline-3-carboxylate injection sensitivity <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba(a</e1> ligands effects sensitive lines selected sensitivities <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba(a</e1> site agonist beta-carboline-3-carboxylate injection sensitivity <e2>seizures</e2>
D001569_D012640 NONE <e1>benzodiazepine</e1> site agonist beta-carboline-3-carboxylate injection sensitivity <e2>seizures</e2>
D003975_D012640 NONE <e1>diazepam-induced</e1> anxiolysis measured recording states <e2>seizures</e2>
D003975_D012640 NONE <e1>diazepam-induced</e1> sedation test anxiolysis measured recording states <e2>seizures</e2>
D010852_D012640 CID <e1>picrotoxin-</e1> <e2>seizures</e2>
D010433_D012640 CID <e1>pentylenetetrazol-induced</e1> picrotoxin- <e2>seizures</e2>
18951540
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias <e2>disease</e2>
17879945
D019438_D050197 CID <e1>ritonavir</e1> treatment increases formation <e2>lesion</e2>
4027862
D003891_D003693 CID <e1>desipramine-induced</e1> <e2>delirium</e2>
D003891_D003693 CID <e1>desipramine</e1> treated patient developed <e2>delirium</e2>
7862923
D002220_D012559 NONE <e1>carbamazepine</e1> switched <e2>schizophrenic</e2>
D002220_D019965 NONE <e1>carbamazepine</e1> switched schizophrenic patients <e2>psychotic</e2>
C036006_D012559 NONE <e1>oxcarbazepine</e1> switched <e2>schizophrenic</e2>
C036006_D019965 NONE <e1>oxcarbazepine</e1> switched schizophrenic patients <e2>psychotic</e2>
D006220_D012559 NONE <e1>haloperidol</e1> using <e2>schizophrenic</e2>
D006220_D019965 NONE <e1>haloperidol</e1> using schizophrenic patients <e2>psychotic</e2>
D002746_D012559 NONE <e1>chlorpromazine</e1> haloperidol using <e2>schizophrenic</e2>
D002746_D019965 NONE <e1>chlorpromazine</e1> haloperidol using schizophrenic patients <e2>psychotic</e2>
D003024_D012559 NONE <e1>clozapine</e1> chlorpromazine haloperidol using <e2>schizophrenic</e2>
D003024_D019965 NONE <e1>clozapine</e1> chlorpromazine haloperidol using schizophrenic patients <e2>psychotic</e2>
18221780
D016202_D010146 NONE <e1>nmda</e1> enhancement differences model <e2>pain</e2>
D016202_D010146 NONE <e1>nmda</e1> antagonists model <e2>pain</e2>
D016202_D059787 NONE <e1>nmda</e1> enhancement differences comparisons models <e2>pain</e2>
D016202_D059787 NONE <e1>n-methyl-d-aspartate</e1> antagonists enhance models <e2>pain</e2>
D016202_D059787 NONE <e1>nmda</e1> n-methyl-d-aspartate antagonists enhance models <e2>pain</e2>
D016202_D059787 NONE <e1>nmda</e1> antagonists interaction distinguished those observed models <e2>pain</e2>
D009020_D010146 NONE <e1>morphine</e1> antihyperalgesia enhancement differences model <e2>pain</e2>
D009020_D010146 NONE <e1>morphine</e1> antagonists model <e2>pain</e2>
D009020_D059787 NONE <e1>morphine</e1> antihyperalgesia enhancement differences comparisons models <e2>pain</e2>
D009020_D059787 NONE <e1>morphine</e1> effects enhance models <e2>pain</e2>
D009020_D059787 NONE <e1>morphine</e1> antinociception enhancement seen males models <e2>pain</e2>
D009020_D059787 NONE <e1>morphine</e1> antagonists interaction distinguished those observed models <e2>pain</e2>
D002211_D010146 NONE <e1>capsaicin</e1> model <e2>pain</e2>
D002211_D059787 NONE <e1>capsaicin</e1> model differences comparisons models <e2>pain</e2>
D002211_D006930 CID <e1>capsaicin</e1> administration induced <e2>hyperalgesia</e2>
D003915_D059787 NONE <e1>dextromethorphan</e1> enhancement seen males models <e2>pain</e2>
17261653
D003000_D001919 CID <e1>clonidine-induced</e1> <e2>bradycardia</e2>
7858459
D005472_D003221 CID <e1>5-fluorouracil</e1> infusion induced <e2>confusion</e2>
D005472_D003221 CID <e1>5-fluorouracil</e1> dose lasting lapsed developed symptoms <e2>confusion</e2>
D005472_D003221 CID <e1>5-fluorouracil</e1> dose lasting lapsed developed symptoms confusion <e2>disorientation</e2>
D002955_D003221 CID <e1>acid</e1> infusion induced <e2>confusion</e2>
D002955_D003221 CID <e1>acid</e1> infusion 5-fluorouracil dose lasting lapsed developed symptoms <e2>confusion</e2>
D002955_D003221 CID <e1>acid</e1> infusion 5-fluorouracil dose lasting lapsed developed symptoms confusion <e2>disorientation</e2>
D002945_D013274 NONE <e1>cisplatinum</e1> incorporating chemotherapy acid <e2>adenocarcinoma</e2>
D005047_D013274 NONE <e1>etoposide</e1> cisplatinum incorporating chemotherapy acid <e2>adenocarcinoma</e2>
D005472_D013274 NONE <e1>5-fluorouracil</e1> cisplatinum incorporating chemotherapy acid <e2>adenocarcinoma</e2>
D002955_D013274 NONE <e1>acid</e1> <e2>adenocarcinoma</e2>
D005472_D001523 NONE <e1>5-fluorouracil</e1> dose lasting lapsed developed symptoms confusion disorientation <e2>irritability</e2>
D005472_D003128 CID <e1>5-fluorouracil</e1> dose lasting lapsed <e2>coma</e2>
D002955_D001523 NONE <e1>acid</e1> infusion 5-fluorouracil dose lasting lapsed developed symptoms confusion disorientation <e2>irritability</e2>
D002955_D003128 CID <e1>acid</e1> infusion 5-fluorouracil dose lasting lapsed <e2>coma</e2>
D002955_D020258 NONE <e1>acid</e1> unlikely associated condition <e2>neurotoxicity</e2>
D005472_D020258 NONE <e1>5-fluorouracil</e1> <e2>neurotoxicity</e2>
D005472_D020258 NONE <e1>5-fluorouracil</e1> <e2>neurotoxicity</e2>
D005463_D020258 NONE <e1>fluoroacetate</e1> blockade pathogenesis <e2>neurotoxicity</e2>
C007744_D020258 NONE <e1>fluorocitrate</e1> fluoroacetate blockade pathogenesis <e2>neurotoxicity</e2>
D013831_D020258 NONE <e1>thiamine</e1> deficiency fluoroacetate blockade pathogenesis <e2>neurotoxicity</e2>
C007419_D020258 NONE <e1>dihydrouracil</e1> deficiency fluoroacetate blockade pathogenesis <e2>neurotoxicity</e2>
D005472_D009369 NONE <e1>5-fluorouracil/folinic</e1> therapy become regimen <e2>cancers</e2>
D002955_D009369 NONE <e1>acid</e1> therapy become regimen <e2>cancers</e2>
2234245
D003676_D014786 NONE <e1>desferrioxamine</e1> receiving patients ocular <e2>toxicity</e2>
D003676_D014786 NONE <e1>desferrioxamine</e1> receiving patients monitored detection <e2>toxicity</e2>
D003676_D014786 NONE <e1>desferrioxamine</e1> receiving patients complication <e2>toxicity</e2>
D003676_D006311 NONE <e1>desferrioxamine</e1> receiving patients ocular <e2>toxicity</e2>
D003676_D006311 NONE <e1>desferrioxamine</e1> receiving patients monitored detection <e2>toxicity</e2>
D003676_D006311 NONE <e1>desferrioxamine</e1> receiving patients complication <e2>toxicity</e2>
D003676_D034381 NONE <e1>desferrioxamine</e1> withdrawal resulted reversal hearing <e2>loss</e2>
D003676_D064420 NONE <e1>desferrioxamine</e1> doses receiving patients appeared <e2>toxicity</e2>
-1_D064420 NONE <e1>aluminium</e1> ferritin levels normalization coincided appeared <e2>toxicity</e2>
17437408
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
18020536
D001569_D004244 CID <e1>bzds/rds</e1> use associated <e2>dizziness</e2>
D001569_D007319 CID <e1>bzds/rds</e1> use associated dizziness inability <e2>sleep</e2>
D001569_D005221 CID <e1>bzds/rds</e1> use associated dizziness inability sleep awaking <e2>tiredness</e2>
D001569_D003866 CID <e1>bzds/rds</e1> use associated dizziness inability sleep awaking tiredness <e2>symptoms</e2>
9625142
D002443_D056486 CID <e1>ceftriaxone</e1> induced erythroblastocytopenia <e2>hepatitis</e2>
D002443_D056486 CID <e1>ceftriaxone</e1> ingesting developed <e2>hepatitis</e2>
D002443_D000744 CID <e1>ceftriaxone</e1> induced erythroblastocytopenia hepatitis <e2>anemia</e2>
D002443_-1 NONE <e1>ceftriaxone</e1> induced <e2>erythroblastocytopenia</e2>
D047090_D000744 NONE <e1>lactam</e1> antibiotic withholding returned was increase decrease caused <e2>anemia</e2>
D047090_-1 NONE <e1>lactam</e1> antibiotic withholding returned was increase decrease caused anemia <e2>erythroblastocytopenia</e2>
D001663_D000744 NONE <e1>bilirubin</e1> increase decrease caused <e2>anemia</e2>
D001663_-1 NONE <e1>bilirubin</e1> increase decrease caused anemia <e2>erythroblastocytopenia</e2>
16403073
D007654_D016171 CID <e1>ketoconazole</e1> induced torsades <e2>pointes</e2>
D007654_D016171 CID <e1>ketoconazole</e1> taking developed torsades <e2>pointes</e2>
D007654_D016171 CID <e1>ketoconazole</e1> taking developed torsades pointes <e2>tdp</e2>
D007654_D016171 CID <e1>ketoconazole</e1> ikr action prolong induce <e2>tdp.</e2>
D007654_D016171 CID <e1>ketoconazole</e1> administered induce <e2>tdp.</e2>
D007654_D003324 NONE <e1>ketoconazole</e1> taking developed <e2>disease</e2>
D007654_D008133 CID <e1>ketoconazole</e1> taking developed <e2>interval</e2>
D007654_D008133 CID <e1>ketoconazole</e1> ikr action prolong induce administered patients factors <e2>syndrome</e2>
D007654_D008133 CID <e1>ketoconazole</e1> administered patients factors <e2>syndrome</e2>
D007654_D009181 NONE <e1>ketoconazole</e1> taking treatment <e2>infection</e2>
3341566
D009599_D006470 NONE <e1>nitroprusside-induced</e1> hypotension greater <e2>hemorrhage</e2>
D009599_D006470 NONE <e1>nitroprusside</e1> infusion <e2>hemorrhage</e2>
D009599_D006470 NONE <e1>nitroprusside</e1> infusion hemorrhage <e2>hem</e2>
D009599_D006470 NONE <e1>snp</e1> infusion <e2>hemorrhage</e2>
D009599_D006470 NONE <e1>snp</e1> infusion hemorrhage <e2>hem</e2>
D009599_D006470 NONE <e1>snp</e1> group that compared lower hypotension <e2>hem-induced</e2>
D009599_D006470 NONE <e1>snp</e1> group hg mm group <e2>hem</e2>
D009599_D006470 NONE <e1>snp</e1> <e2>hem</e2>
D009599_D007022 CID <e1>nitroprusside-induced</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> group that compared lower <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> group hg mm spv <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> hem groups hg down <e2>hypotension</e2>
15009014
D002211_D006940 CID <e1>capsaicin</e1> induced increases <e2>flow</e2>
D001285_D006940 NONE <e1>atropine</e1> pre-administration abolished increases <e2>flow</e2>
19058010
D010936_D009203 NONE <e1>tea</e1> effect <e2>infarction</e2>
D010936_D009203 NONE <e1>tea</e1> effects investigate aimed bound <e2>infarction</e2>
D010936_D009203 NONE <e1>tea</e1> effect <e2>infarction</e2>
D014810_D009203 NONE <e1>e</e1> combination tea effect <e2>infarction</e2>
D014810_D009203 NONE <e1>e</e1> tea effects investigate aimed bound <e2>infarction</e2>
D014810_D009203 NONE <e1>e</e1> tea effect <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>(iso)-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>iso</e1> <e2>infarction</e2>
2096243
C017367_D019965 CID <e1>carmofur-induced</e1> <e2>disorders</e2>
C017367_D019965 CID <e1>carmofur-induced</e1> leukoencephalopathy onset period female observed <e2>disorder</e2>
C017367_D056784 CID <e1>carmofur-induced</e1> <e2>leukoencephalopathy</e2>
C017367_D056784 CID <e1>carmofur-induced</e1> <e2>leukoencephalopathy</e2>
C017367_D010554 NONE <e1>carmofur-induced</e1> leukoencephalopathy result <e2>syndrome</e2>
3676049
D007530_D007022 CID <e1>isoflurane-induced</e1> <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane-induced</e1> <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> dose increasing induced <e2>hypotension</e2>
D007530_D002532 NONE <e1>isoflurane-induced</e1> hypotension patients subjected <e2>aneurysms</e2>
D007530_D002532 NONE <e1>isoflurane-induced</e1> hypotension patients subjected craniotomy clipping <e2>aneurysm</e2>
D010100_D007022 NONE <e1>oxygen</e1> flow measured <e2>hypotension</e2>
D010100_D002532 NONE <e1>oxygen</e1> flow measured hypotension patients subjected craniotomy clipping <e2>aneurysm</e2>
D014978_D013345 NONE <e1>xenon-133</e1> anaesthesia using measured <e2>haemorrhage</e2>
D007530_D013345 NONE <e1>isoflurane</e1> concentration maintained measured <e2>haemorrhage</e2>
D009609_D013345 NONE <e1>oxide</e1> % % concentration maintained measured <e2>haemorrhage</e2>
D010100_D013345 NONE <e1>oxygen</e1> oxide % % concentration maintained measured <e2>haemorrhage</e2>
D008628_D007022 NONE <e1>hg</e1> induced <e2>hypotension</e2>
D007530_D000783 NONE <e1>isoflurane</e1> concentration reduced clipping <e2>aneurysm</e2>
10706004
D012964_D006973 NONE <e1>sodium</e1> affinities changes <e2>hypertension</e2>
D012964_D006973 NONE <e1>(na</e1> affinities changes <e2>hypertension</e2>
D012964_D006973 NONE <e1>sodium</e1> level elevation documented models <e2>hypertension</e2>
D012964_D006973 NONE <e1>na+</e1> transport disturbances basis assess studied response <e2>hypertension</e2>
D012964_D006973 NONE <e1>(na</e1> response <e2>hypertension</e2>
D012964_D006973 NONE <e1>(na</e1> activity increased recovery <e2>hypertension</e2>
D012964_D006973 NONE <e1>na+-extrusion</e1> accompanied <e2>hypertension</e2>
D012964_D006973 NONE <e1>na+-binding</e1> properties consequence accompanied <e2>hypertension</e2>
D012964_D006973 NONE <e1>(na</e1> properties consequence accompanied <e2>hypertension</e2>
D000255_D006973 NONE <e1>atp</e1> sodium affinities changes <e2>hypertension</e2>
D000255_D006973 NONE <e1>atp-binding</e1> site affinity increased recovery <e2>hypertension</e2>
D000255_D006973 NONE <e1>atp</e1> value revealed increased recovery <e2>hypertension</e2>
D011188_D006973 NONE <e1>k)-atpase</e1> (na affinities changes <e2>hypertension</e2>
D011188_D006973 NONE <e1>k)-atpase</e1> (na response <e2>hypertension</e2>
D011188_D006973 NONE <e1>k)-atpase</e1> increased recovery <e2>hypertension</e2>
D011188_D006973 NONE <e1>k)-atpase</e1> (na properties consequence accompanied <e2>hypertension</e2>
D009569_D006973 CID <e1>oxide</e1> <e2>hypertension</e2>
D009569_D006973 CID <e1>no</e1> synthesis inhibition induces <e2>hypertension</e2>
D009569_D006973 CID <e1>no-deficient</e1> <e2>hypertension</e2>
D009569_D006973 CID <e1>no-synthase</e1> inhibition induced <e2>hypertension</e2>
D009569_D006973 CID <e1>no-synthase</e1> inhibition induced <e2>hypertension</e2>
D019331_D006973 NONE <e1>ester</e1> inhibition induced <e2>hypertension</e2>
D019331_D006973 NONE <e1>l-name</e1> ester inhibition induced <e2>hypertension</e2>
D009569_D003866 NONE <e1>no-synthase</e1> inhibition induced hypertension accompanied na+-extrusion <e2>depressed</e2>
D012964_D003866 NONE <e1>na+-extrusion</e1> <e2>depressed</e2>
D012964_D003866 NONE <e1>na+-binding</e1> properties consequence accompanied na+-extrusion <e2>depressed</e2>
D012964_D003866 NONE <e1>(na</e1> properties consequence accompanied na+-extrusion <e2>depressed</e2>
D011188_D003866 NONE <e1>k)-atpase</e1> (na properties consequence accompanied na+-extrusion <e2>depressed</e2>
10737864
D003000_D001919 CID <e1>clonidine</e1> induces withdrawal <e2>bradycardia</e2>
D003000_D001919 CID <e1>clonidine</e1> effects mirror hypothesized exhibits induces withdrawal <e2>bradycardia</e2>
D003000_D001919 CID <e1>clonidine-induced</e1> <e2>bradycardia</e2>
12617329
D006170_D007674 NONE <e1>arabic</e1> <e2>nephrotoxicity</e2>
D006170_D007674 NONE <e1>arabic</e1> failure induced <e2>nephrotoxicity</e2>
D006170_D007674 NONE <e1>arabic</e1> treatment induced amelioration some indices <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gentamicin</e1> <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gm</e1> <e2>nephrotoxicity</e2>
D005839_D007674 NONE <e1>gm</e1> <e2>nephrotoxicity</e2>
D006170_D058186 CID <e1>arabic</e1> <e2>failure</e2>
D005839_D058186 CID <e1>gentamicin</e1> nephrotoxicity induced <e2>failure</e2>
D005839_D058186 CID <e1>gm</e1> nephrotoxicity induced <e2>failure</e2>
D003404_D007674 NONE <e1>creatinine</e1> concentrations measuring assessed <e2>nephrotoxicity</e2>
D014508_D007674 NONE <e1>urea</e1> creatinine concentrations measuring assessed <e2>nephrotoxicity</e2>
D005978_D007674 NONE <e1>glutathione</e1> plasma concentrations measuring assessed <e2>nephrotoxicity</e2>
D005978_D007674 NONE <e1>gsh</e1> glutathione plasma concentrations measuring assessed <e2>nephrotoxicity</e2>
D005839_D007683 NONE <e1>gm-induced</e1> <e2>necrosis</e2>
D005839_D007683 NONE <e1>gm</e1> rats severe appeared <e2>necrosis</e2>
D005839_D007683 NONE <e1>gm</e1> those appeared <e2>necrosis</e2>
D006170_D007683 NONE <e1>arabic</e1> severe appeared <e2>necrosis</e2>
6466532
D006024_D001919 NONE <e1>glycopyrrolate</e1> comparison prevention <e2>bradycardia</e2>
D006024_D001919 NONE <e1>glycopyrrolate</e1> kg-1 administration effectiveness prevent arrhythmia <e2>bradycardia</e2>
D006024_D001145 NONE <e1>glycopyrrolate</e1> comparison <e2>arrhythmias</e2>
D006024_D001145 NONE <e1>glycopyrrolate</e1> kg-1 administration effectiveness prevent <e2>arrhythmia</e2>
D001285_D001919 NONE <e1>atropine</e1> glycopyrrolate comparison prevention <e2>bradycardia</e2>
D001285_D001919 NONE <e1>atropine</e1> kg-1 administration effectiveness prevent arrhythmia <e2>bradycardia</e2>
D001285_D001145 NONE <e1>atropine</e1> glycopyrrolate comparison <e2>arrhythmias</e2>
D001285_D001145 NONE <e1>atropine</e1> kg-1 administration effectiveness prevent <e2>arrhythmia</e2>
D013390_D001919 CID <e1>suxamethonium</e1> doses arrhythmias comparison prevention <e2>bradycardia</e2>
D013390_D001919 CID <e1>suxamethonium</e1> doses prevent arrhythmia <e2>bradycardia</e2>
D013390_D001145 NONE <e1>suxamethonium</e1> doses <e2>arrhythmias</e2>
D013390_D001145 NONE <e1>suxamethonium</e1> doses prevent <e2>arrhythmia</e2>
9199746
D000583_D064420 NONE <e1>amikacin</e1> <e2>toxicity</e2>
D000617_D009877 NONE <e1>aminoglycosides</e1> improved prognosis <e2>endophthalmitis</e2>
D000617_D007238 NONE <e1>aminoglycosides</e1> improved impair <e2>infarction</e2>
D000583_D012164 CID <e1>amikacin</e1> <e2>toxicity</e2>
D000583_D012164 CID <e1>amikacin</e1> treatment case <e2>toxicity</e2>
D000583_D013290 NONE <e1>amikacin</e1> toxicity case treatment <e2>endophthalmitis</e2>
D000583_D013290 NONE <e1>amikacin</e1> treatment <e2>endophthalmitis</e2>
D014640_D012164 NONE <e1>vancomycin</e1> amikacin treatment case <e2>toxicity</e2>
D014640_D013290 NONE <e1>vancomycin</e1> amikacin treatment <e2>endophthalmitis</e2>
D019793_D013684 NONE <e1>fluorescein</e1> angiography confirmed closure <e2>telangiectasis</e2>
17175308
D020123_D011507 CID <e1>sirolimus</e1> conversion <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> therapy consequence reported <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> conversion displayed <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> use common <e2>proteinuria</e2>
D020123_D051436 NONE <e1>srl</e1> treated <e2>nephropathy</e2>
D020123_D007674 NONE <e1>srl</e1> treated nephropathy <e2>can</e2>
D020123_D007674 NONE <e1>srl</e1> treated nephropathy <e2>nephropathy</e2>
D020123_D009369 NONE <e1>srl</e1> treated nephropathy <e2>neoplasia</e2>
D020123_D012514 NONE <e1>srl</e1> treated nephropathy neoplasia n <e2>sarcoma</e2>
D020123_D012878 NONE <e1>srl</e1> treated nephropathy neoplasia n sarcoma <e2>cancers</e2>
D020123_D007414 NONE <e1>srl</e1> treated nephropathy neoplasia n <e2>tumors</e2>
D020123_D002292 NONE <e1>srl</e1> treated nephropathy neoplasia <e2>carsinom</e2>
3750012
D010396_D009157 CID <e1>penicillamine</e1> caused <e2>gravis</e2>
D010396_D009157 CID <e1>penicillamine</e1> had <e2>gravis</e2>
D010396_D001172 NONE <e1>penicillamine</e1> caused <e2>arthritis</e2>
D010396_D001172 NONE <e1>penicillamine</e1> had <e2>arthritis</e2>
D002738_D009157 CID <e1>chloroquine</e1> therapy penicillamine caused <e2>gravis</e2>
D002738_D009157 CID <e1>chloroquine</e1> therapy penicillamine had <e2>gravis</e2>
D002738_D001172 NONE <e1>chloroquine</e1> therapy penicillamine caused <e2>arthritis</e2>
D002738_D001172 NONE <e1>chloroquine</e1> therapy penicillamine had <e2>arthritis</e2>
18186898
D019259_D006509 NONE <e1>lamivudine</e1> added <e2>infection</e2>
D016559_D000138 NONE <e1>tacrolimus</e1> suspected cause <e2>acidosis</e2>
D016559_D000138 NONE <e1>tacrolimus</e1> suspected replaced sirolimus <e2>acidosis</e2>
D020123_D000138 NONE <e1>sirolimus</e1> replaced suspected cause <e2>acidosis</e2>
D020123_D000138 NONE <e1>sirolimus</e1> <e2>acidosis</e2>
D016559_D005198 CID <e1>tacrolimus</e1> triggered dysfunction resulted suggest <e2>dysfunction</e2>
D016559_D009135 CID <e1>tacrolimus</e1> triggered dysfunction resulted suggest dysfunction <e2>myopathy</e2>
D016559_D028361 NONE <e1>tacrolimus</e1> triggered <e2>dysfunction</e2>
D019259_D005198 CID <e1>lamivudine</e1> augmented triggered dysfunction resulted suggest <e2>dysfunction</e2>
D019259_D009135 CID <e1>lamivudine</e1> augmented triggered dysfunction resulted suggest dysfunction <e2>myopathy</e2>
D019259_D028361 NONE <e1>lamivudine</e1> augmented triggered <e2>dysfunction</e2>
16330293
12084448
D007069_D001927 CID <e1>ifosfamide</e1> <e2>encephalopathy</e2>
D007069_D020820 NONE <e1>ifosfamide</e1> encephalopathy presenting <e2>asterixis</e2>
D007069_D020820 NONE <e1>ifosfamide</e1> administration discontinued resolved <e2>asterixis</e2>
D007069_D020820 NONE <e1>ifosfamide</e1> infusion presence <e2>asterixis</e2>
D007069_D020820 NONE <e1>ifx</e1> use associated suggest patient presence <e2>asterixis</e2>
D007069_D009207 CID <e1>ifosfamide</e1> infusion <e2>myoclonus</e2>
D007069_D009207 CID <e1>ifosfamide</e1> infusion presence patient suggest associated <e2>myoclonus</e2>
D007069_D009207 CID <e1>ifx</e1> use associated <e2>myoclonus</e2>
D007069_D010954 NONE <e1>ifosfamide</e1> <e2>plasmacytoma</e2>
15458908
D020849_D010024 NONE <e1>raloxifene</e1> evaluation outcomes enrolled <e2>osteoporosis</e2>
D020849_D054556 CID <e1>raloxifene</e1> associated risk <e2>thromboembolism</e2>
D020849_D054556 CID <e1>raloxifene</e1> associated risk <e2>thromboembolism</e2>
D020849_D002386 NONE <e1>raloxifene</e1> increase risk <e2>cataracts</e2>
D020849_D002386 NONE <e1>raloxifene</e1> associated was risk <e2>cataracts</e2>
D020849_D005705 NONE <e1>raloxifene</e1> increase risk cataracts <e2>disease</e2>
D020849_D005705 NONE <e1>raloxifene</e1> associated was risk cataracts <e2>disease</e2>
D020849_D004714 NONE <e1>raloxifene</e1> increase risk cataracts <e2>hyperplasia</e2>
D020849_D004714 NONE <e1>raloxifene</e1> associated was risk cataracts disease <e2>hyperplasia</e2>
D020849_D016889 NONE <e1>raloxifene</e1> increase risk cataracts <e2>cancer</e2>
D020849_D016889 NONE <e1>raloxifene</e1> associated was risk cataracts <e2>cancer</e2>
17491223
D004280_D017202 CID <e1>dobutamine-induced</e1> <e2>ischemia</e2>
D004280_D017202 CID <e1>dobutamine-induced</e1> <e2>ischemia</e2>
D004280_D017202 CID <e1>dobutamine-induced</e1> <e2>ischemia</e2>
D004280_D007511 NONE <e1>dobutamine-induced</e1> ischemia detecting assess using standard comparison assess presence <e2>ischemia</e2>
D017256_D017202 NONE <e1>tc99m-sestamibi</e1> emission tomography using assess detecting <e2>ischemia</e2>
D017256_D007511 NONE <e1>tc99m-sestamibi</e1> emission tomography using standard comparison assess presence <e2>ischemia</e2>
10091617
D012642_D007024 CID <e1>selegiline-induced</e1> <e2>hypotension</e2>
D012642_D007024 CID <e1>selegiline</e1> therapy associated <e2>hypotension</e2>
D012642_D007024 CID <e1>selegiline</e1> withdrawal abolished <e2>hypotension</e2>
D012642_D007024 CID <e1>selegiline</e1> stopping consequences course shed mechanisms causes <e2>hypotension</e2>
D012642_D007024 CID <e1>selegiline</e1> patients marked <e2>hypotension</e2>
D012642_D007024 CID <e1>selegiline</e1> withdrawal ameliorated <e2>hypotension</e2>
D012642_D007024 CID <e1>selegiline</e1> stopping reduced systolic <e2>pressures</e2>
D012642_D007024 CID <e1>selegiline</e1> associated <e2>hypotension</e2>
D012642_D010300 NONE <e1>selegiline-induced</e1> hypotension <e2>disease</e2>
D012642_D010300 NONE <e1>selegiline</e1> receive randomized found trial group <e2>disease</e2>
D012642_D010300 NONE <e1>selegiline</e1> receive randomized found mortality patients <e2>disease</e2>
D012642_D010300 NONE <e1>selegiline</e1> receive randomized found mortality patients disease <e2>pd</e2>
D012642_D010300 NONE <e1>selegiline</e1> receiving patients <e2>pd</e2>
D012642_D010300 NONE <e1>selegiline</e1> patients <e2>pd</e2>
D007980_D010300 NONE <e1>l-dopa</e1> day receive randomized found trial group <e2>disease</e2>
D007980_D010300 NONE <e1>l-dopa</e1> day receive randomized found mortality patients <e2>disease</e2>
D007980_D010300 NONE <e1>l-dopa</e1> day receive randomized found mortality patients disease <e2>pd</e2>
D007980_D010300 NONE <e1>l-dopa</e1> taking those randomized found trial group <e2>disease</e2>
D007980_D010300 NONE <e1>l-dopa</e1> taking those randomized found mortality patients <e2>disease</e2>
D007980_D010300 NONE <e1>l-dopa</e1> taking those randomized found mortality patients disease <e2>pd</e2>
D007980_D007024 NONE <e1>l-dopa</e1> selegiline therapy associated <e2>hypotension</e2>
D007980_D007024 NONE <e1>l-dopa</e1> combination selegiline associated <e2>hypotension</e2>
2951327
D009638_D013610 NONE <e1>norepinephrine</e1> rate <e2>tachycardia</e2>
D009638_D007022 NONE <e1>norepinephrine</e1> rate tachycardia 99 observed <e2>hypotension</e2>
D006830_D013610 NONE <e1>hydralazine</e1> induced hypotension observed 99 <e2>tachycardia</e2>
D006830_D007022 CID <e1>hydralazine</e1> induced <e2>hypotension</e2>
D005996_D013610 NONE <e1>nitroglycerin</e1> hydralazine induced hypotension observed 99 <e2>tachycardia</e2>
D005996_D007022 CID <e1>nitroglycerin</e1> hydralazine induced <e2>hypotension</e2>
19657887
D000431_D005483 CID <e1>alcohol</e1> ingestion hour developed flushing <e2>face</e2>
D000431_D013610 CID <e1>alcohol</e1> ingestion hour developed flushing face <e2>tachycardia</e2>
D000431_D004417 CID <e1>alcohol</e1> ingestion hour developed flushing face tachycardia <e2>dyspnea</e2>
D004221_D005483 NONE <e1>disulfiram-like</e1> syndrome developed <e2>flushing</e2>
D004221_D013610 NONE <e1>disulfiram-like</e1> syndrome developed flushing <e2>tachycardia</e2>
D004221_D007022 NONE <e1>disulfiram-like</e1> syndrome developed flushing <e2>hypotension</e2>
2071257
D005997_D000647 NONE <e1>l-alpha-glyceryl-phosphorylcholine</e1> effect <e2>amnesia</e2>
D012601_D000647 NONE <e1>scopolamine</e1> caused effect <e2>amnesia</e2>
D005997_D008569 NONE <e1>l-alpha-glycerylphosphorylcholine</e1> effects <e2>impairment</e2>
D005997_D008569 NONE <e1>l-alpha-gfc</e1> l-alpha-glycerylphosphorylcholine effects <e2>impairment</e2>
D012601_D008569 CID <e1>scopolamine</e1> induced <e2>impairment</e2>
D012601_D008569 CID <e1>scopolamine</e1> induced attention <e2>memory</e2>
2375138
D008874_D006323 CID <e1>midazolam-associated</e1> cardiorespiratory <e2>arrest</e2>
D008874_D006323 CID <e1>midazolam</e1> administration associated <e2>arrest</e2>
D008874_D003643 NONE <e1>midazolam-associated</e1> cardiorespiratory arrest <e2>death</e2>
D008874_D003643 NONE <e1>midazolam</e1> administration associated arrest <e2>death</e2>
1436384
D000661_D020258 CID <e1>amphetamine-induced</e1> <e2>neurotoxicity</e2>
D000661_D020258 CID <e1>amphetamine</e1> effect <e2>neurotoxic</e2>
D004298_D020258 NONE <e1>dopamine</e1> neurons <e2>neurotoxicity</e2>
D004298_D020258 NONE <e1>dopamine</e1> neurons effect <e2>neurotoxic</e2>
C070935_D020258 NONE <e1>ly274614</e1> rodents neurons <e2>neurotoxicity</e2>
C070935_D020258 NONE <e1>ly274614</e1> antagonist involves effect <e2>neurotoxic</e2>
D000596_D020258 NONE <e1>acid</e1> antagonist ly274614 rodents neurons <e2>neurotoxicity</e2>
D016202_D020258 NONE <e1>nmda</e1> receptors involves effect <e2>neurotoxic</e2>
D016202_D020258 NONE <e1>nmda</e1> antagonist involves effect <e2>neurotoxic</e2>
12443032
D003042_D002637 CID <e1>cocaine</e1> related <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> tendency produce <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> tendency ought faced victim <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> use related <e2>pain</e2>
11135224
D017239_D002289 NONE <e1>paclitaxel</e1> chemotherapy approach <e2>carcinoma</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> feasibility treat <e2>nsclc</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> combination treated patients <e2>nsclc</e2>
D017239_D002289 NONE <e1>paclitaxel</e1> combination tolerated shows activity <e2>nsclc</e2>
D002945_D002289 NONE <e1>cisplatin</e1> paclitaxel chemotherapy approach <e2>carcinoma</e2>
D002945_D002289 NONE <e1>cisplatin-based</e1> combinations improve quality life <e2>carcinoma</e2>
D002945_D002289 NONE <e1>cisplatin-based</e1> combinations improve quality life carcinoma <e2>nsclc</e2>
D002945_D002289 NONE <e1>cisplatin</e1> paclitaxel feasibility treat <e2>nsclc</e2>
D002945_D002289 NONE <e1>cisplatin</e1> day given combination treated patients <e2>nsclc</e2>
D002945_D002289 NONE <e1>cisplatin</e1> paclitaxel combination tolerated shows activity <e2>nsclc</e2>
C056507_D002289 NONE <e1>gemcitabine</e1> combination chemotherapy approach <e2>carcinoma</e2>
C056507_D002289 NONE <e1>gemcitabine</e1> combination feasibility treat <e2>nsclc</e2>
C056507_D002289 NONE <e1>gemcitabine</e1> day combination treated patients <e2>nsclc</e2>
C056507_D002289 NONE <e1>gemcitabine</e1> paclitaxel combination tolerated shows activity <e2>nsclc</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> feasibility <e2>toxicity</e2>
D002945_D064420 NONE <e1>cisplatin</e1> paclitaxel feasibility <e2>toxicity</e2>
C056507_D064420 NONE <e1>gemcitabine</e1> combination feasibility <e2>toxicity</e2>
3403780
D000082_D003128 NONE <e1>paracetamol-associated</e1> <e2>coma</e2>
D000082_D000138 CID <e1>paracetamol-associated</e1> coma <e2>acidosis</e2>
D000082_D000138 CID <e1>paracetamol</e1> ingestion failure <e2>acidosis</e2>
D000082_D058186 CID <e1>paracetamol</e1> ingestion failure <e2>failure</e2>
D000082_D058186 NONE <e1>paracetamol-associated</e1> coma <e2>failure</e2>
D000082_D017093 NONE <e1>paracetamol-associated</e1> coma <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol</e1> ingestion failure <e2>failure</e2>
2632720
D007654_D006973 CID <e1>ketoconazole</e1> treatment complication <e2>hypertension</e2>
D007654_D006973 CID <e1>ketoconazole</e1> basis treated patients developed <e2>hypertension</e2>
D007654_D006973 CID <e1>ketoconazole</e1> therapy achieved demonstrated <e2>hypertension</e2>
D007654_D006973 CID <e1>ketoconazole</e1> doses treatment induce blockade leading <e2>hypertension</e2>
D007654_D003480 NONE <e1>ketoconazole</e1> basis treated patients <e2>syndrome</e2>
D006854_D006973 NONE <e1>cortisol</e1> levels achieved demonstrated <e2>hypertension</e2>
17042910
C065179_D006973 NONE <e1>atorvastatin</e1> effects <e2>hypertension</e2>
C065179_D006973 NONE <e1>atorvastatin</e1> possesses reduced production forms <e2>hypertension</e2>
C065179_D006973 NONE <e1>ato</e1> atorvastatin possesses reduced production forms <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone</e1> (dex)-induced <e2>hypertension</e2>
D003907_D006973 CID <e1>(dex)-induced</e1> <e2>hypertension</e2>
D009569_D006973 NONE <e1>oxide</e1> deficiency associated dysfunction characterized <e2>hypertension</e2>
D009569_D006973 NONE <e1>no</e1> deficiency associated dysfunction characterized <e2>hypertension</e2>
D009569_D006973 NONE <e1>no</e1> availability improve reported properties possesses reduced production forms <e2>hypertension</e2>
D013481_D006973 NONE <e1>superoxide</e1> production dysfunction characterized <e2>hypertension</e2>
D013481_D006973 NONE <e1>o2-</e1> superoxide production dysfunction characterized <e2>hypertension</e2>
D013481_D006973 NONE <e1>o2-</e1> production forms <e2>hypertension</e2>
3780846
D009020_D009127 CID <e1>morphine</e1> produced <e2>rigidity</e2>
D009020_D009127 CID <e1>morphine</e1> produced <e2>rigidity</e2>
D009020_D009127 CID <e1>morphine</e1> dose controls showed <e2>rigidity</e2>
D009020_D009127 CID <e1>morphine</e1> days treated rats showed showed <e2>rigidity</e2>
D009020_D009127 CID <e1>morphine</e1> dose <e2>rigidity</e2>
D009020_D009127 CID <e1>morphine</e1> action assumed <e2>rigidity</e2>
D009020_D018476 CID <e1>morphine</e1> days treated rats showed showed rigidity dose less <e2>akinetic</e2>
D009020_D018476 CID <e1>morphine</e1> dose less <e2>akinetic</e2>
D006220_D009127 CID <e1>haloperidol</e1> series used order block estimate degree tolerance <e2>rigidity</e2>
D006220_D009127 CID <e1>haloperidol</e1> enhanced <e2>rigidity</e2>
3693336
D014229_D001714 CID <e1>triazolam-induced</e1> episodes <e2>mania</e2>
D014229_D001714 CID <e1>triazolam</e1> doses induced episodes <e2>mania</e2>
D014229_D001714 CID <e1>triazolam</e1> action duration coincident excitement <e2>manic</e2>
D014229_D003866 NONE <e1>triazolam-induced</e1> episodes patient <e2>depressed</e2>
D014229_D003866 NONE <e1>triazolam</e1> doses induced woman <e2>depressed</e2>
12523465
C022189_D006212 CID <e1>zonisamide</e1> associated <e2>hallucinations</e2>
C022189_D006212 CID <e1>zonisamide</e1> treatment experienced patients describe reported <e2>hallucinations</e2>
C022189_D006212 CID <e1>zonisamide</e1> treatment experienced <e2>hallucinations</e2>
C022189_D012640 NONE <e1>zonisamide</e1> drug used treat types <e2>seizures</e2>
15649445
D012110_D004409 CID <e1>reserpine</e1> change glutamate elicit <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine-</e1> <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine-</e1> models <e2>dyskinesia</e2>
D012110_D004409 CID <e1>reserpine-</e1> models dyskinesia <e2>td</e2>
D012110_D004409 CID <e1>reserpine</e1> induced <e2>dyskinesia</e2>
D006220_D004409 CID <e1>haloperidol</e1> treatments subchronic reserpine change glutamate elicit <e2>dyskinesia</e2>
D006220_D004409 CID <e1>haloperidol-induced</e1> <e2>dyskinesia</e2>
D006220_D004409 CID <e1>haloperidol-induced</e1> dyskinesia reserpine- models <e2>dyskinesia</e2>
D006220_D004409 CID <e1>haloperidol-induced</e1> dyskinesia reserpine- models dyskinesia <e2>td</e2>
D006220_D004409 CID <e1>haloperidol</e1> subchronic induced <e2>dyskinesia</e2>
D018698_D004409 NONE <e1>glutamate</e1> elicit <e2>dyskinesia</e2>
D018698_D004409 NONE <e1>glutamate</e1> uptake decrease correlates increase incidence <e2>diskinesia</e2>
18631865
D020123_D051436 NONE <e1>rapamycin</e1> inhibitors target conversion observed <e2>nephropathy</e2>
D020123_D051436 NONE <e1>sirolimus</e1> inhibitors target conversion observed <e2>nephropathy</e2>
D020123_D011507 CID <e1>sirolimus</e1> due <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> due remained observed <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> therapy observed remained due <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> therapy observed <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> received transplantation therapy observed remained due <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> received transplantation therapy observed <e2>proteinuria</e2>
1085609
D011736_D012640 NONE <e1>pyridoxine</e1> <e2>convulsions</e2>
D011736_D012640 NONE <e1>pyridoxine</e1> administering hours ceased <e2>fits</e2>
D011736_D012640 NONE <e1>pyridoxine</e1> deficiency aetiology suggesting ceased <e2>fits</e2>
D007538_D012640 CID <e1>isoniazid</e1> therapy <e2>convulsions</e2>
D007538_D012640 CID <e1>isoniazid</e1> therapy mg/kg infant admitted days <e2>fits</e2>
D007538_D012640 CID <e1>isoniazid</e1> secondary deficiency aetiology suggesting ceased <e2>fits</e2>
D007538_D014376 NONE <e1>isoniazid</e1> therapy mg/kg infant <e2>tuberculosis</e2>
891050
D003276_D006463 CID <e1>contraceptives</e1> taking woman <e2>syndrome</e2>
D003276_D006463 CID <e1>contraceptives</e1> taking woman syndrome <e2>hus</e2>
D006493_D001002 NONE <e1>heparin</e1> treated rose onset <e2>anuria</e2>
D004176_D001002 NONE <e1>dipyridamole</e1> heparin treated rose onset <e2>anuria</e2>
7199841
C004616_D010243 CID <e1>2-chloroprocaine-ce</e1> seven injection received animals developed <e2>paralysis</e2>
D002045_D010243 NONE <e1>bupivacaine</e1> received animals none developed <e2>paralysis</e2>
C004616_D013118 CID <e1>2-chloroprocaine-ce</e1> received animals cords showed <e2>necrosis</e2>
11256525
D019808_D001002 CID <e1>losartan</e1> administration <e2>anuria</e2>
D019808_D001002 CID <e1>losartan</e1> administration developed episodes <e2>anuria</e2>
D019808_D001002 CID <e1>losartan</e1> mg dose resulted <e2>anuria</e2>
D019808_D001002 CID <e1>losartan</e1> prescribed developed episode <e2>anuria</e2>
D019808_D006973 NONE <e1>losartan</e1> administration developed kidney man <e2>hypertensive</e2>
D019808_D051436 NONE <e1>losartan</e1> administration developed kidney <e2>insufficiency</e2>
D019808_D006331 NONE <e1>losartan</e1> <e2>dysfunction</e2>
D005665_D001002 NONE <e1>furosemide</e1> lasted <e2>anuria</e2>
D000588_D001002 NONE <e1>amine</e1> infusion furosemide lasted <e2>anuria</e2>
D000809_D012078 NONE <e1>renin-angiotensin</e1> system activation resulted <e2>stenosis</e2>
D000809_D006333 NONE <e1>renin-angiotensin</e1> system activation resulted stenosis combined <e2>failure</e2>
D000804_D014652 NONE <e1>ii</e1> losartan cause complications patients <e2>disease</e2>
D019808_D014652 NONE <e1>losartan</e1> cause complications patients <e2>disease</e2>
3412544
D000082_D014523 NONE <e1>paracetamol</e1> cause <e2>cancer</e2>
D000082_D007681 NONE <e1>paracetamol</e1> cause cancer <e2>necrosis</e2>
D000082_D007681 NONE <e1>paracetamol</e1> phenacetin consumption associated risk developing <e2>necrosis</e2>
D000082_D007681 NONE <e1>paracetamol</e1> consumption <e2>necrosis</e2>
D010615_D007681 CID <e1>phenacetin</e1> consumption associated risk developing <e2>necrosis</e2>
D010615_D007681 CID <e1>phenacetin</e1> consumption increased risk <e2>necrosis</e2>
D010615_D007680 CID <e1>phenacetin</e1> consumption increased risk cancer pelvis <e2>bladder</e2>
D010615_D007680 NONE <e1>phenacetin</e1> consumption associated risk developing necrosis pelvis <e2>bladder</e2>
D010615_D014516 NONE <e1>phenacetin</e1> consumption associated risk developing necrosis pelvis <e2>bladder</e2>
D010615_D014516 NONE <e1>phenacetin</e1> consumption increased risk cancer <e2>cancer</e2>
D010615_D001749 CID <e1>phenacetin</e1> consumption increased risk cancer pelvis <e2>bladder</e2>
D010615_D001749 NONE <e1>phenacetin</e1> consumption associated risk developing necrosis pelvis <e2>bladder</e2>
D000082_D007680 NONE <e1>paracetamol</e1> phenacetin consumption associated risk developing necrosis pelvis <e2>bladder</e2>
D000082_D014516 NONE <e1>paracetamol</e1> phenacetin consumption associated risk developing necrosis pelvis <e2>bladder</e2>
D000082_D014516 NONE <e1>paracetamol</e1> consumption risk substantiate unable was suggestion association cancer <e2>ureter</e2>
D000082_D001749 NONE <e1>paracetamol</e1> phenacetin consumption associated risk developing necrosis pelvis <e2>bladder</e2>
D000082_D009369 NONE <e1>paracetamol</e1> consumption necrosis any <e2>cancers</e2>
9862868
D004997_D002780 CID <e1>estradiol</e1> treatment used models <e2>cholestasis</e2>
D004997_D002780 CID <e1>ee</e1> estradiol treatment used models <e2>cholestasis</e2>
D004997_D001651 NONE <e1>estradiol</e1> treatment <e2>cholestasis</e2>
D004997_D001651 NONE <e1>ee</e1> estradiol treatment <e2>cholestasis</e2>
2008831
D008755_D000788 NONE <e1>methylergonovine</e1> administration patients <e2>angina</e2>
D008755_D000788 NONE <e1>methylergonovine</e1> administration effects studied patients <e2>angina</e2>
D008755_D000788 NONE <e1>methylergonovine</e1> dose injection use tests have sensitivity <e2>angina</e2>
D008755_D002637 NONE <e1>methylergonovine</e1> administration effects studied patients angina patients <e2>pain</e2>
D008755_D000787 NONE <e1>methylergonovine</e1> administration effects studied patients others <e2>pectoris</e2>
D008755_D013035 NONE <e1>methylergonovine</e1> dose injection use tests <e2>spasm</e2>
17020434
D014859_D020521 NONE <e1>warfarin</e1> reduces risk <e2>stroke</e2>
D014859_D020521 NONE <e1>warfarin</e1> superior preventing <e2>strokes</e2>
D001241_D020521 NONE <e1>aspirin</e1> reduces reduces risk <e2>stroke</e2>
D001241_D020521 NONE <e1>aspirin</e1> superior preventing <e2>strokes</e2>
C426686_D004617 NONE <e1>ximelagatran</e1> found efficient prevention <e2>events</e2>
C426686_D056486 CID <e1>ximelagatran</e1> found withdrawn tests <e2>function</e2>
D014812_D004617 NONE <e1>k</e1> drugs efficient prevention <e2>events</e2>
D014812_D056486 NONE <e1>k</e1> drugs efficient found withdrawn tests <e2>function</e2>
C055162_D001281 NONE <e1>clopidogrel</e1> <e2>fibrillation</e2>
C055162_D001281 NONE <e1>clopidogrel</e1> therapy superior demonstrated study active-w trial clopidogrel <e2>fibrillation</e2>
C055162_D004617 NONE <e1>clopidogrel</e1> trial active-w study demonstrated superior prevention <e2>events</e2>
C055162_D004617 NONE <e1>clopidogrel</e1> therapy superior prevention <e2>events</e2>
C081309_D001281 NONE <e1>irbesartan</e1> trial clopidogrel <e2>fibrillation</e2>
C081309_D004617 NONE <e1>irbesartan</e1> trial active-w study demonstrated superior prevention <e2>events</e2>
D014859_D001281 NONE <e1>warfarin</e1> superior demonstrated study active-w trial clopidogrel <e2>fibrillation</e2>
D014859_D004617 NONE <e1>warfarin</e1> superior prevention <e2>events</e2>
D001241_D001281 NONE <e1>aspirin</e1> clopidogrel therapy superior demonstrated study active-w trial clopidogrel <e2>fibrillation</e2>
D001241_D004617 NONE <e1>aspirin</e1> clopidogrel therapy superior prevention <e2>events</e2>
C479958_D001281 NONE <e1>idraparinux</e1> evaluated patients <e2>fibrillation</e2>
D000809_D001281 NONE <e1>angiotensin-converting</e1> inhibitors hold <e2>fibrillation</e2>
D000809_D020257 NONE <e1>angiotensin-converting</e1> inhibitors hold <e2>remodelling</e2>
D000804_D001281 NONE <e1>ii</e1> drugs inhibitors hold <e2>fibrillation</e2>
D000804_D020257 NONE <e1>ii</e1> drugs inhibitors hold <e2>remodelling</e2>
11745184
D002945_D001943 NONE <e1>cisplatin</e1> <e2>carcinoma</e2>
D002945_D001943 NONE <e1>cisplatin</e1> has used treatment <e2>carcinoma</e2>
D002945_D001943 NONE <e1>cisplatin</e1> observed limited treatment <e2>carcinoma</e2>
D002945_D001943 NONE <e1>cisplatin</e1> associated toxicities cisplatin observed limited treatment <e2>carcinoma</e2>
D002945_D001943 NONE <e1>cisplatin</e1> combination study conducted patients <e2>carcinoma</e2>
D004999_D001943 NONE <e1>wr-2721</e1> cisplatin <e2>carcinoma</e2>
D004999_D001943 NONE <e1>amifostine</e1> wr-2721 cisplatin <e2>carcinoma</e2>
D004999_D001943 NONE <e1>amifostine</e1> cisplatin combination study conducted patients <e2>carcinoma</e2>
D002945_D064420 NONE <e1>cisplatin</e1> <e2>toxicities</e2>
D002945_D064420 NONE <e1>cisplatin</e1> associated <e2>toxicities</e2>
D002945_D064420 NONE <e1>cisplatin</e1> addition observed effect <e2>toxicity</e2>
D002945_D007674 CID <e1>cisplatin</e1> toxicities associated cisplatin e.g. <e2>nephrotoxicity</e2>
D002945_D007674 CID <e1>cisplatin</e1> e.g. <e2>nephrotoxicity</e2>
D002945_D007674 CID <e1>cisplatin</e1> trials suggested reduced incidence <e2>nephrotoxicity</e2>
D002945_D007674 CID <e1>cisplatin-induced</e1> <e2>nephrotoxicity</e2>
D002945_D006311 CID <e1>cisplatin</e1> toxicities associated cisplatin e.g. nephrotoxicity <e2>ototoxicity</e2>
D002945_D006311 CID <e1>cisplatin</e1> e.g. nephrotoxicity <e2>ototoxicity</e2>
D002945_D006311 CID <e1>cisplatin</e1> trials suggested reduced incidence nephrotoxicity <e2>ototoxicity</e2>
D002945_D006311 CID <e1>cisplatin-induced</e1> nephrotoxicity <e2>ototoxicity</e2>
D002945_D020258 NONE <e1>cisplatin</e1> toxicities associated cisplatin e.g. nephrotoxicity <e2>neurotoxicity</e2>
D002945_D020258 NONE <e1>cisplatin</e1> e.g. nephrotoxicity <e2>neurotoxicity</e2>
D002945_D009422 CID <e1>cisplatin</e1> trials suggested reduced incidence nephrotoxicity <e2>neuropathy</e2>
D002945_D009422 CID <e1>cisplatin-induced</e1> nephrotoxicity <e2>neuropathy</e2>
D004999_D007674 NONE <e1>amifostine</e1> cisplatin trials suggested reduced incidence <e2>nephrotoxicity</e2>
D004999_D006311 NONE <e1>amifostine</e1> cisplatin trials suggested reduced incidence nephrotoxicity <e2>ototoxicity</e2>
D004999_D009422 NONE <e1>amifostine</e1> cisplatin trials suggested reduced incidence nephrotoxicity <e2>neuropathy</e2>
D004999_D009369 NONE <e1>amifostine</e1> addition observed effect <e2>tumor-protective</e2>
D004999_D064420 NONE <e1>amifostine</e1> addition observed effect <e2>toxicity</e2>
D002945_D009369 NONE <e1>cisplatin</e1> addition observed effect <e2>tumor-protective</e2>
8410052
D019344_D001480 NONE <e1>lactate</e1> infusion produced injury <e2>cortex</e2>
D010862_D002544 CID <e1>pilocarpine-induced</e1> epilepticus evoked infarcts <e2>reticulata</e2>
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>epilepticus</e2>
14657095
D000666_D002311 CID <e1>b</e1> therapy related dilated <e2>cardiomyopathy</e2>
D000666_D002311 CID <e1>b</e1> therapy months developed failure <e2>cardiomyopathy</e2>
D000666_D002311 CID <e1>amb</e1> b therapy months developed failure <e2>cardiomyopathy</e2>
D000666_D006333 CID <e1>b</e1> therapy months developed <e2>failure</e2>
D000666_D006333 CID <e1>amb</e1> b therapy months developed <e2>failure</e2>
D000666_D006333 CID <e1>amb.</e1> substituted abnormalities <e2>failure</e2>
D000666_D006333 CID <e1>amb.</e1> toxicity recognize important substituted abnormalities <e2>failure</e2>
D000666_D003047 NONE <e1>b</e1> therapy months developed <e2>coccidioidomycosis</e2>
D000666_D003047 NONE <e1>amb</e1> b therapy months developed <e2>coccidioidomycosis</e2>
C101425_D006333 NONE <e1>posaconazole</e1> resolved abnormalities <e2>failure</e2>
C101425_D064420 NONE <e1>posaconazole</e1> resolved abnormalities substituted important recognize <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb.</e1> substituted important recognize <e2>toxicity</e2>
D000666_D064420 NONE <e1>amb.</e1> <e2>toxicity</e2>
2334618
D009020_D001049 NONE <e1>morphine</e1> infusion receiving patients compared incidence <e2>apnoea</e2>
D002045_D001049 NONE <e1>bupivacaine</e1> infusion receiving patients infusion receiving patients compared incidence <e2>apnoea</e2>
D009020_D020181 CID <e1>morphine</e1> infusion had patients frequently occurred obstructive <e2>apnoea</e2>
D009020_D020182 CID <e1>morphine</e1> infusion had patients frequently occurred obstructive <e2>apnoea</e2>
D009020_D013610 NONE <e1>morphine</e1> group incidence <e2>tachyarrhythmias</e2>
D009020_D018879 CID <e1>morphine</e1> group incidence <e2>beats</e2>
8437969
D002927_D054138 CID <e1>cimetidine</e1> associated <e2>arrest</e2>
D002927_D054138 CID <e1>cimetidine</e1> receiving developed episodes <e2>arrest</e2>
D002927_D054138 CID <e1>cimetidine</e1> associated <e2>arrest</e2>
D002927_D001919 CID <e1>cimetidine</e1> infusions administration associated development <e2>bradyarrhythmias</e2>
D002927_D007938 NONE <e1>cimetidine</e1> receiving developed man <e2>leukemia</e2>
D002927_D006331 NONE <e1>cimetidine</e1> receiving developed man history <e2>disease</e2>
D002927_D001145 NONE <e1>cimetidine</e1> administration related <e2>arrhythmias</e2>
D011899_D001145 NONE <e1>ranitidine</e1> treatment recur disappeared related <e2>arrhythmias</e2>
2870085
C047847_D013610 NONE <e1>flestolol</e1> produced attenuation <e2>tachycardia</e2>
D007545_D013610 CID <e1>isoproterenol-induced</e1> <e2>tachycardia</e2>
C047847_D013617 NONE <e1>flestolol</e1> reduced rate patients <e2>tachyarrhythmia</e2>
C047847_D000789 NONE <e1>flestolol</e1> infusion found patients <e2>angina</e2>
C047847_D002637 NONE <e1>flestolol</e1> infusion found safe effective controlling <e2>pain</e2>
7053303
D002927_D003704 CID <e1>cimetidine</e1> case <e2>dementia</e2>
D002927_D003704 CID <e1>cimetidine</e1> levels had group was case <e2>dementia</e2>
D002927_D003704 CID <e1>cimetidine</e1> levels induce <e2>dementia</e2>
D002927_D008107 NONE <e1>cimetidine</e1> case was group liver <e2>disease</e2>
D002927_D008107 NONE <e1>cimetidine</e1> levels had group liver <e2>disease</e2>
D002927_D007674 NONE <e1>cimetidine</e1> case was group liver <e2>disease</e2>
D002927_D007674 NONE <e1>cimetidine</e1> levels had group liver <e2>disease</e2>
12921865
D013256_D012640 NONE <e1>steroids</e1> <e2>kindled-seizures</e2>
D013256_D012640 NONE <e1>steroid</e1> receptor increase sensitivity effects cocaine engendered administration kindling <e2>seizure</e2>
D003042_D012640 CID <e1>cocaine</e1> <e2>kindled-seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> engendered administration kindling <e2>seizure</e2>
D003042_D012640 CID <e1>cocaine</e1> administration kindling <e2>seizure</e2>
D003042_D012640 CID <e1>cocaine-kindled</e1> <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine</e1> administration induced <e2>seizures</e2>
D013256_D009422 NONE <e1>steroids</e1> demonstrate actions have relevance host <e2>disorders</e2>
D013256_D001523 NONE <e1>steroids</e1> demonstrate actions have relevance host <e2>disorders</e2>
D005680_D012640 NONE <e1>acid</e1> modulate steroid receptor increase sensitivity effects cocaine engendered administration kindling <e2>seizure</e2>
D005680_D012640 NONE <e1>gaba(a</e1> acid modulate steroid receptor increase sensitivity effects cocaine engendered administration kindling <e2>seizure</e2>
D005680_D012640 NONE <e1>gaba(a</e1> modulators all suppressed expression <e2>seizures</e2>
D011280_D012640 NONE <e1>allopregnanolone</e1> tested ability suppress expression <e2>seizures</e2>
D011280_D012640 NONE <e1>3alpha-hydroxy-5alpha-pregnan-20-one</e1> allopregnanolone tested ability suppress expression <e2>seizures</e2>
D011280_D012640 NONE <e1>pregnanolone</e1> allopregnanolone tested ability suppress expression <e2>seizures</e2>
D011280_D012640 NONE <e1>3alpha-hydroxy-5beta-pregnan-20-one</e1> pregnanolone allopregnanolone tested ability suppress expression <e2>seizures</e2>
D011280_D012640 NONE <e1>allopregnanolone</e1> derivative ganaxolone allopregnanolone tested ability suppress expression <e2>seizures</e2>
D011280_D012640 NONE <e1>allopregnanolone</e1> inhibited suppressed expression <e2>seizures</e2>
C105051_D012640 NONE <e1>ganaxolone</e1> allopregnanolone tested ability suppress expression <e2>seizures</e2>
C105051_D012640 NONE <e1>3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one</e1> allopregnanolone derivative ganaxolone allopregnanolone tested ability suppress expression <e2>seizures</e2>
C105051_D012640 NONE <e1>ganaxolone</e1> allopregnanolone inhibited suppressed expression <e2>seizures</e2>
16904497
D013256_D011128 NONE <e1>steroid</e1> injection <e2>syndrome</e2>
D013256_D011843 NONE <e1>steroid</e1> injections therapy methods <e2>radiculopathy</e2>
D014221_D011128 NONE <e1>triamcinolone</e1> injection caused <e2>syndrome</e2>
D002045_D011128 CID <e1>bupivacaine</e1> injection caused <e2>syndrome</e2>
D013256_D017116 NONE <e1>steroid</e1> injection scheduled features woman <e2>pain</e2>
D013256_D010146 NONE <e1>steroid</e1> injection scheduled features woman <e2>pain</e2>
D013256_D009422 NONE <e1>steroid</e1> injections examination vigilance <e2>deterioration</e2>
12596116
D015282_D000860 NONE <e1>octreotide-induced</e1> <e2>hypoxemia</e2>
D015282_D006976 CID <e1>octreotide-induced</e1> hypoxemia <e2>hypertension</e2>
D015282_D006976 CID <e1>octreotide</e1> developed <e2>hypertension</e2>
D015282_D005402 NONE <e1>octreotide</e1> developed enhance resolution <e2>fistula</e2>
16337777
D010862_D004827 NONE <e1>pilocarpine</e1> induced <e2>epilepsy</e2>
D010862_D013226 NONE <e1>pilocarpine</e1> model phase sufficient generation <e2>epilepticus</e2>
D010862_D004833 CID <e1>pilocarpine</e1> model <e2>epilepsy</e2>
18503483
D016559_D020968 CID <e1>tacrolimus-associated</e1> <e2>neuritis</e2>
C107135_D020968 NONE <e1>everolimus</e1> conversion recovery <e2>neuritis</e2>
11334364
D000082_D009336 CID <e1>acetaminophen-induced</e1> nephrotoxicity deaths apoptotic <e2>necrotic</e2>
D000082_D009336 CID <e1>aap</e1> drugs induced addition <e2>necrosis</e2>
D000082_D007674 CID <e1>acetaminophen-induced</e1> <e2>nephrotoxicity</e2>
D000082_D007674 CID <e1>acetaminophen</e1> prevent <e2>nephrotoxicity</e2>
D000082_D007674 CID <e1>(aap)-induced</e1> <e2>nephrotoxicity</e2>
D000082_D008171 NONE <e1>acetaminophen-induced</e1> nephrotoxicity <e2>toxicity</e2>
D000082_D008171 NONE <e1>acetaminophen</e1> prevent nephrotoxicity <e2>toxicity</e2>
D000082_D008171 NONE <e1>(aap)-induced</e1> nephrotoxicity <e2>toxicity</e2>
D000082_D066126 NONE <e1>acetaminophen-induced</e1> nephrotoxicity <e2>cardiotoxicity</e2>
D000082_D066126 NONE <e1>acetaminophen</e1> prevent nephrotoxicity <e2>cardiotoxicity</e2>
D000082_D066126 NONE <e1>(aap)-induced</e1> nephrotoxicity <e2>cardiotoxicity</e2>
D000638_D009336 CID <e1>amiodarone-induced</e1> toxicity nephrotoxicity deaths apoptotic <e2>necrotic</e2>
D000638_D009336 CID <e1>ami</e1> aap drugs induced addition <e2>necrosis</e2>
D000638_D007674 NONE <e1>amiodarone-induced</e1> toxicity <e2>nephrotoxicity</e2>
D000638_D007674 NONE <e1>amiodarone</e1> (ami)-induced toxicity <e2>nephrotoxicity</e2>
D000638_D007674 NONE <e1>(ami)-induced</e1> toxicity <e2>nephrotoxicity</e2>
D000638_D008171 CID <e1>amiodarone-induced</e1> <e2>toxicity</e2>
D000638_D008171 CID <e1>amiodarone</e1> (ami)-induced <e2>toxicity</e2>
D000638_D008171 CID <e1>(ami)-induced</e1> <e2>toxicity</e2>
D000638_D066126 NONE <e1>amiodarone-induced</e1> toxicity nephrotoxicity <e2>cardiotoxicity</e2>
D000638_D066126 NONE <e1>amiodarone</e1> (ami)-induced toxicity nephrotoxicity <e2>cardiotoxicity</e2>
D000638_D066126 NONE <e1>(ami)-induced</e1> toxicity nephrotoxicity <e2>cardiotoxicity</e2>
D004317_D009336 CID <e1>doxorubicin-induced</e1> cardiotoxicity nephrotoxicity deaths apoptotic <e2>necrotic</e2>
D004317_D009336 CID <e1>dox</e1> aap drugs induced addition <e2>necrosis</e2>
D004317_D007674 NONE <e1>doxorubicin-induced</e1> cardiotoxicity <e2>nephrotoxicity</e2>
D004317_D007674 NONE <e1>doxorubicin</e1> cardiotoxicity <e2>nephrotoxicity</e2>
D004317_D007674 NONE <e1>(dox)-induced</e1> cardiotoxicity <e2>nephrotoxicity</e2>
D004317_D008171 NONE <e1>doxorubicin-induced</e1> cardiotoxicity nephrotoxicity <e2>toxicity</e2>
D004317_D008171 NONE <e1>doxorubicin</e1> cardiotoxicity nephrotoxicity <e2>toxicity</e2>
D004317_D008171 NONE <e1>(dox)-induced</e1> cardiotoxicity nephrotoxicity <e2>toxicity</e2>
D004317_D066126 CID <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>(dox)-induced</e1> <e2>cardiotoxicity</e2>
C511402_D009336 NONE <e1>extract</e1> protection deaths apoptotic <e2>necrotic</e2>
C511402_D009336 NONE <e1>gspe</e1> blocked organs <e2>necrosis</e2>
C511402_D007674 NONE <e1>extract</e1> protection deaths <e2>nephrotoxicity</e2>
C511402_D007674 NONE <e1>extract</e1> ability prevent <e2>nephrotoxicity</e2>
C511402_D007674 NONE <e1>gspe</e1> extract ability prevent <e2>nephrotoxicity</e2>
C511402_D008171 NONE <e1>extract</e1> protection deaths nephrotoxicity <e2>toxicity</e2>
C511402_D008171 NONE <e1>extract</e1> ability prevent nephrotoxicity <e2>toxicity</e2>
C511402_D008171 NONE <e1>gspe</e1> extract ability prevent nephrotoxicity <e2>toxicity</e2>
C511402_D066126 NONE <e1>extract</e1> protection deaths nephrotoxicity <e2>cardiotoxicity</e2>
C511402_D066126 NONE <e1>extract</e1> ability prevent nephrotoxicity <e2>cardiotoxicity</e2>
C511402_D066126 NONE <e1>gspe</e1> extract ability prevent nephrotoxicity <e2>cardiotoxicity</e2>
C511402_D017695 NONE <e1>gspe</e1> preexposure revealed moderate <e2>damage</e2>
19346865
D008795_D001927 CID <e1>metronidazole-induced</e1> encephalopathy <e2>lesion</e2>
D008795_D001927 CID <e1>metronidazole-induced</e1> <e2>encephalopathy</e2>
D008795_D001927 CID <e1>metronidazole-induced</e1> encephalopathy <e2>lesions</e2>
D008795_D001927 CID <e1>metronidazole-induced</e1> <e2>encephalopathy</e2>
D008795_D001927 CID <e1>metronidazole-induced</e1> <e2>encephalopathy</e2>
D008795_D001927 CID <e1>metronidazole-induced</e1> encephalopathy characteristic considered <e2>lesions</e2>
D008795_D001927 CID <e1>metronidazole-induced</e1> <e2>encephalopathy</e2>
D008795_D007239 NONE <e1>metronidazole</e1> taking treat <e2>infection</e2>
3970039
D000477_D015470 CID <e1>agents</e1> treated patients have risk development <e2>leukemia</e2>
D000477_D015470 CID <e1>agents</e1> associated have risk development <e2>leukemia</e2>
D000477_D008228 CID <e1>agents</e1> treated patients have associated development <e2>lymphoma</e2>
D000477_D008228 CID <e1>agents</e1> associated development <e2>lymphoma</e2>
D001379_D015470 NONE <e1>azathioprine</e1> agents associated have risk development <e2>leukemia</e2>
D001379_D008228 CID <e1>azathioprine</e1> agents associated development <e2>lymphoma</e2>
D003520_D001749 CID <e1>cyclophosphamide</e1> therapy increases risk carcinoma <e2>bladder</e2>
D003520_D002277 CID <e1>cyclophosphamide</e1> therapy increases risk carcinoma <e2>bladder</e2>
D001379_D001172 NONE <e1>azathioprine</e1> treated patients <e2>arthritis</e2>
D001379_D009369 NONE <e1>azathioprine</e1> treated patients studies incidence most <e2>cancers</e2>
D003520_D001172 NONE <e1>cyclophosphamide</e1> azathioprine treated patients <e2>arthritis</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> azathioprine treated patients studies incidence most <e2>cancers</e2>
D000477_D009369 NONE <e1>agents</e1> drugs use reserved collected data risk <e2>malignancy</e2>
D000477_D001172 NONE <e1>agents</e1> drugs use reserved collected data risk <e2>arthritis</e2>
D000477_D001172 NONE <e1>agents</e1> drugs use treatment <e2>arthritis</e2>
2266990
D008454_D020388 NONE <e1>mazindol</e1> trial <e2>dystrophy</e2>
D008454_D020388 NONE <e1>mazindol</e1> trial conducted boys <e2>dystrophy</e2>
D008454_D020388 NONE <e1>mazindol</e1> doses slow progression weakness <e2>dystrophy</e2>
D008454_D001068 CID <e1>mazindol</e1> attributable effects included <e2>appetite</e2>
D008454_D001068 CID <e1>mazindol</e1> dosage reduced included <e2>appetite</e2>
D008454_D014987 CID <e1>mazindol</e1> attributable effects included appetite <e2>mouth</e2>
D008454_D014987 CID <e1>mazindol</e1> dosage reduced included appetite <e2>mouth</e2>
D008454_D012817 CID <e1>mazindol</e1> attributable effects included appetite <e2>symptoms</e2>
D008454_D012817 CID <e1>mazindol</e1> dosage reduced included appetite <e2>symptoms</e2>
D008454_D018908 NONE <e1>mazindol</e1> doses slow progression <e2>weakness</e2>
6861444
D009638_D006973 CID <e1>noradrenaline</e1> infusion caused <e2>hypertension</e2>
D009638_D006973 CID <e1>noradrenaline</e1> infusion <e2>hypertension</e2>
D009638_D006973 CID <e1>noradrenaline</e1> levels produced <e2>hypertension</e2>
137340
D009020_D006948 CID <e1>morphine-induced</e1> increase <e2>activity</e2>
D009020_D006948 CID <e1>morphine-induced</e1> increase <e2>activity</e2>
D009020_D006948 CID <e1>morphine-hc1</e1> mg/kg administration produced increase <e2>activity</e2>
D009020_D006948 CID <e1>morphine-induced</e1> <e2>hyperactivity</e2>
D009020_D006948 CID <e1>morphine</e1> produced <e2>hyperactivity</e2>
D012601_D006948 CID <e1>scopolamine</e1> potentiated <e2>hyperactivity</e2>
D010830_D006948 NONE <e1>physostigmine</e1> attenuated potentiated <e2>hyperactivity</e2>
D019832_D006948 NONE <e1>methscopolamine</e1> had effect <e2>hyperactivity</e2>
D009388_D006948 NONE <e1>neostigmine</e1> methscopolamine had effect <e2>hyperactivity</e2>
D010134_D006948 NONE <e1>p-chlorophenylalamine</e1> pretreatment caused change <e2>hyperactivity</e2>
D012701_D006948 NONE <e1>serotonin</e1> depletor pretreatment caused change <e2>hyperactivity</e2>
227508
D003000_D006973 NONE <e1>clonidine</e1> produced pressure decrease rats <e2>hypertensive</e2>
D003000_D006973 NONE <e1>clonidine</e1> rats <e2>hypertensive</e2>
D003000_D006973 NONE <e1>clonidine-suppressible</e1> binding influence influence membranes rats <e2>hypertensive</e2>
-1_D006973 NONE <e1>nalozone</e1> reversed inhibited rats <e2>hypertensive</e2>
-1_D006973 NONE <e1>[3h]-naloxone</e1> binding influence membranes rats <e2>hypertensive</e2>
-1_D006973 NONE <e1>[3h]-dihydroergocryptine</e1> binding influence influence membranes rats <e2>hypertensive</e2>
D008750_D007022 CID <e1>alpha-methyldopa</e1> effect <e2>hypotensive</e2>
D009270_D007022 NONE <e1>naloxone</e1> reversed effect <e2>hypotensive</e2>
D009270_D006973 NONE <e1>naloxone</e1> binding influence membranes rats <e2>hypertensive</e2>
16680561
D003891_D009325 CID <e1>desipramine</e1> treatment events reported frequent which <e2>nausea</e2>
D003891_D009325 CID <e1>desipramine</e1> receiving reported frequent which <e2>nausea</e2>
D003891_D009325 CID <e1>desipramine</e1> treated patients reported frequent which <e2>nausea</e2>
D003891_D006261 CID <e1>desipramine</e1> treatment events reported frequent which nausea <e2>headache</e2>
D003891_D006261 CID <e1>desipramine</e1> receiving reported frequent which nausea <e2>headache</e2>
D003891_D006261 CID <e1>desipramine</e1> treated patients reported frequent which nausea <e2>headache</e2>
C476217_D009325 CID <e1>cinacalcet</e1> desipramine receiving reported frequent which <e2>nausea</e2>
C476217_D009325 CID <e1>cinacalcet</e1> desipramine treated patients reported frequent which <e2>nausea</e2>
C476217_D006261 CID <e1>cinacalcet</e1> desipramine receiving reported frequent which nausea <e2>headache</e2>
C476217_D006261 CID <e1>cinacalcet</e1> desipramine treated patients reported frequent which nausea <e2>headache</e2>
7881871
D011692_D007674 CID <e1>aminonucleoside-induced</e1> <e2>nephropathy</e2>
D011692_D007674 CID <e1>aminonucleoside</e1> pathogenesis implicated <e2>nephropathy</e2>
D011692_D007674 CID <e1>(pan)-induced</e1> implicated <e2>nephropathy</e2>
D011692_D007674 CID <e1>pan</e1> <e2>nephropathy</e2>
D010100_D007674 NONE <e1>oxygen</e1> species implicated <e2>nephropathy</e2>
D010100_D011507 NONE <e1>oxygen</e1> species implicated reducing <e2>proteinuria</e2>
D011692_D011507 CID <e1>aminonucleoside</e1> pathogenesis implicated reducing <e2>proteinuria</e2>
D011692_D011507 CID <e1>(pan)-induced</e1> implicated reducing <e2>proteinuria</e2>
D011692_D011507 CID <e1>pan</e1> nephropathy mediating <e2>injury</e2>
16740173
6666578
D010396_D001018 CID <e1>d-penicillamine-induced</e1> <e2>angiopathy</e2>
9249847
D014700_D013611 CID <e1>verapamil</e1> ablation <e2>tachycardia</e2>
D014700_D013611 CID <e1>verapamil</e1> block beats caused ablation attack <e2>avrt</e2>
D014700_D014927 NONE <e1>verapamil</e1> ablation patient <e2>syndrome</e2>
D014700_D002311 NONE <e1>verapamil</e1> ablation patient syndrome <e2>cardiomyopathy</e2>
3107448
D005905_D056486 CID <e1>glyburide-induced</e1> <e2>hepatitis</e2>
D005905_D056486 CID <e1>glyburide</e1> reports exist <e2>hepatotoxicity</e2>
D005905_D056486 CID <e1>glyburide</e1> therapy initiation developed <e2>syndrome</e2>
D005905_D056486 CID <e1>glyburide</e1> produce <e2>illness</e2>
D013453_D056486 NONE <e1>sulfonylureas</e1> reported <e2>hepatotoxicity</e2>
D013453_D056486 NONE <e1>sulfonylurea</e1> glyburide reports exist <e2>hepatotoxicity</e2>
D005905_D003924 NONE <e1>glyburide</e1> therapy initiation developed patients <e2>mellitus</e2>
6387529
D003975_D016584 NONE <e1>diazepam</e1> patients <e2>disorder</e2>
D003975_D016584 NONE <e1>diazepam</e1> doses effects performance patients <e2>disorders</e2>
D003975_D000379 NONE <e1>diazepam</e1> patients disorder <e2>agoraphobia</e2>
D003975_D000379 NONE <e1>diazepam</e1> doses effects performance patients disorders <e2>agoraphobia</e2>
D011433_D016584 NONE <e1>propranolol</e1> diazepam patients <e2>disorder</e2>
D011433_D016584 NONE <e1>propranolol</e1> effects performance patients <e2>disorders</e2>
D011433_D000379 NONE <e1>propranolol</e1> diazepam patients disorder <e2>agoraphobia</e2>
D011433_D000379 NONE <e1>propranolol</e1> effects performance patients disorders <e2>agoraphobia</e2>
D003975_D008569 CID <e1>diazepam</e1> greater impaired <e2>recall</e2>
D011433_D008569 CID <e1>propranolol</e1> diazepam greater impaired <e2>recall</e2>
18083142
D009638_D001008 NONE <e1>norepinephrine</e1> signaling critical expression <e2>anxiety</e2>
D009638_D001008 NONE <e1>norepinephrine</e1> lack mice performance evaluated methods examine contribution <e2>anxiety</e2>
D009638_D001008 NONE <e1>ne</e1> norepinephrine lack mice performance evaluated methods examine contribution <e2>anxiety</e2>
D003042_D001008 CID <e1>cocaine-induced</e1> <e2>anxiety</e2>
D003042_D001008 CID <e1>cocaine</e1> effects underlying mechanisms studied paid states induced cocaine <e2>anxiety</e2>
D003042_D001008 CID <e1>cocaine</e1> <e2>anxiety</e2>
D003042_D001008 CID <e1>cocaine-induced</e1> <e2>anxiety</e2>
D003042_D001008 CID <e1>cocaine</e1> increased behavior <e2>anxiety-like</e2>
D003042_D001008 CID <e1>cocaine-induced</e1> <e2>anxiety</e2>
D003042_D001008 CID <e1>cocaine-induced</e1> behavior <e2>anxiety-like</e2>
D003042_D001008 CID <e1>cocaine-induced</e1> <e2>anxiety</e2>
D004298_D001008 NONE <e1>dopamine</e1> knockout performance evaluated methods examine contribution <e2>anxiety</e2>
D004298_D001008 NONE <e1>dopamine</e1> beta-hydroxylase inhibitor disulfiram administration attenuated <e2>anxiety</e2>
D004221_D001008 NONE <e1>disulfiram</e1> administration attenuated <e2>anxiety</e2>
D011433_D001008 NONE <e1>propranolol</e1> pretreatment blocked behavior <e2>anxiety-like</e2>
D011224_D001008 NONE <e1>prazosin</e1> blocked behavior <e2>anxiety-like</e2>
D015016_D001008 NONE <e1>yohimbine</e1> prazosin blocked behavior <e2>anxiety-like</e2>
3173180
D008795_D006463 CID <e1>metronidazole</e1> treatment <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> treatment developed <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> involvement aetiology <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> involvement established suggest action evidence changes <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> involvement established suggest link treatment cases <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> treatment link suggest established involvement aetiology <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> treatment link suggest action evidence changes <e2>syndrome</e2>
D008795_D006463 CID <e1>metronidazole</e1> treatment cases <e2>syndrome</e2>
2578334
D001374_D011230 CID <e1>5-azacytidine</e1> potentiates initiation induced <e2>carcinogens</e2>
D001374_D011230 CID <e1>5-azacytidine</e1> <e2>process</e2>
D001374_D011230 CID <e1>5-azc</e1> 5-azacytidine <e2>process</e2>
D001564_D011230 CID <e1>benzo[a]-pyrene</e1> carcinogens induced synthesis phase rats given test validity hypothesis plays initiation <e2>process</e2>
D008770_D011230 CID <e1>n-methyl-n-nitrosourea</e1> carcinogens induced synthesis phase rats given test validity hypothesis plays initiation <e2>process</e2>
D019813_D011230 CID <e1>1,2-dimethylhydrazine</e1> carcinogens induced synthesis phase rats given test validity hypothesis plays initiation <e2>process</e2>
D019813_D011230 CID <e1>1,2-dmh</e1> 1,2-dimethylhydrazine carcinogens induced synthesis phase rats given test validity hypothesis plays initiation <e2>process</e2>
8669433
D000082_D007676 NONE <e1>acetaminophen</e1> use factor <e2>failure</e2>
D000082_D007676 NONE <e1>acetaminophen</e1> use associated <e2>failure</e2>
D000082_D007676 NONE <e1>acetaminophen</e1> use associated failure <e2>esrd</e2>
D000082_D007676 NONE <e1>acetaminophen</e1> phenacetin contribute burden <e2>esrd</e2>
D000082_D007676 NONE <e1>acetaminophen</e1> use increases risk <e2>esrd</e2>
D010615_D007676 CID <e1>phenacetin</e1> comparison use factor <e2>failure</e2>
D010615_D007676 CID <e1>phenacetin</e1> use associated development <e2>failure</e2>
D010615_D007676 CID <e1>phenacetin</e1> use associated development failure <e2>disease</e2>
D010615_D007676 CID <e1>phenacetin</e1> use associated development failure disease <e2>esrd</e2>
D010615_D007676 CID <e1>phenacetin</e1> contribute burden <e2>esrd</e2>
8741744
D009538_D009069 NONE <e1>nicotine</e1> caused <e2>hypoactivity</e2>
D009538_D009069 NONE <e1>nicotine-induced</e1> hyperactivity enhanced blunted <e2>hypoactivity</e2>
D009538_D006948 CID <e1>nicotine</e1> caused hypoactivity blunted enhanced <e2>hyperactivity</e2>
D009538_D006948 CID <e1>nicotine-induced</e1> <e2>hyperactivity</e2>
2894766
D012460_D008180 CID <e1>sulfasalazine-induced</e1> <e2>erythematosus</e2>
D012460_D008180 CID <e1>sulfasalazine-induced</e1> <e2>lupus</e2>
D012460_D008180 CID <e1>sulfasalazine</e1> use physicians aware signs <e2>syndrome</e2>
D012460_D008180 CID <e1>sulfasalazine-induced</e1> <e2>syndrome</e2>
D012460_D011014 CID <e1>sulfasalazine</e1> therapy receiving man developed <e2>pneumonitis</e2>
D012460_D010996 CID <e1>sulfasalazine</e1> therapy receiving man developed pneumonitis <e2>effusions</e2>
D012460_D002305 CID <e1>sulfasalazine</e1> therapy receiving man developed pneumonitis evidence <e2>tamponade</e2>
D012460_D003093 NONE <e1>sulfasalazine</e1> therapy <e2>colitis</e2>
D012460_D012700 NONE <e1>sulfasalazine-induced</e1> lupus had manifested <e2>serositis</e2>
D012460_D015212 NONE <e1>sulfasalazine</e1> use treat patients <e2>disease</e2>
D012460_D015212 NONE <e1>sulfasalazine-induced</e1> syndrome signs aware physicians use treat patients <e2>disease</e2>
19729346
D010098_D010146 NONE <e1>oxycodone</e1> dose effects objective measured <e2>pain</e2>
D010098_D059350 NONE <e1>oxycodone</e1> dose response adults suffering <e2>pain</e2>
14513889
D007654_D009422 NONE <e1>ketoconazole-induced</e1> <e2>sequelae</e2>
D007654_D018908 CID <e1>ketoconazole</e1> ingestion developed weakness <e2>extremities</e2>
D007654_D010243 CID <e1>ketoconazole</e1> ingestion developed weakness extremities <e2>paralysis</e2>
D007654_D004401 CID <e1>ketoconazole</e1> ingestion developed weakness extremities paralysis <e2>dysarthria</e2>
D007654_D014202 CID <e1>ketoconazole</e1> ingestion developed weakness extremities paralysis dysarthria <e2>tremor</e2>
20633755
D013390_D001049 CID <e1>suxamethonium</e1> induced <e2>apnea</e2>
D013390_D001049 CID <e1>suxamethonium</e1> causes <e2>apnea</e2>
D009943_D001049 CID <e1>poisons</e1> deactivated gets <e2>apnea</e2>
D009943_D001049 CID <e1>compound</e1> attempt information concealed ensued <e2>apnea</e2>
8319760
D019808_D009401 NONE <e1>753</e1> dup prevents development <e2>nephrosis</e2>
D011692_D009401 NONE <e1>aminonucleoside-induced</e1> <e2>nephrosis</e2>
D011692_D009401 NONE <e1>aminonucleoside-induced</e1> <e2>nephrosis</e2>
D001806_D009404 NONE <e1>urea</e1> increase appearance <e2>syndromes</e2>
D001806_D011507 NONE <e1>urea</e1> increase appearance syndromes <e2>proteinuria</e2>
D001806_D034141 NONE <e1>urea</e1> increase appearance syndromes proteinuria <e2>hypoalbuminemia</e2>
D001806_D006937 NONE <e1>urea</e1> increase appearance <e2>hypercholesterolemia</e2>
D011692_D009404 CID <e1>aminonucleoside</e1> injection induced appearance <e2>syndromes</e2>
D011692_D011507 CID <e1>aminonucleoside</e1> injection induced appearance syndromes <e2>proteinuria</e2>
D011692_D034141 CID <e1>aminonucleoside</e1> injection induced appearance syndromes proteinuria <e2>hypoalbuminemia</e2>
D011692_D006937 CID <e1>aminonucleoside</e1> injection induced appearance <e2>hypercholesterolemia</e2>
D019808_D009404 NONE <e1>753</e1> dup administration inhibited appearance <e2>syndromes</e2>
D019808_D009404 NONE <e1>losartan</e1> dup administration inhibited appearance <e2>syndromes</e2>
D019808_D011507 NONE <e1>753</e1> dup administration inhibited appearance syndromes <e2>proteinuria</e2>
D019808_D011507 NONE <e1>losartan</e1> dup administration inhibited appearance syndromes <e2>proteinuria</e2>
D019808_D034141 NONE <e1>753</e1> dup administration inhibited appearance syndromes proteinuria <e2>hypoalbuminemia</e2>
D019808_D034141 NONE <e1>losartan</e1> dup administration inhibited appearance syndromes proteinuria <e2>hypoalbuminemia</e2>
D019808_D006937 NONE <e1>753</e1> dup administration inhibited appearance <e2>hypercholesterolemia</e2>
D019808_D006937 NONE <e1>losartan</e1> dup administration inhibited appearance <e2>hypercholesterolemia</e2>
D000804_D009404 NONE <e1>ii</e1> antagonist administration inhibited appearance <e2>syndromes</e2>
D000804_D011507 NONE <e1>ii</e1> antagonist administration inhibited appearance syndromes <e2>proteinuria</e2>
D000804_D034141 NONE <e1>ii</e1> antagonist administration inhibited appearance syndromes proteinuria <e2>hypoalbuminemia</e2>
D000804_D006937 NONE <e1>ii</e1> antagonist administration inhibited appearance <e2>hypercholesterolemia</e2>
D000809_D009401 NONE <e1>renin-angiotensin</e1> system involvement development <e2>nephrosis</e2>
11147747
D018490_D014549 CID <e1>antidepressants</e1> <e2>incontinence</e2>
D018490_D014549 CID <e1>antidepressants</e1> secondary <e2>incontinence</e2>
C047426_D014549 CID <e1>venlafaxine</e1> taking experienced <e2>incontinence</e2>
C047426_D014549 CID <e1>venlafaxine</e1> developed third describe patients developed <e2>incontinence</e2>
D012701_D014549 NONE <e1>serotonin</e1> inhibitors secondary <e2>incontinence</e2>
D017374_D014549 CID <e1>paroxetine</e1> patients developed <e2>incontinence</e2>
D020280_D014549 CID <e1>sertraline</e1> paroxetine patients developed <e2>incontinence</e2>
D016651_D014549 CID <e1>carbonate</e1> taking cases 2 contributed <e2>incontinence</e2>
20882060
D009496_D002375 NONE <e1>neurotensin</e1> effects <e2>catalepsy</e2>
D009496_D002375 NONE <e1>neurotensin</e1> infusions <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D009496_D010302 NONE <e1>neurotensin</e1> effects <e2>symptoms</e2>
D006220_D010302 NONE <e1>haloperidol-induced</e1> <e2>symptoms</e2>
3496378
D014217_D002779 CID <e1>troleandomycin-induced</e1> hepatitis <e2>cholestasis</e2>
D014217_D002779 CID <e1>troleandomycin-induced</e1> hepatitis followed <e2>cholestasis</e2>
D014217_D002779 CID <e1>troleandomycin-induced</e1> hepatitis follow <e2>cholestasis</e2>
D014217_D056486 CID <e1>troleandomycin-induced</e1> <e2>hepatitis</e2>
D014217_D056486 CID <e1>troleandomycin-induced</e1> <e2>hepatitis</e2>
D014217_D056486 CID <e1>troleandomycin-induced</e1> <e2>hepatitis</e2>
D014217_D007565 CID <e1>troleandomycin</e1> administration occurred <e2>jaundice</e2>
D014217_D004802 CID <e1>troleandomycin</e1> administration occurred associated <e2>hypereosinophilia</e2>
16005948
-1_D062787 NONE <e1>gnc92h2</e1> evaluation immunotherapy <e2>overdose</e2>
-1_D062787 NONE <e1>gnc92h2</e1> potential examined using model <e2>overdose</e2>
-1_D062787 NONE <e1>gnc92h2</e1> potential support tool <e2>overdose</e2>
D003042_D062787 NONE <e1>cocaine</e1> use continues proportions treatment <e2>overdose</e2>
D003042_D064420 NONE <e1>cocaine</e1> <e2>toxicity</e2>
D003042_D012640 CID <e1>cocaine</e1> toxicity blockade observed <e2>seizures</e2>
D003042_D003643 NONE <e1>cocaine</e1> toxicity blockade observed seizures % <e2>death</e2>
D003042_D003643 NONE <e1>post-cocaine</e1> injection prevented <e2>death</e2>
-1_D064420 NONE <e1>gnc92h2</e1> dose observed blockade <e2>toxicity</e2>
-1_D012640 NONE <e1>gnc92h2</e1> dose observed <e2>seizures</e2>
-1_D003643 NONE <e1>gnc92h2</e1> dose observed seizures % <e2>death</e2>
-1_D003643 NONE <e1>gnc92h2</e1> prevented <e2>death</e2>
11897407
C067171_D009203 NONE <e1>99mtc-glucarate</e1> detection <e2>infarction</e2>
C067171_D009203 NONE <e1>99mtc-glucarate</e1> easy used study biodistribution rats <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D007238 NONE <e1>isoproterenol</e1> obtained implies model used produce <e2>infarction</e2>
D007545_D007238 NONE <e1>isoproterenol</e1> administration developed h <e2>infarct</e2>
D005937_D007238 NONE <e1>acid</e1> based radiopharmaceutical new <e2>infarct-avid</e2>
567256
D004054_D006394 CID <e1>diethylstilbestrol</e1> associated <e2>liver</e2>
D004054_D006394 CID <e1>diethylstilbestrol</e1> adenocarcinoma treated man occurred angiosarcoma <e2>liver</e2>
D004054_D008113 CID <e1>diethylstilbestrol</e1> associated <e2>liver</e2>
D004054_D008113 CID <e1>diethylstilbestrol</e1> adenocarcinoma treated man occurred angiosarcoma <e2>liver</e2>
D004054_D008113 NONE <e1>diethylstilbestrol</e1> adenocarcinoma <e2>liver</e2>
D004054_D000230 NONE <e1>diethylstilbestrol</e1> adenocarcinoma <e2>liver</e2>
15515654
D003676_D006311 NONE <e1>dfo</e1> other factor <e2>ototoxic</e2>
D003676_D006319 CID <e1>dfo</e1> reduction submitted subjects <e2>snhl</e2>
D003676_D034381 NONE <e1>dfo</e1> role development <e2>impairment</e2>
18162529
D012313_D006966 NONE <e1>acid</e1> levels inhibition <e2>hyperprolactinemic</e2>
D004958_D006966 NONE <e1>estradiol</e1> dependent levels inhibition <e2>hyperprolactinemic</e2>
D004958_D006966 NONE <e1>estradiol</e1> levels presence caused <e2>hyperprolactinemia</e2>
D004967_D006966 NONE <e1>estrogen-induced</e1> lh secretion pulsatile inhibited <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>dopamine</e1> sulpiride induced <e2>hyperprolactinemia</e2>
D013469_D006966 CID <e1>sulpiride</e1> induced <e2>hyperprolactinemia</e2>
D013256_D006966 NONE <e1>steroid-dependent</e1> manner inhibited <e2>hyperprolactinemia</e2>
11587867
D014750_D001927 NONE <e1>vincristin</e1> administration <e2>myeloencephalopathy</e2>
D014750_D054198 NONE <e1>vincristine</e1> instillation girl <e2>leucemia</e2>
D014750_D054198 NONE <e1>vincristine</e1> instillation girl man <e2>lymphoma</e2>
D014750_D003711 CID <e1>vincristine</e1> exposed areas transformation degeneration myelin <e2>axons</e2>
D014750_D009410 CID <e1>vincristine</e1> exposed areas transformation degeneration myelin <e2>axons</e2>
D014750_-1 NONE <e1>vincristine</e1> exposed areas <e2>transformation</e2>
2312209
D007548_D009203 CID <e1>dinitrate</e1> administration <e2>infarction</e2>
D007548_D009203 CID <e1>dinitrate</e1> administration <e2>infarction</e2>
D007548_D009336 NONE <e1>dinitrate</e1> administration infarction suffered 78-year-old <e2>necrosis</e2>
6229975
D013999_D009203 NONE <e1>timolol</e1> long-term treatment changes <e2>infarction</e2>
D013999_D009203 NONE <e1>timolol</e1> long-term treatment effect <e2>infarction</e2>
D013999_D009203 NONE <e1>timolol</e1> placebo patients study evaluated effect <e2>infarction</e2>
D013999_D001919 NONE <e1>timolol-induced</e1> <e2>bradycardia</e2>
D013999_D007238 NONE <e1>timolol</e1> group remained increased <e2>re-infarction</e2>
10901305
D007649_D050723 NONE <e1>ketamine</e1> sedation reduction <e2>fractures</e2>
D007649_D050723 NONE <e1>ketamine</e1> safety treatment <e2>fractures</e2>
D007649_D050723 NONE <e1>ketamine</e1> administration manipulation <e2>fracture</e2>
D007649_D050723 NONE <e1>ketamine</e1> provided facilitate reduction <e2>fractures</e2>
D007649_D004204 NONE <e1>ketamine</e1> administration manipulation fracture <e2>dislocation</e2>
7988234
D008790_D000799 CID <e1>metoprolol</e1> administration <e2>angioedema</e2>
D008790_D000799 CID <e1>metoprolol</e1> given resulting <e2>angioedema</e2>
D017706_D000799 CID <e1>lisinopril</e1> therapy secondary <e2>angioedema</e2>
D013256_D000799 NONE <e1>steroids</e1> therapy resolved <e2>angioedema</e2>
D004155_D000799 NONE <e1>diphenhydramine</e1> hydrochloride steroids therapy resolved <e2>angioedema</e2>
2054792
D004317_D005334 NONE <e1>adriamycin</e1> combined <e2>hyperthermia</e2>
D004317_D005334 NONE <e1>adriamycin-mediated</e1> activity enhancement <e2>hyperthermia</e2>
D004317_D005334 NONE <e1>adriamycin-mediated</e1> activity enhanced <e2>hyperthermia</e2>
D004317_D005334 NONE <e1>adriamycin-mediated</e1> effect enhances <e2>hyperthermia</e2>
D004317_D009369 NONE <e1>adriamycin</e1> combined hyperthermia <e2>tumor</e2>
D004317_D064420 NONE <e1>adriamycin-mediated</e1> activity enhancement <e2>toxicities</e2>
D004317_D064420 NONE <e1>adriamycin-mediated</e1> effect enhances increased <e2>toxicity</e2>
20621845
D002122_D017545 CID <e1>cacl2-induced</e1> <e2>aneurysm</e2>
D002122_D017545 CID <e1>chloride</e1> establish model <e2>aneurysm</e2>
D002122_D017545 CID <e1>chloride</e1> establish model aneurysm <e2>taa</e2>
D002122_D017545 CID <e1>chloride</e1> injury explore role formation <e2>taa</e2>
D002122_D017545 CID <e1>cacl(2))-induced</e1> injury chloride establish model <e2>aneurysm</e2>
D002122_D017545 CID <e1>cacl(2))-induced</e1> injury chloride establish model aneurysm <e2>taa</e2>
D002122_D017545 CID <e1>cacl(2))-induced</e1> injury explore role formation <e2>taa</e2>
D002122_D017545 CID <e1>)</e1> establishes model <e2>taa</e2>
D002122_D014652 NONE <e1>chloride</e1> <e2>injury</e2>
D002122_D014652 NONE <e1>cacl(2))-induced</e1> <e2>injury</e2>
1835291
D009241_D029424 NONE <e1>bromide</e1> effects <e2>disease</e2>
D009241_D029424 NONE <e1>bromide</e1> dose effects compared study patients <e2>disease</e2>
D009241_D029424 NONE <e1>ipratropium</e1> bronchodilator theophylline patients <e2>obstruction</e2>
D013806_D029424 NONE <e1>theophylline</e1> bromide effects <e2>disease</e2>
D013806_D029424 NONE <e1>theophylline</e1> tablets effects compared study patients <e2>disease</e2>
D013806_D029424 NONE <e1>theophylline</e1> patients <e2>obstruction</e2>
D013806_D002318 CID <e1>theophylline</e1> use experienced those involve <e2>systems</e2>
D013806_D005767 CID <e1>theophylline</e1> use experienced those involve <e2>systems</e2>
347884
D006220_D019967 NONE <e1>haloperidol</e1> study found effective treatment belonging <e2>group</e2>
2445283
D012254_D006478 NONE <e1>ribavirin</e1> tolerance patients <e2>fever</e2>
D012254_D006478 NONE <e1>ribavirin</e1> tolerance studied patients <e2>fever</e2>
D012254_D006478 NONE <e1>ribavirin</e1> tolerance studied patients fever <e2>ahf</e2>
D012254_D006478 NONE <e1>ribavirin</e1> has effect cases <e2>ahf</e2>
D012254_D006478 NONE <e1>ribavirin</e1> effect days <e2>ahf</e2>
D012254_D014766 NONE <e1>ribavirin</e1> administration resulted neutralization <e2>viremia</e2>
D012254_D000740 CID <e1>ribavirin</e1> has managed <e2>anemia</e2>
17854040
D019259_D006509 NONE <e1>lamivudine-resistance</e1> patients <e2>infected</e2>
D019259_D006509 NONE <e1>lamivudine-resistance</e1> associated mutations <e2>co-infected</e2>
D019259_D006509 NONE <e1>lamivudine-resistant</e1> virus <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine-na</e1> carriers strains investigate virus <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine-na</e1> patients <e2>infected</e2>
D019259_D006509 NONE <e1>lamivudine-na</e1> patients studied patients <e2>mono-infected</e2>
D019259_D006509 NONE <e1>lamivudine-na</e1> patients studied patients patients <e2>co-infected</e2>
D019259_D006509 NONE <e1>lamivudine-resistant</e1> strains detected patients <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine-resistant</e1> strains detected patients patients <e2>co-infected</e2>
D019259_D006509 NONE <e1>lamivudine-resistant</e1> strains patients <e2>co-infected</e2>
D019259_D006509 NONE <e1>lamivudine-containing</e1> active treatment result seen remains likely have implications management patients <e2>co-infected</e2>
D019259_D015658 NONE <e1>lamivudine-resistance</e1> patients <e2>co-infection</e2>
D019259_D015658 NONE <e1>lamivudine-resistance</e1> associated mutations <e2>co-infected</e2>
D019259_D015658 NONE <e1>lamivudine-resistant</e1> virus investigate strains <e2>co-infection</e2>
D019259_D015658 NONE <e1>lamivudine-na</e1> carriers strains <e2>co-infection</e2>
D019259_D015658 NONE <e1>lamivudine-na</e1> patients <e2>co-infection</e2>
D019259_D015658 NONE <e1>lamivudine-na</e1> patients studied patients patients <e2>co-infected</e2>
D019259_D015658 NONE <e1>lamivudine-resistant</e1> strains detected patients patients <e2>co-infected</e2>
D019259_D015658 NONE <e1>lamivudine-resistant</e1> strains patients <e2>co-infected</e2>
D019259_D015658 NONE <e1>lamivudine-containing</e1> active treatment result seen remains likely have implications management patients <e2>co-infected</e2>
D012964_D006509 NONE <e1>therapy-na</e1> lamivudine-resistance patients <e2>infected</e2>
D012964_D006509 NONE <e1>therapy-na</e1> lamivudine-resistance associated mutations <e2>co-infected</e2>
D012964_D006509 NONE <e1>lamivudine-na</e1> carriers strains investigate virus <e2>b</e2>
D012964_D006509 NONE <e1>lamivudine-na</e1> patients <e2>infected</e2>
D012964_D006509 NONE <e1>lamivudine-na</e1> patients studied patients <e2>mono-infected</e2>
D012964_D006509 NONE <e1>lamivudine-na</e1> patients studied patients patients <e2>co-infected</e2>
D012964_D006509 NONE <e1>therapy-na</e1> strains patients <e2>co-infected</e2>
D012964_D015658 NONE <e1>therapy-na</e1> lamivudine-resistance patients <e2>co-infection</e2>
D012964_D015658 NONE <e1>therapy-na</e1> lamivudine-resistance associated mutations <e2>co-infected</e2>
D012964_D015658 NONE <e1>lamivudine-na</e1> carriers strains <e2>co-infection</e2>
D012964_D015658 NONE <e1>lamivudine-na</e1> patients <e2>co-infection</e2>
D012964_D015658 NONE <e1>lamivudine-na</e1> patients studied patients patients <e2>co-infected</e2>
D012964_D015658 NONE <e1>therapy-na</e1> strains patients <e2>co-infected</e2>
7468724
D013726_D002318 CID <e1>terbutaline</e1> treatment associated <e2>complications</e2>
D013726_D002318 CID <e1>terbutaline</e1> treated patients occurred <e2>complications</e2>
D013726_D007752 NONE <e1>terbutaline</e1> treatment <e2>labor</e2>
D013726_D007752 NONE <e1>terbutaline</e1> treated <e2>labor</e2>
7269015
D002066_D006470 CID <e1>busulfan-induced</e1> <e2>cystitis</e2>
D002066_D006470 CID <e1>busulfan-induced</e1> <e2>cystitis</e2>
D002066_D003556 CID <e1>busulfan-induced</e1> <e2>cystitis</e2>
D002066_D003556 CID <e1>busulfan-induced</e1> <e2>cystitis</e2>
D002066_D003556 CID <e1>busulfan</e1> <e2>cystitis</e2>
D002066_D003556 CID <e1>busulfan</e1> appearances radiation <e2>cystitis</e2>
D003520_D003556 NONE <e1>cyclophosphamide-induced</e1> cystitis radiation appearances busulfan <e2>cystitis</e2>
D003520_D003556 NONE <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D002066_D002277 NONE <e1>busulfan</e1> tendency induce atypia <e2>carcinoma</e2>
15899738
D003401_D001281 CID <e1>creatine</e1> supplementation associated <e2>fibrillation</e2>
D003401_D001145 NONE <e1>creatine</e1> linked development <e2>arrhythmia</e2>
12615818
D017373_D054556 CID <e1>acetate</e1> prescribed risk <e2>thromboembolism</e2>
D017373_D054556 CID <e1>cpa/ee</e1> associated <e2>thromboembolism</e2>
D017373_D054556 CID <e1>cpa/ee</e1> associated thromboembolism <e2>vte</e2>
D017373_D054556 CID <e1>cpa/ee</e1> associated <e2>vte</e2>
D017373_D054556 CID <e1>cpa/ee</e1> use associated <e2>vte</e2>
D004997_D054556 CID <e1>estradiol</e1> combination prescribed risk <e2>thromboembolism</e2>
D004997_D054556 CID <e1>cpa/ee</e1> associated <e2>thromboembolism</e2>
D004997_D054556 CID <e1>cpa/ee</e1> associated thromboembolism <e2>vte</e2>
D004997_D054556 CID <e1>cpa/ee</e1> associated <e2>vte</e2>
D004997_D054556 CID <e1>cpa/ee</e1> use associated <e2>vte</e2>
D017373_D000152 NONE <e1>acetate</e1> licensed treatment women <e2>acne</e2>
D017373_D000152 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed treatment women <e2>acne</e2>
D017373_D000152 NONE <e1>cpa/ee</e1> associated vte risk estimate conducted analysis years <e2>acne</e2>
D017373_D000152 NONE <e1>cpa/ee</e1> women <e2>acne</e2>
D017373_D006628 NONE <e1>acetate</e1> licensed treatment women acne <e2>hirsutism</e2>
D017373_D006628 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed treatment women acne <e2>hirsutism</e2>
D017373_D006628 NONE <e1>cpa/ee</e1> associated vte risk estimate conducted analysis years acne <e2>hirsutism</e2>
D017373_D006628 NONE <e1>cpa/ee</e1> women acne <e2>hirsutism</e2>
D017373_D011085 NONE <e1>acetate</e1> licensed option <e2>syndrome</e2>
D017373_D011085 NONE <e1>acetate</e1> licensed option syndrome <e2>pcos</e2>
D017373_D011085 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed option <e2>syndrome</e2>
D017373_D011085 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed option syndrome <e2>pcos</e2>
D017373_D011085 NONE <e1>cpa/ee</e1> associated vte risk estimate conducted analysis years acne hirsutism <e2>pcos</e2>
D017373_D011085 NONE <e1>cpa/ee</e1> women acne hirsutism <e2>pcos</e2>
D004997_D000152 NONE <e1>estradiol</e1> combined acetate licensed treatment women <e2>acne</e2>
D004997_D000152 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed treatment women <e2>acne</e2>
D004997_D000152 NONE <e1>cpa/ee</e1> associated vte risk estimate conducted analysis years <e2>acne</e2>
D004997_D000152 NONE <e1>cpa/ee</e1> women <e2>acne</e2>
D004997_D006628 NONE <e1>estradiol</e1> combined acetate licensed treatment women acne <e2>hirsutism</e2>
D004997_D006628 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed treatment women acne <e2>hirsutism</e2>
D004997_D006628 NONE <e1>cpa/ee</e1> associated vte risk estimate conducted analysis years acne <e2>hirsutism</e2>
D004997_D006628 NONE <e1>cpa/ee</e1> women acne <e2>hirsutism</e2>
D004997_D011085 NONE <e1>estradiol</e1> combined acetate licensed option <e2>syndrome</e2>
D004997_D011085 NONE <e1>estradiol</e1> combined acetate licensed option syndrome <e2>pcos</e2>
D004997_D011085 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed option <e2>syndrome</e2>
D004997_D011085 NONE <e1>cpa/ee</e1> estradiol combined acetate licensed option syndrome <e2>pcos</e2>
D004997_D011085 NONE <e1>cpa/ee</e1> associated vte risk estimate conducted analysis years acne hirsutism <e2>pcos</e2>
D004997_D011085 NONE <e1>cpa/ee</e1> women acne hirsutism <e2>pcos</e2>
D003276_D054556 NONE <e1>contraceptives</e1> risk <e2>thromboembolism</e2>
D003276_D054556 NONE <e1>contraceptives</e1> risk thromboembolism <e2>vte</e2>
12483326
D016190_D005128 NONE <e1>carboplatin</e1> injection <e2>toxicity</e2>
D016190_D005128 NONE <e1>carboplatin</e1> said known <e2>toxicity</e2>
D016190_D005128 NONE <e1>carboplatin</e1> injection case <e2>toxicity</e2>
D016190_D005128 NONE <e1>carboplatin</e1> injection performing aware <e2>toxicity</e2>
D016190_D009916 NONE <e1>carboplatin</e1> injection <e2>toxicity</e2>
D016190_D009916 NONE <e1>carboplatin</e1> said known <e2>toxicity</e2>
D016190_D009916 NONE <e1>carboplatin</e1> injection case <e2>toxicity</e2>
D016190_D005909 NONE <e1>carboplatin</e1> injection <e2>glioblastomas</e2>
D016190_D005909 NONE <e1>carboplatin</e1> injection <e2>glioblastomas</e2>
D002945_D005128 NONE <e1>cisplatin</e1> effects have said known <e2>toxicity</e2>
D002945_D009916 NONE <e1>cisplatin</e1> effects have said known <e2>toxicity</e2>
D016190_D064420 NONE <e1>carboplatin</e1> <e2>toxicity</e2>
7292072
D003891_D017180 CID <e1>desipramine</e1> toxicity <e2>tachycardia</e2>
D003891_D017180 CID <e1>desipramine</e1> toxicity induced <e2>tachycardia</e2>
D003891_D064420 NONE <e1>desipramine</e1> <e2>toxicity</e2>
D003891_D064420 NONE <e1>desipramine</e1> <e2>toxicity</e2>
9401499
D013988_D000741 CID <e1>ticlopidine-induced</e1> <e2>anemia</e2>
D013988_D000741 CID <e1>ticlopidine-induced</e1> <e2>anemia</e2>
D013988_D000741 CID <e1>ticlopidine-induced</e1> <e2>anemia</e2>
D013988_D000380 CID <e1>ticlopidine</e1> initiation weeks occurred <e2>agranulocytosis</e2>
9195768
D018170_D010292 CID <e1>sumatriptan</e1> use <e2>sensations</e2>
17147461
D020123_D011507 CID <e1>sirolimus-associated</e1> <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> associated <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus-associated</e1> <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> effects knowledge minimised use monitoring <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> effects knowledge minimised use occurs <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> use monitoring <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolimus</e1> use occurs <e2>proteinuria</e2>
D020123_D007674 CID <e1>sirolimus-associated</e1> proteinuria <e2>dysfunction</e2>
D020123_D007674 CID <e1>sirolimus</e1> represents <e2>nephropathy</e2>
D020123_D007674 CID <e1>sirolimus</e1> share designated drug <e2>non-nephrotoxic</e2>
D020123_D058186 NONE <e1>sirolimus</e1> associated proteinuria <e2>dysfunction</e2>
D020123_D058186 NONE <e1>sirolimus</e1> associated <e2>dysfunction</e2>
D000809_D011507 NONE <e1>angiotensin-converting</e1> inhibitors use use monitoring <e2>proteinuria</e2>
D000809_D011507 NONE <e1>angiotensin-converting</e1> inhibitors use use occurs <e2>proteinuria</e2>
D000804_D011507 NONE <e1>ii</e1> receptor blockers inhibitors use use monitoring <e2>proteinuria</e2>
D000804_D011507 NONE <e1>ii</e1> receptor blockers inhibitors use use occurs <e2>proteinuria</e2>
12464714
C093622_D008881 NONE <e1>rizatriptan</e1> mg ergotamine/caffeine <e2>migraine</e2>
C093622_D008881 NONE <e1>rizatriptan</e1> agonist absorption treatment <e2>migraine</e2>
C093622_D008881 NONE <e1>rizatriptan</e1> mg tablet patients treating attack <e2>migraine</e2>
D004878_D008881 NONE <e1>ergotamine/caffeine</e1> <e2>migraine</e2>
D004878_D008881 NONE <e1>ergotamine</e1> tablet patients treating attack <e2>migraine</e2>
D002110_D008881 NONE <e1>ergotamine/caffeine</e1> <e2>migraine</e2>
D002110_D008881 NONE <e1>mg/caffeine</e1> ergotamine tablet patients treating attack <e2>migraine</e2>
D012701_D008881 NONE <e1>5-ht(1b/1d</e1> agonist absorption treatment <e2>migraine</e2>
C093622_D006261 NONE <e1>rizatriptan</e1> preferring patients % cited reason relief <e2>headache</e2>
C093622_D006261 NONE <e1>rizatriptan</e1> % relief <e2>headache</e2>
C093622_D006261 NONE <e1>rizatriptan</e1> superior % relief <e2>headache</e2>
D004878_D006261 NONE <e1>ergotamine/caffeine</e1> preferred patients % % cited reason relief <e2>headache</e2>
D004878_D006261 NONE <e1>ergotamine/caffeine</e1> % % relief <e2>headache</e2>
D004878_D006261 NONE <e1>ergotamine/caffeine</e1> superior % relief <e2>headache</e2>
D002110_D006261 NONE <e1>ergotamine/caffeine</e1> preferred patients % % cited reason relief <e2>headache</e2>
D002110_D006261 NONE <e1>ergotamine/caffeine</e1> % % relief <e2>headache</e2>
D002110_D006261 NONE <e1>ergotamine/caffeine</e1> superior % relief <e2>headache</e2>
C093622_D010146 NONE <e1>rizatriptan</e1> favor also endpoint being <e2>pain</e2>
C093622_D010146 NONE <e1>rizatriptan</e1> h free <e2>pain</e2>
C093622_D010146 NONE <e1>rizatriptan</e1> superior free <e2>pain</e2>
C093622_D010146 NONE <e1>rizatriptan</e1> taking patients % free <e2>pain</e2>
D004878_D010146 NONE <e1>ergotamine/caffeine</e1> treated % compared free <e2>pain</e2>
D004878_D010146 NONE <e1>ergotamine/caffeine</e1> patients % compared had free <e2>pain</e2>
D002110_D010146 NONE <e1>ergotamine/caffeine</e1> treated % compared free <e2>pain</e2>
D002110_D010146 NONE <e1>ergotamine/caffeine</e1> patients % compared had free <e2>pain</e2>
C093622_D009325 CID <e1>rizatriptan</e1> superior proportions patients <e2>nausea</e2>
C093622_D009325 CID <e1>rizatriptan</e1> events dizziness <e2>nausea</e2>
C093622_D014839 NONE <e1>rizatriptan</e1> superior proportions patients nausea <e2>vomiting</e2>
C093622_D012001 NONE <e1>rizatriptan</e1> superior proportions patients nausea vomiting <e2>phonophobia</e2>
C093622_D020795 NONE <e1>rizatriptan</e1> superior proportions patients nausea vomiting phonophobia <e2>photophobia</e2>
D004878_D009325 NONE <e1>ergotamine/caffeine</e1> superior proportions patients <e2>nausea</e2>
D004878_D009325 NONE <e1>ergotamine/caffeine</e1> rizatriptan events dizziness <e2>nausea</e2>
D004878_D014839 NONE <e1>ergotamine/caffeine</e1> superior proportions patients nausea <e2>vomiting</e2>
D004878_D012001 NONE <e1>ergotamine/caffeine</e1> superior proportions patients nausea vomiting <e2>phonophobia</e2>
D004878_D020795 NONE <e1>ergotamine/caffeine</e1> superior proportions patients nausea vomiting phonophobia <e2>photophobia</e2>
D002110_D009325 NONE <e1>ergotamine/caffeine</e1> superior proportions patients <e2>nausea</e2>
D002110_D009325 NONE <e1>ergotamine/caffeine</e1> rizatriptan events dizziness <e2>nausea</e2>
D002110_D014839 NONE <e1>ergotamine/caffeine</e1> superior proportions patients nausea <e2>vomiting</e2>
D002110_D012001 NONE <e1>ergotamine/caffeine</e1> superior proportions patients nausea vomiting <e2>phonophobia</e2>
D002110_D020795 NONE <e1>ergotamine/caffeine</e1> superior proportions patients nausea vomiting phonophobia <e2>photophobia</e2>
C093622_D004244 CID <e1>rizatriptan</e1> events <e2>dizziness</e2>
C093622_D006970 NONE <e1>rizatriptan</e1> events dizziness <e2>somnolence</e2>
D004878_D004244 NONE <e1>ergotamine/caffeine</e1> rizatriptan events <e2>dizziness</e2>
D004878_D006970 NONE <e1>ergotamine/caffeine</e1> rizatriptan events dizziness <e2>somnolence</e2>
D002110_D004244 NONE <e1>ergotamine/caffeine</e1> rizatriptan events <e2>dizziness</e2>
D002110_D006970 NONE <e1>ergotamine/caffeine</e1> rizatriptan events dizziness <e2>somnolence</e2>
18619688
D004317_D003643 NONE <e1>adriamycin-induced</e1> <e2>death</e2>
D004317_D003643 NONE <e1>adriamycin</e1> induced rats failure pathogenesis plays <e2>death</e2>
D004317_D006333 CID <e1>adriamycin-induced</e1> death plays model <e2>failure</e2>
D004317_D006333 CID <e1>adriamycin</e1> induced <e2>failure</e2>
D004317_D006333 CID <e1>adriamycin</e1> induced <e2>failure</e2>
D004317_D006333 CID <e1>adriamycin</e1> induced failure progression involved investigate develop strategy <e2>failure</e2>
D004317_D006333 CID <e1>adriamycin</e1> induced rats model <e2>failure</e2>
D004317_D006333 CID <e1>adriamycin</e1> induced rats <e2>failure</e2>
D004317_D006333 CID <e1>adriamycin</e1> caused <e2>failure</e2>
C025946_D006333 NONE <e1>3-methyladenine</e1> methods used model <e2>failure</e2>
C025946_D006333 NONE <e1>3ma</e1> 3-methyladenine methods used model <e2>failure</e2>
11250767
D011441_D014657 NONE <e1>propylthiouracil-induced</e1> <e2>vasculitis</e2>
D011441_D014657 NONE <e1>propylthiouracil-induced</e1> manifesting <e2>vasculitis</e2>
D011441_D014657 NONE <e1>uracil</e1> therapy associated <e2>vasculitis</e2>
D011441_D014657 NONE <e1>uracil</e1> therapy attributable <e2>vasculitis</e2>
D011441_D010493 CID <e1>propylthiouracil-induced</e1> vasculitis conjunction <e2>pericarditis</e2>
D011441_D010493 CID <e1>propylthiouracil-induced</e1> manifesting <e2>pericarditis</e2>
D011441_D010493 CID <e1>propylthiouracil</e1> developed syndrome <e2>pericarditis</e2>
D011441_D010493 CID <e1>uracil</e1> therapy associated vasculitis reports <e2>pericarditis</e2>
D011441_D010493 CID <e1>uracil</e1> therapy attributable vasculitis manifestation <e2>pericarditis</e2>
D011441_D006980 NONE <e1>propylthiouracil</e1> treated <e2>hyperthyroidism</e2>
D011441_D005334 CID <e1>propylthiouracil</e1> developed syndrome pericarditis <e2>fever</e2>
D011441_D005921 CID <e1>propylthiouracil</e1> developed syndrome pericarditis <e2>glomerulonephritis</e2>
11706060
D019344_D009202 NONE <e1>lactate</e1> elevates causes <e2>cardiomyopathy</e2>
D019344_D009202 NONE <e1>lactate</e1> <e2>cardiomyopathy</e2>
D019344_D009202 NONE <e1>lactate</e1> cardiomyopathy <e2>cm</e2>
D019344_D009202 NONE <e1>la</e1> lactate <e2>cardiomyopathy</e2>
D019344_D009202 NONE <e1>la</e1> lactate cardiomyopathy <e2>cm</e2>
D019344_D009202 NONE <e1>la</e1> determination mrna underwent echocardiography quantitation abundance markers <e2>cm</e2>
D019344_D009202 NONE <e1>la</e1> <e2>cm</e2>
D019344_D000163 NONE <e1>lactate</e1> elevates mice <e2>aids</e2>
D019344_D000163 NONE <e1>lactate</e1> <e2>aids</e2>
D019344_D000163 NONE <e1>la</e1> lactate <e2>aids</e2>
D019344_D000163 NONE <e1>la</e1> mice <e2>aids</e2>
D019344_D028361 NONE <e1>lactate</e1> cardiomyopathy implicated mechanisms <e2>dysfunction</e2>
D019344_D028361 NONE <e1>la</e1> lactate cardiomyopathy implicated mechanisms <e2>dysfunction</e2>
D015215_D000163 NONE <e1>zidovudine</e1> combination treated mice <e2>aids</e2>
D019259_D000163 NONE <e1>lamivudine</e1> zidovudine combination treated mice <e2>aids</e2>
D019469_D000163 NONE <e1>indinavir</e1> zidovudine combination treated mice <e2>aids</e2>
D002118_D009202 NONE <e1>calcium</e1> atpase factor encoding mrna underwent echocardiography quantitation abundance markers <e2>cm</e2>
9100294
D002118_D018376 NONE <e1>calcium</e1> channel blockers exposed fetuses <e2>alterations</e2>
D002118_D018376 NONE <e1>calcium</e1> channel blocker <e2>alterations</e2>
D002118_D018376 NONE <e1>calcium</e1> channel blockers induce <e2>malformations</e2>
D002118_D018376 NONE <e1>calcium</e1> channel blockers one administered offspring examined day gestation <e2>malformations</e2>
D002118_D018376 NONE <e1>calcium</e1> channel blockers each exposure observed incidence <e2>malformations</e2>
D020748_D018376 CID <e1>5967</e1> 40 ro blocker <e2>alterations</e2>
D014700_D018376 CID <e1>verapamil</e1> significant observed incidence <e2>malformations</e2>
D009543_D018376 CID <e1>nifedipine</e1> verapamil significant observed incidence <e2>malformations</e2>
16867021
D006632_D002375 NONE <e1>histamine</e1> ligands effect <e2>catalepsy</e2>
D001058_D002375 NONE <e1>apomorphine-induced</e1> behavior <e2>catalepsy</e2>
D001058_D002375 NONE <e1>apomorphine</e1> used induced <e2>catalepsy</e2>
D001058_D002375 NONE <e1>apomorphine-induced</e1> climbing reducing reducing potentiating <e2>catalepsy</e2>
D000661_D002375 NONE <e1>amphetamine-induced</e1> activities behavior <e2>catalepsy</e2>
D000661_D002375 NONE <e1>amphetamine</e1> apomorphine used induced <e2>catalepsy</e2>
D000661_D002375 NONE <e1>amphetamine-induced</e1> hyperactivity reducing potentiating <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> prior administration resulted increase times <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
C069357_D002375 NONE <e1>(r)-alpha-methylhistamine</e1> cause <e2>catalepsy</e2>
C069357_D002375 NONE <e1>ramh</e1> (r)-alpha-methylhistamine cause <e2>catalepsy</e2>
C052075_D002375 CID <e1>thioperamide</e1> (r)-alpha-methylhistamine cause <e2>catalepsy</e2>
C052075_D002375 CID <e1>thp</e1> thioperamide (r)-alpha-methylhistamine cause <e2>catalepsy</e2>
C052075_D002375 CID <e1>thp</e1> administration resulted increase times <e2>catalepsy</e2>
C052075_D002375 CID <e1>thp</e1> exhibited potentiating <e2>catalepsy</e2>
D000661_D006948 CID <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D000661_D006948 CID <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
C052075_D006948 NONE <e1>thp</e1> <e2>hyperactivity</e2>
C052075_D006948 NONE <e1>thp</e1> exhibited potentiating reducing <e2>hyperactivity</e2>
D006220_D006948 NONE <e1>haloperidol-induced</e1> catalepsy potentiating reducing <e2>hyperactivity</e2>
D001058_D006948 NONE <e1>apomorphine-induced</e1> climbing reducing reducing <e2>hyperactivity</e2>
19269743
D002211_D010146 CID <e1>capsaicin-induced</e1> <e2>pain</e2>
D002211_D010146 CID <e1>capsaicin</e1> doses injections received order address memory <e2>pain</e2>
D002211_D010146 CID <e1>capsaicin</e1> doses discriminate magnitude <e2>pain</e2>
84204
D002927_D003221 CID <e1>cimetidine-associated</e1> <e2>confusion</e2>
D002927_D003221 CID <e1>cimetidine-associated</e1> <e2>confusion</e2>
D002927_D051437 NONE <e1>cimetidine</e1> trough-concentrations had <e2>dysfunction</e2>
D002927_D008107 NONE <e1>cimetidine</e1> trough-concentrations had <e2>dysfunction</e2>
11027905
D007649_D009369 NONE <e1>ketamine</e1> effect patients <e2>cancer</e2>
D007649_D009369 NONE <e1>ketamine</e1> doses bolus given patients <e2>cancer</e2>
D009020_D009369 NONE <e1>morphine</e1> therapy patients <e2>cancer</e2>
D009020_D009369 NONE <e1>morphine</e1> unrelieved patients <e2>cancer</e2>
D009020_D010146 NONE <e1>morphine</e1> responsive <e2>pain</e2>
D009020_D010146 NONE <e1>morphine</e1> unrelieved <e2>pain</e2>
D009020_D010146 NONE <e1>morphine</e1> analgesia improve syndromes <e2>pain</e2>
D016202_D010146 NONE <e1>n-methyl-d-aspartate</e1> antagonists effective improving syndromes <e2>pain</e2>
D016202_D010146 NONE <e1>nmda</e1> n-methyl-d-aspartate antagonists effective improving syndromes <e2>pain</e2>
D016202_D009437 NONE <e1>n-methyl-d-aspartate</e1> antagonists effective improving syndromes <e2>pain</e2>
D016202_D009437 NONE <e1>nmda</e1> n-methyl-d-aspartate antagonists effective improving syndromes <e2>pain</e2>
D007649_D010146 NONE <e1>ketamine</e1> antagonists effective improving syndromes <e2>pain</e2>
D007649_D010146 NONE <e1>ketamine</e1> doses bolus given patients unrelieved <e2>pain</e2>
D007649_D010146 NONE <e1>ketamine</e1> reduced intensity <e2>pain</e2>
D007649_D010146 NONE <e1>ketamine</e1> improve syndromes <e2>pain</e2>
D007649_D009437 NONE <e1>ketamine</e1> antagonists effective improving syndromes <e2>pain</e2>
D007649_D009437 NONE <e1>ketamine</e1> improve syndromes <e2>pain</e2>
D009020_D009437 NONE <e1>morphine</e1> analgesia improve syndromes <e2>pain</e2>
3409645
D008727_D007172 CID <e1>methotrexate</e1> taking co-morbidity associated found common <e2>impotence</e2>
7234705
D011342_D017180 CID <e1>procainamide-induced</e1> <e2>tachycardia</e2>
D011342_D017180 CID <e1>procainamide-induced</e1> <e2>tachycardia</e2>
D011342_D017180 CID <e1>procainamide</e1> mg administration appeared <e2>tachycardia</e2>
D011342_D017180 CID <e1>procainamide</e1> mg administration treatment <e2>tachycardia</e2>
D011342_D017180 CID <e1>procainamide</e1> therapy continuation inserted reoccur <e2>tachycardia</e2>
D011342_D017180 CID <e1>procainamide</e1> produce <e2>tachycardia</e2>
D011342_D018879 NONE <e1>procainamide</e1> administered treatment <e2>contractions</e2>
D011342_D001282 NONE <e1>procainamide</e1> administered treatment contractions <e2>flutter</e2>
D011342_D008133 NONE <e1>procainamide</e1> produce <e2>syndrome</e2>
1549199
D007980_D064420 NONE <e1>levodopa</e1> therapy dose correct is started attempt titrate carbidopa-levodopa point normality lead <e2>toxicity</e2>
D007980_D064420 NONE <e1>carbidopa-levodopa</e1> point normality lead <e2>toxicity</e2>
D002230_D064420 NONE <e1>carbidopa-levodopa</e1> point normality lead <e2>toxicity</e2>
D007980_D005767 CID <e1>levodopa-induced</e1> psychosis hypotension <e2>disorders</e2>
D007980_D007024 CID <e1>levodopa-induced</e1> psychosis <e2>hypotension</e2>
D007980_D011618 NONE <e1>levodopa-induced</e1> <e2>psychosis</e2>
D007980_D012893 NONE <e1>levodopa-induced</e1> psychosis hypotension disorders <e2>disturbances</e2>
D007980_D020447 CID <e1>levodopa-induced</e1> psychosis hypotension disorders disturbances <e2>parasomnias</e2>
18308784
C035054_D007859 NONE <e1>rg1</e1> restores impairment <e2>learning</e2>
C035054_D007859 NONE <e1>rg1</e1> ameliorate <e2>impairment</e2>
C035054_D007859 NONE <e1>rg1</e1> effect <e2>impairment</e2>
D009020_D007859 CID <e1>morphine</e1> administration induced <e2>learning</e2>
D009020_D007859 CID <e1>morphine</e1> administration effect <e2>impairment</e2>
D036145_D007859 NONE <e1>ginsenoside</e1> rg1 ameliorate <e2>impairment</e2>
18768591
D004317_D009404 CID <e1>doxorubicin-induced</e1> <e2>syndrome</e2>
D004317_D009404 CID <e1>doxorubicin</e1> treatment resulted mice leading <e2>syndrome</e2>
D004317_D007674 NONE <e1>doxorubicin-induced</e1> <e2>nephropathy</e2>
D004317_D016055 NONE <e1>doxorubicin-induced</e1> nephropathy leads <e2>retention</e2>
D004317_D005355 NONE <e1>doxorubicin-induced</e1> nephropathy leads retention <e2>fibrosis</e2>
D012964_D007674 NONE <e1>sodium</e1> channel retention leads <e2>nephropathy</e2>
D012964_D016055 NONE <e1>sodium</e1> channel <e2>retention</e2>
D012964_D005355 NONE <e1>sodium</e1> channel retention <e2>fibrosis</e2>
D000450_D005355 NONE <e1>aldosterone-sensitive</e1> serum- shown participate mediate <e2>fibrosis</e2>
D004317_D011507 CID <e1>doxorubicin</e1> treatment resulted <e2>proteinuria</e2>
D004317_D001201 CID <e1>doxorubicin</e1> treatment resulted mice leading syndrome <e2>ascites</e2>
D004317_D006949 CID <e1>doxorubicin</e1> treatment resulted mice leading syndrome ascites <e2>lipidemia</e2>
D004317_D034141 CID <e1>doxorubicin</e1> treatment resulted mice leading syndrome ascites <e2>hypoalbuminemia</e2>
D000450_D009404 NONE <e1>aldosterone</e1> levels increased mice <e2>nephrotic</e2>
D012964_D015430 NONE <e1>sodium</e1> excretion reached associated <e2>gain</e2>
D014508_D009404 NONE <e1>urea</e1> concentrations increased course <e2>syndrome</e2>
D014508_D014511 NONE <e1>urea</e1> concentrations increased mice leading <e2>uremia</e2>
1967484
D013469_D004421 CID <e1>sulpiride-induced</e1> <e2>dystonia</e2>
D013469_D004421 CID <e1>sulpiride</e1> therapy starting developed <e2>dystonia</e2>
D013469_D004421 CID <e1>sulpiride-induced</e1> <e2>dystonia</e2>
D013469_D004409 NONE <e1>sulpiride-induced</e1> <e2>dyskinesia</e2>
D013469_D010302 NONE <e1>sulpiride-induced</e1> dyskinesia <e2>parkinsonism</e2>
12707296
D001120_D006973 NONE <e1>l-arginine</e1> transport humans <e2>hypertension</e2>
D001120_D006973 NONE <e1>l-arginine-nitric</e1> system implicated <e2>hypertension</e2>
D001120_D006973 NONE <e1>l-arginine</e1> system abnormalities associated increases <e2>pressure</e2>
D006854_D006973 NONE <e1>cortisol-induced</e1> <e2>hypertension</e2>
D006854_D006973 NONE <e1>cortisol-induced</e1> <e2>hypertension</e2>
D006854_D006973 NONE <e1>cortisol-induced</e1> increases <e2>pressure</e2>
D009569_D006973 NONE <e1>oxide</e1> system implicated <e2>hypertension</e2>
2440413
D001556_D012640 NONE <e1>gamma-hexachlorocyclohexane</e1> effects <e2>seizures</e2>
D001556_D012640 NONE <e1>lindane</e1> gamma-hexachlorocyclohexane effects <e2>seizures</e2>
D001556_D012640 NONE <e1>gamma-hexachlorocyclohexane</e1> shown decrease <e2>seizure</e2>
D001556_D012640 NONE <e1>gamma-hexachlorocyclohexane</e1> shown decrease increase <e2>seizures</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> gamma-hexachlorocyclohexane shown decrease <e2>seizure</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> gamma-hexachlorocyclohexane shown decrease increase <e2>seizures</e2>
D001556_D012640 NONE <e1>lindane</e1> ingredient gamma-hexachlorocyclohexane shown decrease <e2>seizure</e2>
D001556_D012640 NONE <e1>lindane</e1> ingredient gamma-hexachlorocyclohexane shown decrease increase <e2>seizures</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> exposure decrease <e2>seizure</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> exposure decrease increase <e2>seizures</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> exposure decrease <e2>seizure</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> exposure decrease increase <e2>seizures</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> administration h tested severity response agents <e2>seizure-inducing</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> administration hour increased activity agents <e2>seizure-inducing</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> response h observed increased activity agents <e2>seizure-inducing</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> induced activity <e2>seizure</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> induced activity seizure occur decreased agents <e2>seizure-inducing</e2>
D001556_D012640 NONE <e1>gamma-hch</e1> h site responsible decrease activity <e2>seizure</e2>
D010433_D012640 CID <e1>ptz</e1> pentylenetrazol <e2>seizure</e2>
D010433_D012640 CID <e1>ptz</e1> pentylenetrazol seizure decrease increase <e2>seizures</e2>
D010433_D012640 CID <e1>ptz-induced</e1> seizures increase decrease <e2>seizure</e2>
D010433_D012640 CID <e1>ptz-induced</e1> <e2>seizures</e2>
D010433_D012640 CID <e1>ptz</e1> activity <e2>seizure</e2>
D010433_D012640 CID <e1>ptz</e1> activity decreased activity <e2>seizure</e2>
D010433_D012640 CID <e1>ptz</e1> induced activity <e2>seizure</e2>
D010433_D012640 CID <e1>ptz</e1> induced activity seizure occur decreased agents <e2>seizure-inducing</e2>
D010852_D012640 CID <e1>picrotoxin</e1> ptz activity <e2>seizure</e2>
D010852_D012640 CID <e1>picrotoxin</e1> ptz activity decreased activity <e2>seizure</e2>
D010852_D012640 CID <e1>ptx</e1> picrotoxin ptz activity <e2>seizure</e2>
D010852_D012640 CID <e1>ptx</e1> picrotoxin ptz activity decreased activity <e2>seizure</e2>
D010852_D012640 CID <e1>ptx</e1> ptz induced activity <e2>seizure</e2>
D010852_D012640 CID <e1>ptx</e1> ptz induced activity seizure occur decreased agents <e2>seizure-inducing</e2>
D015097_D012640 CID <e1>acid</e1> activity decreased activity <e2>seizure</e2>
D015097_D012640 CID <e1>acid</e1> activity <e2>seizure</e2>
D015097_D012640 CID <e1>mpa</e1> acid activity decreased activity <e2>seizure</e2>
D015097_D012640 CID <e1>mpa</e1> acid activity <e2>seizure</e2>
D001640_D012640 CID <e1>bicuculline</e1> acid activity decreased activity <e2>seizure</e2>
D001640_D012640 CID <e1>bicuculline</e1> acid activity <e2>seizure</e2>
D001640_D012640 CID <e1>bcc</e1> bicuculline acid activity decreased activity <e2>seizure</e2>
D001640_D012640 CID <e1>bcc</e1> bicuculline acid activity <e2>seizure</e2>
C034818_D012640 CID <e1>6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate</e1> acid activity decreased activity <e2>seizure</e2>
C034818_D012640 CID <e1>6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate</e1> acid activity <e2>seizure</e2>
C034818_D012640 CID <e1>dmcm</e1> 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate acid activity decreased activity <e2>seizure</e2>
C034818_D012640 CID <e1>dmcm</e1> 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate acid activity <e2>seizure</e2>
D013331_D012640 CID <e1>strychnine</e1> acid activity decreased activity <e2>seizure</e2>
D013331_D012640 CID <e1>strychnine</e1> acid activity <e2>seizure</e2>
D013331_D012640 CID <e1>str</e1> strychnine acid activity decreased activity <e2>seizure</e2>
D013331_D012640 CID <e1>str</e1> strychnine acid activity <e2>seizure</e2>
D005680_D012640 NONE <e1>gaba-a</e1> receptor-linked channel site responsible decrease activity <e2>seizure</e2>
1527456
D008012_D014012 NONE <e1>lignocaine</e1> instillation treatment <e2>tinnitus</e2>
D008012_D014012 NONE <e1>lidocaine</e1> lignocaine instillation treatment <e2>tinnitus</e2>
D008012_D014012 NONE <e1>lignocaine</e1> instillation treating <e2>ist</e2>
D008012_D014012 NONE <e1>lidocaine</e1> lignocaine instillation treating <e2>ist</e2>
2515254
D005996_D008881 CID <e1>nitroglycerin</e1> application sided one received patients <e2>migraine</e2>
D005996_D008881 CID <e1>nitroglycerin</e1> induced attacks <e2>migraine</e2>
D005996_D008881 CID <e1>nitroglycerin</e1> attack developed patients <e2>migraine</e2>
D005996_D008881 CID <e1>nitroglycerin</e1> effect <e2>migraine-inducing</e2>
D005996_D008881 CID <e1>nitroglycerin</e1> effect seems suggesting importance development crisis <e2>migraine</e2>
D005996_D010146 NONE <e1>nitroglycerin</e1> effect seems depend stimulation site <e2>pain</e2>
20080983
C048833_D012893 NONE <e1>modafinil</e1> effect <e2>sleepiness</e2>
C048833_D012893 NONE <e1>modafinil</e1> associated decrease <e2>sleepiness</e2>
C048833_D012893 NONE <e1>modafinil</e1> promotes decreases <e2>sleepiness</e2>
D003042_D012893 CID <e1>cocaine</e1> users <e2>sleepiness</e2>
D003042_D012893 CID <e1>cocaine</e1> users <e2>sleepiness</e2>
3125768
D015760_D009127 CID <e1>alfentanil-induced</e1> <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil-induced</e1> <e2>rigidity</e2>
D015760_D009127 CID <e1>alfentanil</e1> prevented <e2>rigidity</e2>
C032943_D009127 NONE <e1>metocurine</e1> abolished <e2>rigidity</e2>
20698227
D012254_D000743 NONE <e1>ribavirin</e1> <e2>anemia</e2>
D012254_D006461 NONE <e1>ribavirin</e1> found found cause <e2>hemolysis</e2>
C473478_D006461 CID <e1>sunitinib</e1> inhibitors number angiogenesis inhibit found found cause <e2>hemolysis</e2>
C471405_D006461 CID <e1>sorafenib</e1> sunitinib inhibitors number angiogenesis inhibit found found cause <e2>hemolysis</e2>
C100416_D019698 NONE <e1>2a</e1> treated patients infected <e2>virus</e2>
D012254_D019698 NONE <e1>ribavirin</e1> 2a treated patients infected <e2>virus</e2>
D012254_D019698 NONE <e1>ribavirin</e1> anemia patients <e2>c</e2>
D012254_D000740 NONE <e1>ribavirin</e1> <e2>anemia</e2>
18261172
D020123_D011507 CID <e1>sirolimus-based</e1> immunosuppression switch development <e2>proteinuria</e2>
D020123_D011507 CID <e1>sirolmus</e1> lacks reported <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> sirolmus lacks reported <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> associated <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> associated <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> switch develop <e2>proteinuria</e2>
D020123_D011507 CID <e1>srl</e1> used therapy monitored <e2>proteinuria</e2>
D020123_D007674 NONE <e1>sirolmus</e1> lacks effects <e2>nephrotoxic</e2>
D020123_D007674 NONE <e1>srl</e1> sirolmus lacks effects <e2>nephrotoxic</e2>
D020123_D007674 NONE <e1>srl</e1> associated proteinuria reported lacks effects <e2>nephrotoxic</e2>
D020123_D007674 NONE <e1>srl</e1> used increased <e2>dysfunction</e2>
D000806_D011507 NONE <e1>inhibitor</e1> reduced development <e2>proteinuria</e2>
D000806_D011507 NONE <e1>acei/arb</e1> therapy monitored <e2>proteinuria</e2>
D057911_D011507 NONE <e1>blocker</e1> therapy inhibitor reduced development <e2>proteinuria</e2>
D057911_D011507 NONE <e1>arb</e1> blocker therapy inhibitor reduced development <e2>proteinuria</e2>
D057911_D011507 NONE <e1>acei/arb</e1> therapy monitored <e2>proteinuria</e2>
D000806_D007674 NONE <e1>acei/arb</e1> therapy used increased <e2>dysfunction</e2>
D057911_D007674 NONE <e1>acei/arb</e1> therapy used increased <e2>dysfunction</e2>
7834920
D012293_D005921 CID <e1>rifampin</e1> therapy associated <e2>glomerulonephritis</e2>
D012293_D005921 CID <e1>rifampin</e1> treated patient <e2>glomerulonephritis</e2>
D012293_D005921 CID <e1>rifampin</e1> treated patient crescents documents occurrence <e2>glomerulonephritis</e2>
D012293_D005921 CID <e1>rifampin</e1> treated patient crescents <e2>glomerulonephritis</e2>
D012293_D014397 NONE <e1>rifampin</e1> therapy <e2>tuberculosis</e2>
D012293_D014397 NONE <e1>rifampin</e1> regimen <e2>tuberculosis</e2>
D012293_D051437 CID <e1>rifampin</e1> regimen underwent discovered developed signs <e2>failure</e2>
D007538_D014397 NONE <e1>isoniazid</e1> rifampin regimen <e2>tuberculosis</e2>
D007538_D051437 NONE <e1>isoniazid</e1> rifampin regimen underwent discovered developed signs <e2>failure</e2>
11928786
D016642_D064420 NONE <e1>bupropion</e1> <e2>toxicity</e2>
D016642_D064420 NONE <e1>zyban</e1> bupropion <e2>toxicity</e2>
D003975_D012640 NONE <e1>diazepam</e1> treated <e2>seizures</e2>
D003975_D013610 NONE <e1>diazepam</e1> treated treated <e2>tachycardia</e2>
D000241_D012640 NONE <e1>adenosine</e1> treated treated <e2>seizures</e2>
D000241_D013610 NONE <e1>adenosine</e1> treated <e2>tachycardia</e2>
D016642_D020258 NONE <e1>zyban</e1> caused neurological <e2>toxicity</e2>
D016642_D002318 NONE <e1>zyban</e1> caused neurological <e2>toxicity</e2>
D016642_D062787 NONE <e1>zyban</e1> caused <e2>overdose</e2>
3560095
D005480_D001171 NONE <e1>flurbiprofen</e1> treatment <e2>arthritis</e2>
D005480_D001171 NONE <e1>flurbiprofen</e1> treated patients <e2>arthritis</e2>
D005480_D001168 NONE <e1>flurbiprofen</e1> treated patients had decreases indices <e2>arthritis</e2>
8701950
D016559_D000743 CID <e1>fk506</e1> therapy complicating <e2>anemia</e2>
D016559_D000743 CID <e1>tacrolimus</e1> therapy complicating <e2>anemia</e2>
D016559_D000743 CID <e1>fk506</e1> therapy recipients episodes <e2>anemia</e2>
D016559_D000743 CID <e1>fk506</e1> therapy recipients episodes anemia <e2>maha</e2>
D016559_D000743 CID <e1>tacrolimus</e1> therapy recipients episodes <e2>anemia</e2>
D016559_D000743 CID <e1>tacrolimus</e1> therapy recipients episodes anemia <e2>maha</e2>
D016559_D000743 CID <e1>fk506</e1> discontinuation led resolution <e2>maha</e2>
D016559_D000743 CID <e1>fk506</e1> reintroduction led recurrence <e2>maha</e2>
D016559_D000743 CID <e1>fk506-associated</e1> <e2>maha</e2>
D016559_D000743 CID <e1>fk506</e1> seem cross-react a drug known induce <e2>maha</e2>
D000305_D000743 NONE <e1>corticosteroids</e1> replacement discontinuation led resolution <e2>maha</e2>
D001241_D000743 NONE <e1>aspirin</e1> corticosteroids replacement discontinuation led resolution <e2>maha</e2>
D004176_D000743 NONE <e1>dipyridamole</e1> replacement discontinuation led resolution <e2>maha</e2>
D016572_D000743 NONE <e1>a</e1> drug known induce <e2>maha</e2>
D016572_D000743 NONE <e1>cya</e1> a drug known induce <e2>maha</e2>
18809400
D008063_D028361 NONE <e1>acid</e1> prevents <e2>damage</e2>
D008063_D028361 NONE <e1>acid</e1> neuroprotective investigates plays <e2>damage</e2>
D008063_D028361 NONE <e1>acid</e1> effects depend plays <e2>damage</e2>
D008063_D028361 NONE <e1>acid</e1> exerts rescues <e2>toxicity</e2>
D008063_D020258 NONE <e1>acid</e1> prevents damage <e2>neurotoxicity</e2>
D008063_D020258 NONE <e1>acid</e1> neuroprotective <e2>neurotoxicity</e2>
D008063_D020258 NONE <e1>acid</e1> effects depend plays investigates neuroprotective <e2>neurotoxicity</e2>
D008063_D020258 NONE <e1>acid</e1> exerts effects <e2>neurotoxicity</e2>
D008063_D009422 NONE <e1>acid</e1> prevents damage <e2>neuropathy</e2>
D008063_D009410 NONE <e1>acid</e1> neuroprotective investigates plays <e2>cascade</e2>
D008063_D009410 NONE <e1>acid</e1> effects depend plays <e2>cascade</e2>
D017239_D010523 CID <e1>paclitaxel</e1> neurons cultures exposing mimic <e2>neuropathy</e2>
D002945_D010523 CID <e1>cisplatin</e1> paclitaxel neurons cultures exposing mimic <e2>neuropathy</e2>
D008063_D001480 NONE <e1>acid</e1> efficacy investigating preventing <e2>damage</e2>
D008063_D001480 NONE <e1>acid</e1> agents exposure function <e2>damage</e2>
D002945_D028361 NONE <e1>cisplatin</e1> cause <e2>impairment</e2>
D002945_D028361 NONE <e1>cisplatin</e1> induced neurotoxicity event <e2>toxicity</e2>
D017239_D028361 NONE <e1>paclitaxel</e1> cisplatin cause <e2>impairment</e2>
D017239_D028361 NONE <e1>paclitaxel</e1> both event <e2>toxicity</e2>
D017239_D020258 NONE <e1>paclitaxel</e1> both event <e2>neurotoxicity</e2>
D002945_D020258 NONE <e1>cisplatin</e1> induced <e2>neurotoxicity</e2>
D008063_D010523 NONE <e1>acid</e1> reduce risk developing <e2>toxicity</e2>
11961407
D014443_D009401 NONE <e1>tyrosine</e1> phosphatase <e2>nephrosis</e2>
D011692_D009401 CID <e1>pan</e1> <e2>nephrosis</e2>
D011692_D009401 CID <e1>aminonucleoside</e1> <e2>nephrosis</e2>
D011692_D009401 CID <e1>aminonucleoside</e1> injection induced <e2>nephrosis</e2>
D011692_D009401 CID <e1>pan</e1> injection induced <e2>nephrosis</e2>
D011692_D011507 CID <e1>pan</e1> injection days analyzed include phase <e2>proteinuria</e2>
D011692_D011507 CID <e1>pan</e1> injection days analyzed include phase phase <e2>proteinuria</e2>
D011692_D005921 NONE <e1>pan</e1> injection days analyzed include phase phase proteinuria associated <e2>glomerulosclerosis</e2>
11581460
D005283_D016055 CID <e1>fentanyl</e1> reports infusion result retention <e2>urine</e2>
D005283_D009127 NONE <e1>fentanyl</e1> administration effects reported include <e2>rigidity</e2>
D005283_D007022 CID <e1>fentanyl</e1> administration effects reported include rigidity <e2>hypotension</e2>
D005283_D012131 CID <e1>fentanyl</e1> administration effects reported include rigidity hypotension <e2>depression</e2>
D005283_D001919 CID <e1>fentanyl</e1> administration effects reported include rigidity <e2>bradycardia</e2>
D005283_D001745 CID <e1>fentanyl</e1> infusion result leading cases <e2>retention</e2>
D005283_D006869 NONE <e1>fentanyl</e1> infusion result leading mimicking <e2>hydronephrosis</e2>
2024540
D004656_D006333 NONE <e1>enalapril</e1> safety phase patients <e2>failure</e2>
D011224_D006333 NONE <e1>prazosin</e1> enalapril safety phase patients <e2>failure</e2>
D000806_D006333 NONE <e1>inhibitors</e1> treatment patients <e2>failure</e2>
D000806_D007022 CID <e1>inhibitors</e1> cases <e2>hypotension</e2>
D000806_D007022 CID <e1>inhibitor</e1> safety assess designed incidence severity <e2>hypotension</e2>
D004656_D007022 NONE <e1>enalapril</e1> assess designed incidence severity <e2>hypotension</e2>
D004656_D007022 NONE <e1>enalapril</e1> received patients experienced <e2>hypotension</e2>
D011224_D007022 CID <e1>prazosin-controlled</e1> trial designed incidence severity <e2>hypotension</e2>
D011224_D007022 CID <e1>prazosin</e1> received patients <e2>hypotension</e2>
19300402
D001920_D006930 NONE <e1>bradykinin</e1> receptors antagonists induced <e2>hyperalgesia</e2>
D001920_D006930 NONE <e1>bradykinin</e1> receptors inhibition reduces <e2>hyperalgesia</e2>
D001920_D006930 NONE <e1>bradykinin</e1> products involved <e2>hyperalgesia</e2>
D001920_D006930 NONE <e1>bradykinin</e1> activity participates <e2>hyperalgesia</e2>
D001920_D006930 NONE <e1>bradykinin</e1> activity participates seemed bradykinin <e2>hyperalgesia</e2>
D001920_D006930 NONE <e1>bradykinin</e1> seemed participates <e2>hyperalgesia</e2>
D001920_D006930 NONE <e1>bradykinin</e1> <e2>hyperalgesia</e2>
D001920_D003929 NONE <e1>bradykinin</e1> receptors antagonists induced model <e2>neuropathy</e2>
D001920_D003929 NONE <e1>bradykinin</e1> influence model diabetic <e2>neuropathy</e2>
D009569_D006930 NONE <e1>oxide</e1> synthase inhibitors antagonists induced <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> synthase inhibition reduces <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> activity inhibition reduces <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> synthase products involved <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> activation synthase products involved <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> synthase participates <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> synthase participates seemed bradykinin <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> pathway activate seemed participates <e2>hyperalgesia</e2>
D009569_D006930 NONE <e1>no</e1> pathway activate seemed bradykinin <e2>hyperalgesia</e2>
D009569_D003929 NONE <e1>oxide</e1> synthase inhibitors antagonists induced model <e2>neuropathy</e2>
D009569_D003929 NONE <e1>no</e1> synthase inhibitor influence model diabetic <e2>neuropathy</e2>
D009569_D003929 NONE <e1>no</e1> synthase inhibitor inhibitor influence model diabetic <e2>neuropathy</e2>
D009569_D003929 NONE <e1>no</e1> synthase inhibitor inhibitor inhibitor influence model diabetic <e2>neuropathy</e2>
D014750_D006930 CID <e1>vincristine</e1> antagonists induced <e2>hyperalgesia</e2>
D014750_D006930 CID <e1>vincristine</e1> produced <e2>hyperalgesia</e2>
D014750_D006930 CID <e1>vincristine-induced</e1> bradykinin seemed participates <e2>hyperalgesia</e2>
D014750_D006930 CID <e1>vincristine-induced</e1> bradykinin <e2>hyperalgesia</e2>
D014750_D003929 NONE <e1>vincristine</e1> antagonists induced model <e2>neuropathy</e2>
D013311_D006930 CID <e1>streptozotocin</e1> vincristine antagonists induced <e2>hyperalgesia</e2>
D013311_D006930 CID <e1>streptozotocin-induced</e1> <e2>hyperalgesia</e2>
D013311_D006930 CID <e1>streptozotocin-induced</e1> hyperalgesia participates seemed bradykinin <e2>hyperalgesia</e2>
D013311_D003929 CID <e1>streptozotocin</e1> vincristine antagonists induced model <e2>neuropathy</e2>
D009569_D010523 NONE <e1>no</e1> synthase inhibitor influence model diabetic <e2>neuropathy</e2>
D009569_D010523 NONE <e1>no</e1> synthase inhibitor inhibitor influence model diabetic <e2>neuropathy</e2>
D009569_D010523 NONE <e1>no</e1> synthase inhibitor inhibitor inhibitor influence model diabetic <e2>neuropathy</e2>
D001920_D010523 NONE <e1>bradykinin</e1> influence model diabetic <e2>neuropathy</e2>
C065679_D003929 NONE <e1>140</e1> hoe bradykinin influence model diabetic <e2>neuropathy</e2>
C065679_D010523 NONE <e1>140</e1> hoe bradykinin influence model diabetic <e2>neuropathy</e2>
C065679_D010523 NONE <e1>140</e1> hoe des-arg10hoe <e2>neuropathy</e2>
C078665_D003929 NONE <e1>140</e1> hoe ip influence model diabetic <e2>neuropathy</e2>
C078665_D010523 NONE <e1>140</e1> hoe ip influence model diabetic <e2>neuropathy</e2>
C078665_D010523 NONE <e1>140</e1> des-arg10hoe <e2>neuropathy</e2>
D001920_D009437 NONE <e1>bradykinin</e1> antagonists doses administration effective alleviation <e2>pain</e2>
D009569_D009437 NONE <e1>no</e1> inhibitors doses administration effective alleviation <e2>pain</e2>
11642480
D015283_D004409 CID <e1>citalopram</e1> adolescent <e2>twitching</e2>
D015283_D004409 CID <e1>citalopram</e1> treatment response boy exhibited <e2>twitching</e2>
D015283_D003866 NONE <e1>citalopram</e1> adolescent <e2>depressed</e2>
D015283_D003865 NONE <e1>citalopram</e1> treatment response boy <e2>depression</e2>
15859940
D016572_D064420 NONE <e1>cyclosporine</e1> drug-related <e2>toxicity</e2>
D016559_D064420 NONE <e1>tacrolimus</e1> cyclosporine drug-related <e2>toxicity</e2>
D016572_D057049 CID <e1>cyclosporine</e1> secondary related drug cause <e2>microangiopathy</e2>
8595686
D013874_D010146 NONE <e1>thiopentone</e1> pretreatment <e2>pain</e2>
D013874_D010146 NONE <e1>thiopentone</e1> reduces reduces incidence <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> <e2>pain</e2>
D015742_D010146 CID <e1>propofol</e1> injection <e2>pain</e2>
D008012_D010146 NONE <e1>lidocaine</e1> reduces incidence <e2>pain</e2>
11263551
D016572_D010146 CID <e1>cyclosporine-</e1> levels reduction led relief <e2>pain</e2>
D016572_D010146 CID <e1>cyclosporine</e1> effect rare syndrome <e2>pain</e2>
D016559_D010146 CID <e1>tacrolimus</e1> trough cyclosporine- levels reduction led relief <e2>pain</e2>
D016559_D010146 CID <e1>tacrolimus</e1> cyclosporine effect rare syndrome <e2>pain</e2>
D002118_D010146 NONE <e1>calcium</e1> channel blockers administration reduction led relief <e2>pain</e2>
D016572_-1 NONE <e1>cyclosporine</e1> effect rare syndrome <e2>cips</e2>
D016559_-1 NONE <e1>tacrolimus</e1> cyclosporine effect rare syndrome <e2>cips</e2>
2572625
C084599_D056486 CID <e1>clotiazepam-induced</e1> <e2>hepatitis</e2>
C084599_D056486 CID <e1>clotiazepam</e1> administration onset necrosis developed <e2>hepatitis</e2>
C084599_D056486 CID <e1>clotiazepam</e1> related administration interfere induce relapse <e2>hepatitis</e2>
C084599_D056486 CID <e1>clotiazepam</e1> induce <e2>hepatitis</e2>
C084599_D056486 CID <e1>clotiazepam</e1> induce suggests is <e2>hepatotoxicity</e2>
C084599_D056486 CID <e1>clotiazepam</e1> hepatotoxicity is suggests induce <e2>hepatitis</e2>
C084599_D056486 CID <e1>clotiazepam</e1> <e2>hepatotoxicity</e2>
C084599_D047508 NONE <e1>clotiazepam</e1> administration onset <e2>necrosis</e2>
C013295_D056486 NONE <e1>thienodiazepine</e1> derivative patient developed <e2>hepatitis</e2>
C013295_D047508 NONE <e1>thienodiazepine</e1> derivative patient developed <e2>necrosis</e2>
D001569_D056486 NONE <e1>benzodiazepines</e1> administration interfere induce relapse <e2>hepatitis</e2>
D001569_D056486 NONE <e1>benzodiazepines</e1> clotiazepam hepatotoxicity is suggests induce <e2>hepatitis</e2>
D001569_D056486 NONE <e1>benzodiazepines</e1> clotiazepam <e2>hepatotoxicity</e2>
10406016
C007789_D002543 NONE <e1>fucoidan</e1> treatment <e2>hemorrhage</e2>
C007789_D002543 NONE <e1>fucoidan</e1> tested model <e2>hemorrhage</e2>
C007789_D001925 NONE <e1>fucoidan</e1> tested reported reduce <e2>damage</e2>
C007789_D020141 CID <e1>fucoidan-treated</e1> rats exhibited evidence <e2>clotting</e2>
C007789_D020141 CID <e1>fucoidan-treated</e1> rats exhibited evidence clotting <e2>hemodilution</e2>
C007789_D006406 NONE <e1>fucoidan-treated</e1> rats exhibited had <e2>hematomas</e2>
C007789_D006406 NONE <e1>fucoidan-treated</e1> rats exhibited had tended have inflammation vicinity <e2>hematoma</e2>
C007789_D007249 NONE <e1>fucoidan-treated</e1> rats exhibited had tended have <e2>inflammation</e2>
12820454
D016729_D000740 CID <e1>acetate</e1> cab received evaluated <e2>anemia</e2>
D016729_D000740 CID <e1>lhrh-a</e1> acetate cab received evaluated <e2>anemia</e2>
D005485_D000740 CID <e1>flutamide</e1> days received evaluated <e2>anemia</e2>
2476560
D001556_D012532 NONE <e1>lindane</e1> consider initiated treatment <e2>scabies</e2>
D001556_D012532 NONE <e1>hexachloride</e1> lindane consider initiated treatment <e2>scabies</e2>
D001556_D002493 CID <e1>lindane</e1> toxic <e2>system</e2>
D001556_D000741 CID <e1>lindane</e1> toxic associated <e2>anaemia</e2>
3560096
D013467_D006947 CID <e1>sulindac</e1> therapy associated <e2>hyperkalemia</e2>
D013467_D006947 CID <e1>sulindac</e1> administration days developed describe patients ranging <e2>hyperkalemia</e2>
D013467_D006947 CID <e1>sulindac</e1> <e2>hyperkalemia</e2>
D007213_D006947 CID <e1>indomethacin</e1> agents complication recognized <e2>hyperkalemia</e2>
D011188_D006947 NONE <e1>potassium</e1> effect known medications given suggestive relationship sulindac <e2>hyperkalemia</e2>
1009330
C004658_D003556 NONE <e1>p-choloroaniline</e1> factor <e2>cystitis</e2>
C010882_D003556 CID <e1>chlorhexidine-digluconate</e1> <e2>cystitis</e2>
D007612_D003556 CID <e1>kanamycin-colistin</e1> irrigations percentage associated <e2>cystitis</e2>
D003091_D003556 CID <e1>kanamycin-colistin</e1> irrigations percentage associated <e2>cystitis</e2>
D011206_D003556 CID <e1>povidone-iodine</e1> kanamycin-colistin irrigations percentage associated <e2>cystitis</e2>
C005253_D003556 NONE <e1>picloxydine</e1> irrigations appeared have incidence <e2>cystitis</e2>
19387625
D002211_D010146 NONE <e1>capsaicin-induced</e1> hyperalgesia modulation intensity <e2>pain</e2>
D002211_D010146 NONE <e1>capsaicin-induced</e1> hyperalgesia attention affected ratings <e2>pain</e2>
D002211_D010146 NONE <e1>capsaicin</e1> treatment interaction showing findings suggest affect <e2>pain</e2>
D002211_D010146 NONE <e1>capsaicin-induced</e1> hyperalgesia affect <e2>pain</e2>
D002211_D006930 CID <e1>capsaicin-induced</e1> <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin-induced</e1> <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin-untreated</e1> condition that similar magnitude modulation <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> treatment interaction showing findings suggest affect <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin-induced</e1> <e2>hyperalgesia</e2>
18821488
C080436_D064420 NONE <e1>8-aminoquinoline</e1> 5-(l-hexyloxy)-6-methoxy-4-methylquinoline administration <e2>toxicity</e2>
C068820_D064420 NONE <e1>5-(l-hexyloxy)-6-methoxy-4-methylquinoline</e1> administration <e2>toxicity</e2>
C068820_D064420 NONE <e1>wr242511</e1> 5-(l-hexyloxy)-6-methoxy-4-methylquinoline administration <e2>toxicity</e2>
C068820_D064420 NONE <e1>wr242511</e1> pursued dissociated <e2>toxicity</e2>
C068820_D008708 NONE <e1>wr242511</e1> doses produced <e2>methemoglobinemia</e2>
C068820_D006456 CID <e1>wr242511</e1> postinjection noted <e2>hemoglobinuria</e2>
C068820_D011041 NONE <e1>wr242511</e1> pursued pretreatment <e2>poisoning</e2>
3782049
D008972_D012206 CID <e1>molindone</e1> administration <e2>rhabdomyolysis</e2>
D008972_D012206 CID <e1>molindone</e1> administration <e2>rhabdomyolysis</e2>
D008972_D012559 NONE <e1>molindone</e1> administration rhabdomyolysis illustrate reported case patient <e2>schizophrenic</e2>
D008972_D058186 CID <e1>molindone</e1> administration rhabdomyolysis <e2>failure</e2>
8690168
D006497_D003928 NONE <e1>sulphate-associated</e1> sites membrane rats <e2>nephropathy</e2>
D013311_D003928 CID <e1>streptozotocin-induced</e1> <e2>nephropathy</e2>
D006497_D003920 NONE <e1>sulphate-associated</e1> sites studied induction <e2>diabetes</e2>
D006497_D003920 NONE <e1>sulphate</e1> charge barrier/density found rats <e2>streptozotocin-diabetic</e2>
D013311_D003920 NONE <e1>streptozotocin</e1> induction <e2>diabetes</e2>
D013311_D003920 NONE <e2><e1>streptozotocin-diabetic</e1></e2>
C015445_D003920 NONE <e1>blue</e1> employing studied induction <e2>diabetes</e2>
1468485
D010100_D006470 NONE <e1>oxygen</e1> therapy control <e2>cystitis</e2>
D010100_D003556 NONE <e1>oxygen</e1> therapy control <e2>cystitis</e2>
D003520_D006470 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D006470 CID <e1>cyclophosphamide</e1> therapy case <e2>cystitis</e2>
D003520_D006470 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> therapy case <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D014890 NONE <e1>cyclophosphamide</e1> therapy <e2>granulomatosis</e2>
D015237_D006470 NONE <e1>alpha</e1> saline irrigation treatment failed control <e2>hemorrhage</e2>
88336
D002719_D013375 NONE <e1>chlormethiazole</e1> <e2>symptoms</e2>
D002719_D062787 NONE <e1>chlormethiazole</e1> doses received took <e2>overdose</e2>
D002719_D062787 NONE <e1>chlormethiazole</e1> intoxication those two <e2>overdose</e2>
D000431_D013375 NONE <e1>alcohol</e1> withdrawal <e2>symptoms</e2>
D000431_D062787 NONE <e1>alcohol</e1> withdrawal symptoms chlormethiazole doses received took <e2>overdose</e2>
D009567_D013375 NONE <e1>nitrazepam</e1> overdose took received doses chlormethiazole <e2>symptoms</e2>
D009567_D062787 CID <e1>nitrazepam</e1> <e2>overdose</e2>
D009567_D062787 CID <e1>nitrazepam</e1> patient <e2>overdose</e2>
D009567_D003128 CID <e1>nitrazepam</e1> patient overdose two those intoxication conformed criteria <e2>coma</e2>
D002719_D003128 CID <e1>chlormethiazole</e1> intoxication conformed criteria <e2>coma</e2>
9334596
D013739_D007172 NONE <e1>testosterone</e1> patients referred <e2>dysfunction</e2>
D013739_D007172 NONE <e1>testosterone</e1> levels most seemed have role <e2>dysfunction</e2>
D013739_D007172 NONE <e1>testosterone</e1> prevalences <e2>dysfunction</e2>
D013739_D020018 CID <e1>testosterone</e1> screened screened basis <e2>desire</e2>
D013739_D020018 CID <e1>testosterone</e1> gynecomastia <e2>desire</e2>
D013739_D020018 CID <e1>testosterone</e1> determining cases <e2>desire</e2>
D013739_D020018 CID <e1>testosterone</e1> cases % missed determining cases <e2>desire</e2>
D013739_D020018 CID <e1>testosterone</e1> determined cases <e2>desire</e2>
D013739_D020018 CID <e1>testosterone</e1> gynecomastia <e2>desire</e2>
D013739_D006177 NONE <e1>testosterone</e1> screened screened basis desire <e2>gynecomastia</e2>
D013739_D006177 NONE <e1>testosterone</e1> <e2>gynecomastia</e2>
D013739_D006177 NONE <e1>testosterone</e1> <e2>gynecomastia</e2>
C004648_D007006 NONE <e1>heptylate</e1> consisted <e2>hypogonadism</e2>
C004648_D006966 NONE <e1>heptylate</e1> consisted hypogonadism bromocriptine <e2>hyperprolactinemia</e2>
D001971_D007006 NONE <e1>bromocriptine</e1> <e2>hypogonadism</e2>
D001971_D006966 NONE <e1>bromocriptine</e1> <e2>hyperprolactinemia</e2>
D013739_D010911 NONE <e1>testosterone</e1> determination discovered <e2>tumors</e2>
D013739_D007027 NONE <e1>testosterone</e1> levels most seemed result <e2>dysfunction</e2>
1919871
D001241_D007681 CID <e1>aspirin</e1> treatment developed <e2>necrosis</e2>
D001241_D007681 CID <e1>aspirin</e1> treatment developed necrosis <e2>rpn</e2>
D000082_D007681 CID <e1>paracetamol</e1> treatment developed <e2>necrosis</e2>
D000082_D007681 CID <e1>paracetamol</e1> treatment developed necrosis <e2>rpn</e2>
8955532
D001920_D006973 NONE <e1>bradykinin</e1> receptors activation role <e2>hypertension</e2>
D001920_D006973 NONE <e1>bradykinin</e1> synthesis/release role activate disruption <e2>hypertension</e2>
D001920_D006973 NONE <e1>bradykinin</e1> synthesis/release related disruption <e2>hypertension</e2>
D003911_D006973 NONE <e1>dextran</e1> clearance quantitated <e2>hypertension</e2>
D010656_D006973 CID <e1>phenylephrine-induced</e1> <e2>hypertension</e2>
C065679_D006973 NONE <e1>hoe-140</e1> vehicle treated rats <e2>hypertension</e2>
19037603
D019259_D012216 NONE <e1>lamivudine</e1> therapy <e2>disorders</e2>
D019259_D012216 NONE <e1>lamivudine</e1> administration patients <e2>disease</e2>
D019259_D012216 NONE <e1>lamivudine</e1> therapies immunosuppressive <e2>diseases</e2>
D006514_D012216 NONE <e1>antigen</e1> administration patients <e2>disease</e2>
D006514_D012216 NONE <e1>ag</e1> antigen administration patients <e2>disease</e2>
D006514_D012216 NONE <e1>ag</e1> patients <e2>diseases</e2>
809711
D010656_D009203 NONE <e1>phenylephrine</e1> effects patients <e2>infarction</e2>
D010656_D009203 NONE <e1>phenylephrine</e1> addition beneficial treatment patients <e2>infarction</e2>
D005996_D009203 NONE <e1>nitroglycerin</e1> effects patients <e2>infarction</e2>
D005996_D009203 NONE <e1>nitroglycerin</e1> shown reduce <e2>infarction</e2>
D005996_D009203 NONE <e1>nitroglycerin-induced</e1> hypotension reverse agents dog potentiated shown reduce <e2>infarction</e2>
D005996_D009203 NONE <e1>nitroglycerin</e1> received patients <e2>infarctions</e2>
D005996_D009203 NONE <e1>nitroglycerin</e1> addition beneficial treatment patients <e2>infarction</e2>
D005996_D007022 CID <e1>nitroglycerin</e1> shown potentiated dog agents reverse <e2>hypotension</e2>
D005996_D007022 CID <e1>nitroglycerin-induced</e1> <e2>hypotension</e2>
17600377
C524754_D003072 NONE <e1>p-coumarate</e1> compound attenuates <e2>deficits</e2>
C524754_D003072 NONE <e1>p-coumarate</e1> improve <e2>decline</e2>
C524754_D003072 NONE <e1>p-coumarate</e1> found attenuate <e2>deficits</e2>
C524754_D003072 NONE <e1>p-coumarate</e1> candidate characterized death decline <e2>function</e2>
C524754_D003704 NONE <e1>p-coumarate</e1> compound attenuates shows models <e2>dementia</e2>
D012601_D003072 CID <e1>scopolamine-injected</e1> rats <e2>decline</e2>
C544092_D003072 NONE <e1>42)-infused</e1> rats improve <e2>decline</e2>
C544092_D003072 NONE <e1>42)-infused</e1> rats hippocampus observed death reduce using found attenuate <e2>deficits</e2>
C524754_D000544 NONE <e1>p-coumarate</e1> candidate <e2>disease</e2>
C524754_D009410 NONE <e1>p-coumarate</e1> candidate characterized <e2>death</e2>
10526274
C056507_D002289 NONE <e1>gemcitabine</e1> patients <e2>carcinoma</e2>
C056507_D002289 NONE <e1>gem</e1> combination patients <e2>nsclc</e2>
C030852_D002289 NONE <e1>vinorelbine</e1> gemcitabine patients <e2>carcinoma</e2>
C030852_D002289 NONE <e1>vnb</e1> gem combination patients <e2>nsclc</e2>
D002945_D002289 NONE <e1>cisplatin</e1> receive gemcitabine patients <e2>carcinoma</e2>
D002945_D002289 NONE <e1>cisplatin</e1> receiving contraindication those <e2>nsclc</e2>
D002945_D002289 NONE <e1>cisplatin</e1> receiving had age included patients <e2>nsclc</e2>
C030852_D064420 NONE <e1>vinorelbine</e1> therapy obtain <e2>toxicity</e2>
C030852_D064420 NONE <e1>vnb</e1> vinorelbine therapy obtain <e2>toxicity</e2>
C030852_D064420 NONE <e1>vnb</e1> gem combination efficacy <e2>toxicity</e2>
C056507_D064420 NONE <e1>gemcitabine</e1> vinorelbine therapy obtain <e2>toxicity</e2>
C056507_D064420 NONE <e1>gem</e1> gemcitabine vinorelbine therapy obtain <e2>toxicity</e2>
C056507_D064420 NONE <e1>gem</e1> combination efficacy <e2>toxicity</e2>
D002945_D064420 NONE <e1>cisplatin</e1> receiving contraindication those nsclc patients combination efficacy <e2>toxicity</e2>
6692345
D001241_D001749 NONE <e1>aspirin</e1> co-administration resulted incidence <e2>carcinomas</e2>
D001241_D013274 NONE <e1>aspirin</e1> co-administration resulted incidence induction <e2>tumors</e2>
D005200_D001749 CID <e1>n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1> co-administration resulted incidence <e2>carcinomas</e2>
D005200_D001749 CID <e1>fanft</e1> n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide co-administration resulted incidence <e2>carcinomas</e2>
D005200_D001749 CID <e1>fanft-induced</e1> <e2>carcinomas</e2>
D005200_D013274 CID <e1>n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1> co-administration resulted incidence induction <e2>tumors</e2>
D005200_D013274 CID <e1>fanft</e1> n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide co-administration resulted incidence induction <e2>tumors</e2>
D005200_D013274 CID <e1>fanft-induced</e1> carcinomas incidence induction <e2>tumors</e2>
D005200_D063646 NONE <e1>fanft</e1> <e2>carcinogenesis</e2>
D005200_D063646 NONE <e1>fanft</e1> effect involved <e2>carcinogenesis</e2>
D001241_D063646 NONE <e1>aspirin</e1> effect involved <e2>carcinogenesis</e2>
2950248
D004176_D017202 NONE <e1>dipyridamole-induced</e1> <e2>ischemia</e2>
D004176_D017202 NONE <e1>dipyridamole</e1> therapy effect reported demonstrated <e2>ischemia</e2>
D004176_D017202 NONE <e1>dipyridamole-induced</e1> <e2>ischemia</e2>
D004176_D000787 CID <e1>dipyridamole</e1> administration occurred changes <e2>angina</e2>
D004176_D003324 NONE <e1>dipyridamole</e1> therapy effect reported demonstrated occur <e2>disease</e2>
D004176_D003324 NONE <e1>dipyridamole-induced</e1> ischemia demonstrated occur <e2>disease</e2>
D004176_D007511 NONE <e1>dipyridamole-induced</e1> <e2>ischemia</e2>
18791946
D002939_D013921 CID <e1>ciprofloxacin</e1> associated <e2>thrombocytopenia</e2>
D002939_D013921 CID <e1>ciprofloxacin</e1> precipitate <e2>thrombocytopenia</e2>
D002939_D000743 CID <e1>ciprofloxacin</e1> associated thrombocytopenia <e2>anaemia</e2>
D002939_D000743 CID <e1>ciprofloxacin</e1> precipitate thrombocytopenia <e2>anaemia</e2>
D002939_D015746 CID <e1>ciprofloxacin</e1> administration reported <e2>pain</e2>
D002939_D007565 CID <e1>ciprofloxacin</e1> administration reported pain <e2>jaundice</e2>
D002939_D014552 NONE <e1>ciprofloxacin</e1> administration suspect <e2>infection</e2>
17344566
D019821_D003161 CID <e1>simvastatin-induced</e1> <e2>syndrome</e2>
D019821_D003161 CID <e1>simvastatin</e1> thyroxine taking male presented <e2>syndrome</e2>
D019821_D009135 NONE <e1>simvastatin-induced</e1> syndrome <e2>myonecrosis</e2>
D019821_D009135 NONE <e1>simvastatin</e1> thyroxine taking male presented syndrome <e2>myonecrosis</e2>
D019821_D007037 NONE <e1>simvastatin-induced</e1> syndrome associated <e2>hypothyroidism</e2>
D019821_D007037 NONE <e1>simvastatin</e1> thyroxine taking male <e2>hypothyroid</e2>
D013974_D007037 NONE <e1>thyroxine</e1> taking male <e2>hypothyroid</e2>
D013974_D003161 NONE <e1>thyroxine</e1> taking male presented <e2>syndrome</e2>
D013974_D009135 NONE <e1>thyroxine</e1> taking male presented syndrome <e2>myonecrosis</e2>
